
<html lang="en"     class="pb-page"  data-request-id="7a2f78e3-2599-4594-8a64-c482129cae88"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2021.64.issue-9;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.1c00138;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis" /></meta><meta name="dc.Creator" content="Oscar  Mammoliti" /></meta><meta name="dc.Creator" content="Adeline  Palisse" /></meta><meta name="dc.Creator" content="Caroline  Joannesse" /></meta><meta name="dc.Creator" content="Sandy  El Bkassiny" /></meta><meta name="dc.Creator" content="Brigitte  Allart" /></meta><meta name="dc.Creator" content="Alex  Jaunet" /></meta><meta name="dc.Creator" content="Christel  Menet" /></meta><meta name="dc.Creator" content="Beatrice  Coornaert" /></meta><meta name="dc.Creator" content="Kathleen  Sonck" /></meta><meta name="dc.Creator" content="Inge  Duys" /></meta><meta name="dc.Creator" content="Philippe  Clément-Lacroix" /></meta><meta name="dc.Creator" content="Line  Oste" /></meta><meta name="dc.Creator" content="Monica  Borgonovi" /></meta><meta name="dc.Creator" content="Emanuelle  Wakselman" /></meta><meta name="dc.Creator" content="Thierry  Christophe" /></meta><meta name="dc.Creator" content="Nicolas  Houvenaghel" /></meta><meta name="dc.Creator" content="Mia  Jans" /></meta><meta name="dc.Creator" content="Bertrand  Heckmann" /></meta><meta name="dc.Creator" content="Laurent  Sanière" /></meta><meta name="dc.Creator" content="Reginald  Brys" /></meta><meta name="dc.Description" content="Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, only a few antagon..." /></meta><meta name="Description" content="Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, only a few antagon..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 3, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00138" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00138" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00138" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00138" /></link>
        
    
    

<title>Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00138" /></meta><meta property="og:title" content="Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0023.jpeg" /></meta><meta property="og:description" content="Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, only a few antagonists have been so far disclosed. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. A pyridazine series with improved lipophilic efficiency and with no CYP inhibition liability was identified by scaffold hopping. Further optimization led to the discovery of 40 (GLPG2938), a compound with exquisite potency on a phenotypic IL8 release assay, good pharmacokinetics, and good activity in a bleomycin-induced model of pulmonary fibrosis." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00138"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00138">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00138&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00138&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00138&amp;href=/doi/10.1021/acs.jmedchem.1c00138" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 6037-6058</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00120" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00152" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Oscar Mammoliti</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Oscar Mammoliti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#deb1adbdbfacf0b3bfb3b3b1b2b7aab79eb9b2aeb9f0bdb1b3"><span class="__cf_email__" data-cfemail="472834242635692a262a2a282b2e332e07202b37206924282a">[email protected]</span></a>. Phone: +32 15 34 29 00.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Oscar++Mammoliti">Oscar Mammoliti</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1521-9254" title="Orcid link">http://orcid.org/0000-0002-1521-9254</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adeline Palisse</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adeline Palisse</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#a4c5c0c1c8cdcac18ad4c5c8cdd7d7c1e4c3c8d4c38ac7cbc9"><span class="__cf_email__" data-cfemail="abcacfcec7c2c5ce85dbcac7c2d8d8ceebccc7dbcc85c8c4c6">[email protected]</span></a>. Phone: +32 15 34 29 00.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adeline++Palisse">Adeline Palisse</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Caroline Joannesse</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Caroline Joannesse</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Caroline++Joannesse">Caroline Joannesse</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sandy El Bkassiny</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sandy El Bkassiny</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sandy++El+Bkassiny">Sandy El Bkassiny</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brigitte Allart</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brigitte Allart</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brigitte++Allart">Brigitte Allart</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alex Jaunet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alex Jaunet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alex++Jaunet">Alex Jaunet</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christel Menet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christel Menet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christel++Menet">Christel Menet</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Beatrice Coornaert</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Beatrice Coornaert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Beatrice++Coornaert">Beatrice Coornaert</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kathleen Sonck</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kathleen Sonck</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen++Sonck">Kathleen Sonck</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Inge Duys</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Inge Duys</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Inge++Duys">Inge Duys</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philippe Clément-Lacroix</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philippe Clément-Lacroix</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philippe++Cl%C3%A9ment-Lacroix">Philippe Clément-Lacroix</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Line Oste</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Line Oste</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Line++Oste">Line Oste</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Monica Borgonovi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Monica Borgonovi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Monica++Borgonovi">Monica Borgonovi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emanuelle Wakselman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emanuelle Wakselman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emanuelle++Wakselman">Emanuelle Wakselman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thierry Christophe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thierry Christophe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thierry++Christophe">Thierry Christophe</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicolas Houvenaghel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicolas Houvenaghel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicolas++Houvenaghel">Nicolas Houvenaghel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mia Jans</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mia Jans</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mia++Jans">Mia Jans</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bertrand Heckmann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bertrand Heckmann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bertrand++Heckmann">Bertrand Heckmann</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Laurent Sanière</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laurent Sanière</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laurent++Sani%C3%A8re">Laurent Sanière</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Reginald Brys</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Reginald Brys</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Reginald++Brys">Reginald Brys</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00138&amp;href=/doi/10.1021%2Facs.jmedchem.1c00138" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 6037–6058</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 3, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 January 2021</li><li><span class="item_label"><b>Published</b> online</span>3 May 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00138" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00138</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6037%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DOscar%2BMammoliti%252C%2BAdeline%2BPalisse%252C%2BCaroline%2BJoannesse%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D9%26contentID%3Dacs.jmedchem.1c00138%26title%3DDiscovery%2Bof%2Bthe%2BS1P2%2BAntagonist%2BGLPG2938%2B%25281-%255B2-Ethoxy-6-%2528trifluoromethyl%2529-4-pyridyl%255D-3-%255B%255B5-methyl-6-%255B1-methyl-3-%2528trifluoromethyl%2529pyrazol-4-yl%255Dpyridazin-3-yl%255Dmethyl%255Durea%2529%252C%2Ba%2BPreclinical%2BCandidate%2Bfor%2Bthe%2BTreatment%2Bof%2BIdiopathic%2BPulmonary%2BFibrosis%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6058%26publicationDate%3DMay%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00138"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1212</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00138" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Oscar&quot;,&quot;last_name&quot;:&quot;Mammoliti&quot;},{&quot;first_name&quot;:&quot;Adeline&quot;,&quot;last_name&quot;:&quot;Palisse&quot;},{&quot;first_name&quot;:&quot;Caroline&quot;,&quot;last_name&quot;:&quot;Joannesse&quot;},{&quot;first_name&quot;:&quot;Sandy&quot;,&quot;last_name&quot;:&quot;El Bkassiny&quot;},{&quot;first_name&quot;:&quot;Brigitte&quot;,&quot;last_name&quot;:&quot;Allart&quot;},{&quot;first_name&quot;:&quot;Alex&quot;,&quot;last_name&quot;:&quot;Jaunet&quot;},{&quot;first_name&quot;:&quot;Christel&quot;,&quot;last_name&quot;:&quot;Menet&quot;},{&quot;first_name&quot;:&quot;Beatrice&quot;,&quot;last_name&quot;:&quot;Coornaert&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;Sonck&quot;},{&quot;first_name&quot;:&quot;Inge&quot;,&quot;last_name&quot;:&quot;Duys&quot;},{&quot;first_name&quot;:&quot;Philippe&quot;,&quot;last_name&quot;:&quot;Clément-Lacroix&quot;},{&quot;first_name&quot;:&quot;Line&quot;,&quot;last_name&quot;:&quot;Oste&quot;},{&quot;first_name&quot;:&quot;Monica&quot;,&quot;last_name&quot;:&quot;Borgonovi&quot;},{&quot;first_name&quot;:&quot;Emanuelle&quot;,&quot;last_name&quot;:&quot;Wakselman&quot;},{&quot;first_name&quot;:&quot;Thierry&quot;,&quot;last_name&quot;:&quot;Christophe&quot;},{&quot;first_name&quot;:&quot;Nicolas&quot;,&quot;last_name&quot;:&quot;Houvenaghel&quot;},{&quot;first_name&quot;:&quot;Mia&quot;,&quot;last_name&quot;:&quot;Jans&quot;},{&quot;first_name&quot;:&quot;Bertrand&quot;,&quot;last_name&quot;:&quot;Heckmann&quot;},{&quot;first_name&quot;:&quot;Laurent&quot;,&quot;last_name&quot;:&quot;Sanière&quot;},{&quot;first_name&quot;:&quot;Reginald&quot;,&quot;last_name&quot;:&quot;Brys&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;6037-6058&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00138&quot;},&quot;abstract&quot;:&quot;Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, only a few antagonists have been so far disclosed. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. A pyridazine series with improved lipophilic efficiency and with no CYP inhibition liability was identified by scaffold hopping. Further optimization led to the discovery of 40 (GLPG2938), a compound with exquisite potency on a phenotypic IL8 release assay, good pharmacokinetics, and good activity in a bleomycin-induced model of pulmonary fibrosis.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00138&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00138" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00138&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00138" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00138&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00138" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00138&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00138&amp;href=/doi/10.1021/acs.jmedchem.1c00138" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00138" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00138" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00138%26sid%3Dliteratum%253Aachs%26pmid%3D33939425%26genre%3Darticle%26aulast%3DMammoliti%26date%3D2021%26atitle%3DDiscovery%2Bof%2Bthe%2BS1P2%2BAntagonist%2BGLPG2938%2B%25281-%255B2-Ethoxy-6-%2528trifluoromethyl%2529-4-pyridyl%255D-3-%255B%255B5-methyl-6-%255B1-methyl-3-%2528trifluoromethyl%2529pyrazol-4-yl%255Dpyridazin-3-yl%255Dmethyl%255Durea%2529%252C%2Ba%2BPreclinical%2BCandidate%2Bfor%2Bthe%2BTreatment%2Bof%2BIdiopathic%2BPulmonary%2BFibrosis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D9%26spage%3D6037%26epage%3D6058%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=290703" title="Pyridines">Pyridines</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/jmcmar.2021.64.issue-9/20210513/jmcmar.2021.64.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, only a few antagonists have been so far disclosed. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. A pyridazine series with improved lipophilic efficiency and with no CYP inhibition liability was identified by scaffold hopping. Further optimization led to the discovery of <b>40</b> (GLPG2938), a compound with exquisite potency on a phenotypic IL8 release assay, good pharmacokinetics, and good activity in a bleomycin-induced model of pulmonary fibrosis.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56673" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56673" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Sphingolipids are a class of membrane lipids. Apart from their structural role in membrane biology, they can also act as signaling messengers. Among them, lysophospholipid sphingosine-1-phosphate (S1P, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) plays a role in regulating a wide range of biological processes, including cell growth, cell survival, angiogenesis, and lymphocyte trafficking.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> S1P is generated from sphingosine by phosphorylation of the C1 hydroxyl group. This process is mediated by sphingosine kinases (SPHK1 and SPHK2). The intracellular level of S1P is negatively regulated by S1P phosphatases (SGPP1 and SGPP2) and by sphingosine-1-phosphate lyase (SPL), which catalyzes the irreversible degradation of S1P to ethanolamine phosphate and 2-<i>trans</i> hexadecenal.<a onclick="showRef(event, 'cit1b'); return false;" href="javascript:void(0);" class="ref cit1b">(1b)</a> The intracellular S1P is exported outside the cell by specific transporters, including SPNS2 (Sphingolipid Transporter 2). Extracellular S1P then signals through five G coupled protein receptors (GPCRs), S1P1, S1P2, S1P3, S1P4, and S1P5. S1P1, S1P2, and S1P3 are widely expressed, while the expression of S1P4 and S1P5 is restricted to particular organs (lymphoid, hematopoietic, and pulmonary tissue for S1P4 and brain and spleen for S1P5).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of sphingosine-1-phosphate (S1P, <b>1</b>), FTY720 (<b>2</b>), and its active form, FTY720-P (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">S1P1 activation promotes the lymphocytes egress from lymph nodes to sites of inflammation. In fact, modulation of the S1P1 receptor has demonstrated to be effective in multiple models of auto-immune diseases by depleting the circulating lymphocytes.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Moreover, Fingolimod (FTY720/Gilenya, compound <b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), a functional antagonist of S1P1, has been approved for relapsing multiple sclerosis.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> FTY720 is a prodrug, which is activated <i>in vivo</i> by phosphorylation. The active form (FTY720-P, <b>3</b>) negatively modulates S1P1 by acting as an internalizing agonist.</div><div class="NLM_p">On the other hand, FTY720 has also been associated to pro-fibrotic events in preclinical toxicological studies,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> in animal models,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and in various <i>in vitro</i> settings.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In particular, Sobel <i>et al.</i> showed that FTY720-P caused a robust stimulation of extracellular matrix (ECM) deposition and induced fibrotic gene expression in normal human lung fibroblasts (NHLF).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> These effects were attributed to S1P2 and S1P3 activation. This was in contrast with a previous report that showed that FTY720-P was not able to displace S1<sup>33</sup>P from membranes derived from S1P2 overexpressing CHO cells.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Sobel and colleagues, however, were able to show FTY720-P-mediated S1P2 receptor activation with impedance assays in different cell types. FTY720-P also induced an increased ECM synthesis in myofibroblasts; this effect was ascribed only to S1P2 modulation as expression levels of S1P3 were considerably low in those cells. Sobel <i>et al.</i> also showed that FTY720-P induced myofibroblast contraction, a phenomenon associated with fibrosis, in a S1P2-dependent manner.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">These reports came to join many other lines of evidence linking S1P2 activation to fibrotic diseases.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Among those, it has been reported that S1P2-deficient mice showed increased liver regeneration capacity and ameliorated fibrosis in liver injury models.<a onclick="showRef(event, 'cit11g'); return false;" href="javascript:void(0);" class="ref cit11g">(11g)</a> S1P is increased in the bronchoalveolar lavage (BAL) fluid and in plasma of idiopathic pulmonary fibrosis (IPF) patients;<a onclick="showRef(event, 'cit11h'); return false;" href="javascript:void(0);" class="ref cit11h">(11h)</a> it was also shown that S1P promotes endothelial to mesenchymal transition (EMT), a hallmark of fibrosis, in TGFβ-stimulated A549 cells by activation of S1P2 and S1P3.<a onclick="showRef(event, 'cit11h'); return false;" href="javascript:void(0);" class="ref cit11h">(11h)</a> Very recently, it has been shown that S1P2-deficient mice have reduced inflammation and fibrosis markers in the bleomycin (BLM)-induced pulmonary fibrosis model.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Another account reported that genetic deletion of S1P2 resulted in attenuated lung fibrosis in the BLM mouse model. These effects were recapitulated by prophylactic administration of an undisclosed S1P2 antagonist.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> All this evidence suggests that blocking S1P-mediated S1P2 signaling may be effective against fibrotic diseases.</div><div class="NLM_p">It has been shown that in approximately half of the cases S1P2<sup>−/−</sup> mice develop cell lymphomas after 1.5–2 years of age.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> This effect has been linked to the increase in germinal center (GC) B cells. Successive research, however, showed that, in humans, also another Gα13 coupled receptor, P2RY8, for which no orthologues have been identified in mice, promotes growth regulation and local confinement of GC B cells, suggesting a possible redundant role for S1P2.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">Despite the attractiveness of S1P2 as a target, only few documents describe the optimization of S1P2 antagonists<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and there are no reports of clinical studies. This is in stark contrast with the number of S1P1 modulators that have entered clinical development.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Some representative S1P2 antagonists are highlighted in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. Notably, the first report of synthetic S1P2 antagonists<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> exemplifies the S1P2 antagonist JTE-013 (compound <b>4</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), a compound that has been widely reported in the literature. Other noteworthy reports are from Novartis,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> from Ono Pharmaceutical,<a onclick="showRef(event, 'ref16 ref20'); return false;" href="javascript:void(0);" class="ref ref16 ref20">(16,20)</a> and, more recently, from Timothy Hla,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> who describes S1P2 antagonists (e.g., compound <b>8</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) whose structures are reminiscent of an allosteric agonist, CYM-5520 (compound <b>9</b>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of published S1P2 antagonists (<b>4</b>–<b>8</b>) and allosteric antagonist CYM-5520 (<b>9</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Some of the antagonists so far described may have potential shortcomings. Novartis reported biological activity data only for a limited set of compounds, including compounds <b>5</b> and <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Compound <b>5</b> has a high TPSA (125.5) and a low clogD at pH 7.4 (−0.63, SimPlus)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> combined with the presence of a carboxylic acid and three other carbonyls. The combination of these attributes could very well result in low permeability and, therefore, low oral absorption. On the other hand, compound <b>6</b> features highly lipophilic and flexible groups, which are potentially prone to oxidative metabolism. Ono Pharmaceutical has also been active in the field. Compound <b>7</b> constitutes an improvement from molecules previously reported, which were suffering from low bioavailability. However, despite good bioavailability in mice and dogs, bioavailability in monkeys was low (12%).<a onclick="showRef(event, 'cit16c'); return false;" href="javascript:void(0);" class="ref cit16c">(16c)</a> Moreover, compound <b>7</b> possesses three benzene rings and the number of carboaromatic rings has been shown to correlate negatively with drug developability.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> JTE-013 (compound <b>4</b>) features a hydrazine moiety, a functional group that has been associated with hepatotoxicity and drug-induced systemic lupus erythematosus.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> JTE-013 has been extensively used as chemical probe in cellular assays. However, even though it has been proved to be a bona fide S1P2 antagonist, some reports call into question its selectivity and specificity.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p last">The biological evidence so far accumulated on the role of S1P2 in fibrosis prompted us to initiate a drug discovery campaign aiming at identifying S1P2 antagonists to validate this therapeutic hypothesis. Moreover, the limitations of existing S1P2 antagonists served also as a stimulus to provide improved chemical matter.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31700" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31700" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To find new starting points, two consecutive HTS campaigns were conducted; however, they failed to identify progressable hits. We therefore decided to focus on a pyridine core to generate new chemical matter (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Some S1P2 antagonists are based on fused bicyclic scaffolds, which are reminiscent of the 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine scaffold of the JTE-013 (e.g., compounds <b>10</b> and <b>11</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In some cases, the 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine was redeployed, with different substituents.<a onclick="showRef(event, 'cit27b ref28'); return false;" href="javascript:void(0);" class="ref cit27b ref28">(27b,28)</a> Synthesis and decoration of fused bicyclic scaffolds may entail long and laborious syntheses and also reduce the breadth of the explorable chemical space. For this reason, we opted for designs based on chemical enablement, which is “the efficient bond disconnection that facilitates the synthesis of libraries that probe multiple hypotheses”.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> To this end, the focus was placed on a new pyridine scaffold, which would allow to introduce a broad diversity of groups. For ease of synthesis, a methyl group was introduced instead of the recurring bulkier isopropyl group at the C4 position (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). This was also aiming at having a smaller pharmacophore. The newly introduced substituents may cause the scaffold to tilt in the binding pocket. In that case, the smaller methyl group could be a better fit for avoiding potential clashes with the protein.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical enablement to obtain S1P2 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Two vectors were chosen for exploration, from the C5 and C6 position of the pyridine core, respectively. A structurally diverse set of groups was initially employed, with more than 40 compounds synthesized (a selection is presented in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). To ensure the most effective receptor blockade, antagonists able to shut down S1P2 signaling across multiple pathways were sought.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> To this end, potential antagonists were tested in a calcium flux assay (Gq involved) in CHO cells overexpressing the human S1P2 receptor, as well as in a GTPγS assay (mainly G<sub>i</sub> involved), also based on the human S1P2 receptor. Small substituents, such as dimethylamino or CN, showed modest potency in both assays (compounds <b>12</b>–<b>15</b>). Aromatic groups, on the other hand, showed an improvement, with compound <b>19</b> displaying the best combination of potencies in the GTPγS and calcium flux assays, when tested in antagonist mode. None of the compounds showed any activity when tested in agonist mode (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>; this was also the case for all compounds reported in this manuscript; for this reason, it will not be mentioned further). Six-membered aromatic rings (such as <b>21</b>) were also active. However, the pyrazole motif was considered more attractive, in virtue of the reduced lipophilicity and size. The ethyl ester <b>16</b> showed submicromolar potency in the calcium flux assay. Ester groups, however, are potentially hydrolyzed very quickly by esterases, making them, most of the times, unsuitable for progression. For this reason, a few amide replacements were explored (compounds <b>22</b>–<b>24</b>). These derivatives, however, showed a marked drop in potency. Compounds <b>16</b>, <b>17</b>, and <b>19</b> were able to compete with radiolabeled S1P in membranes derived from stable cell lines overexpressing the human S1P2 receptor. This indicated that these compounds were most probably orthosteric antagonists. Again, compound <b>19</b> was the most potent and, in virtue of this, it was selected for further optimization.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial Exploration of the Pyridine Core: LHS Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0015.gif" alt="" id="gr14" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0016.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Assay run in antagonist mode.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Assay run in agonist mode.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Experiments aiming at determining the IC<sub>50</sub> values were performed at least twice, unless otherwise stated. When multiple experiments were performed, the geometrical mean is provided.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">IC<sub>50</sub> for each run (<i>n</i> = 5) in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Table S10</a>. NT = not tested.</p></div></div><div></div></div><div class="NLM_p">Finding a replacement for the hydrazine urea was the next focus of the optimization. Some examples from the literature showed that it was possible to replace the hydrazine linker on fused bicyclic scaffolds.<a onclick="showRef(event, 'cit27a'); return false;" href="javascript:void(0);" class="ref cit27a">(27a)</a> It could not be anticipated, however, if those replacements would have been compatible with the pyridine scaffold. Designs were guided by the idea of keeping a hydrogen bond donor and a hydrogen bond acceptor at the same distance from the core as in the hydrazine-based molecules showed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The hydrogen bond donor was connected to the core by a benzylic CH<sub>2</sub> instead of an NH spacer (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compounds were also profiled for liver microsomal stability. Scaled clearance values, corrected for microsomal binding (fu, mic), were used (Clint, u, see <a class="ref internalNav" href="#eq3" aria-label="eqs 3">eqs 3</a>–<a class="ref internalNav" href="#eq5" aria-label="5">5</a>, <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). The benzimidazole-based compounds <b>25</b> and <b>26</b> showed good potency, but they also showed high <i>in vitro</i> clearance in mouse liver microsomes (MLMs). Indoles <b>27</b> and <b>28</b> possessed good potency, but, also in this case, the <i>in vitro</i> clearance was too high (Clint, u > 34 L/h/kg). Amides <b>29</b> and <b>30</b> resulted in total loss of activity. Urea <b>31</b>, on the other hand, displayed submicromolar potency in both GTPγS and calcium flux assays. A quick exploration of the aromatic right-hand side led to urea <b>32</b>, which had improved potency in comparison with <b>31</b>. Compound <b>32</b> showed also a marked improved LipE<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> (obtained from the calcium flux assay and clogD). The right-hand side pyridine conferred to <b>31</b> a much greater microsomal stability comparing with the phenyl ring of matched pair <b>33</b> (>10x), highlighting the importance of this group for metabolic stability. The compounds were also profiled in a phenotypic assay based on S1P-stimulated IL8 production in human lung fibroblasts (HFL1). Elevated levels of IL8, a neutrophilic chemoattractant, have been linked to IPF<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and S1P has been shown to stimulate IL8 secretion by signaling through S1P2.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The majority of the compounds in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> presented IC<sub>50</sub> values in the IL8 assay in line with the GTPγS assay. Compounds <b>32</b> and <b>33</b> showed the highest shift (5x).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Linker Optimization in the Pyridine Scaffold</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0017.gif" alt="" id="gr16" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0018.gif" alt="" id="gr17" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Antagonist mode.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Experiments aiming at determining the IC<sub>50</sub> values were performed at least twice, unless otherwise stated. When multiple experiments were performed, the geometrical mean is provided.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Fraction unbound in microsomes (fu, mic) experimentally determined, unless otherwise stated.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Fu, mic calculated.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last">Precipitation at high dose. NT = not tested.</p></div></div><div></div></div><div class="NLM_p">To ameliorate clearance and further improve potency, a broader exploration of the C5 position of the pyridine was undertaken (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). To this end, a chemical enablement strategy based on a urea protecting group was implemented (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). The protecting group allowed us to perform certain reactions, such as Buchwald and Ullmann couplings, in a convergent fashion. The 2-ethoxy-6-(trifluoromethyl)pyridin-4-amine group was selected for the right-hand side. This group conferred a level of potency similar to the 2-chloro-6-ethoxypyridin-4-amine group (cfr <b>34</b> and <b>98</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a>), but it had also the advantage to be unreactive in cross-coupling conditions, while the 2-chloro-6-ethoxypyridin-4-amine could potentially react on the C2 position. Following this and other less convergent approaches, some of them described above, more than 60 analogs were prepared to broadly investigate the C5 position (the full SAR is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Table S4</a>, Supporting Information). Essentially three chemotypes were explored: CC-linked (hetero)aryl groups, (hetero)alkyl/(hetero)aryl secondary amines, and (hetero)alkyl tertiary amines (green, orange, and blue, respectively, in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The CC-linked (hetero)aryls and the secondary amines showed high potency in both calcium flux and GTPγS assays, while the tertiary amines were in general less potent, especially in the GTPγS assay. Some of the compounds were profiled in the IL8 phenotypic assay and in the microsomal stability assay. Only few compounds showed a good balance between potency and clearance. The best compound in this aspect for each chemotype is shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Broad exploration of pyridine’s C5 position by a chemical enablement strategy. (a) Representation of chemotypes. (b) Potency in calcium flux assay vs potency in GTPγS assay. (c) Clearance unbound in mouse liver microsomes vs potency in IL8 assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Broad Investigation of Pyridine’s C5 Position: Best Compounds per Chemotype</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0019.gif" alt="" id="gr18" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="/" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cpd</th><th class="colsep0 rowsep0" align="center" char=".">clogD</th><th class="colsep0 rowsep0" align="center">S1P2 calcium flux<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a> (<b>LipE</b>)</th><th class="colsep0 rowsep0" align="center" char=".">S1P2 GTPγS IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">IL8 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="/">Clint, u<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a> mouse/human (L/h/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="left">11 (<b>4.4</b>)</td><td class="colsep0 rowsep0" align="char" char=".">22<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char="/">27/9.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="left">12<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a> (<b>4.8</b>)</td><td class="colsep0 rowsep0" align="char" char=".">55</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="char" char="/">52/16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="left">16 (<b>4.2</b>)</td><td class="colsep0 rowsep0" align="char" char=".">105</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char="/">30/7.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Antagonist mode.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Experiments aiming at determining the IC<sub>50</sub> values were performed at least twice, unless otherwise stated. When multiple experiments were performed, the geometrical mean is provided.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Fraction unbound in microsomes (fu, mic) experimentally determined, unless otherwise stated. NT = not tested.</p></div></div></div><div class="NLM_p">The CF<sub>3</sub> group in <b>34</b> was an improvement in comparison with the methyl group of matched pair <b>32</b>, especially in the IL8 phenotypic assay (7x improvement, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). To measure the phenotypic activity in a more physiological setting, compounds <b>32</b> and <b>34</b> were tested in the presence of 2% human serum albumin (HSA, equivalent to approximately 40% serum). Serum could not be used as it contains S1P. The presence of HSA could also offset potential binding to plastics and medium for more lipophilic compounds, leading to a better estimate of the relevant free IC<sub>50</sub>. The free IC<sub>50</sub> values were obtained estimating the fraction unbound in the medium (fu, medium) from the human plasma protein binding (hPPB) according to <a class="ref internalNav" href="#eq1" aria-label="eqs 1">eqs 1</a> and <a class="ref internalNav" href="#eq2" aria-label="2">2</a> in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> For a set of compounds, the binding to the assay medium containing HSA was directly measured and it was in agreement with the binding calculated from PPB values. For <b>32</b> and <b>34</b>, the absolute IC<sub>50</sub> values in the presence of HSA were 3039 and 572 nM, while the free IC<sub>50</sub> values were 28 and 1.4 nM, respectively. The improvement for <b>34</b> was thus greater than the 1 log unit increase in lipophilicity.</div><div class="NLM_p">Also, compounds <b>35</b> and <b>36</b> showed good potency (with <b>36</b> being somewhat weaker in the GTPγS assay) and improved clearance. However, none of them was superior to <b>34</b>. The secondary amines, like <b>35</b>, showed a similar profile to CC-linked derivatives, with no apparent advantage to compensate for the extra H bond donor. Therefore, they were not investigated further. For the tertiary amines, like <b>36</b>, the data indicated that it could be more challenging to obtain a good balance between potency and clearance (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). For this reason, their progression was also put on hold.</div><div class="NLM_p">The new lead <b>34</b> displayed strong CYP inhibition (recombinant 2C19, 2C9, and 3A4, 100%, 83%, and 83% inhibition at 10 μM, respectively, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Table S5</a>, Supporting Information). CYP inhibition was a general feature of the pyridine series. To remove this liability, and to improve clearance, a scaffold hopping strategy privileging more polar cores was envisaged. A pyridazine-based scaffold was selected and synthesized. The benefits of the CH to N switch have already been reviewed elsewhere.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Compound <b>37</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) retained good potency with lower lipophilicity, thus resulting in an improved LipE (4.4 vs 5.0). CYP inhibition was mitigated (recombinant 2C19, 2C9, and 3A4, 61%, 58%, and 23% inhibition at 10 μM, respectively, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Table S5</a>, Supporting Information). Clearance was improved, especially in human liver microsomes. A broader analysis of matched pairs between the pyridine and the pyridazine scaffolds clearly showed the latter to be an improvement as all matched pairs had better LipE (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Lipophilicity vs pIC<sub>50</sub> (calcium flux) for matched pairs between pyridine and pyridazine series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR of Right-Hand Side Groups in the Pyridazine-Based Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0020.gif" alt="" id="gr19" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0022.gif" alt="" id="gr20" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Antagonist mode.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Experiments aiming at determining the IC<sub>50</sub> values were performed at least twice, unless otherwise stated. When multiple experiments were performed, the geometrical mean is provided.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Fraction unbound in microsomes (fu, mic) experimentally determined, unless otherwise stated. NT = not tested.</p></div></div><div></div></div><div class="NLM_p">The exploration of the right-hand side was the next focus of the optimization. At first, pyridine-4-amines with two substituents (C2 and C6 positions) were evaluated (<b>37</b>–<b>45</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In the presence of the ethoxy group, electron-withdrawing substituents showed good potencies (Cl, CN, and CF<sub>3</sub> in <b>37</b>, <b>39</b>, and <b>40</b>, respectively). <b>40</b> was exquisitely potent in the IL8 assay (free IC<sub>50</sub>: 0.60 nM). Replacement of the electron-withdrawing groups by a methyl group in <b>41</b> resulted in a considerable loss of potency (5–10x) across all assays. The compounds from this set showed in general good microsomal stability, especially in humans. Replacement of the ethyl group in <b>37</b> by a CH<sub>2</sub>CHF<sub>2</sub> group was tolerated (<b>38</b>). On the other hand, more polar groups were poorly tolerated (<b>42</b> and <b>45</b>) or lost all activity (<b>43</b> and <b>44</b>).</div><div class="NLM_p">In a second set of compounds (<b>46</b>–<b>51</b>), the C3 position of the right-hand side pyridine-4-amine was investigated. This position was selected in reason of the ortho directing properties of the alkoxy groups, which allowed for a regioselective bromination at the C3 position for further derivatization (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Scheme S4</a>, Supporting Information). Methyl substitution in compounds <b>46</b> and <b>47</b> resulted in similar potency in the calcium flux and GTPγS assays comparing with matched pairs <b>37</b> and <b>39</b>. This change resulted, however, in a marked increase in potency in the IL8 phenotypic assay (about 10x for both compounds). When this change was applied to <b>41</b>, an increase in potency of about 10x in all assays was obtained (compound <b>48</b>). This “magic methyl” effect<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> was also accompanied by retention of good metabolic stability (human) and improved LipE. A chlorine atom had a very similar effect for compound <b>50</b>. Replacement with CN resulted in total loss of activity (compound <b>51</b>). Other groups were investigated, but, in general, they resulted to be worse than the methyl group and chlorine atom.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p">The exploration of the right-hand side resulted in molecules with very good potency and microsomal stability. Compounds <b>37</b>, <b>40</b>, and <b>48</b> were therefore selected for pharmacokinetic studies in preclinical species. The potent compound <b>47</b> was excluded because it showed tolerability issues after single dose administration (both iv and po) in mice. Compound <b>37</b> showed low to moderate half-life across species and low bioavailability in general (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Therefore, it was not progressed further, also considering its low solubility. Compound <b>40</b>, on the other hand, showed good pharmacokinetics, with long half-life, low clearance, and good bioavailability in all species, especially in dogs. Plasma protein binding was quite high; from the PK data, however, a free concentration covering the IL8 IC<sub>50</sub> was attainable. Although solubility was low both in FaSSGF and FaSSIF media, this did not forbid to obtain good bioavailability with simple formulations, at least at low doses in mice and dogs. Compound <b>48</b>, on the other hand, showed shorter half-life and higher clearance in all species comparing with <b>40</b>, while having a markedly increased solubility in the FaSSGF medium (>200x). This improvement resulted most probably from the basicity of the pyridine group (measured pKa: 4.32), which allowed the compound to have high solubility in the FaSSGF medium (pH = 1.6). The pKa of <b>40</b> could not be measured, indicating lack of protonation even at low pH values. Solubility, even when limited to low pH values, was deemed important in order to achieve dose-proportional exposure in toxicology studies, when usually high doses are administered.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetics in Preclinical Species and Selected <i>In Vitro</i> Data for <b>37</b>, <b>40</b>, and <b>48</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">iv PK preclinical species (dose: 1 mg/kg)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="2" align="center">thermodynamic solubility</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd</th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">Cl (L/h/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Vss (L/kg)</th><th class="colsep0 rowsep0" align="center">F (po dose)</th><th class="colsep0 rowsep0" align="center" char=".">PPB (% bound)<a class="ref internalNav" href="#t5fn7" aria-label="g">g</a></th><th class="colsep0 rowsep0" align="center">FaSSGF (μg/mL)</th><th class="colsep0 rowsep0" align="center">FaSSIF (μg/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">0.55</td><td class="colsep0 rowsep0" align="char" char=".">0.62</td><td class="colsep0 rowsep0" align="char" char=".">0.49</td><td class="colsep0 rowsep0" align="left">20% (5 mg/kg)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">99.8</td><td class="colsep0 rowsep0" rowspan="3" align="left">5</td><td class="colsep0 rowsep0" rowspan="3" align="left">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">0.38</td><td class="colsep0 rowsep0" align="left">10% (5 mg/kg)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">99.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">0.47</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="left">30% (5 mg/kg)<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char=".">98.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">0.24</td><td class="colsep0 rowsep0" align="char" char=".">0.81</td><td class="colsep0 rowsep0" align="left">64% (5 mg/kg)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">99.9</td><td class="colsep0 rowsep0" rowspan="3" align="left">2.7</td><td class="colsep0 rowsep0" rowspan="3" align="left">23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">0.091</td><td class="colsep0 rowsep0" align="char" char=".">0.35</td><td class="colsep0 rowsep0" align="left">29% (5 mg/kg)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">>99.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">7.6</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="left">100% (5 mg/kg)<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char=".">99.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">0.45</td><td class="colsep0 rowsep0" align="char" char=".">0.73</td><td class="colsep0 rowsep0" align="char" char=".">0.47</td><td class="colsep0 rowsep0" align="left">29% (5 mg/kg)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">98.6</td><td class="colsep0 rowsep0" rowspan="3" align="left">505</td><td class="colsep0 rowsep0" rowspan="3" align="left">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">0.37</td><td class="colsep0 rowsep0" align="char" char=".">0.54</td><td class="colsep0 rowsep0" align="left">84% (10 mg/kg)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">99.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">0.66</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="left">39% (1 mg/kg)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">97.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Male CD1 mice (<i>n</i> = 6), male Sprague Dawley rats (<i>n</i> = 3, unless otherwise stated), and male Beagle dogs (<i>n</i> = 3) were used in these studies. Numbers of animals are referring to each study. All values were obtained from plasma.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Vehicle was PEG200/water (60/40; v/v).</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Vehicle was Tween 80/MC 0.5%.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Vehicle was PEG400/MC 0.5%.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Vehicle was MC 0.5%.</p></div><div class="footnote" id="t5fn6"><sup><sup>f</sup></sup><p class="last"><i>n</i> = 2 for the iv route.</p></div><div class="footnote" id="t5fn7"><sup><sup>g</sup></sup><p class="last">4 h incubation at a 5 μM compound concentration in plasma.</p></div></div></div><div class="NLM_p">Other compounds were designed and synthesized to improve solubility, specifically by replacing the methyl group at the N1 position of the pyrazole or the methyl at the C5 position of the pyridazine core with more polar groups.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> None of these compounds, however, possessed a balanced profile in terms of potency, metabolic stability, and solubility in order to be progressed further.</div><div class="NLM_p">Compound <b>40</b> confirmed to be active against S1P2 in the radioligand-based binding assay as well as in an arrestin-based assay. It was also potent against the murine S1P2 receptor (mS1P2, arrestin assay, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Table S1</a>, Supporting Information). In terms of selectivity, <b>40</b> did not have any meaningful activity against any of the other S1P receptors (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Table S1</a>, Supporting Information). When profiled against a broad panel of receptors, transporters, and enzymes (Cerep Diversity Panel, compound tested at 10 μM), only a few targets were picked up with inhibition, binding, or activation >50%. Follow up dose responses on eight targets showed IC<sub>50</sub> values to be only in the micromolar range for all these targets (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Table S3</a>, Supporting Information). Compound <b>48</b> was also active against mS1P2 and showed complete selectivity against the other S1P receptors (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Table S2</a>, Supporting Information). No meaningful inhibition, binding, or activation was picked up in the Cerep Diversity Panel. Both <b>40</b> and <b>48</b> showed no meaningful inhibition against a panel of 154 kinases when tested in a single dose at 1 μM.</div><div class="NLM_p">Compound <b>40</b> was tested in a cell contraction assay with human pulmonary fibroblasts (HPFs). Fibroblast contraction is a phenomenon observed during wound healing as well as in many fibrotic disorders.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In the cell contraction assay, myofibroblasts that have been pre-treated with TGF-β for 4 days are suspended in a collagen gel lattice mixture. Stress build-up continues for another 3 days. Upon release of the gels from the well, the gel lattice will start to shrink due to the myofibroblast contraction, which can be further stimulated by S1P addition, resulting in a reduced surface area. As it could be seen in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, compound <b>40</b> significantly prevented the S1P-mediated contraction at all tested concentrations.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Activity of compound <b>40</b> in a cell contraction assay in HPF cells. S1P was used as trigger at 1 μM. Bar height: mean values. Error bars: 95% CI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From the data presented above, compounds <b>40</b> and <b>48</b> emerged as potent and selective S1P2 antagonists with good ADMET and PK. This and their confirmed potency against the murine S1P2 receptor made them suitable candidates for the bleomycin-induced pulmonary fibrosis <i>in vivo</i> model. The BLM-induced fibrosis is one of the most accepted models of IPF.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Compounds <b>40</b> (dosed at 1, 3, and 10 mg/kg BID) and <b>48</b> (3, 10, and 30 mg/kg BID) were therefore evaluated in a prophylactic setting, together with the reference compound pirfenidone (dosed at 50 mg/kg BID), an approved treatment for IPF.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In this model, BLM was dosed intranasally to mice. Pirfenidone or an S1P2 antagonist was administered twice a day orally for 14 days. The efficacy of the treatments was evaluated by assessing the histopathological changes in lung architecture. To this end, the modification of the Ashcroft score introduced by Matsuse was used.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> After 14 days, administration of BLM caused widespread epithelial damage, inflammation in the lungs, fibrosis, and lung structural distortion, as evidenced by the Ashcroft score in the vehicle groups (orange squares and dots, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Pirfenidone and compounds <b>40</b> and <b>48</b> displayed a marked protective effect at all dosed tested, resulting in statistically significant reduction of the Ashcroft score.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Ashcroft score at D14 following intranasal bleomycin challenge. Data are given as group median. *<i>p</i> < 0.05 vs BLM/vehicle control (Mann–Whitney test). #<i>p</i> < 0.05 vs BLM/Vehicle (Wilcoxon signed-rank test); cpd <b>40</b>: <i>n</i> = 15 per group; cpd <b>48</b>: <i>n</i> = 14 per group. Animals: male C57BL/6 mice (<b>40</b>: 8 weeks old on arrival; <b>48</b>: 7 weeks old on arrival. One week acclimation).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A steady-state PK study was performed on the doses of 3 and 10 mg/kg BID for compound <b>40</b>. The exposures appeared to be in both cases well above the IC<sub>50</sub> values obtained from the IL8 assay (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Figure S1</a>, Supporting Information).</div><div class="NLM_p">As both compounds showed very good activity in the BLM model, <b>40</b> and <b>48</b> were both engaged in rat toxicology studies. After analysis of the toxicological profiles and ensuing therapeutic windows, compound <b>40</b> was selected for further progression.</div><div class="NLM_p last">Compound <b>40</b> displayed no hERG inhibition and limited CYP inhibition and had no liabilities in terms of chemical or plasma stability (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Tables S5–S8</a>, Supporting Information). No genotoxicity was detected. <b>40</b> was therefore nominated as a preclinical candidate (GLPG2938) for treatment in IPF. Subsequent CMC work in preclinical development resulted in the production of amorphous batches, which resulted in improved solubility. This allowed the smooth running of dose-ranging studies in dogs and rats.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84381" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84381" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Final compounds <b>12</b>–<b>21</b> were synthesized according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. In summary, Buchwald–Hartwig conditions with <i>tert</i>-butyl hydrazinecarboxylate were used to obtain intermediates <b>6</b>–<b>10a</b>, <b>12a</b>, and <b>17a</b> from the respective aryl halides. Intermediates <b>12a</b> and <b>17a</b> were coupled with aromatic boronic acids/esters to obtain intermediates <b>13</b>–<b>15a</b> and <b>18</b>–<b>19a</b>. Finally, the hydrazine derivatives <b>6</b>–<b>10a</b>, <b>13</b>–<b>15a</b>, and <b>18</b>–<b>19a</b> underwent a two-step sequence featuring urea formation by reaction with 2,6-dichloro-4-isocyanatopyridine followed by Boc deprotection in acidic medium.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>12</b>–<b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl hydrazinecarboxylate, Cs<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, toluene, 100 °C; (b) 2,6-dichloro-4-isocyanatopyridine, THF, rt; (c) 4 M HCl in 1,4-dioxane, DCM, 40 °C; (d) Ar-B(OR)<sub>2</sub>, 2 M K<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane, 130 °C, μw; (e) Ar-B(OR)<sub>2</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane, 150 °C, μw.</p></p></figure><div class="NLM_p">Compounds <b>22</b>–<b>24</b> were synthesized according to <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Intermediate ester <b>10a</b> was hydrolyzed by LiOH to acid <b>1b</b>, which underwent urea formation. Final compounds were obtained after Boc deprotection and HATU-based amide coupling with the corresponding amines.</div><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>22</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>10a</b>, LiOH, H<sub>2</sub>O/THF; (b) 2,6-dichloro-4-isocyanatopyridine, THF, rt; (c) 4 M HCl in 1,4-dioxane, DCM, 40 °C; (d) R<sup>1</sup>R<sup>2</sup>NH, HATU, DIPEA, DMF, DCM, rt.</p></p></figure><div class="NLM_p">Compounds <b>25</b> and <b>27</b>–<b>34</b> were synthesized according to <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Intermediate <b>1c</b> was obtained from <b>11a</b> after a regioselective coupling under Negishi conditions. Intermediates <b>2</b>–<b>3c</b> were obtained after Suzuki coupling. Reduction of the nitrile group in the presence of BH<sub>3</sub>·SMe<sub>2</sub> yielded primary amine intermediates <b>4</b>–<b>5c</b>. S<sub>N</sub>Ar reaction with 2,5,6-trichloro-1<i>H</i>-benzo[<i>d</i>]imidazole yielded compound <b>25</b>. A series of HATU-mediated couplings between <b>4c</b> and the corresponding carboxylic acids delivered compounds <b>27</b>–<b>30</b>. Ureas <b>31</b> and <b>33</b> were obtained after coupling of <b>4c</b> with the corresponding isocyanates. Intermediates <b>4</b>–<b>5c</b> were coupled with 2-chloro-6-ethoxypyridin-4-amine using 1,1′-carbonyl-di-(1,2,4-triazole) (CDT) to obtain ureas <b>32</b> and <b>34</b>.</div><figure id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>25</b> and <b>27</b>–<b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 150 °C; (b) Ar-B(OR)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane, H<sub>2</sub>O, 100 °C; (c) BH<sub>3</sub>·SMe<sub>2</sub>, THF, 45 °C; (d) 2,5,6-trichloro-1<i>H</i>-benzo[<i>d</i>]imidazole, MeCN, 170 °C, μw; (e) RCOOH, HATU, DIPEA, DMF, DCM, rt or 45 °C; (f) RNCO, THF, rt; (g) 2-chloro-6-ethoxypyridin-4-amine, CDT, pyridine, DCM, rt.</p></p></figure><div class="NLM_p">The synthetic sequence described in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> led to compound <b>26</b>. The bromide <b>1d</b> underwent Suzuki coupling with 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole to afford intermediate <b>2d</b>. Reductive amination with the aminobenzimidazole <b>6d</b> gave the desired product <b>26</b>. During the optimization of the reductive amination step, it was observed that the reducing agent was not necessary for the reduction of the imine intermediate. It was concluded that the titanium tetraisopropoxide played the roles of both Lewis acid and reducing agent in a similar way as the aluminum triisopropoxide does in the Meerwein–Schmidt–Ponndorf–Verley reduction.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Compound <b>122</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Scheme S31</a>) was also obtained with this procedure. Moreover, a preliminary investigation showed that these conditions were working also on other substrates. Two examples are reported in the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a> (compounds <b>123</b> and <b>124</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Scheme S32</a>). <b>6d</b> was synthesized in three steps. The ethoxy group was installed by S<sub>N</sub>Ar on the bis-chloropyridine <b>3d</b> with ethanol. After reduction of the nitro group in <b>4d</b> with zinc, the bis-aminopyridine <b>5d</b> was cyclized using cyanogen bromide to obtain the 2-aminobenzimidazole <b>6d</b>.</div><figure id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Cs<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane, H<sub>2</sub>O, 100 °C; (b) EtOH, NaH, rt; (c) Zn, NH<sub>4</sub>Cl, MeOH, rt; (d) CNBr, EtOH, 45 °C; (e) Ti(O<i>i</i>Pr)<sub>4</sub>, EtOH, 60 °C.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> describes the synthesis of compound <b>35</b>. Nitrile derivative <b>1c</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) was reduced and Boc protected in a one-pot procedure to favor purification. Intermediate <b>2e</b>, obtained after Boc deprotection from <b>1e</b>, was coupled with ethoxy-6-(trifluoromethyl)pyridin-4-amine to form urea <b>3e</b>. At this stage, a protecting group based on a 1,3,5-triazinan-2-one was envisaged. The <i>tert</i>-butyl group helped for the isolation of the protected urea, ensuring a straightforward chromatographic separation. The strategy adopted here is not widely exploited as we could find only one account for such protecting group applied to a urea bearing an aryl motif.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The urea so protected underwent Buchwald–Hartwig coupling with 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine. The product was subsequently deprotected in strongly basic conditions to yield the final compound <b>35</b>.</div><figure id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH<sub>4</sub>, NiCl<sub>2</sub>·6H<sub>2</sub>O, Boc<sub>2</sub>O, MeOH, rt; (b) TFA, DCM, 45 °C; (c) 2-ethoxy-6-(trifluoromethyl)pyridin-4-amine, CDT, pyridine, DCM, 45 °C; then <b>2e</b>, DIPEA, THF, rt; (d) HCHO (37% H<sub>2</sub>O), 4-methylmorpholine, <i>t</i>BuNH<sub>2,</sub> EtOH/H<sub>2</sub>O, 100 °C; (e) 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine, Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, NaO<i>t</i>Bu, toluene, 70 °C; (f) 1,4-dioxane/6 M NaOH, 100 °C.</p></p></figure><div class="NLM_p">The synthesis of compounds <b>37</b>–<b>43</b>, <b>46</b>–<b>48</b>, <b>50</b>, and <b>51</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a><b>)</b> commenced with the hydrolysis of 3,6-dichloro-4-methylpyridazine followed by a Negishi coupling to obtain nitrile <b>3f</b>. Chlorination with POCl<sub>3</sub> provided <b>4f</b>, which was coupled with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)-1<i>H</i>-pyrazole under Suzuki conditions to yield intermediate <b>5f</b>. The nitrile group was then reduced using hydrogen gas and palladium on charcoal in the presence of HCl. The acidic environment was necessary to prevent intermolecular attack of the amino group on the partially reduced imine. Alternatively, <b>5f</b> could be reduced using a mixture of NaBH<sub>4</sub>, TFA, and NiCl<sub>2</sub>·6H<sub>2</sub>O. The resulting amines <b>6f</b> (HCl salt) and <b>7f</b> (free base) were coupled to the corresponding aminopyridine in the presence of 1,1′-carbonyl-di-(1,2,4-triazole) (CDT) and pyridine to afford the desired products <b>37</b>–<b>43</b>, <b>46</b>–<b>48</b>, <b>50</b>, and <b>51</b>. When the HCl salt <b>6f</b> was used, DIPEA as a base on top of pyridine and THF as a co-solvent were necessary to obtain good conversions.</div><figure id="sch6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>37</b>–<b>43</b>, <b>46</b>–<b>48</b>, <b>50</b>, and <b>51</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions (a) 3.3 M NaOH, reflux; (b) Zn(CN)<sub>2</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, DMF, 120 °C; (c) POCl<sub>3</sub>, MeCN, reflux; (d) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, rt; then 2.5 M Na<sub>2</sub>CO<sub>3</sub>, 85 °C; (e) Pd/C, H<sub>2</sub> gas (1 atm), 6 M HCl, MeOH, rt; (f) NaBH<sub>4</sub>, TFA, NiCl<sub>2</sub>.6H<sub>2</sub>O, MeOH, rt; (g) RNH<sub>2</sub>, CDT, pyridine, DCM, 45 °C; then <b>6f</b>, DIPEA, THF, rt; (h) RNH<sub>2</sub>, CDT, pyridine, DCM, 45 °C; then <b>7f</b>, rt.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60150" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60150" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this manuscript, we described the discovery of the preclinical candidate GLPG2938 (compound <b>40</b>), a novel S1P2 receptor inhibitor possessing high potency, exquisite selectivity, and very good pharmacokinetics. The efficacy obtained in the BLM model at low doses advocated strongly for its progression in development for the treatment of IPF. A key role in this discovery was played by adopting chemical enablement strategies; this allowed us to identify the 5-pyrazol-4-yl-pyridine motif as the key element for further optimization. Chemical enablement also allowed a quick and broad exploration of the space around the pyridine’s C5 position. Considerations on lipophilicity were also very important as they led to the pyridazine-based series. This change brought molecules with better LipE and helped to solve a potential CYP inhibition issue.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53305" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53305" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Experimental Methods</h3><div class="NLM_p">All reagents were of commercial grade and were used as received without further purification, unless otherwise stated. Commercially available anhydrous solvents were used for reactions conducted under an inert atmosphere. Reagent-grade solvents were used in all other cases, unless otherwise specified. Column chromatography was performed on silica gel 60 (35–70 μm). Thin layer chromatography was carried out using pre-coated silica gel F-254 plates (thickness 0.25 mm). Purification with preparatory HPLC was performed with a Waters FractionLynx system coupled to a 2996 PDA detector and a Waters Mass detector QDA. For the basic method, column used: Waters XBridge prep (C18, 10 μm OBD, 19 x 100 mm); for the acidic method, column used: Waters XSelect CSH (C18, 5 μm OBD, 19 x 100 mm). Flow rate: 20 mL/min. <sup>1</sup>H NMR spectra were recorded on a Bruker DPX 400 NMR spectrometer (400 MHz). Chemical shifts (δ) for <sup>1</sup>H NMR spectra are reported in parts per million (ppm) relative to tetramethylsilane (δ 0.00) or the appropriate residual solvent peak, i.e., CHCl<sub>3</sub> (δ 7.27), as an internal reference. Multiplicities are given as singlet (s), doublet (d), triplet (t), quartet (q), quintuplet (quin), multiplet (m), and broad (br). Ultraviolet and electrospray MS spectra were obtained on a Waters platform LC/MS spectrometer or with Waters Acquity H-Class UPLC coupled to a Waters mass detector QDA. Purities were determined by LCMS analysis (UV traces determined with an Acquity PDA detector) using two methods. Method A: column used: Waters Acquity UPLC CSH C18 1.7 μm, 2.1 mm ID x 50 mm L; MeCN/H<sub>2</sub>O gradients (H<sub>2</sub>O contains 0.1% formic acid); Method B: column used: Waters Acquity UPLC BEH C18 1.7 μm, 2.1 mm ID x 50 mmL; MeCN/H<sub>2</sub>O gradients (H<sub>2</sub>O contains 13.4 mM NH<sub>3</sub>). All reported final compounds were analyzed with one of these analytical methods and had purities ≥95%.</div><div class="NLM_p last">High-resolution mass spectrometry (HRMS) analyses were performed with a Waters Xevo-G2-XS QTof mass spectrometer coupled to a Waters UPLC H-class system (column: Acquity BEH C18, 100*2.1 mm, 1.7 μm particle size, elution: formic acid 0.1% in water/formic acid 0.1% in acetonitrile 95:5 to 5:95 in 5.2 min, flow: 0.8 mL/min) equipped with a PDA detector (UV detection: total absorbance 210–400 nm), a column heater module, and controlled by Masslynx Software. Microwave heating was performed with a Biotage Initiator. The melting points were measured with a Mettler Toledo, MP50 melting point system.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Procedure for Preparation of Boc-Protected 2-Hydrazineylpyridines <b>6</b>–<b>10a</b>, <b>12a</b>, and <b>17a</b></h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>tert</i>-Butyl 1-(5-Bromo-4-methylpyridin-2-yl)hydrazine-1-carboxylate (<b>12a</b>)</h4><div class="NLM_p last">Pd<sub>2</sub>(dba)<sub>3</sub> (334 mg, 0.365 mmol, 0.05 eq) and dppf (606 mg, 1.09 mmol, 0.15 eq) were added to a degassed solution of 2,5-dibromo-4-methylpyridine <b>11a</b> (1.83 g, 7.29 mmol, 1.0 eq), <i>tert</i>-butyl hydrazinecarboxylate (963 mg, 7.29 mmol, 1.0 eq), and Cs<sub>2</sub>CO<sub>3</sub> (2.38 g, 7.29 mmol, 1.0 eq) in dry toluene (36 mL, 0.2 M). The reaction mixture was stirred at 100 °C for 2.5 h. The reaction was cooled down to room temperature and filtered over Celite. The filtrate was washed with saturated aqueous NaHCO<sub>3</sub> solution. The compound was extracted with DCM, and the organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The crude material was purified by column chromatography (SiO<sub>2</sub>, petroleum ether/EtOAc, 100:0 to 0:100 over 20 CV) to afford <i>tert</i>-butyl 1-(5-bromo-4-methylpyridin-2-yl)hydrazine-1-carboxylate (1.07 g, 44% yield). LCMS: <i>m</i>/<i>z</i> = 302.0, 304.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> tert-Butyl <i>N</i>-Amino-<i>N</i>-[5-(dimethylamino)-4-methyl-2-pyridyl]carbamate (<b>6a</b>)</h4><div class="NLM_p last">This compound was prepared from <b>1a</b> according to the general procedure used for the preparation of <b>12a</b>. LCMS: <i>m</i>/<i>z</i> = 267.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>tert</i>-Butyl <i>N</i>-Amino-<i>N</i>-(5-cyano-4-methyl-2-pyridyl)carbamate (<b>7a</b>)</h4><div class="NLM_p last">This compound was prepared from <b>2a</b> according to the general procedure used for the preparation of <b>12a</b>. LCMS: <i>m</i>/<i>z</i> = 193.2 ((M – 56) + H)<sup>+</sup>.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>tert</i>-Butyl <i>N</i>-Amino-<i>N</i>-(6-cyano-4-methyl-2-pyridyl)carbamate (<b>8a</b>)</h4><div class="NLM_p last">This compound was prepared from <b>3a</b> according to the general procedure used for the preparation of <b>12a</b>. LCMS: <i>m</i>/<i>z</i> = 249.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>tert</i>-Butyl <i>N</i>-Amino-<i>N</i>-[6-(hydroxymethyl)-4-methyl-2-pyridyl]carbamate (<b>9a</b>)</h4><div class="NLM_p last">This compound was prepared from <b>4a</b> according to the general procedure used for the preparation of <b>12a</b>. LCMS: <i>m</i>/<i>z</i> = 254.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Ethyl 6-[Amino(<i>tert</i>-butoxycarbonyl)amino]-4-methylpyridine-2-carboxylate (<b>10a</b>)</h4><div class="NLM_p last">This compound was prepared from <b>5a</b> according to the general procedure used for the preparation of <b>12a</b>. LCMS: <i>m</i>/<i>z</i> = 296.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>tert</i>-Butyl <i>N</i>-Amino-<i>N</i>-(6-chloro-4-methyl-2-pyridyl)carbamate (<b>17a</b>)</h4><div class="NLM_p last">This compound was prepared from <b>16a</b> according to the general procedure used for the preparation of <b>12a</b>. LCMS: <i>m</i>/<i>z</i> = 258.0 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure for Preparation of Boc-Protected 2-Hydrazineylpyridines <b>13–15a</b></h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>tert</i>-Butyl <i>N</i>-Amino-<i>N</i>-[5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]carbamate (<b>15a</b>)</h4><div class="NLM_p last">To a degassed solution of <i>tert</i>-butyl <i>N</i>-amino-<i>N</i>-(5-bromo-4-methyl-2-pyridyl)carbamate <b>12a</b> (200 mg, 0.661 mmol, 1.0 eq), 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (221 mg, 0.993 mmol, 1.5 eq), and K<sub>2</sub>CO<sub>3</sub> (2 M in H<sub>2</sub>O, 1.1 mL, 2.3 mmol, 3.5 eq) in 1,4-dioxane (7 mL, 0.1 M) was added Pd(dppf)Cl<sub>2</sub> (27 mg, 0.033 mmol, 0.05 eq), and the reaction was stirred at 130 °C under microwave irradiation until reaction completion. It was then cooled to room temperature and partitioned between saturated aqueous NaHCO<sub>3</sub> and DCM. The compound was extracted using a phase separator, and the organic layer was concentrated to dryness to obtain compound <b>15a</b>, which was used without further purification. LCMS: <i>m</i>/<i>z</i> = 318.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>tert</i>-Butyl <i>N</i>-Amino-<i>N</i>-[4-methyl-5-(1-methylpyrazol-4-yl)-2-pyridyl]carbamate (<b>13a</b>)</h4><div class="NLM_p last">This compound was prepared from <b>12a</b> according to the general procedure used for the preparation of <b>15a</b>. LCMS: <i>m</i>/<i>z</i> = 304.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>tert</i>-Butyl <i>N</i>-Amino-<i>N</i>-[4-methyl-5-(1-methylpyrazol-3-yl)-2-pyridyl]carbamate (<b>14a</b>)</h4><div class="NLM_p last">This compound was prepared from <b>12a</b> according to the general procedure used for the preparation of <b>15a</b>. LCMS: <i>m</i>/<i>z</i> = 304.1 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Procedure for Preparation of Boc-Protected 2-Hydrazineylpyridines <b>18–19a</b></h3><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>tert</i>-Butyl <i>N</i>-Amino-<i>N</i>-[6-(4-fluorophenyl)-4-methyl-2-pyridyl]carbamate (<b>19a</b>)</h4><div class="NLM_p last">To a degassed solution of <i>tert</i>-butyl 1-(6-chloro-4-methylpyridin-2-yl)hydrazine-1-carboxylate <b>17a</b> (200 mg, 0.776 mmol, 1.0 eq), (4-fluorophenyl)boronic acid (163 mg, 1.16 mmol, 1.5 eq), and Na<sub>2</sub>CO<sub>3</sub> (2 M in H<sub>2</sub>O, 1.36 mL, 2.72 mmol, 3.5 eq) in 1,4-dioxane (5 mL, 0.15 M) was added Pd(dppf)Cl<sub>2</sub> (32 mg, 0.04 mmol, 0.05 eq), and the reaction was stirred at 150 °C under microwave irradiation until reaction completion. It was then cooled to room temperature and partitioned between saturated aqueous NaHCO<sub>3</sub> and DCM. The compound was extracted using a phase separator, and the organic layer was concentrated to dryness to obtain compound <b>19a</b>, which was used without further purification. LCMS: <i>m</i>/<i>z</i> = 318.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>tert</i>-Butyl <i>N</i>-Amino-<i>N</i>-[4-methyl-6-(1-methylpyrazol-4-yl)-2-pyridyl]carbamate (<b>18a</b>)</h4><div class="NLM_p last">This compound was prepared from <b>17a</b> according to the general procedure used for the preparation of <b>19a</b>. LCMS: <i>m</i>/<i>z</i> = 304.2 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> General Procedure for Preparation of Ureas <b>12</b>–<b>21</b></h3><div id="sec5_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-(5-Cyano-4-methylpyridin-2-yl)-<i>N</i>-(2,6-dichloropyridin-4-yl)hydrazine-1-carboxamide (<b>13</b>)</h4><div class="NLM_p last">2,6-Dichloro-4-isocyanatopyridine (0.10 mL, 0.81 mmol, 1 eq) in THF was added to a mixture of <i>N</i>-amino-<i>N</i>-(5-cyano-4-methyl-2-pyridyl)carbamate <b>7a</b> (200 mg, 0.81 mmol, 1 eq) in THF (8 mL final volume). The reaction was stirred at room temperature until the disappearance of the starting material (4 h). The mixture was partitioned between DCM and water. The two phases were separated; the organic layer was dried (filtered through phase separator) and concentrated. The residue was taken up in DCM (8 mL), and 4 M HCl in 1,4-dioxane (2.0 mL, 8.1 mmol, 10 eq) was added to the mixture. The reaction was stirred at 40 °C until completion (1.5 h). The reaction was quenched with saturated NaHCO<sub>3</sub>, and the two layers were separated. The aqueous layer was further extracted with DCM. The combined organic layers were dried (filtered through phase separator) and concentrated. The residue was purified by preparatory HPLC (gradient from 30% MeCN to 55% MeCN in water/0.1% formic acid) to obtain the title product (11 mg, 4% yield). LCMS: method A, <i>R</i><sub>t</sub>: 1.16 min; purity: >99%, <i>m</i>/<i>z</i> = 336.9 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.78 (s, 1H), 9.22 (s, 1H), 8.99 (s, 1H), 8.45 (s, 1H), 7.68 (s, 2H), 6.64 (s, 1H), 2.38 (s, 3H).</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 1-(2,6-Dichloro-4-pyridyl)-3-[[5-(dimethylamino)-4-methyl-2-pyridyl]amino]urea (<b>12</b>)</h4><div class="NLM_p last">This compound was prepared from <b>6a</b> according to the general procedure used for the preparation of <b>13</b>. LCMS: method A, <i>R</i><sub>t</sub>: 0.90 min; purity: >99%, <i>m</i>/<i>z</i> = 355.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.65 (s, 1H), 8.80 (s, 1H), 8.03 (s, 1H), 7.84 (s, 2H), 6.50 (s, 1H), 2.60 (s, 6H), 2.21 (s, 3H).</div></div><div id="sec5_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 1-[(6-Cyano-4-methyl-2-pyridyl)amino]-3-(2,6-dichloro-4-pyridyl)urea (<b>14</b>)</h4><div class="NLM_p last">This compound was prepared from <b>8a</b> according to the general procedure used for the preparation of <b>13</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.20 min; purity: >99%, <i>m</i>/<i>z</i> = 337.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.74 (s, 1H), 8.95–8.91 (m, 2H), 7.72 (s, 2H), 7.25 (s, 1H), 6.79 (s, 1H), 2.29 (s, 3H).</div></div><div id="sec5_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 1-(2,6-Dichloro-4-pyridyl)-3-[[6-(hydroxymethyl)-4-methyl-2-pyridyl]amino]urea (<b>15</b>)</h4><div class="NLM_p last">This compound was prepared from <b>9a</b> according to the general procedure used for the preparation of <b>13</b>. LCMS: method A, <i>R</i><sub>t</sub>: 0.87 min; purity: >99%, <i>m</i>/<i>z</i> = 342.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.77 (s, 1H), 8.88 (s, 1H), 7.76 (s, 2H), 6.78 (s, 1H), 6.44 (s, 1H), 4.42 (s, 2H), 2.27 (s, 3H).</div></div><div id="sec5_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Ethyl 6-[2-[(2,6-Dichloro-4-pyridyl)carbamoyl]hydrazino]-4-methylpyridine-2-carboxylate (<b>16</b>)</h4><div class="NLM_p last">This compound was prepared from <b>10a</b> according to the general procedure used for the preparation of <b>13</b>. LCMS: method A, <i>R</i><sub>t</sub>: 1.28 min; purity: >99%, <i>m</i>/<i>z</i> = 384.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.84 (s, 1H), 8.94 (s, 1H), 8.70 (s, 1H), 7.66 (s, 2H), 7.33 (s, 1H), 6.73 (s, 1H), 4.30 (q, <i>J</i> = 7.1 Hz, 2H), 2.32 (s, 3H), 1.29 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec5_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 1-(2,6-Dichloro-4-pyridyl)-3-[[4-methyl-5-(1-methylpyrazol-4-yl)-2-pyridyl]amino]urea (<b>17</b>)</h4><div class="NLM_p last">This compound was prepared from <b>13a</b> according to the general procedure used for the preparation of <b>13</b>. LCMS: method A, <i>R</i><sub>t</sub>: 0.94 min; purity: >99%, <i>m</i>/<i>z</i> = 392.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.68 (s, 1H), 8.90 (s, 1H), 8.32 (s, 1H), 8.07 (s, 1H), 7.90 (s, 2H), 7.62 (s, 1H), 6.57 (s, 1H), 3.87 (s, 3H), 2.29 (s, 3H).</div></div><div id="sec5_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 1-(2,6-Dichloro-4-pyridyl)-3-[[4-methyl-5-(1-methylpyrazol-3-yl)-2-pyridyl]amino]urea (<b>18</b>)</h4><div class="NLM_p last">This compound was prepared from <b>14a</b> according to the general procedure used for the preparation of <b>13</b>. LCMS: method A, <i>R</i><sub>t</sub>: 0.99 min; purity: >99%, <i>m</i>/<i>z</i> = 392.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (s, 1H), 8.39 (s, 1H), 8.23–8.20 (m, 1H), 7.87 (s, 1H), 7.73 (s, 1H), 6.78 (s, 1H), 6.56 (s, 1H), 6.50 (s, 1H), 6.46 (s, 1H), 3.87 (s, 3H), 2.39 (s, 3H).</div></div><div id="sec5_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 1-(2,6-Dichloro-4-pyridyl)-3-[[5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]amino]urea (<b>19</b>)</h4><div class="NLM_p last">This compound was prepared from <b>15a</b> according to the general procedure used for the preparation of <b>13</b>. LCMS: method A, <i>R</i><sub>t</sub>: 0.95 min; purity: >99%, <i>m</i>/<i>z</i> = 406.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.70 (s, 1H), 8.81 (s, 1H), 8.32 (s, 1H), 8.02–7.46 (m, 4H), 6.59 (s, 1H), 3.78 (s, 3H), 2.12 (s, 3H), 2.03 (s, 3H).</div></div><div id="sec5_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 1-(2,6-Dichloro-4-pyridyl)-3-[[4-methyl-6-(1-methylpyrazol-4-yl)-2-pyridyl]amino]urea (<b>20</b>)</h4><div class="NLM_p last">This compound was prepared from <b>18a</b> according to the general procedure used for the preparation of <b>13</b>. LCMS: method A, <i>R</i><sub>t</sub>: 1.11 min; purity: >99%, <i>m</i>/<i>z</i> = 392.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.11 (s, 1H), 9.12 (s, 1H), 8.38 (s, 1H), 8.10 (s, 1H), 7.70 (s, 2H), 7.14 (s, 1H), 6.63 (s, 1H), 3.91 (s, 3H), 2.34 (s, 3H).</div></div><div id="sec5_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-(2,6-Dichloro-4-pyridyl)-3-[[6-(4-fluorophenyl)-4-methyl-2-pyridyl]amino]urea (<b>21</b>)</h4><div class="NLM_p last">This compound was prepared from <b>19a</b> according to the general procedure used for the preparation of <b>13</b>. LCMS: method A, <i>R</i><sub>t</sub>: 1.44 min; purity: >99%, <i>m</i>/<i>z</i> = 406.6 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.76 (s, 1H), 8.85 (s, 1H), 8.42 (s, 1H), 8.11–8.03 (m, 2H), 7.84 (s, 2H), 7.27 (t, <i>J</i> = 8.9 Hz, 3H), 6.48 (s, 1H), 2.31 (s, 3H).</div></div><div id="sec5_5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 6-[Amino(<i>tert</i>-butoxycarbonyl)amino]-4-methylpyridine-2-carboxylic acid (<b>1b</b>)</h4><div class="NLM_p last">A solution of LiOH (1.8 g, 43 mmol, 2.8 eq) in H<sub>2</sub>O (15 mL) was added to a mixture of ethyl 6-[amino(<i>tert</i>-butoxycarbonyl)amino]-4-methylpyridine-2-carboxylate <b>10a</b> (4.4 g, 15 mmol, 1 eq) in THF (30 mL). The reaction was stirred for 2 h at room temperature. The reaction mixture was acidified and extracted with DCM. The two phases were separated. The organic layer was dried (filtered through phase separator) and concentrated to afford the desired product (3 g, 75% yield). LCMS: <i>m</i>/<i>z</i> = 268.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 6-[<i>tert</i>-Butoxycarbonyl-[(2,6-dichloro-4-pyridyl)carbamoylamino]amino]-4-methylpyridine-2-carboxylic acid (<b>2b</b>)</h4><div class="NLM_p last">2,6-Dichloro-4-isocyanatopyridine (1.4 mL, 11 mmol, 1 eq) in THF was added to a mixture of <i>N</i>-amino-<i>N</i>-(5-cyano-4-methyl-2-pyridyl)carbamate <b>1b</b> (2.9 g, 11 mmol, 1 eq) in THF (110 mL final volume). The reaction was stirred at room temperature until the disappearance of the starting material (2.5 h). The mixture was partitioned between DCM and water. The two phases were separated; the organic layer was dried (filtered through phase separator) and concentrated to afford the desired product (4.2 g, 84% yield). LCMS: <i>m</i>/<i>z</i> = 456.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 6-[2-[(2,6-Dichloro-4-pyridyl)carbamoyl]hydrazino]-4-methylpyridine-2-carboxylic acid (<b>3b</b>)</h4><div class="NLM_p last">A 4 M HCl solution in 1,4-dioxane (23 mL, 92 mmol, 10 eq) was added to a mixture of 6-[<i>tert</i>-butoxycarbonyl-[(2,6-dichloro-4-pyridyl)carbamoylamino]amino]-4-methylpyridine-2-carboxylic acid <b>2b</b> (4.2 g, 9.2 mmol, 1 eq) in DCM (92 mL). The resulting mixture was stirred at 40 °C for 2 h. The mixture was concentrated, and the residue was washed with methyl <i>tert</i>-butyl ether to afford the desired product (3.0 g, 92% yield). LCMS: <i>m</i>/<i>z</i> = 356.0 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> General Procedure for Preparation of Amides <b>22</b>–<b>24</b></h3><div id="sec5_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>N</i>-Cyclopropyl-6-[2-[(2,6-dichloro-4-pyridyl)carbamoyl]hydrazino]-4-methylpyridine-2-carboxamide (<b>23</b>)</h4><div class="NLM_p last">A solution of HATU (53 mg, 0.14 mmol, 1 eq) in dry DMF (1 mL) was added to a mixture of cyclopropanamine (8.8 mg, 0.154 mmol, 1.1 eq), 6-[2-[(2,6-dichloro-4-pyridyl)carbamoyl]hydrazino]-4-methylpyridine-2-carboxylic acid <b>3b</b> (50 mg, 0.14 mmol, 1 eq), and DIPEA (50 μL, 0.28 mmol, 2 eq) in dry DCM (1.4 mL). The reaction was stirred at room temperature until full conversion. The reaction mixture was quenched with saturated NaHCO<sub>3</sub>, and the resulting mixture was extracted with DCM. The two phases were separated. The organic layer was dried (filtered through phase separator) and concentrated. The residue was purified by preparatory HPLC (gradient from 35% MeCN to 60% MeCN in water/0.1% formic acid) to afford the desired product (5 mg, 10% yield). LCMS: method B, <i>R</i><sub>t</sub>: 1.21 min; purity: >99%, <i>m</i>/<i>z</i> = 356.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.84 (s, 1H), 8.86 (s, 1H), 8.52 (s, 1H), 8.04 (d, <i>J</i> = 4.6 Hz, 1H), 7.83–7.54 (m, 2H), 7.26 (s, 1H), 6.67 (s, 1H), 2.87–2.76 (m, 1H), 2.31 (s, 3H), 0.79–0.64 (m, 2H), 0.50–0.42 (m, 2H).</div></div><div id="sec5_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 6-[2-[(2,6-Dichloro-4-pyridyl)carbamoyl]hydrazino]-<i>N</i>,<i>N</i>,4-trimethylpyridine-2-carboxamide (<b>22</b>)</h4><div class="NLM_p last">This compound was prepared from <b>3b</b> according to the general procedure used for the preparation of <b>23</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.14 min; purity: 95%, <i>m</i>/<i>z</i> = 383.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.94 (s, 1H), 8.49 (s, 1H), 7.80 (s, 3H), 6.76 (s, 2H), 6.54 (s, 1H), 6.50 (s, 1H), 2.93 (s, 3H), 2.88 (s, 3H), 2.27 (s, 3H).</div></div><div id="sec5_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-Cyclopropyl-6-[2-[(2,6-dichloro-4-pyridyl)carbamoyl]hydrazino]-<i>N</i>,4-dimethylpyridine-2-carboxamide (<b>24</b>)</h4><div class="NLM_p last">This compound was prepared from <b>3b</b> according to the general procedure used for the preparation of <b>23</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.22 min; purity: >99%, <i>m</i>/<i>z</i> = 409.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.68 (s, 1H), 8.79 (s, 1H), 8.53 (s, 1H), 7.66 (d, <i>J</i> = 119.1 Hz, 2H), 6.76 (s, 1H), 6.54 (s, 1H), 2.90 (s, 3H), 2.81–2.75 (m, 1H), 2.27 (s, 3H), 0.43–0.12 (m, 4H).</div></div><div id="sec5_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 5-(1,3-Dimethylpyrazol-4-yl)-4-methylpyridine-2-carbaldehyde (<b>2d</b>)</h4><div class="NLM_p last">Pd(dppf)Cl<sub>2</sub> (204 mg, 0.25 mmol, 0.1 eq) was added to a degassed mixture of 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (670 mg, 3.0 mmol, 1.2 eq), 5-bromo-4-methylpicolinaldehyde <b>1d</b> (500 mg, 2.5 mmol, 1 eq), and Cs<sub>2</sub>CO<sub>3</sub> (2.04 g, 6.25 mmol, 2.5 eq) in 10:1 1,4-dioxane/H<sub>2</sub>O (12 mL). The reaction was stirred at 95 °C for 4 h. The mixture was filtered through Celite. The filtrate was partitioned between DCM and H<sub>2</sub>O. The two phases were separated. The aqueous layer was extracted with DCM. The combined organic layers were dried (filtered through a phase separator) and concentrated to afford the desired product (363 mg, 68% yield). LCMS: <i>m</i>/<i>z</i> = 216.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 6-Chloro-2-ethoxy-3-nitropyridin-4-amine (<b>4d</b>)</h4><div class="NLM_p last">NaH in 60% mineral oil (154 mg, 3.84 mmol, 2 eq) was added to a mixture of 2,6-dichloro-3-nitropyridin-4-amine <b>3d</b> (400 mg, 1.92 mmol, 1 eq) in EtOH (6.4 mL). The reaction was stirred at room temperature for 1 h. Water was added, and the resulting mixture was extracted with DCM. The two phases were separated. The organic layer was dried (filtered through phase separator) and concentrated to afford the desired product, which was used as such in the next step. LCMS: <i>m</i>/<i>z</i> = 218.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 6-Chloro-2-ethoxypyridine-3,4-diamine (<b>5d</b>)</h4><div class="NLM_p last">Zn dust (1.5 g, 23 mmol, 12 eq) and NH<sub>4</sub>Cl (1.23 g, 23 mmol, 12 eq) were added to a mixture of 6-chloro-2-ethoxy-3-nitropyridin-4-amine <b>4d</b> (1.92 mmol, 1 eq) in MeOH (13 mL). The reaction was stirred at room temperature for 2.5 h. The mixture was filtered through Celite and concentrated. The residue was taken up in DCM. The resulting mixture was washed with saturated NaHCO<sub>3</sub>. The two phases were separated. The organic layer was dried (filtered through a phase separator) and concentrated to afford the desired product, which was used as such in the next step. LCMS: <i>m</i>/<i>z</i> = 188.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 6-Chloro-4-ethoxy-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-amine (<b>6d</b>)</h4><div class="NLM_p last">CNBr (5 M MeCN solution, 1 mL, 5.8 mmol, 3 eq) was added to a mixture of 6-chloro-4-ethoxy-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-amine <b>5d</b> (1.9 mmol, 1 eq) in EtOH (3.8 mL). The mixture was stirred at 45 °C overnight. The mixture was concentrated. The residue was taken up in EtOAc. The organic mixture was washed with saturated NaHCO<sub>3</sub>, and the two phases were separated. The aqueous layer was extracted with EtOAc. The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to afford the desired product (50 mg, 12% yield). LCMS: <i>m</i>/<i>z</i> = 213.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 6-Chloro-<i>N</i>-[[5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methyl]-4-ethoxy-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-amine (<b>26</b>)</h4><div class="NLM_p last">Ti(O<i>i</i>Pr)<sub>4</sub> (0.21 mL, 0.705 mmol, 3 eq) was added to a mixture of 6-chloro-4-ethoxy-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-amine <b>6d</b> (50 mg, 0.24 mmol, 1 eq) and 5-(1,3-dimethylpyrazol-4-yl)-4-methylpyridine-2-carbaldehyde <b>2d</b> (101 mg, 0.47 mmol, 2 eq) in EtOH (0.5 mL). The reaction was stirred at 60 °C overnight. The mixture was diluted with MeOH. Na<sub>2</sub>SO<sub>4</sub>·10H<sub>2</sub>O was added, and the mixture was stirred for 30 min. The mixture was filtered, and the filtrate was concentrated. The residue was taken up in EtOAc and washed with 1 M NaOH. The two phases were separated. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was purified by preparatory HPLC (gradient from 20% MeCN to 45% MeCN in water/0.1% formic acid) to afford the desired product (3.0 mg, 3% yield). LCMS: method B, <i>R</i><sub>t</sub>: 1.16 min; purity: >99%, <i>m</i>/<i>z</i> = 412.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.56 (s, 1H), 8.26 (s, 1H), 7.73 (s, 1H), 7.44 (s, 1H), 7.26 (s, 1H), 6.88 (s, 1H), 4.61 (d, <i>J</i> = 5.9 Hz, 2H), 4.36 (s, 2H), 3.80 (s, 3H), 2.18 (s, 3H), 2.06 (s, 3H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec5_6_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 5-Bromo-4-methylpyridine-2-carbonitrile (<b>1c</b>)</h4><div class="NLM_p last">A mixture of 2,5-dibromo-4-methylpyridine <b>11a</b> (5 g, 20 mmol, 1 eq), Zn(CN)<sub>2</sub> (2.81 g, 23.9 mmol, 1.2 eq) and Pd(PPh<sub>3</sub>)<sub>4</sub> (2.3 g, 2.0 mmol, 0.1 eq) in DMF (100 mL) was heated at 150 °C under microwave irradiation for 5 min. The mixture was filtered through Celite. The filtrate was diluted with DCM. The resulting mixture was washed (sat NaHCO<sub>3</sub> and brine), dried (filtered through a phase separator) and concentrated. The residue was purified by flash column chromatography (SiO<sub>2</sub>, 95:5 petroleum ether/EtOAc) to afford the desired product (4.4 g, 100% yield). LCMS: <i>m</i>/<i>z</i> = 198.9 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> General Procedure for Preparation of Nitriles <b>2–3c</b></h3><div id="sec5_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 5-(1,3-Dimethylpyrazol-4-yl)-4-methylpyridine-2-carbonitrile (<b>2c</b>)</h4><div class="NLM_p last">Pd(dppf)Cl<sub>2</sub> (415 mg, 0.51 mmol, 0.1 eq) was added to a degassed mixture containing 5-bromo-4-methylpyridine-2-carbonitrile <b>1c</b> (1.0 g, 5.1 mmol, 1 eq), 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (1.35 g, 6.09 mmol, 1.2 eq), and Cs<sub>2</sub>CO<sub>3</sub> (4.10 g, 12.7 mmol, 2.5 eq) in 4:1 1,4-dioxane/H<sub>2</sub>O (20 mL). The reaction mixture was stirred at 100 °C for 2.5 h. The mixture was cooled to room temperature and quenched with H<sub>2</sub>O. The resulting mixture was extracted with DCM. The organic layer was dried (filtered through a phase separator) and concentrated to dryness to afford the desired product (550 mg, 51% yield). LCMS: <i>m</i>/<i>z</i> = 213.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4-Methyl-5-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridine-2-carbonitrile (<b>3c</b>)</h4><div class="NLM_p last">This compound was prepared from <b>1c</b> according to the general procedure used for the preparation of <b>2c</b>. LCMS: <i>m</i>/<i>z</i> = 267.1 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> General Procedure for Preparation of Amines <b>4–5c</b></h3><div id="sec5_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> [5-(1,3-Dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methanamine (<b>4c</b>)</h4><div class="NLM_p last">BH<sub>3</sub>·SMe<sub>2</sub> (2.4 mL, 25 mmol, 5 eq) was slowly added to a mixture of 5-(1,3-dimethylpyrazol-4-yl)-4-methylpyridine-2-carbonitrile <b>2c</b> (1.1 g, 5.1 mmol, 1 eq) in THF at room temperature. The reaction mixture was stirred at 45 °C for 1 h. The mixture was cooled to 0 °C, and MeOH was carefully added. The resulting mixture was concentrated. The residue was taken up in DCM, and 2 M HCl was added. The two phases were separated. The aqueous layer was basified and extracted with DCM. The two phases were separated. The organic layer was dried (filtered through a phase separator) and concentrated to afford the desired product (400 mg, 36% yield). LCMS: <i>m</i>/<i>z</i> = 217.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> [4-Methyl-5-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-2-pyridyl]methanamine (<b>5c</b>)</h4><div class="NLM_p last">This compound was prepared from <b>3c</b> according to the general procedure used for the preparation of <b>4c</b>. LCMS: <i>m</i>/<i>z</i> = 271.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 5,6-Dichloro-<i>N</i>-[[5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methyl]-1<i>H</i>-benzimidazol-2-amine (<b>25</b>)</h4><div class="NLM_p last">A mixture of [5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methanamine <b>4c</b> (100 mg, 0.46 mmol, 1.2 eq) and 2,5,6-trichloro-1<i>H</i>-benzo[<i>d</i>]imidazole (85 mg, 0.39 mmol, 1 eq) in acetonitrile (0.5 mL) was stirred at 170 °C under microwave conditions for 40 min. The mixture was partitioned between DCM and H<sub>2</sub>O. The two phases were separated. The organic layer was dried (filtered through phase separator) and concentrated. The residue was purified by preparatory HPLC (gradient from 30% MeCN to 55% MeCN in water/0.5% NH<sub>3</sub>) to afford the desired product (7.5 mg, 5% yield). LCMS: method A, <i>R</i><sub>t</sub>: 0.95 min; purity: >99%, <i>m</i>/<i>z</i> = 401.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.09 (s, 1H), 8.26 (s, 1H), 7.74 (s, 1H), 7.55 (t, <i>J</i> = 6.0 Hz, 1H), 7.32–7.28 (m, 3H), 4.60 (d, <i>J</i> = 5.9 Hz, 2H), 3.80 (s, 3H), 2.18 (s, 3H), 2.06 (s, 3H).</div></div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> General Procedure for Preparation of Amides <b>27</b>, <b>29</b>, and <b>30</b></h3><div id="sec5_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 4,6-Dichloro-<i>N</i>-[[5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methyl]-1<i>H</i>-indole-2-carboxamide (<b>27</b>)</h4><div class="NLM_p last">A solution of HATU (131 mg, 0.35 mmol, 1 eq) in dry DMF (1 mL) was added to a mixture of [5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methanamine <b>4c</b> (75 mg, 0.35 mmol, 1 eq), 4,6-dichloro-1<i>H</i>-indole-2-carboxylic acid (88 mg, 0.38 mmol, 1.1 eq), and DIPEA (120 μL, 0.69 mmol, 2 eq) in dry DCM (3.5 mL). The reaction was stirred at room temperature until full conversion. The reaction mixture was partitioned between DCM and saturated NH<sub>4</sub>Cl. The two phases were separated. The organic layer was dried (filtered through phase separator) and concentrated. The residue was purified by preparatory HPLC (gradient from 35% MeCN to 60% MeCN in water/0.1% formic acid) to afford the desired product (2.0 mg, 1% yield). LCMS: method B, <i>R</i><sub>t</sub>: 1.19 min; purity: >99%, <i>m</i>/<i>z</i> = 428.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.18 (s, 1H), 9.34 (t, <i>J</i> = 6.0 Hz, 1H), 8.26 (s, 1H), 7.74 (s, 1H), 7.46–7.41 (m, 1H), 7.38 (d, <i>J</i> = 0.9 Hz, 1H), 7.29–7.24 (m, 2H), 4.59 (d, <i>J</i> = 6.0 Hz, 2H), 3.81 (s, 3H), 2.20 (s, 3H), 2.07 (s, 3H).</div></div><div id="sec5_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 2,6-Dichloro-<i>N</i>-[[5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methyl]pyridine-4-carboxamide (<b>29</b>)</h4><div class="NLM_p last">This compound was prepared from <b>4c</b> according to the general procedure used for the preparation of <b>27</b>. LCMS: method A, <i>R</i><sub>t</sub>: 1.19 min; purity: >99%, <i>m</i>/<i>z</i> = 390.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, Chloroform-<i>d</i>) δ 8.35 (s, 1H), 7.87 (s, 1H), 7.71 (s, 2H), 7.31 (s, 1H), 7.22 (s, 1H), 4.73 (d, <i>J</i> = 4.5 Hz, 2H), 3.94 (s, 3H), 2.29 (s, 3H), 2.19 (s, 3H).</div></div><div id="sec5_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 2-(3,4-Dichlorophenyl)-<i>N</i>-[[5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methyl]acetamide (<b>30</b>)</h4><div class="NLM_p last">This compound was prepared from <b>4c</b> according to the general procedure used for the preparation of <b>27</b>. LCMS: method A, <i>R</i><sub>t</sub>: 1.23 min; purity: >99%, <i>m</i>/<i>z</i> = 403.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, Chloroform-<i>d</i>) δ 8.27 (s, 1H), 7.48–7.39 (m, 2H), 7.28 (s, 1H), 7.19 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 7.15–7.10 (m, 1H), 6.86 (s, 1H), 4.54 (d, <i>J</i> = 5.0 Hz, 2H), 3.93 (s, 3H), 3.61 (s, 2H), 2.24 (d, <i>J</i> = 0.6 Hz, 3H), 2.17 (s, 3H).</div></div><div id="sec5_9_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 4,6-Dichloro-<i>N</i>-[[5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methyl]-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamide (<b>28</b>)</h4><div class="NLM_p last">A solution of HATU (131 mg, 0.35 mmol, 1 eq) in dry DMF (1 mL) was added to a mixture of [5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methanamine <b>4c</b> (75 mg, 0.35 mmol, 1 eq), 4,6-dichloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxylic acid (88 mg, 0.38 mmol, 1.1 eq), and DIPEA (120 μL, 0.69 mmol, 2 eq) in dry DCM (3.5 mL). The reaction was stirred at 45 °C until full conversion. The reaction mixture was partitioned between DCM and saturated NH<sub>4</sub>Cl. The two phases were separated. The organic layer was dried (filtered through phase separator) and concentrated. The residue was purified by preparatory HPLC (gradient from 35% MeCN to 60% MeCN in water/0.5% NH<sub>3</sub>) to afford the desired product (15 mg, 10% yield). LCMS: method B, <i>R</i><sub>t</sub>: 1.15 min; purity: >99%, <i>m</i>/<i>z</i> = 429.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.63 (d, <i>J</i> = 2.1 Hz, 1H), 9.45 (t, <i>J</i> = 6.0 Hz, 1H), 8.26 (s, 1H), 7.74 (s, 1H), 7.47 (dd, <i>J</i> = 2.1, 1.0 Hz, 1H), 7.43 (d, <i>J</i> = 0.9 Hz, 1H), 7.28 (s, 1H), 4.60 (d, <i>J</i> = 5.9 Hz, 2H), 3.81 (s, 3H), 2.20 (s, 3H), 2.06 (s, 3H).</div></div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> General Procedure for Preparation of Ureas <b>31</b> and <b>33</b></h3><div id="sec5_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 1-(2,6-Dichloro-4-pyridyl)-3-[[5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methyl]urea (<b>31</b>)</h4><div class="NLM_p last">2,6-Dichloro-4-isocyanatopyridine (131 mg, 0.69 mmol, 1 eq) in THF was added to a mixture of [5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methanamine <b>4c</b> (150 mg, 0.69 mmol, 1 eq) in THF (7 mL final volume). The reaction was stirred at room temperature until the disappearance of the starting material (1.25 h). The mixture was partitioned between DCM and H<sub>2</sub>O. The two phases were separated; the organic layer was dried (filtered through phase separator) and concentrated. The residue was purified by preparatory HPLC (gradient from 20% MeCN to 45% MeCN in water/0.1% formic acid) to afford the desired product (2 mg, 1% yield). LCMS: method B, <i>R</i><sub>t</sub>: 1.19 min; purity: >99%, <i>m</i>/<i>z</i> = 405.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.05 (s, 1H), 8.25 (s, 1H), 7.73 (s, 1H), 7.58–7.48 (m, 3H), 7.25 (s, 1H), 4.40 (d, <i>J</i> = 5.5 Hz, 2H), 3.81 (s, 3H), 2.21 (s, 3H), 2.06 (s, 3H).</div></div><div id="sec5_10_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 1-(3,5-Dichlorophenyl)-3-[[5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methyl]urea (<b>33</b>)</h4><div class="NLM_p last">This compound was prepared from <b>4c</b> according to the general procedure used for the preparation of <b>31</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.31 min; purity: >99%, <i>m</i>/<i>z</i> = 404.1 (M + H)<sup>+</sup>. HRMS: calcd mass for C<sub>19</sub>H<sub>20</sub>Cl<sub>2</sub>N<sub>5</sub>O (M + H)<sup>+</sup> 404.1039; found 404.1042; difference 0.6 ppm. <sup>1</sup>H NMR (400 MHz, Chloroform-<i>d</i>) δ 8.43 (s, 1H), 8.26 (s, 1H), 7.31–7.24 (m, 4H), 6.92 (s, 1H), 6.79 (s, 1H), 4.54 (s, 2H), 3.91 (s, 3H), 2.26 (s, 3H), 2.14 (s, 3H).</div></div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> General Procedure for Preparation of Ureas <b>32</b> and <b>34</b></h3><div id="sec5_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 1-(2-Chloro-6-ethoxy-4-pyridyl)-3-[[4-methyl-5-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-2-pyridyl]methyl]urea (<b>34</b>)</h4><div class="NLM_p last">A mixture of 2-chloro-6-ethoxypyridin-4-amine (25 mg, 0.15 mmol, 0.5 eq), pyridine (35 μL, 0.44 mmol, 1.5 eq), and 1,1′-carbonyl-di-(1,2,4-triazole) (36 mg, 0.22 mmol, 0.75 eq) in DCM (1.5 mL) was stirred at room temperature for 0.5 h. [4-Methyl-5-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-2-pyridyl]methanamine <b>5c</b> (80 mg, 0.30 mmol, 1 eq) was added, and the mixture was stirred at room temperature for 2 h. The mixture was diluted (DCM), washed (saturated NH<sub>4</sub>Cl and saturated NaHCO<sub>3</sub>), dried (filtered through phase separator), and concentrated. The residue was purified by preparatory HPLC (gradient from 40% MeCN to 65% MeCN in water/0.1% formic acid) to afford the desired product (14 mg, 20% yield). LCMS: method B, <i>R</i><sub>t</sub>: 1.36 min; purity: >99%, <i>m</i>/<i>z</i> = 469.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.49 (s, 1H), 8.25 (s, 1H), 8.07 (s, 1H), 7.29 (s, 1H), 7.18–7.10 (m, 2H), 6.78 (d, <i>J</i> = 1.5 Hz, 1H), 4.41 (d, <i>J</i> = 5.5 Hz, 2H), 4.21 (q, <i>J</i> = 7.0 Hz, 2H), 3.99 (s, 3H), 2.16 (s, 3H), 1.28 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.2, 158.3, 154.8, 152.0, 149.8, 148.1, 147.0, 138.3 (d, <i>J</i> = 35.2 Hz), 134.1, 125.5, 122.5, 126.8–118.0 (m), 116.0, 105.8, 95.7, 62.3, 44.6, 39.9, 19.8, 14.9.</div></div><div id="sec5_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 1-(2-Chloro-6-ethoxy-4-pyridyl)-3-[[5-(1,3-dimethylpyrazol-4-yl)-4-methyl-2-pyridyl]methyl]urea (<b>32</b>)</h4><div class="NLM_p last">This compound was prepared from <b>4c</b> according to the general procedure used for the preparation of <b>34</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.23 min; purity: >99%, <i>m</i>/<i>z</i> = 415.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.46 (s, 1H), 8.26 (s, 1H), 7.75 (s, 1H), 7.25 (s, 1H), 7.13 (s, 2H), 6.78 (s, 1H), 4.39 (d, <i>J</i> = 5.4 Hz, 2H), 4.22 (q, <i>J</i> = 7.0 Hz, 2H), 3.81 (s, 3H), 2.21 (s, 3H), 2.07 (s, 3H), 1.28 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.2, 156.6, 154.8, 152.0, 149.7, 148.1, 146.2, 145.6, 131.4, 128.0, 122.8, 115.4, 105.8, 95.7, 62.3, 44.6, 38.8, 20.1, 14.9, 12.6.</div></div><div id="sec5_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> <i>tert</i>-Butyl ((5-Bromo-4-methylpyridin-2-yl)methyl)carbamate (<b>1e</b>)</h4><div class="NLM_p last">NaBH<sub>4</sub> (13.5 g, 357 mmol, 7 eq) was added in portions to a mixture of 5-bromo-4-methylpyridine-2-carbonitrile <b>1c</b> (10 g, 51 mmol, 1 eq), NiCl<sub>2</sub>·6H<sub>2</sub>O (2.4 g, 10 mmol, 0.2 eq), and Boc<sub>2</sub>O (33 g, 6.4 mmol, 5 eq) in MeOH (170 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 h. A further 50 mg of NaBH<sub>4</sub> was added, and the reaction was stirred for 1 h. The reaction mixture was filtered through Celite and concentrated. The residue was taken up in DCM and saturated NaHCO<sub>3</sub>. The two layers were filtered and separated. The organic layer was dried (filtered through phase separator) and concentrated to afford the desired product (7.5 g, 49% yield). LCMS: <i>m</i>/<i>z</i> = 300.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> (5-Bromo-4-methylpyridin-2-yl)methanamine TFA Salt (<b>2e</b>)</h4><div class="NLM_p last">A mixture of <i>tert</i>-butyl ((5-bromo-4-methylpyridin-2-yl)methyl)carbamate <b>1e</b> (7.5 g, 25 mmol, 1 eq) and TFA (14 mL) in DCM (50 mL) was stirred at 45 °C for 1.5 h. The mixture was concentrated. Toluene (100 mL) was added, and the resulting mixture was concentrated (this operation was done twice) to yield the desired product (4.6 g, 58% yield). LCMS: <i>m</i>/<i>z</i> = 200.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_11_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 1-((5-Bromo-4-methylpyridin-2-yl)methyl)-3-(2-ethoxy-6-(trifluoromethyl)pyridin-4-yl)urea (<b>3e</b>)</h4><div class="NLM_p last">A mixture of 1,1′-carbonyl-di-(1,2,4-triazole) (CDT, 4.14 g, 25.3 mmol, 1.7 eq), 2-ethoxy-6-(trifluoromethyl)pyridin-4-amine <b>4g</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a>) (5.21 g, 25.3 mmol, 1.7 eq), and pyridine (5.6 mL, 69 mmol, 4.6 eq) in DCM (115 mL) was stirred at 45 °C for 30 min, and then the content was added to a flask containing (5-bromo-4-methylpyridin-2-yl)methanamine TFA salt (4.6 g, 14.6 mmol, 1 eq) and DIPEA (16 mL, 92 mmol, 6.3 eq) in THF (15 mL). The reaction was stirred at room temperature for 2 h. The reaction was quenched with H<sub>2</sub>O. The resulting mixture was extracted with DCM (3x). The combined organic phase was washed (1 M HCl), dried (filtered through a phase separator), and concentrated to afford the desired product (3.2 g, 51% yield). LCMS: <i>m</i>/<i>z</i> = 435.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_11_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 1-((5-Bromo-4-methylpyridin-2-yl)methyl)-5-(<i>tert</i>-butyl)-3-(2-ethoxy-6-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazinan-2-one (<b>4e</b>)</h4><div class="NLM_p last">A mixture of 1-((5-bromo-4-methylpyridin-2-yl)methyl)-3-(2-ethoxy-6-(trifluoromethyl)pyridin-4-yl)urea <b>3e</b> (3.2 g, 7.4 mmol, 1 eq), formaldehyde (37% H<sub>2</sub>O, 12 mL, 148 mmol, 20 eq), 4-methylmorpholine (16.3 mL, 148 mmol, 20 eq), and <i>t</i>-BuNH<sub>2</sub> (15.7 mL, 148 mmol, 20 eq) in 1:1 EtOH/H<sub>2</sub>O (74 mL) was stirred at 100 °C for 1 h. The mixture was diluted with EtOAc and H<sub>2</sub>O. The two phases were separated, and the aqueous layer was further extracted with EtOAc. The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was purified by flash column chromatography (SiO<sub>2</sub>, 90:10 to 30:70 petroleum ether/EtOAc) to afford the desired product as a yellow oil (2.5 g, 64% yield). LCMS: <i>m</i>/<i>z</i> = 530.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_11_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 1-[[5-[(1,3-Dimethylpyrazol-4-yl)amino]-4-methyl-2-pyridyl]methyl]-3-[2-ethoxy-6-(trifluoromethyl)-4-pyridyl]urea (<b>35</b>)</h4><div class="NLM_p last">A mixture of 1-((5-bromo-4-methylpyridin-2-yl)methyl)-5-(<i>tert</i>-butyl)-3-(2-ethoxy-6-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazinan-2-one <b>4e</b> (55 mg, 0.10 mmol, 1 eq), 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine (33 mg, 0.3 mmol, 3 eq), Pd<sub>2</sub>(dba)<sub>3</sub> (9 mg, 0.01 mmol, 0.1 eq), BINAP (12 mg, 0.02 mmol, 0.2 eq), and NaO<i>t</i>Bu (14 mg, 0.15 mmol, 1.5 eq) in dry toluene (0.3 mL) was degassed with N<sub>2</sub>. The mixture was stirred at 70 °C overnight. The mixture was diluted with EtOAc and washed with H<sub>2</sub>O. The two phases were separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was taken up in 1:1 1,4-dioxane/6 M NaOH (2 mL). The resulting mixture was stirred at 100 °C overnight. The mixture was partitioned between EtOAc and H<sub>2</sub>O. The two phases were separated. The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was purified by preparatory HPLC (gradient from 20% MeCN to 45% MeCN in water/0.1% formic acid) to afford the desired product (2.2 mg, 5% yield). LCMS: method B, <i>R</i><sub>t</sub>: 1.30 min; purity: >99%, <i>m</i>/<i>z</i> = 464.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.64 (s, 1H), 7.54 (d, <i>J</i> = 4.3 Hz, 2H), 7.50 (d, <i>J</i> = 1.6 Hz, 1H), 7.11 (t, <i>J</i> = 5.6 Hz, 1H), 7.04–6.98 (m, 2H), 6.49 (s, 1H), 4.32–4.20 (m, 4H), 3.75 (s, 3H), 2.20 (s, 3H), 1.95 (s, 3H), 1.30 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec5_11_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 6-Chloro-4-methyl-pyridazin-3-ol (<b>2f</b>)</h4><div class="NLM_p last">3,6-Dichloro-4-methylpyridazine <b>1f</b> (2.97 g, 18.2 mmol, 1 eq) in aqueous 3.3 M NaOH (30 mL) was stirred at reflux temperature for 1 h. Once cooled at room temperature, aqueous 50% acetic acid (10 mL) was added to pH ≈ 6 and the resulting solid filtered and washed with water. Purification by silica chromatography (EtOAc/petroleum ether; 25:75 to 100:0) afforded the desired compound (1 g, 38% yield). LCMS: <i>m</i>/<i>z</i> = 144.9, 146.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_11_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 6-Hydroxy-5-methylpyridazine-3-carbonitrile (<b>3f</b>)</h4><div class="NLM_p last">A mixture of 6-chloro-4-methyl-pyridazin-3-ol <b>2f</b> (21.7 g, 150 mmol, 1 eq), Zn(CN)<sub>2</sub> (22.9 g, 195 mmol, 1.3 eq), Pd<sub>2</sub>(dba)<sub>3</sub> (6.87 g, 7.5 mmol, 0.05 eq), and 1,1′-bis(diphenylphosphino)ferrocene (6.64 g, 12 mmol, 0.08 eq) in DMF (150 mL) was degassed under nitrogen and heated at 120 °C for 1 h. The resulting mixture was diluted with DCM and saturated NaHCO<sub>3</sub>. The aqueous layer was separated and extracted with DCM and DCM/<i>i</i>PrOH (4:1), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The residue was triturated with a mixture of petroleum ether/EtOAc (3:1), filtered, washed with petroleum ether, and dried to afford the desired compound (17.4 g, 86% yield). LCMS: <i>m</i>/<i>z</i> = 135.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_11_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 6-Chloro-5-methylpyridazine-3-carbonitrile (<b>4f</b>)</h4><div class="NLM_p last">POCl<sub>3</sub> (31 mL, 333 mmol, 3 eq) was added to 6-hydroxy-5-methylpyridazine-3-carbonitrile <b>3f</b> (15 g, 111 mmol, 1 eq) in acetonitrile (200 mL), and the resulting mixture was heated at reflux temperature until completion of the reaction (4 h). The cooled mixture was concentrated under reduced pressure, and the residue was diluted in acetonitrile (200 mL). This solution was poured into a stirred mixture of ice-cold DCM and aqueous NaHCO<sub>3</sub>. Solid NaHCO<sub>3</sub> was added in portions to attain a pH of approximately 7. Both layers were separated, and the aqueous layer was extracted with DCM. The combined organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to afford the desired compound (16.5 g, 97% yield). LCMS: <i>m</i>/<i>z</i> = 154.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_11_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 5-Methyl-6-(1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl)pyridazine-3-carbonitrile (<b>5f</b>)</h4><div class="NLM_p last">Pd(PPh<sub>3</sub>)<sub>4</sub> (7.44 g, 6.64 mmol, 0.1 eq) was added to a degassed suspension of 6-chloro-5-methylpyridazine-3-carbonitrile <b>4f</b> (64 mmol, 1.0 eq) and 1-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3-trifluoromethyl-1<i>H</i>-pyrazole (12.4 g, 45 mmol, 0.7 eq) in DMF (275 mL). The resulting mixture was stirred at room temperature for 1 h. A 2.5 M aqueous Na<sub>2</sub>CO<sub>3</sub> solution (64 mL) was added, and the resulting mixture was stirred at 85 °C until completion. The cooled mixture was filtered on Celite and washed with EtOAc. The organic extract was washed three times with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. Purification by silica chromatography (column: 120 g silica 25 μm; EtOAc/DCM; 0:100 to 10:90) afforded the desired compound (6.8 g, 40% yield). LCMS: <i>m</i>/<i>z</i> = 268.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_11_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> [5-Methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methanamine HCl (<b>6f</b>)</h4><div class="NLM_p last">Pd (10% on charcoal, 4.25 g, 4 mmol, 0.15 eq) was added to a degassed mixture of 5-methyl-6-(1-methyl-3-trifluoromethyl-1<i>H</i>-pyrazol-4-yl)-pyridazine-3-carbonitrile <b>5f</b> (7.3 g, 27.3 mmol, 1 eq) and aq. 6 M HCl (10 mL, 60 mmol, 2.2 eq) in methanol (180 mL). The mixture was stirred at room temperature under hydrogen (1 atm) until completion of the reaction. The resulting mixture was filtered on Celite and washed with methanol and acetonitrile, and the filtrate was concentrated under reduced pressure. The residue was triturated with Et<sub>2</sub>O to afford the hydrochloride salt of the desired compound (8.0 g, 95% yield). LCMS: <i>m</i>/<i>z</i> = 272.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_11_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> [5-Methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methanamine (<b>7f</b>)</h4><div class="NLM_p last">NaBH<sub>4</sub> (462 mg, 12.2 mmol, 5 eq) was added portionwise to a mixture of 5-methyl-6-(1-methyl-3-trifluoromethyl-1<i>H</i>-pyrazol-4-yl)-pyridazine-3-carbonitrile <b>5f</b> (2.44 mmol, 1 eq), TFA (0.94 mL, 12.2 mmol, 5 eq) and NiCl<sub>2</sub>·6H<sub>2</sub>O (233 mg, 0.98 mmol, 0.4 eq) in MeOH (10 mL) at 0 °C. After 3 h, a further 230 mg of NaBH<sub>4</sub> (6.1 mmol, 2.5 eq) was added. The resulting mixture was stirred at room temperature for 3 h. The mixture was filtered over Celite and concentrated under reduced pressure. Purification by SCX resin exchange afforded the desired product as a free base. The product was used as such in the next step. LCMS: <i>m</i>/<i>z</i> = 272.1 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> General Procedure for Preparation of Ureas <b>37</b>, <b>42</b>, <b>43</b>, and <b>48</b></h3><div id="sec5_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 1-(2-Chloro-6-ethoxypyridin-4-yl)-3-[5-methyl-6-(1-methyl-3-trifluoromethyl-1<i>H</i>-pyrazol-4-yl)-pyridazin-3-ylmethyl]urea (<b>37</b>)</h4><div class="NLM_p last">1,1′-Carbonyl-di-(1,2,4-triazole) (726 mg, 4.42 mmol, 1.5 eq) was added to a mixture of 2-chloro-6-ethoxypyridin-4-ylamine (356 mg, 2.07 mmol, 0.7 eq) in pyridine (0.71 mL, 8.85 mmol, 3 eq) and DCM (15 mL). The reaction mixture was stirred at 45 °C for 30 min. Once cooled to room temperature, [5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methanamine <b>7f</b> (800 mg, 2.95 mmol, 1.0 eq) was added and the resulting mixture was stirred at room temperature for 1 h. The mixture was diluted with DCM and washed with saturated aqueous NH<sub>4</sub>Cl and saturated aqueous NaHCO<sub>3</sub>. The organic phase was filtered through a phase separator and concentrated under reduced pressure. The residue was purified by silica chromatography (MeOH/DCM; 0:100 to 4:96) followed by triturated in a mixture of methyl <i>tert</i>-butyl ether/petroleum ether to afford the desired compound (650 mg, 65% yield). LCMS: method B, <i>R</i><sub>t</sub>: 1.30 min; purity: >99%, <i>m</i>/<i>z</i> = 470.2 (M + H)<sup>+</sup>. HRMS: calcd mass for C<sub>19</sub>H<sub>20</sub>ClF<sub>3</sub>N<sub>7</sub>O<sub>2</sub> (M + H)<sup>+</sup> 470.1314; found 470.1321; difference 1.6 ppm. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.47 (s, 1H), 8.29 (s, 1H), 7.56 (d, <i>J</i> = 1.0 Hz, 1H), 7.28 (t, <i>J</i> = 5.6 Hz, 1H), 7.13 (d, <i>J</i> = 1.5 Hz, 1H), 6.78 (d, <i>J</i> = 1.5 Hz, 1H), 4.61 (d, <i>J</i> = 5.6 Hz, 2H), 4.22 (q, <i>J</i> = 7.0 Hz, 2H), 4.02 (s, 3H), 2.26 (d, <i>J</i> = 0.9 Hz, 3H), 1.28 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.2, 159.4, 154.9, 153.5, 151.9, 148.2, 138.7 (q, <i>J</i> = 36.1 Hz), 137.8, 134.3, 126.6, 126.3–117.3 (m), 116.7, 105.9, 95.8, 62.4, 43.3, 40.2, 19.2, 14.9. mp = 205 °C.</div></div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> General Procedure for Preparation of Ureas <b>38</b>–<b>41</b>, <b>46</b>, <b>47</b>, and <b>50</b>–<b>51</b></h3><div id="sec5_13_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 1-(2-Ethoxy-6-trifluoromethylpyridin-4-yl)-3-[5-methyl-6-(1-methyl-3-trifluoromethyl-1<i>H</i>-pyrazol-4-yl)-pyridazin-3-ylmethyl]urea (<b>40</b>)</h4><div class="NLM_p last">A mixture of 1,1′-carbonyl-di-(1,2,4-triazole) (1.14 g, 6.97 mmol, 1.2 eq) was added to a mixture of 2-ethoxy-6-(trifluoromethyl)pyridin-4-amine <b>4g</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a>) (1.44 g, 6.97 mmol, 1.2 eq) in dry pyridine (1.41 mL, 17.4 mmol, 3.0 eq) and dry DCM (29 mL). The resulting mixture was stirred at 45 °C for 30 min. The abovementioned mixture was added to a suspension of [5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methanamine hydrochloride salt <b>6f</b> (2.0 g, 5.81 mmol, 1.0 eq) and diisopropylethylamine (4.0 mL, 4.0 eq) in dry THF (8.0 mL). The resulting mixture was stirred at room temperature for 30 min. The reaction was performed four times with the same amounts. After completion, the reactions were combined. The resulting mixture was diluted with DCM and water. The organic phase was washed with 1 M HCl solution, filtered through a phase separator, and concentrated under reduced pressure. The crudes were gathered and purified by flash chromatography on silica gel (eluting with Et<sub>2</sub>O/Acetone 95/5 to 90/10) to give, after trituration in MTBE/MeCN, the desired compound (11.0 g, 94% yield). LCMS: method B, <i>R</i><sub>t</sub>: 1.36 min; purity: >99%, <i>m</i>/<i>z</i> = 504.3 (M + H)<sup>+</sup>. HRMS: calcd mass for C<sub>20</sub>H<sub>20</sub>F<sub>6</sub>N<sub>7</sub>O<sub>2</sub> (M + H)<sup>+</sup> 504.1577; found 504.1586; difference 1.7 ppm. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.68 (s, 1H), 8.29 (s, 1H), 7.57 (s, 1H), 7.52 (d, <i>J</i> = 1.6 Hz, 1H), 7.37 (t, <i>J</i> = 5.5 Hz, 1H), 7.05 (d, <i>J</i> = 1.6 Hz, 1H), 4.62 (d, <i>J</i> = 5.5 Hz, 2H), 4.29 (q, <i>J</i> = 7.0 Hz, 2H), 4.02 (s, 3H), 2.26 (d, <i>J</i> = 0.8 Hz, 3H), 1.31 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.0, 159.4, 155.0, 153.5, 151.0, 144.8 (q, <i>J</i> = 33.5 Hz), 138.7 (q, <i>J</i> = 36.1 Hz), 137.8, 134.3, 126.6, 126.0–117.7 (m), 126.1–117.6 (m), 116.7, 104.5 (d, J = 3.8 Hz), 99.8, 62.3, 43.3, 39.8, 19.2, 14.8. mp = 205 °C.</div></div><div id="sec5_13_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 1-[2-Chloro-6-(2,2-difluoroethoxy)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea (<b>38</b>)</h4><div class="NLM_p last">This compound was prepared from <b>6f</b> and <b>2h</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a>) according to the general procedure used for the preparation of <b>40</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.32 min; purity: >99%, <i>m</i>/<i>z</i> = 506.3 (M + H)<sup>+</sup>. HRMS: calcd mass for C<sub>19</sub>H<sub>18</sub>ClF<sub>5</sub>N<sub>7</sub>O<sub>2</sub> (M + H)<sup>+</sup> 506.1125; found 506.1134; difference 1.7 ppm. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.57 (s, 1H), 8.29 (s, 1H), 7.57 (d, <i>J</i> = 0.9 Hz, 1H), 7.35 (t, <i>J</i> = 5.6 Hz, 1H), 7.21 (d, <i>J</i> = 1.5 Hz, 1H), 6.91 (d, <i>J</i> = 1.5 Hz, 1H), 6.35 (tt, <i>J</i> = 54.5, 3.4 Hz, 1H), 4.62 (d, <i>J</i> = 5.6 Hz, 2H), 4.50 (td, <i>J</i> = 15.1, 3.4 Hz, 2H), 4.02 (s, 3H), 2.26 (d, <i>J</i> = 0.9 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.9, 159.3, 154.9, 153.5, 152.3, 147.9, 138.7 (q, <i>J</i> = 36.1 Hz), 137.8, 134.3, 126.6, 121.9 (q, <i>J</i> = 268.9 Hz), 116.7, 114.4 (t, <i>J</i> = 238.9 Hz), 106.9, 95.9, 64.4 (t, <i>J</i> = 26.6 Hz), 43.3, 40.1, 19.2. mp = 221–222 °C.</div></div><div id="sec5_13_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 1-(2-Cyano-6-ethoxy-4-pyridyl)-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea (<b>39</b>)</h4><div class="NLM_p last">This compound was prepared from <b>6f</b> and <b>2i</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a>) according to the general procedure used for the preparation of <b>40</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.24 min; purity: >99%, <i>m</i>/<i>z</i> = 461.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.62 (s, 1H), 8.29 (s, 1H), 7.57 (t, <i>J</i> = 1.5 Hz, 2H), 7.40 (t, <i>J</i> = 5.6 Hz, 1H), 7.13 (d, <i>J</i> = 1.8 Hz, 1H), 4.62 (d, <i>J</i> = 5.6 Hz, 2H), 4.27 (q, <i>J</i> = 7.0 Hz, 2H), 4.02 (s, 3H), 2.26 (d, <i>J</i> = 0.8 Hz, 3H), 1.30 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec5_13_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 1-(2-Ethoxy-6-methyl-4-pyridyl)-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea (<b>41</b>)</h4><div class="NLM_p last">This compound was prepared from <b>6f</b> and <b>2l</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a>) according to the general procedure used for the preparation of <b>40</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.16 min; purity: >99%, <i>m</i>/<i>z</i> = 450.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.14 (s, 1H), 8.31 (s, 1H), 7.56 (s, 1H), 7.19–7.12 (m, 1H), 6.74 (d, <i>J</i> = 4.3 Hz, 2H), 4.60 (d, <i>J</i> = 5.5 Hz, 2H), 4.22 (q, <i>J</i> = 7.0 Hz, 2H), 4.02 (s, 3H), 2.27 (d, <i>J</i> = 3.2 Hz, 6H), 1.27 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.2, 159.6, 156.1, 155.2, 153.4, 150.0, 138.7 (d, J = 36.1 Hz), 137.8, 134.3, 126.6, 126.1–117.1 (m), 116.7, 105.9, 94.4, 61.1, 43.2, 39.9, 24.6, 19.2, 15.1.</div></div><div id="sec5_13_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 1-[2-Chloro-6-(2-methoxyethoxy)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea (<b>42</b>)</h4><div class="NLM_p last">This compound was prepared from <b>7f</b> and <b>3h</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a>) according to the general procedure used for the preparation of <b>37</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.21 min; purity: >99%, <i>m</i>/<i>z</i> = 500.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.49 (s, 1H), 8.29 (s, 1H), 7.56 (d, <i>J</i> = 1.0 Hz, 1H), 7.31 (t, <i>J</i> = 5.6 Hz, 1H), 7.15 (d, <i>J</i> = 1.5 Hz, 1H), 6.81 (d, <i>J</i> = 1.6 Hz, 1H), 4.61 (d, <i>J</i> = 5.5 Hz, 2H), 4.33–4.26 (m, 2H), 4.02 (s, 3H), 3.65–3.58 (m, 2H), 3.29 (s, 4H), 2.26 (d, <i>J</i> = 0.8 Hz, 3H).</div></div><div id="sec5_13_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 1-[2-[2-(Dimethylamino)ethoxy]-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea (<b>43</b>)</h4><div class="NLM_p last">This compound was prepared from <b>7f</b> and <b>2k</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a>) according to the general procedure used for the preparation of <b>37</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.31 min; purity: >99%, <i>m</i>/<i>z</i> = 547.3 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.75 (s, 1H), 8.31 (s, 1H), 7.57 (s, 1H), 7.51 (s, 1H), 7.43 (t, <i>J</i> = 5.8 Hz, 1H), 7.07 (s, 1H), 4.62 (d, <i>J</i> = 5.5 Hz, 2H), 4.33 (t, <i>J</i> = 5.8 Hz, 2H), 4.02 (s, 3H), 2.59 (t, <i>J</i> = 5.8 Hz, 2H), 2.27 (s, 3H), 2.19 (s, 6H).</div></div><div id="sec5_13_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 1-(6-Chloro-2-ethoxy-3-methyl-4-pyridyl)-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea (<b>46</b>)</h4><div class="NLM_p last">This compound was prepared from <b>6f</b> and <b>3j</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a>) according to the general procedure used for the preparation of <b>40</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.38 min; purity: >99%, <i>m</i>/<i>z</i> = 484.2 (M + H)<sup>+</sup>. HRMS: calcd mass for C<sub>20</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>7</sub>O<sub>2</sub> (M + H)<sup>+</sup> 484.1470; found 484.1474; difference 0.8 ppm. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.52 (s, 1H), 8.32 (s, 1H), 7.88 (d, <i>J</i> = 12.8 Hz, 2H), 7.61 (s, 1H), 4.64 (d, <i>J</i> = 5.3 Hz, 2H), 4.25 (q, <i>J</i> = 7.0 Hz, 2H), 4.03 (s, 3H), 2.28 (s, 3H), 2.03 (s, 3H), 1.31 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec5_13_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 1-(6-Cyano-2-ethoxy-3-methyl-4-pyridyl)-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea (<b>47</b>)</h4><div class="NLM_p last">This compound was prepared from <b>6f</b> and <b>3m</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a>) according to the general procedure used for the preparation of <b>40</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.32 min; purity: >99%, <i>m</i>/<i>z</i> = 475.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.68 (s, 1H), 8.35 (s, 1H), 8.30 (s, 1H), 7.87 (t, <i>J</i> = 5.3 Hz, 1H), 7.61 (s, 1H), 4.65 (d, <i>J</i> = 5.3 Hz, 2H), 4.31 (q, <i>J</i> = 7.0 Hz, 2H), 4.02 (s, 3H), 2.30–2.25 (m, 3H), 2.11 (s, 3H), 1.33 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec5_13_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 1-(2-Ethoxy-3,6-dimethyl-4-pyridyl)-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea (<b>48</b>)</h4><div class="NLM_p last">This compound was prepared from <b>7f</b> and <b>2o</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a>) according to the general procedure used for the preparation of <b>37</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.29 min; purity: >99%, <i>m</i>/<i>z</i> = 464.2 (M + H)<sup>+</sup>. HRMS: calcd mass for C<sub>21</sub>H<sub>25</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> (M + H)<sup>+</sup> 464.2016; found 464.2027; difference 2.3 ppm. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.30 (d, <i>J</i> = 1.1 Hz, 1H), 8.21 (s, 1H), 7.67 (t, <i>J</i> = 5.5 Hz, 1H), 7.63–7.56 (m, 2H), 4.62 (d, <i>J</i> = 5.4 Hz, 2H), 4.26 (q, <i>J</i> = 7.0 Hz, 2H), 4.02 (s, 3H), 2.30–2.24 (m, 6H), 2.00 (s, 3H), 1.29 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.4, 159.5, 155.2, 153.4, 152.2, 147.4, 138.7 (q, <i>J</i> = 36.0 Hz), 137.8, 134.3, 126.8, 121.9 (q, <i>J</i> = 269.2 Hz), 116.7, 106.9, 102.1, 61.3, 43.3, 39.9, 24.6, 19.2, 15.2, 9.6. mp = 195–196 °C.</div></div><div id="sec5_13_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 1-(3-Chloro-2-ethoxy-6-methyl-4-pyridyl)-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea (<b>50</b>)</h4><div class="NLM_p last">This compound was prepared from <b>6f</b> and <b>1n</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a>) according to the general procedure used for the preparation of <b>40</b>. LCMS: method A, <i>R</i><sub>t</sub>: 1.38 min; purity: >99%, <i>m</i>/<i>z</i> = 484.1 (M + H)<sup>+</sup>. HRMS: calcd mass for C<sub>20</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>7</sub>O<sub>2</sub> (M + H)<sup>+</sup> 484.1470; found 484.1479; difference 1.8 ppm. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.62 (s, 1H), 8.30 (d, <i>J</i> = 1.1 Hz, 1H), 8.15 (t, <i>J</i> = 5.5 Hz, 1H), 7.81 (s, 1H), 7.59 (d, <i>J</i> = 0.9 Hz, 1H), 4.63 (d, <i>J</i> = 5.5 Hz, 2H), 4.34 (q, <i>J</i> = 7.1 Hz, 2H), 4.02 (s, 3H), 2.30 (d, <i>J</i> = 0.6 Hz, 3H), 2.27 (d, <i>J</i> = 0.9 Hz, 3H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec5_13_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 1-(3-Cyano-2-ethoxy-6-methyl-4-pyridyl)-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea (<b>51</b>)</h4><div class="NLM_p last">This compound was prepared from <b>6f</b> and <b>1q</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">Supporting Information</a>) according to the general procedure used for the preparation of <b>40</b>. LCMS: method B, <i>R</i><sub>t</sub>: 1.22 min; purity: >99%, <i>m</i>/<i>z</i> = 475.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.16 (s, 1H), 9.04 (s, 1H), 8.26 (s, 1H), 7.47 (s, 1H), 6.53 (s, 1H), 5.43 (s, 2H), 4.46 (q, <i>J</i> = 7.1 Hz, 2H), 4.01 (s, 3H), 2.35 (s, 3H), 2.21 (s, 3H), 1.38 (t, <i>J</i> = 7.0 Hz, 3H).</div></div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> Calcium Flux Assay</h3><div class="NLM_p">The compounds were assessed for they potential agonist activity and, in the same round, for their potential antagonist effect.</div><div id="sec5_14_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Agonist Assay</h4><div class="NLM_p last">CHO cells stably overexpressing human GPCR sphingosine 1-phosphate receptor 2 were seeded in 384-well sterile microplates (50 μL; 7500 cells/well) and were incubated overnight at 37 °C under 5% CO<sub>2</sub>. Cells were subsequently washed twice with 25 μL/well of starvation medium (F-12 Ham’s medium containing 0.1% BSA (FAF)) then starved for 1 h at 37 °C, 5% CO<sub>2</sub> and loaded with 25 μL of Fluo 8 dye diluted in HBSS buffer plus 20 mM HEPES following the recommendations of the manufacturer (Tebu-bio) complemented with 5 mM probenecid. The cells were incubated for 1 h at 37 °C under 5% CO<sub>2</sub>. Dilution series of compounds were diluted in HBSS buffer plus 20 mM HEPES plus 0.1% BSA (FAF). Ten microliters of the diluted compound was added to the cells using the FDSS/μCELL, and intracellular calcium changes were immediately measured by reading the fluorescence for 3 min. The ratio of maximal signal over background before compound injection was used to determine compound response.</div></div><div id="sec5_14_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> Antagonist Assay</h4><div class="NLM_p last">After readout of the agonist activity, the plates were incubated 15 min at 37 °C. Then, the plates were transferred to the FDSS/μCELL reader and cells were stimulated with 10 μL of EC<sub>80</sub> concentration of sphingosine 1-phosphate. Intracellular calcium changes were immediately measured by reading the fluorescence for 3 min. The ratio of maximal signal over background before compound injection was used to determine the compound response. For EC<sub>50</sub>/IC<sub>50</sub> determination, a 10-point dilution series of compounds starting from 23.3 μM and 20 μM highest final concentration for agonist and antagonist, respectively, 1/3 dilution was performed. The obtained ratios for agonist and antagonist readout were normalized versus vehicle and EC<sub>100</sub> of S1P as controls for agonist mode and versus vehicle and EC<sub>80</sub> of S1P for antagonist mode. From these normalized data, EC<sub>50</sub> and IC<sub>50</sub> of the compounds were derived.</div></div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> GTPγS Assay</h3><div class="NLM_p last">The [<sup>35</sup>S] GTPγS assay measures the level of G protein activation following agonist occupation of a GPCR by determining the binding of the non-hydrolyzable analog [<sup>35</sup>S] GTPγS to Gα subunits. Compounds (serial dilutions, 96-well LIA plate) and S1P at EC<sub>80</sub> concentration were incubated with a mixture consisting of membranes derived from stable cell lines overexpressing recombinant human S1P2, [<sup>35</sup>S]GTPγS, and SpA beads (Perkin Elmer, RPNQ0001). Reactions (50 μL cpd + 30 μL S1P2 membrane preincubated with PVT-WGA SPA beads +20 μL S1P at EC<sub>80</sub>) were incubated at room temperature for 4 h followed by centrifugation (20 min, 2000 rpm). Plates were read on a TopCount reader (Molecular Devices, <sup>35</sup>S-GTPγS, 1 min readout time/well) immediately after centrifugation.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> Radioligand-Based Binding Assay</h3><div class="NLM_p last">The following assay can be used for determination of S1PR2 binding. The binding assay measures the potential to compete with radioactively labeled S1P for binding to the receptor. The assay was performed in a 96-well plate where the following reagents are added (final concentrations: 1% DMSO, 7.5 nM radiolabeled S1P, 20 μM to 1 nM 1/3 serial dilutions of test compounds). First, 50 μL of compound solution (serial dilution; 4% DMSO/buffer) is added into the assay plate followed by addition of 100 μL of a mixture consisting of membrane and scintillation proximity assay (SpA) beads [mixture consists of 20 μg/well membranes derived from stable cell lines overexpressing S1PR2, 0.5 mg/well polyvinyltoluene-wheat germ-agglutinin (PVT-WGA) beads (Perkin Elmer, RPNQ0001)]. All components were diluted in assay buffer containing 20 mM Tris pH 7.5; 10 mM MgCl<sub>2</sub>; 100 mM NaCl; 0.4% BSA FAF; 1 mM Na<sub>3</sub>VO<sub>4</sub>) and incubated for 15 min until addition to the assay plate. Subsequently, 50 μL of radioactively labeled S1P (7.5 nM final concentration) was added to the wells (Sphingosine, <span class="smallcaps smallerCapital">d</span>-erythro-[3-<sup>3</sup>H] 1-phosphate; ARC; ART0778). After incubation for 2 h at room temperature, plates were centrifuged at 2000 rpm for 20 min. Plates were read on a TopCount reader (Perkin Elmer) immediately after centrifugation (readout time, 1 min/well).</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> IL8 Assay (in the Absence and Presence of 2% HSA)</h3><div class="NLM_p">The assay was performed in two formats, 96 and 384 wells. The values from the two formats were in good agreement. For the compounds tested in both assays, IC<sub>50</sub> values are reported as geometrical means. For compounds tested only in one of the two assays, IC<sub>50</sub> values are reported without distinction. Two conditions were applied: with and without 2% human serum albumin (HSA, equivalent to approximately 40% serum).</div><div class="NLM_p">Seven days before seeding, HFL-1 cells were thawed in growth/seeding medium (F12K medium complemented with 10% heat-inactivated FBS and 1% Pen/strep) and incubated at 37 °C, 5% CO<sub>2</sub>. Three days before seeding, the cells were split once. Forty (6000 cells/well) or 100 μL (16,000 cells/well) HFL-1 cells were seeded in growth/seeding medium in 384-well or 96-well plates, respectively. Plates were incubated at room temperature for 1 h followed by overnight incubation at 37 °C, 5% CO<sub>2</sub>. The medium was replaced with 64 μL (384 well) or 160 μL (96 well) starvation medium containing 1% heat-inactivated FBS, 1% P/S with or without 1.95% HSA (corresponding to approximately 40% serum) for 16–24 h at 37 °C, 5% CO<sub>2</sub>. Eight microliters of a 10-point serial dilution, 30 μM highest final concentration, 1/3 dilution was added to the cells. Plates were incubated for 1 h at 37 °C, 5% CO<sub>2</sub> followed by the addition of 20 μL (96 format)/8 μL (384 format) S1P at EC<sub>80</sub> concentration (1 μM, 96 format, or 0.5 μM, 384 format, final concentration for plates without HSA; 5 μM, 96 format, or 2 μM, 384 format, final concentration for plates with HSA) to the sample and vehicle wells. No trigger was added to the wells to be used as a positive control. Plates were incubated for 16–24 h at 37 °C, 5% CO<sub>2</sub>. ELISA plates were coated with 40 μL of 1 μg/mL IL8 capture antibody and incubated overnight at 4 °C. ELISA plates were blocked using 80 μL of sucrose blocking buffer for 4 h at room temperature. Forty microliters of the supernatant was harvested on the ELISA plates followed by overnight incubation at 4 °C. Thirty-five microliters of 50 ng/mL detection antibody was added to the ELISA plates, which were incubated for 2 h at room temperature. Subsequently, 35 μL (500 ng/mL) Strep-HRP was added followed by 45–60 min incubation in the dark. Lastly, 50 μL of luminol substrate was added and chemiluminescence was read on the Envision after 5 min room temperature incubation in the dark.</div><div class="NLM_p last">Free IC<sub>50</sub> values were calculated from the following equation:<span class="NLM_disp-formula" id="eq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_m001.gif" alt="" id="_i107" /></img><span class="labelSpan">(1)</span></span>where fu, medium was determined from the following equation:<span class="NLM_disp-formula" id="eq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_m002.gif" alt="" id="_i108" /></img><span class="labelSpan">(2)</span></span>where fu is the fraction unbound from the hPPB assay and protein% is the percentage of serum used in the assay.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> S1P-Induced Collagen Gel Lattice Contraction</h3><div class="NLM_p last">Normal human lung fibroblasts (Promocell) were treated with 1 ng/mL TGF-β (Gibco, PHG92I4) for 4 days in FGM-2 culture medium (Lonza, CC3132). 96 h after seeding the cells in medium containing TGF-β, and the cells were harvested and embedded in collagen lattices. Collagen lattices were prepared by mixing 8 parts PureCol (acidic collagen I solution at 3 mg/mL, Advanced Biomatrix, 5005-100 mL) with 1 part 10X medium or DPBS and 1 part HEPES 0.2 M at pH 8.0 (to neutralize the pH of the collagen solution and the stiffening of the gel), and cells were added in a 1 part/volume of the collagen gel at a cell density of 200,000 cells per gel. Per well of a 24 well plate (Greiner Bio-one, 662160), 550 μL of collagen gel with cells was used, consisting of 400 μL of PureCol, 50 μL of 10X PBS, and 50 μL of HEPES 0.2 M at pH 8.0 together with 50 μL of cell suspension. Plates were incubated for 1.5–2 h at 37 °C 5% CO<sub>2</sub>. After 2 h of gel formation, 1 mL of FGM without serum supplemented with 1 ng/mL TGF-β was added to the collagen gel. The plates were incubated for 72 h at 37 °C 5% CO<sub>2</sub> for stress build-up. Seventy-two hours after collagen gel formation, the gels were treated with compounds diluted in FGM-2 serum free medium. Two hours after compound incubation, 1 μM S1P (Avanti Polar lipids, 860,492) was added and the treated gels were released from the sides of the wells after which the plates were incubated at 37 °C 5% CO<sub>2</sub> for another hour. Images were taken at the end of the assay and analyzed with ImageJ software.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> Liver Microsomal Stability Assay</h3><div class="NLM_p">A 10 mM stock solution of compound in DMSO was diluted three-fold in DMSO. This pre-diluted compound solution was then diluted to 2 μΜ in a 100 mM phosphate buffer (pH 7.4) and pre-warmed at 37 °C. This compound dilution was mixed 1/2 with a microsomal/cofactor mix at 37 °C under shaking at 300 rpm. Final reaction conditions are as follows: 100 pL incubation volume, 1 μΜ test compound (<i>n</i> = 2), 0.2% DMSO, 0.5 mg/mL microsomes (Xeno-Tech, Kansas City, KS, USA), 0.6 U/mL glucose-6-phosphate-dehydrogenase (G6PDH, Roche, 10127671001), 3.3 mM mgCb (Sigma, M2670), 3.3 mM glucose-6-phosphate (Sigma, G-7879), and 1.3 mM NADP+ (Sigma, N-0505). After 30 min of incubation at 300 rpm and 37 °C, the reaction was stopped with 600 μL of STOP solution (Acetonitrile with Diclofenac as internal standard). For the zero-time point, 600 μL of STOP solution were added to the compound dilution before the microsome mix was added. The samples of both time points were centrifuged and filtered, and the supernatant analyzed by LC-MS/MS. The samples were analyzed on LC/MS-MS with a flow rate of 0.6 mL/min. The mobile phase A was 0.1% formic acid in H<sub>2</sub>O, and the mobile phase B was 0.1% formic acid in 90% MeCN and 10% H<sub>2</sub>O. The sample was run under positive or negative ion spray on Pursuit C18, 5 pm (2.0 x 20 mm) column, from Agilent. The instrument responses (peak areas/IS peak area) were referenced to the zero time-point samples (considered as 100%) in order to determine the percentage of compound remaining. Verapamil (1 μΜ) and warfarin (1 μΜ) were used as reference compounds, as unstable and stable compounds, respectively. If the microsomal stability values for these controls are not in the range determined by the historical data, the assay is not validated. The data on microsomal stability are expressed as a percentage of the total amount of compound remaining after 30 min incubation. The solubility of the compound in the final test concentration in 100 mM buffer pH 7.4 was checked using a microscope to indicate whether precipitation occurred. For the calculation of the half-life, a first-order kinetic was assumed. Intrinsic clearance (Clint) and scaled intrinsic clearance (scaled Clint) values were obtained with the equations below:</div><div class="NLM_p">Intrinsic clearance equation:<span class="NLM_disp-formula" id="eq3"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_m003.gif" alt="" id="_i111" /></img><span class="labelSpan">(3)</span></span></div><div class="NLM_p">Scaled intrinsic clearance equation:<span class="NLM_disp-formula" id="eq4"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_m004.gif" alt="" id="_i112" /></img><span class="labelSpan">(4)</span></span></div><div class="NLM_p">To take into account nonspecific binding, scaled Clint values were corrected with the fraction unbound in microsomes (fu, mic),<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> according to the equation below:</div><div class="NLM_p">Scaled intrinsic clearance unbound (clearance unbound) equation:<span class="NLM_disp-formula" id="eq5"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_m005.gif" alt="" id="_i113" /></img><span class="labelSpan">(5)</span></span></div><div class="NLM_p last">Fu, mic values were experimentally determined. In case it was not possible, the values were calculated using a global Random Forest regression model.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> Fu, mic Determination</h3><div class="NLM_p last">Equilibrium dialysis is a technique used to measure microsomal binding. Briefly, the assay was performed in a 96-well Teflon dialysis unit (Dialysis Device, model HTD96b), where each well consists of two chambers separated by a dialysis membrane (membrane strips, MW cutoff 12–14 kDa, HTDialysis). Inactivated liver microsomes (pooled human liver microsomes, Xenotech, protein concentration of 0.5 mg/mL) spiked with a compound (1 μM final concentration, 0.5% DMSO) were added to one chamber and buffer solution (50 mM PBS Buffer) to the other side of the well. Each compound was analyzed in duplicate, for 4 h at 37 °C. At the end of incubation, both chambers were sampled and analyzed by LC-MS/MS. The unbound microsomal fraction (fu, mic) was calculated as the concentration in buffer divided by the total concentration in the microsomal side. Positive controls included in this assay are terfenadine and verapamil.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> PK Mouse</h3><div class="NLM_p last">These studies were performed with naïve male CD1 mice (Janvier France, 4–5 weeks old). Mice were dosed iv via a bolus in the tail vein with a dose level of 1 mg/kg or orally as a single oesophageal gavage with a dose level of 5 mg/kg. For the iv route, the compound was formulated in PEG 200/water (60/40; v/v). For the oral route, the compound was formulated in Tween 80/MC 0.5% or PEG400/MC 0.5%. Before the oral dosing, the animals were deprived of food for at least 12 h before compound administration and 3 h after administration. All animals had free access to tap water. Blood samples were collected under light anesthesia and placed into tubes containing Li-heparin as an anticoagulant. Blood samples were collected up to 24 h after dosing (composite design: <i>n</i> = 6 mice per route, 2 groups of 3 mice sampled at alternate time points). After centrifugation, the resulting plasma samples were assayed by LC-MS/MS with a non-good-laboratory-practice (non-GLP)-validated method. PK parameters were calculated by noncompartmental analysis using WinNonlin software (Certara, Princeton, NJ, USA).</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> PK Rat</h3><div class="NLM_p last">These studies were performed with naïve male Sprague Dawley rats (Janvier France, 6–8 weeks old). Rats were dosed iv via a bolus in the tail vein with a dose level of 1 mg/kg or orally as a single oesophageal gavage with a dose level of 5 mg/kg (10 mg/kg for compound <b>48</b>). For the iv route, the compound was formulated in PEG200/water (60/40; v/v). For the oral route, the compound was formulated in PEG400/MC 0.5%. Before the oral dosing, the animals were deprived of food for at least 12 h before compound administration and 3 h after administration. All animals had free access to tap water. Blood samples were collected under light anesthesia and placed into tubes containing Li-heparin as an anticoagulant. Blood samples were collected up to 24 h after dosing (<i>n</i> = 3 rats per route, <i>n</i> = 2 for the iv PK study of compound <b>40</b>). After centrifugation, the resulting plasma samples were assayed by LC-MS/MS with a non-good-laboratory-practice (non-GLP)-validated method. PK parameters were calculated by noncompartmental analysis using WinNonlin software (Certara, Princeton, NJ, USA).</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> PK Dog</h3><div class="NLM_p last">These studies were performed with non-naïve male Beagle dogs (compound <b>37</b>: age 13.8 months old, origin: Marshall US, North Rose, NY 14516, USA; compound <b>40</b>: age 15.8 months old, origin: Harlan; compound <b>48</b>: age 17.7 months old, origin: Harlan). Dogs (<i>n</i> = 3) were dosed iv via a 10 min infusion via a catheter with a dose level of 1 mg/kg. After a washout of 3 days, they were dosed orally as a single gavage with a dose level of 5 mg/kg or 1 mg/kg in PEG400/MC 0.5% or MC 0.5%. Before administration by the po route, animals were fasted for a period of at least 12 h before treatment, and food was given just after the 3 h blood sampling. All animals had free access to tap water. Blood samples were taken without an anesthetic from a jugular or cephalic vein into tubes containing lithium heparin as an anticoagulant. Blood samples were taken up to 24 h after the start of infusion. After centrifugation, the resulting plasma samples were assayed by LC-MS/MS with a non-good-laboratory-practice (non-GLP)-validated method. PK parameters were calculated by noncompartmental analysis using WinNonlin software (Certara, Princeton, NJ, USA).</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> Prophylactic Bleomycin-Induced Pulmonary Fibrosis 14-day Mice Model</h3><div class="NLM_p">The aim of these studies is to test the efficacy of test compounds in a 14-day model of bleomycin-induced pulmonary fibrosis in mice. The studies were performed at Fidelta Ltd., Zagreb, Croatia.</div><div id="sec5_24_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> Animals</h4><div class="NLM_p last">These studies were carried out on C57BL/6 N male mice, supplied by Charles River, Italy, which are acclimatized for 7 days after arrival in an environment maintained at 22 °C, at 55% relative humidity, with 15–20 air changes per hour under light cycles of 12 h. Mice were 8 weeks old on arrival for the study involving compound <b>40</b> and 7 weeks old on arrival for the study with compound <b>48</b>. Mice pelleted food and water are provided ad libitum. At least 1 day prior to the start of experiment, all animals were allocated randomly into groups of 15 (study with compound <b>40</b>) or 14 (study with compound <b>48</b>). All animal related research is conducted in accordance with the 2010/63/EU and National legislation regulating the use of laboratory animals in scientific research and for other purposes (Official Gazette 55/13).</div></div><div id="sec5_24_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> Materials</h4><div class="NLM_p last">The solvent for the test solutions was prepared by adding 0.5 g of hydroxyethyl cellulose (Natrosol) into 500 mL of aqua distillate (0.1%) under continuous stirring without heating for 5 h on a magnetic stirrer. Anesthetic solution was prepared by adding 1 mL of Narketan (Narketan 10, Vetoquinol, Bern, Switzerland, 03605877535982) and 0.5 mL of Rompun (Rompun, 2%: Bayer, Leverkusen, Germany) into 9 mL of saline. The resulting solution was administered at 10 mL/kg. To prepare a solution for intranasal challenge (i.n.) challenge, 0.8 mg/mL stock solutions of bleomycin (bleomycin sulfate, Enzo Life Sciences, Inc., USA; CAS no. 9041-93-4; cat. no. BML-AP302-0010) were thawed and diluted in 330 μL of saline. Prior to i.n. administration, mice were anesthetized i.p. with the anesthetic solution described above. Fresh pirfenidone formulation was prepared daily in 0.1% Natrosol formulations to a final concentration of 5 mg/mL. Before dosing, animals were weighed and the pirfenidone amount administered was adjusted accordingly to individual weights corresponding to 10 mL/kg body weight, twice daily p.o., with 7.5 h interval between two administrations. Finally, test compound solutions were prepared by dissolving a suitable amount of the test compound in PEG 400 (20% of the final volume) then MC 0.5% (80% of the final volume) to reach final concentrations of 1, 0.3, and 0.1 mg/mL, thus yielding compounds for doses of 10, 3, and 1 mg/kg (compound <b>40</b>) or in an exact volume of MC 0.5% to reach a final concentration of 0.3, 1, and 3 mg/mL for doses of 3, 10, and 30 mg/kg (compound <b>48</b>). Prior to dosing, animals were weighed, and the amount administered was adjusted accordingly to individual weights. The application volume of the test doses corresponds to 10 mL/kg body weight, and the test compounds were administered p.o. twice daily, with 7.5 h interval between two administrations.</div></div><div id="sec5_24_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> Study</h4><div class="NLM_p last">Animals were examined clinically twice daily. Animals were weighed daily starting from day 0. On day 14, 2 h post-dosing with pirfenidone or the test compound, mice were sacrificed by anesthetic overdose. The lungs were excised and weighed individually. For all groups, the whole superior right lung lobe was placed into a Precellys tube containing silica beads and immediately snap frozen in liquid nitrogen and subjected to gene expression analysis. All remaining lungs were placed into marked bottles containing 10% buffered formalin for further histopathological evaluation. For the study involving compound <b>40</b>, two satellite groups were used (<i>n</i> = 6 per groups) to assess the ssPK for the 3 and 10 mg/kg doses, respectively. These animals were treated with bleomycin and the test compound exactly as the other animals in the study. They were sacrificed at day 7. A minimal target volume of 50 μL of blood was collected into Li-heparin anticoagulant tubes for each time point. The tubes were kept on ice until separation. Within maximum 30 min after collection, blood samples were centrifuged at 2000<i>g</i> for 10 min at 4 °C and the resulting plasma samples were aliquoted into polypropylene tubes (1 x 25 μL). Samples were stored frozen at −20 °C until analysis. Blood samples were collected from the tail vein. Lung tissue was collected at sacrifice, after blood sampling for each animal, weighed, placed into tubes, and stored frozen at −80 °C until analysis.</div></div><div id="sec5_24_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> Sample Analysis, Data Processing, and Statistical Evaluation</h4><div class="NLM_p">For histopathological evaluation, whole lungs (except sampled superior right lung) were embedded in paraffin and stained with Mallory’s trichrome. Pulmonary histological changes were assessed using Matsuse modification of Ashcroft score.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> Statistical analysis and graphical presentation were performed using GraphPad Prism software (version 5.04). The Mann–Whitney test was employed. Differences between groups will be considered statistically significant when <i>p</i> < 0.05. For the ssPK study, after centrifugation, the resulting plasma samples were assayed by LC-MS/MS with a non-good-laboratory-practice (non-GLP)-validated method. Lung samples were homogenized and then processed as the plasma samples. PK parameters of compound <b>40</b> were calculated by noncompartmental analysis using WinNonlin software (Certara, Princeton, NJ, USA).</div><div class="NLM_p last">All animal experiments performed in the manuscript were conducted in compliance with institutional guidelines.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i123"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00138" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57451" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57451" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00138?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00138</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Activity of <b>40</b> against S1P receptors; activity of <b>48</b> against S1P receptors; DR of <b>40</b> against receptors and enzymes from a Cerep broad selectivity panel; steady state PK and IC<sub>50</sub> coverage of compound <b>40</b> (IL8 assay) in BLM-induced pulmonary fibrosis model; synthesis of 4-aminopyridines intermediates for the synthesis of final compounds <b>38</b>–<b>51</b>; synthesis of final compounds <b>44</b>, <b>45</b>, and <b>49</b>; synthesis of final compounds <b>36</b>, <b>52</b>–<b>57</b>, <b>97</b>, <b>98</b>, and <b>101</b>; detailed SAR of investigation of the C5 position of pyridine series; synthesis of final compounds <b>65</b>, <b>72</b>, and <b>120</b>–<b>124</b>; recombinant CYP inhibition of compounds <b>34</b>, <b>37</b>, and <b>40</b>; CYP HLM inhibition of compound <b>40</b>; chemical stability at different pH values and plasma stability of compound <b>40</b>; hERG inhibition of compound <b>40</b>; LCMS analyses of compounds <b>34</b>, <b>40</b>, and <b>48</b> and HRMS spectra of <b>40</b> and <b>48</b>; SAR of compounds <b>52</b>–<b>57</b> (from <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> of the main text); and IC<sub>50</sub> values in S1P2 calcium flux assay (all runs) for compounds <b>19</b> and <b>20</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf">jm1c00138_si_001.pdf (742.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_002.csv">jm1c00138_si_002.csv (3.16 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00138" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77640" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77640" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Oscar Mammoliti</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1521-9254" title="Orcid link">http://orcid.org/0000-0002-1521-9254</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2c435f4f4d5e02414d414143404558456c4b405c4b024f4341"><span class="__cf_email__" data-cfemail="026d716163702c6f636f6f6d6e6b766b42656e72652c616d6f">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adeline Palisse</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#066762636a6f68632876676a6f75756346616a76612865696b"><span class="__cf_email__" data-cfemail="c1a0a5a4ada8afa4efb1a0ada8b2b2a481a6adb1a6efa2aeac">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Caroline Joannesse</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandy El Bkassiny</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brigitte Allart</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alex Jaunet</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christel Menet</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span>; 
    <span>Present Address:
                        Present address: Confo Therapeutics, Technologiepark 94, 9052 Ghent/Zwijnaarde, Belgium (C.M.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beatrice Coornaert</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen Sonck</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span>; 
    <span>Present Address:
                        Present address: Aelin Therapeutics, Gaston Geenslaan 1, 3001 Leuven, Belgium (K.S.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Inge Duys</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philippe Clément-Lacroix</span> - <span class="hlFld-Affiliation affiliation">Galapagos
SASU, 102 avenue Gaston Roussel, 93230 Romainville, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Line Oste</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Monica Borgonovi</span> - <span class="hlFld-Affiliation affiliation">Galapagos
SASU, 102 avenue Gaston Roussel, 93230 Romainville, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emanuelle Wakselman</span> - <span class="hlFld-Affiliation affiliation">Galapagos
SASU, 102 avenue Gaston Roussel, 93230 Romainville, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thierry Christophe</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicolas Houvenaghel</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mia Jans</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bertrand Heckmann</span> - <span class="hlFld-Affiliation affiliation">Galapagos
SASU, 102 avenue Gaston Roussel, 93230 Romainville, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laurent Sanière</span> - <span class="hlFld-Affiliation affiliation">Galapagos
SASU, 102 avenue Gaston Roussel, 93230 Romainville, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Reginald Brys</span> - <span class="hlFld-Affiliation affiliation">Galapagos
NV, Generaal De Wittelaan
L11 A3, 2800 Mechelen, Belgium</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i126">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51210" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51210" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Stella Adriaens and Tiny Deschrijver for the work performed in the HPLC purification of the final compounds. We thank Marie-Pierre Delage for performing the HRMS spectra and Pieter Stouten for the description of the model used for the fu, mic calculations.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i127">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17438" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17438" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 45 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fyrst, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saba, J. D.</span></span> <span> </span><span class="NLM_article-title">An update on sphingosine-1-phosphate and other sphingolipid mediators</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1038/nchembio.392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1038%2Fnchembio.392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=20559316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFKitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=489-497&author=H.+Fyrstauthor=J.+D.+Saba&title=An+update+on+sphingosine-1-phosphate+and+other+sphingolipid+mediators&doi=10.1038%2Fnchembio.392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">An update on sphingosine-1-phosphate and other sphingolipid mediators</span></div><div class="casAuthors">Fyrst, Henrik; Saba, Julie D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-497</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sphingolipids comprise a complex family of naturally occurring mols. that are enriched in lipid rafts and contribute to their unique biochem. properties.  Membrane sphingolipids also serve as a reservoir for bioactive metabolites including sphingosine, ceramide, sphingosine 1-phosphate (S1P) and ceramide 1-phosphate.  Among these, S1P has emerged as a central regulator of mammalian biol.  S1P is essential for mammalian brain and cardiac development and for maturation of the systemic circulatory system and lymphatics.  In addn., S1P contributes to trafficking and effector functions of lymphocytes and other hematopoietic cells and protects against various forms of tissue injury.  However, S1P is also an oncogenic lipid that promotes tumor growth and progression.  Recent preclin. and clin. investigations using pharmacol. agents that target S1P, its receptors, and the enzymes required for its biosynthesis and degrdn. demonstrate the promise and potential risks of modulating S1P signaling in treatment strategies for autoimmunity, cancer, cardiovascular disease, and other pathol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp1G3TLMu507Vg90H21EOLACvtfcHk0liCI4wycllD5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFKitLk%253D&md5=6128ea6a4f1a910deed32f7db8827840</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.392%26sid%3Dliteratum%253Aachs%26aulast%3DFyrst%26aufirst%3DH.%26aulast%3DSaba%26aufirst%3DJ.%2BD.%26atitle%3DAn%2520update%2520on%2520sphingosine-1-phosphate%2520and%2520other%2520sphingolipid%2520mediators%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D489%26epage%3D497%26doi%3D10.1038%2Fnchembio.392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Strub, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maceyka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hait, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Extracellular and intracellular actions of sphingosine-1-phosphate</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>688</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1007/978-1-4419-6741-1_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1007%2F978-1-4419-6741-1_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=20919652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=688&publication_year=2010&pages=141-155&author=G.+M.+Strubauthor=M.+Maceykaauthor=N.+C.+Haitauthor=S.+Milstienauthor=S.+Spiegel&title=Extracellular+and+intracellular+actions+of+sphingosine-1-phosphate&doi=10.1007%2F978-1-4419-6741-1_10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular and intracellular actions of sphingosine-1-phosphate</span></div><div class="casAuthors">Strub, Graham M.; Maceyka, Michael; Hait, Nitai C.; Milstien, Sheldon; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">688</span>
        (<span class="NLM_cas:issue">Sphingolipids as Signaling and Regulatory Molecules</span>),
    <span class="NLM_cas:pages">141-155</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator with crucial roles in a wide variety of cellular functions across a broad range of organisms.  Though a simple mol. in structure, S1P functions are complex.  The formation of S1P is catalyzed by one of two sphingosine kinases that have differential cellular distributions as well as both overlapping and opposing functions and which are activated by many different stimuli.  S1P can act on a family of G protein-coupled receptors (S1PRs) that are also differentially expressed in different cell types, which influences the cellular responses to S1P.  In addn. to acting on receptors located on the plasma membrane, S1P can also function inside the cell, independently of S1PRs.  It also appears that both the intracellular location and the isotype of sphingosine kinase involved are major determinants of inside-out signaling of S1P in response to many extracellular stimuli.  This chapter is focused on the current literature on extracellular and intracellular actions of S1P.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra126VCu0n9bVg90H21EOLACvtfcHk0liZgQJesWIbnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFGgsQ%253D%253D&md5=0544bfe25e635257810a6bf5ffad93d6</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1007%2F978-1-4419-6741-1_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4419-6741-1_10%26sid%3Dliteratum%253Aachs%26aulast%3DStrub%26aufirst%3DG.%2BM.%26aulast%3DMaceyka%26aufirst%3DM.%26aulast%3DHait%26aufirst%3DN.%2BC.%26aulast%3DMilstien%26aufirst%3DS.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DExtracellular%2520and%2520intracellular%2520actions%2520of%2520sphingosine-1-phosphate%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2010%26volume%3D688%26spage%3D141%26epage%3D155%26doi%3D10.1007%2F978-1-4419-6741-1_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Blaho, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span> <span> </span><span class="NLM_article-title">An update on the biology of sphingosine 1-phosphate receptors</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1596</span>– <span class="NLM_lpage">1608</span>, <span class="refDoi"> DOI: 10.1194/jlr.R046300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1194%2Fjlr.R046300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=24459205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1596-1608&author=V.+A.+Blahoauthor=T.+Hla&title=An+update+on+the+biology+of+sphingosine+1-phosphate+receptors&doi=10.1194%2Fjlr.R046300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">An update on the biology of sphingosine 1-phosphate receptors</span></div><div class="casAuthors">Blaho, Victoria A.; Hla, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1596-1608</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) is a membrane-derived lysophospholipid that acts primarily as an extracellular signaling mol.  Signals initiated by S1P are transduced by five G protein-coupled receptors, named S1P1-5.  Cellular and temporal expression of the S1P receptors (S1PRs) det. their specific roles in various organ systems, but they are particularly crit. for regulation of the cardiovascular, immune, and nervous systems, with the most well-known contributions of S1PR signaling being modulation of vascular barrier function, vascular tone, and regulation of lymphocyte trafficking.  However, our knowledge of S1PR biol. is rapidly increasing as they become attractive therapeutic targets in several diseases, such as chronic inflammatory pathologies, autoimmunity, and cancer.  Understanding how the S1PRs regulate interactions between biol. systems will allow for greater efficacy in this novel therapeutic strategy as well as characterization of complex physiol. networks.  Because of the rapidly expanding body of research, this review will focus on the most recent advances in S1PRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIZfnE0tv0rbVg90H21EOLACvtfcHk0liZgQJesWIbnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agsrnP&md5=3939398b28359c3be8d38b3b49be3d4c</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R046300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R046300%26sid%3Dliteratum%253Aachs%26aulast%3DBlaho%26aufirst%3DV.%2BA.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DAn%2520update%2520on%2520the%2520biology%2520of%2520sphingosine%25201-phosphate%2520receptors%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2014%26volume%3D55%26spage%3D1596%26epage%3D1608%26doi%3D10.1194%2Fjlr.R046300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstien, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate: an enigmatic signalling lipid</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1038/nrm1103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1038%2Fnrm1103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=12728273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlalt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=397-407&author=S.+Spiegelauthor=S.+Milstien&title=Sphingosine-1-phosphate%3A+an+enigmatic+signalling+lipid&doi=10.1038%2Fnrm1103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate: an enigmatic signalling lipid</span></div><div class="casAuthors">Spiegel, Sarah; Milstien, Sheldon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">397-407</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The evolutionarily conserved actions of the sphingolipid metabolite, sphingosine-1-phosphate (S1P), in yeast, plants, and mammals have shown that it has important functions.  In higher eukaryotes, S1P is the ligand for a family of 5 G protein-coupled receptors.  These S1P receptors are differentially expressed, coupled to various G proteins, and regulate angiogenesis, vascular maturation, cardiac development, and immunity, and are important for directed cell movement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos0XUAxYZwqLVg90H21EOLACvtfcHk0liZgQJesWIbnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlalt7o%253D&md5=689a33cfeb4bae72637b64cd90e6c910</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1038%2Fnrm1103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1103%26sid%3Dliteratum%253Aachs%26aulast%3DSpiegel%26aufirst%3DS.%26aulast%3DMilstien%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%253A%2520an%2520enigmatic%2520signalling%2520lipid%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2003%26volume%3D4%26spage%3D397%26epage%3D407%26doi%3D10.1038%2Fnrm1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2007.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.pharmthera.2007.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=17561264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntFyiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2007&pages=84-105&author=V.+Brinkmann&title=Sphingosine+1-phosphate+receptors+in+health+and+disease%3A+mechanistic+insights+from+gene+deletion+studies+and+reverse+pharmacology&doi=10.1016%2Fj.pharmthera.2007.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1eR"><div class="casContent"><span class="casTitleNuber">1e</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology</span></div><div class="casAuthors">Brinkmann, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-105</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid that is critically involved in the embryonic development of the cardiovascular and central nervous systems.  In the adult, S1P can produce cytoskeletal re-arrangements in many cell types to regulate immune cell trafficking, vascular homeostasis and cell communication in the central nervous system.  S1P is contained in body fluids and tissues at different concns., and excessive prodn. of the pleiotropic mediator at inflammatory sites may participate in various pathol. conditions.  Gene deletion studies and reverse pharmacol. (techniques aiming to identify both ligands and function of receptors) provided evidence that many effects of S1P are mediated via five G-protein-coupled S1P receptor subtypes, and novel therapeutic strategies based on interaction with these receptors are being initiated.  The prototype S1P receptor modulator, FTY720 (fingolimod), targets four of the five S1P receptor subtypes and may act at several levels to modulate lymphocyte trafficking via lymphocytic and endothelial S1P1 and, perhaps, other inflammatory processes through addnl. S1P receptor subtypes.  A recently completed Phase II clin. trial suggested that the drug may provide an effective treatment of relapsing-remitting multiple sclerosis.  FTY720 is currently being evaluated in larger-scale, longer-term, Phase III studies.  This review provides an overview on S1P activities and S1P receptor function in health and disease, and summarizes the clin. experience with FTY720 in transplantation and multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGbwKhZo2vLrVg90H21EOLACvtfcHk0lhYycDlD-joLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntFyiur0%253D&md5=cacdb374439270734f34a0ca4771ca3d</span></div><a href="/servlet/linkout?suffix=cit1e&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2007.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2007.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26atitle%3DSphingosine%25201-phosphate%2520receptors%2520in%2520health%2520and%2520disease%253A%2520mechanistic%2520insights%2520from%2520gene%2520deletion%2520studies%2520and%2520reverse%2520pharmacology%26jtitle%3DPharmacol.%2520Ther.%26date%3D2007%26volume%3D115%26spage%3D84%26epage%3D105%26doi%3D10.1016%2Fj.pharmthera.2007.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mutoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span> <span> </span><span class="NLM_article-title">Insights into the pharmacological relevance of lysophospholipid receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01622.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1111%2Fj.1476-5381.2011.01622.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=21838759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFGqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=829-844&author=T.+Mutohauthor=R.+Riveraauthor=J.+Chun&title=Insights+into+the+pharmacological+relevance+of+lysophospholipid+receptors&doi=10.1111%2Fj.1476-5381.2011.01622.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1fR"><div class="casContent"><span class="casTitleNuber">1f</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the pharmacological relevance of lysophospholipid receptors</span></div><div class="casAuthors">Mutoh, Tetsuji; Rivera, Richard; Chun, Jerold</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">829-844</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The discovery of lysophospholipid (LP) 7-transmembrane, G protein-coupled receptors (GPCRs) that began in the 1990s, together with research into the functional roles of the major LPs known as lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), have opened new research avenues into their biol. processes and mechanisms.  Major examples of LP signaling effects include embryogenesis, nervous system development, vascular development, uterine implantation, immune cell trafficking, and inflammatory reactions.  LP signaling also influences the pathophysiol. of many diseases including cancer, autoimmune and inflammatory diseases, which indicate that LP receptors may be attractive targets for pharmacol. therapies.  A key example of such a therapeutic agent is the S1P receptor modulator FTY720, which upon phosphorylation and continued drug exposure, acts as an S1P receptor functional antagonist.  This compd. (also known as fingolimod or Gilenya) has recently been approved by the FDA for the treatment of relapsing forms of multiple sclerosis.  Continued basic and translational research on LP signaling should provide novel insights into both basic biol. mechanisms, as well as novel therapeutic approaches to combat a range of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1qOGwbmBPirVg90H21EOLACvtfcHk0lhYycDlD-joLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFGqsLs%253D&md5=cf240e202ccfa00c40366f7309e36b78</span></div><a href="/servlet/linkout?suffix=cit1f&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01622.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01622.x%26sid%3Dliteratum%253Aachs%26aulast%3DMutoh%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DR.%26aulast%3DChun%26aufirst%3DJ.%26atitle%3DInsights%2520into%2520the%2520pharmacological%2520relevance%2520of%2520lysophospholipid%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26spage%3D829%26epage%3D844%26doi%3D10.1111%2Fj.1476-5381.2011.01622.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepanovska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwiler, A.</span></span> <span> </span><span class="NLM_article-title">Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">104170</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2019.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.phrs.2019.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=30776422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1Ggu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2020&pages=104170&author=B.+Stepanovskaauthor=A.+Huwiler&title=Targeting+the+S1P+receptor+signaling+pathways+as+a+promising+approach+for+treatment+of+autoimmune+and+inflammatory+diseases&doi=10.1016%2Fj.phrs.2019.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases</span></div><div class="casAuthors">Stepanovska, Bisera; Huwiler, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104170</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The past two decades of intense research have revealed a key role of the sphingolipid mol. sphingosine 1-phosphate (S1P) in regulating multiple physiol. and pathophysiol. processes including cell proliferation and survival, cell migration, inflammatory mediator synthesis and tissue remodeling.  S1P mainly acts through five high-affinity G protein-coupled S1P receptors, which are ubiquitously expressed and mediate a complex network of signaling in a cell type dependent manner.  S1P receptors have become an attractive pharmacol. target to interfere with S1P-mediated cellular responses, which contribute to various autoimmune and inflammatory diseases.  Pioneering in this field was the synthesis of FTY720 (fingolimod, Gilenya) from myriocin, one of the metabolites of the fungus Isaria sinclairii known from traditional Chinese medicine for its antibacterial and energy boosting effect.  Fingolimod turned out as a very potent immunomodulatory agent that subsequently passed all clin. trials successfully and is now approved for the treatment of relapsing-remitting multiple sclerosis.  Novel S1PR modulators are now being developed with a more selective receptor activation profile and improved pharmacokinetic characteristics.  In this review, we will summarize the state-of-the-art approaches that target directly or indirectly S1P signaling and may be useful as novel strategies to treat autoimmune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdQEm8IluDvrVg90H21EOLACvtfcHk0ljEpXOyAlXS3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1Ggu74%253D&md5=3c40bb1f714671216d3aafeb9d420805</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2019.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2019.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DStepanovska%26aufirst%3DB.%26aulast%3DHuwiler%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520S1P%2520receptor%2520signaling%2520pathways%2520as%2520a%2520promising%2520approach%2520for%2520treatment%2520of%2520autoimmune%2520and%2520inflammatory%2520diseases%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D154%26spage%3D104170%26doi%3D10.1016%2Fj.phrs.2019.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demont, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bit, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowell, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldred, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaskin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renaux, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, G. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smethurst, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witherington, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of tetrahydropyrazolopyridine as sphingosine 1-phosphate receptor 3 (S1P3)-sparing S1P1 agonists active at low oral doses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1003</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01512</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01512" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslertQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1003-1020&author=E.+H.+Demontauthor=J.+M.+Baileyauthor=R.+A.+Bitauthor=J.+A.+Brownauthor=C.+A.+Campbellauthor=N.+Deeksauthor=S.+J.+Dowellauthor=C.+Eldredauthor=P.+Gaskinauthor=J.+R.+J.+Grayauthor=A.+Haynesauthor=D.+J.+Hirstauthor=D.+S.+Holmesauthor=U.+Kumarauthor=M.+A.+Morseauthor=G.+J.+Osborneauthor=J.+F.+Renauxauthor=G.+A.+L.+Sealauthor=C.+A.+Smethurstauthor=S.+Taylorauthor=R.+Watsonauthor=R.+Willisauthor=J.+Witherington&title=Discovery+of+tetrahydropyrazolopyridine+as+sphingosine+1-phosphate+receptor+3+%28S1P3%29-sparing+S1P1+agonists+active+at+low+oral+doses&doi=10.1021%2Facs.jmedchem.5b01512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses</span></div><div class="casAuthors">Demont, Emmanuel H.; Bailey, James M.; Bit, Rino A.; Brown, Jack A.; Campbell, Colin A.; Deeks, Nigel; Dowell, Simon J.; Eldred, Colin; Gaskin, Pam; Gray, James R. J.; Haynes, Andrea; Hirst, David J.; Holmes, Duncan S.; Kumar, Umesh; Morse, Mary A.; Osborne, Greg J.; Renaux, Jessica F.; Seal, Gail A. L.; Smethurst, Chris A.; Taylor, Simon; Watson, Robert; Willis, Robert; Witherington, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1003-1020</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FTY720 is the first oral small mol. approved for the treatment of people suffering from relapsing-remitting multiple sclerosis.  It is a potent agonist of the S1P1 receptor, but its lack of selectivity against the S1P3 receptor has been linked to most of the cardiovascular side effects obsd. in the clinic.  These findings have triggered intensive efforts toward the identification of a second generation of S1P3-sparing S1P1 agonists.  The authors have recently disclosed a series of orally active tetrahydroisoquinoline (THIQ) compds. matching these criteria.  The authors defined and implemented a strategy aiming at the discovery of selective structurally distinct follow-up agonists.  This effort culminated with the identification of a series of orally active tetrahydropyrazolopyridines, e.g. I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrDxdhn4Vr3bVg90H21EOLACvtfcHk0ljEpXOyAlXS3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslertQ%253D%253D&md5=578a3b903bac10da197a83fa2b766722</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01512%26sid%3Dliteratum%253Aachs%26aulast%3DDemont%26aufirst%3DE.%2BH.%26aulast%3DBailey%26aufirst%3DJ.%2BM.%26aulast%3DBit%26aufirst%3DR.%2BA.%26aulast%3DBrown%26aufirst%3DJ.%2BA.%26aulast%3DCampbell%26aufirst%3DC.%2BA.%26aulast%3DDeeks%26aufirst%3DN.%26aulast%3DDowell%26aufirst%3DS.%2BJ.%26aulast%3DEldred%26aufirst%3DC.%26aulast%3DGaskin%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DHaynes%26aufirst%3DA.%26aulast%3DHirst%26aufirst%3DD.%2BJ.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DKumar%26aufirst%3DU.%26aulast%3DMorse%26aufirst%3DM.%2BA.%26aulast%3DOsborne%26aufirst%3DG.%2BJ.%26aulast%3DRenaux%26aufirst%3DJ.%2BF.%26aulast%3DSeal%26aufirst%3DG.%2BA.%2BL.%26aulast%3DSmethurst%26aufirst%3DC.%2BA.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DWillis%26aufirst%3DR.%26aulast%3DWitherington%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520tetrahydropyrazolopyridine%2520as%2520sphingosine%25201-phosphate%2520receptor%25203%2520%2528S1P3%2529-sparing%2520S1P1%2520agonists%2520active%2520at%2520low%2520oral%2520doses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1003%26epage%3D1020%26doi%3D10.1021%2Facs.jmedchem.5b01512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">and references therein.</p></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumruker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heining, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmouder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aradhye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtin, P.</span></span> <span> </span><span class="NLM_article-title">Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">897</span>, <span class="refDoi"> DOI: 10.1038/nrd3248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1038%2Fnrd3248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=21031003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCqsr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=883-897&author=V.+Brinkmannauthor=A.+Billichauthor=T.+Baumrukerauthor=P.+Heiningauthor=R.+Schmouderauthor=G.+Francisauthor=S.+Aradhyeauthor=P.+Burtin&title=Fingolimod+%28FTY720%29%3A+Discovery+and+development+of+an+oral+drug+to+treat+multiple+sclerosis&doi=10.1038%2Fnrd3248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis</span></div><div class="casAuthors">Brinkmann, Volker; Billich, Andreas; Baumruker, Thomas; Heining, Peter; Schmouder, Robert; Francis, Gordon; Aradhye, Shreeram; Burtin, Pascale</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">883-897</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory drug, has opened up new approaches to the treatment of multiple sclerosis, the most common inflammatory disorder of the central nervous system.  Elucidation of the effects of fingolimod - mediated by the modulation of sphingosine 1-phosphate (S1P) receptors - has indicated that its therapeutic activity could be due to regulation of the migration of selected lymphocyte subsets into the central nervous system and direct effects on neural cells, particularly astrocytes.  An improved understanding of the biol. of S1P receptors has also been gained.  This article describes the discovery and development of fingolimod, which was approved by the US Food and Drug Administration in Sept. 2010 as a first-line treatment for relapsing forms of multiple sclerosis, thereby becoming the first oral disease-modifying therapy to be approved for multiple sclerosis in the United States.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr80U6QfXSJMbVg90H21EOLACvtfcHk0ljtwdsIrv6VTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCqsr%252FL&md5=0f6dd60ef115079f3652e9d12d82e215</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd3248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3248%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DBaumruker%26aufirst%3DT.%26aulast%3DHeining%26aufirst%3DP.%26aulast%3DSchmouder%26aufirst%3DR.%26aulast%3DFrancis%26aufirst%3DG.%26aulast%3DAradhye%26aufirst%3DS.%26aulast%3DBurtin%26aufirst%3DP.%26atitle%3DFingolimod%2520%2528FTY720%2529%253A%2520Discovery%2520and%2520development%2520of%2520an%2520oral%2520drug%2520to%2520treat%2520multiple%2520sclerosis%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D883%26epage%3D897%26doi%3D10.1038%2Fnrd3248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span> <i>NDA
02257-FDA Approved Labeling Text for Gilenya (Fingolimod) Capsules</i>. Sep 21, <span class="NLM_year">2010</span>, <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022527s000lbl.pdf" class="extLink">www.accessdata.fda.gov/drugsatfda_docs/label/2010/022527s000lbl.pdf</a> (accessed Dec 15, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+NDA%0A02257-FDA+Approved+Labeling+Text+for+Gilenya+%28Fingolimod%29+Capsules.+Sep+21%2C+2010%2C+www.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2010%2F022527s000lbl.pdf+%28accessed+Dec+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNDA%250A02257-FDA%2520Approved%2520Labeling%2520Text%2520for%2520Gilenya%2520%2528Fingolimod%2529%2520Capsules%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shea, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontaine, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luster, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tager, A. M.</span></span> <span> </span><span class="NLM_article-title">Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2009-0345OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1165%2Frcmb.2009-0345OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=20081052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2010&pages=662-673&author=B.+S.+Sheaauthor=S.+F.+Brooksauthor=B.+A.+Fontaineauthor=J.+Chunauthor=A.+D.+Lusterauthor=A.+M.+Tager&title=Prolonged+exposure+to+sphingosine+1-phosphate+receptor-1+agonists+exacerbates+vascular+leak%2C+fibrosis%2C+and+mortality+after+lung+injury&doi=10.1165%2Frcmb.2009-0345OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury</span></div><div class="casAuthors">Shea, Barry S.; Brooks, Sarah F.; Fontaine, Benjamin A.; Chun, Jerold; Luster, Andrew D.; Tager, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) is a key endogenous regulator of the response to lung injury, maintaining endothelial barrier integrity through interaction with one of its receptors, S1P1.  The short-term administration of S1P or S1P1 receptor agonists enhances endothelial monolayer barrier function in vitro, and attenuates injury-induced vascular leak in the lung and other organ systems in vivo.  Although S1P1 agonists bind to and activate S1P1, several of these agents also induce receptor internalization and degrdn., and may therefore act as functional antagonists of S1P1 after extended exposure.  Here we report on the effects of prolonged exposure to these agents in bleomycin-induced lung injury.  We demonstrate that repeated administration of S1P1 agonists dramatically worsened lung injury after bleomycin challenge, as manifested by increased vascular leak and mortality.  Consistent with these results, prolonged exposure to S1P1 agonists in vitro eliminated the ability of endothelial cell monolayers to respond appropriately to the barrier-protective effects of S1P, indicating a loss of normal S1P-S1P1 signaling.  As bleomycin-induced lung injury progressed, continued exposure to S1P1 agonists also resulted in increased pulmonary fibrosis.  These data indicate that S1P1 agonists can act as functional antagonists of S1P1 on endothelial cells in vivo, which should be considered in developing these agents as therapies for vascular leak syndromes.  Our findings also support the hypothesis that vascular leak is an important component of the fibrogenic response to lung injury, and suggest that targeting the S1P-S1P1 pathway may also be an effective therapeutic strategy for fibrotic lung diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG8d_yM8ZpErVg90H21EOLACvtfcHk0ljtwdsIrv6VTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtr%252FM&md5=1b0c0384272545d0ca4dfb3c4df0c8c9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2009-0345OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2009-0345OC%26sid%3Dliteratum%253Aachs%26aulast%3DShea%26aufirst%3DB.%2BS.%26aulast%3DBrooks%26aufirst%3DS.%2BF.%26aulast%3DFontaine%26aufirst%3DB.%2BA.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26aulast%3DTager%26aufirst%3DA.%2BM.%26atitle%3DProlonged%2520exposure%2520to%2520sphingosine%25201-phosphate%2520receptor-1%2520agonists%2520exacerbates%2520vascular%2520leak%252C%2520fibrosis%252C%2520and%2520mortality%2520after%2520lung%2520injury%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2010%26volume%3D43%26spage%3D662%26epage%3D673%26doi%3D10.1165%2Frcmb.2009-0345OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gellings Lowe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbadini, R. A.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-β-stimulated collagen production by cardiac fibroblasts</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvp056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1093%2Fcvr%2Fcvp056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=19228708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVaktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2009&pages=303-312&author=N.+Gellings+Loweauthor=J.+S.+Swaneyauthor=K.+M.+Morenoauthor=R.+A.+Sabbadini&title=Sphingosine-1-phosphate+and+sphingosine+kinase+are+critical+for+transforming+growth+factor-%CE%B2-stimulated+collagen+production+by+cardiac+fibroblasts&doi=10.1093%2Fcvr%2Fcvp056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-β-stimulated collagen production by cardiac fibroblasts</span></div><div class="casAuthors">Gellings Lowe, Nicole; Swaney, James S.; Moreno, Kelli M.; Sabbadini, Roger A.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">303-312</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims Following injury, fibroblasts transform into myofibroblasts and produce extracellular matrix (ECM).  Excess prodn. of ECM assocd. with cardiac fibrosis severely inhibits cardiac function.  Sphingosine-1-phosphate (S1P), a bioactive lysophospholipid, regulates the function of numerous cell types.  In this study, we detd. the role of S1P in promoting pro-fibrotic actions of cardiac fibroblasts (CFs).  Methods and results S1P-mediated effects on myofibroblast transformation, collagen prodn., and cross-talk with transforming growth factor-β (TGF-β) using mouse CF were examd.  S1P increased α-smooth muscle actin (a myofibroblast marker) and collagen expression in a S1P2 receptor- and Rho kinase-dependent manner.  TGF-β increased sphingosine kinase 1 (SphK1; the enzyme responsible for S1P prodn.) expression and activity.  TGF-β-stimulated collagen prodn. was inhibited by SphK1 or S1P2 siRNA, a SphK inhibitor, and an anti-S1P monoclonal antibody.  Conclusion These findings suggest that TGF-β-stimulated collagen prodn. in CF involves inside-out' S1P signalling whereby S1P produced intracellularly by SphK1 can be released and act in an autocrine/paracrine fashion to activate S1P2 and increase collagen prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorZb1d6ne23bVg90H21EOLACvtfcHk0lgPKNRqWHfFmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVaktrs%253D&md5=1dddcb911770c5bf80022c18ffbe0299</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvp056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvp056%26sid%3Dliteratum%253Aachs%26aulast%3DGellings%2BLowe%26aufirst%3DN.%26aulast%3DSwaney%26aufirst%3DJ.%2BS.%26aulast%3DMoreno%26aufirst%3DK.%2BM.%26aulast%3DSabbadini%26aufirst%3DR.%2BA.%26atitle%3DSphingosine-1-phosphate%2520and%2520sphingosine%2520kinase%2520are%2520critical%2520for%2520transforming%2520growth%2520factor-%25CE%25B2-stimulated%2520collagen%2520production%2520by%2520cardiac%2520fibroblasts%26jtitle%3DCardiovasc.%2520Res.%26date%3D2009%26volume%3D82%26spage%3D303%26epage%3D312%26doi%3D10.1093%2Fcvr%2Fcvp056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tölle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Giet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radeke, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer
Korting, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleuser, B.</span></span> <span> </span><span class="NLM_article-title">Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 <i>signaling</i></span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2007.060485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.2353%2Fajpath.2007.060485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=17200201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FgtlOgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2007&pages=281-292&author=C.+D.+Kellerauthor=P.+R.+Gilauthor=M.+T%C3%B6lleauthor=M.+van+der+Gietauthor=J.+Chunauthor=H.+H.+Radekeauthor=M.+Sch%C3%A4fer%0AKortingauthor=B.+Kleuser&title=Immunomodulator+FTY720+induces+myofibroblast+differentiation+via+the+lysophospholipid+receptor+S1P3+and+Smad3+signaling&doi=10.2353%2Fajpath.2007.060485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling</span></div><div class="casAuthors">Keller Christina D; Rivera Gil Pilar; Tolle Markus; van der Giet Markus; Chun Jerold; Radeke Heinfried H; Schafer-Korting Monika; Kleuser Burkhard</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of pathology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-92</span>
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    </div><div class="casAbstract">The novel immunomodulator FTY720 is an effective immunosuppressive agent in experimental models of transplantation and autoimmunity and is currently undergoing phase III clinical trials for multiple sclerosis.  Phosphorylated FTY720 is a structural analogue of sphingosine 1-phosphate (S1P) and therefore acts as a high-affinity agonist at four of the five G protein-coupled S1P receptors.  It has been well established that there exists a crosstalk between S1P and transforming growth factor (TGF)-beta signaling.  Because TGF-beta is the most prominent inductor of fibrosis and myofibroblasts are primarily responsible for excessive matrix protein formation, we examined whether FTY720, in analogy to TGF-beta, induces differentiation of fibroblasts into myofibroblasts.  Indeed, FTY720 provoked myofibroblast differentiation comparable with that of TGF-beta.  For biological efficacy, FTY720 required endogenous phosphorylation because inhibition of sphingosine kinase completely prevented FTY720 from inducing the differentiation process.  Moreover, we identified the lysophospholipid receptor S1P3 as the crucial receptor subtype for FTY720-induced myofibroblast differentiation because the effect was abolished in fibroblasts isolated from S1P3 knockout mice.  Finally, we determined that downstream of S1P3 signaling Smad3 activation is essential for myofibroblast differentiation in response to FTY720.  Thus, FTY720 may have adverse fibrotic effects related to its activity on S1P3 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZ2f3qQMjhEwwxfk_AGB-EfW6udTcc2eZ3meCJyujp6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FgtlOgtA%253D%253D&md5=fe9a2ae10e35623be18fcbbf26f1daeb</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2007.060485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2007.060485%26sid%3Dliteratum%253Aachs%26aulast%3DKeller%26aufirst%3DC.%2BD.%26aulast%3DGil%26aufirst%3DP.%2BR.%26aulast%3DT%25C3%25B6lle%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BGiet%26aufirst%3DM.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DRadeke%26aufirst%3DH.%2BH.%26aulast%3DSch%25C3%25A4fer%2BKorting%26aufirst%3DM.%26aulast%3DKleuser%26aufirst%3DB.%26atitle%3DImmunomodulator%2520FTY720%2520induces%2520myofibroblast%2520differentiation%2520via%2520the%2520lysophospholipid%2520receptor%2520S1P3%2520and%2520Smad3%2520signaling%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2007%26volume%3D170%26spage%3D281%26epage%3D292%26doi%3D10.2353%2Fajpath.2007.060485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Urata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, M.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate induces α-smooth muscle actin expression in lung fibroblasts via Rho-kinase</span>. <i>Kobe J. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">27</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=16199931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2005&pages=17-27&author=Y.+Urataauthor=Y.+Nishimuraauthor=T.+Hiraseauthor=M.+Yokoyama&title=Sphingosine+1-phosphate+induces+%CE%B1-smooth+muscle+actin+expression+in+lung+fibroblasts+via+Rho-kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate induces alpha-smooth muscle actin expression in lung fibroblasts via Rho-kinase</span></div><div class="casAuthors">Urata, Yoshiko; Nishimura, Yoshihiro; Hirase, Tetsuaki; Yokoyama, Mitsuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Kobe Journal of Medical Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">17-27</span>CODEN:
                <span class="NLM_cas:coden">KJMDA6</span>;
        ISSN:<span class="NLM_cas:issn">0023-2513</span>.
    
            (<span class="NLM_cas:orgname">Kobe University, Graduate School of Medicine</span>)
        </div><div class="casAbstract">Transformation of fibroblasts into myofibroblasts is an important phenomenon that contributes to airway remodeling in bronchial asthma.  Although several articles have recently indicated that a bioactive lysosphingolipid sphingosine 1-phosphate (S1P) plays roles in the pathogenesis of bronchial asthma, the role of S1P in the remodeling process is poorly understood.  In the present study, we examd. the effects of S1P on alpha-smooth muscle actin (SMA) expression and the morphol. in lung fibroblasts.  S1P stimulated the expression of alpha-SMA in a human lung fibroblast cell line WI38 that expresses EDG/S1P receptors.  These processes were inhibited by Y-27632, but not by pertussis toxin.  These results suggest that S1P induces a phenotypic change of lung fibroblasts via Rho-kinase that may lead to airway remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvfNMaUlVJh7Vg90H21EOLACvtfcHk0lhYW2nEZgRO7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWltrc%253D&md5=fdd31d3d13f635ef88c9e816fa6f30da</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUrata%26aufirst%3DY.%26aulast%3DNishimura%26aufirst%3DY.%26aulast%3DHirase%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DM.%26atitle%3DSphingosine%25201-phosphate%2520induces%2520%25CE%25B1-smooth%2520muscle%2520actin%2520expression%2520in%2520lung%2520fibroblasts%2520via%2520Rho-kinase%26jtitle%3DKobe%2520J.%2520Med.%2520Sci.%26date%3D2005%26volume%3D51%26spage%3D17%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menyhart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Killer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renault, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolli, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatfield, J.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate (s1p) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and smad-independent signalling</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">14839</span>– <span class="NLM_lpage">14851</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.426726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1074%2Fjbc.M112.426726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=23589284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1Whsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=14839-14851&author=K.+Sobelauthor=K.+Menyhartauthor=N.+Killerauthor=B.+Renaultauthor=Y.+Bauerauthor=R.+Studerauthor=B.+Steinerauthor=M.+H.+Bolliauthor=O.+Naylerauthor=J.+Gatfield&title=Sphingosine+1-phosphate+%28s1p%29+receptor+agonists+mediate+pro-fibrotic+responses+in+normal+human+lung+fibroblasts+via+S1P2+and+S1P3+receptors+and+smad-independent+signalling&doi=10.1074%2Fjbc.M112.426726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-Phosphate (S1P) Receptor Agonists Mediate Pro-fibrotic Responses in Normal Human Lung Fibroblasts via S1P2 and S1P3 Receptors and Smad-independent Signaling</span></div><div class="casAuthors">Sobel, Katrin; Menyhart, Katalin; Killer, Nina; Renault, Berengere; Bauer, Yasmina; Studer, Rolf; Steiner, Beat; Bolli, Martin H.; Nayler, Oliver; Gatfield, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">14839-14851</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Synthetic sphingosine 1-phosphate receptor 1 modulators constitute a new class of drugs for the treatment of autoimmune diseases.  Sphingosine 1-phosphate (S1P) signaling, however, is also involved in the development of fibrosis.  Using normal human lung fibroblasts, we investigated the induction of fibrotic responses by the S1P receptor (S1PR) agonists S1P, FTY720-P, ponesimod, and SEW2871 and compared them with the responses induced by the known fibrotic mediator TGF-β1.  In contrast to TGF-β1, S1PR agonists did not induce expression of the myofibroblast marker α-smooth muscle actin.  However, TGF-β1, S1P, and FTY720-P caused robust stimulation of extracellular matrix (ECM) synthesis and increased pro-fibrotic marker gene expression including connective tissue growth factor.  Ponesimod showed limited and SEW2871 showed no pro-fibrotic potential in these readouts.  Anal. of pro-fibrotic signaling pathways showed that in contrast to TGF-β1, S1PR agonists did not activate Smad2/3 signaling but rather activated PI3K/Akt and ERK1/2 signaling to induce ECM synthesis.  The strong induction of ECM synthesis by the nonselective agonists S1P and FTY720-P was due to the stimulation of S1P2 and S1P3 receptors, whereas the weaker induction of ECM synthesis at high concns. of ponesimod was due to a low potency activation of S1P3 receptors.  Finally, in normal human lung fibroblast-derived myofibroblasts that were generated by TGF-β1 pretreatment, S1P and FTY720-P were effective stimulators of ECM synthesis, whereas ponesimod was inactive, because of the down-regulation of S1P3R expression in myofibroblasts.  These data demonstrate that S1PR agonists are pro-fibrotic via S1P2R and S1P3R stimulation using Smad-independent pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRUfNcFmSowLVg90H21EOLACvtfcHk0lhYW2nEZgRO7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1Whsrk%253D&md5=d0af5fcbed012ce1554b2239a701d000</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.426726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.426726%26sid%3Dliteratum%253Aachs%26aulast%3DSobel%26aufirst%3DK.%26aulast%3DMenyhart%26aufirst%3DK.%26aulast%3DKiller%26aufirst%3DN.%26aulast%3DRenault%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DY.%26aulast%3DStuder%26aufirst%3DR.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DGatfield%26aufirst%3DJ.%26atitle%3DSphingosine%25201-phosphate%2520%2528s1p%2529%2520receptor%2520agonists%2520mediate%2520pro-fibrotic%2520responses%2520in%2520normal%2520human%2520lung%2520fibroblasts%2520via%2520S1P2%2520and%2520S1P3%2520receptors%2520and%2520smad-independent%2520signalling%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D14839%26epage%3D14851%26doi%3D10.1074%2Fjbc.M112.426726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajdu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quackenbush, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shei, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Card, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keohane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupprecht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span> <span> </span><span class="NLM_article-title">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1126/science.1070238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1126%2Fscience.1070238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=11923495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=346-349&author=S.+Mandalaauthor=R.+Hajduauthor=J.+Bergstromauthor=E.+Quackenbushauthor=J.+Xieauthor=J.+Milliganauthor=R.+Thorntonauthor=G.+J.+Sheiauthor=D.+Cardauthor=C.+Keohaneauthor=M.+Rosenbachauthor=J.+Haleauthor=C.+L.+Lynchauthor=K.+Rupprechtauthor=W.+Parsonsauthor=H.+Rosen&title=Alteration+of+lymphocyte+trafficking+by+sphingosine-1-phosphate+receptor+agonists&doi=10.1126%2Fscience.1070238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span></div><div class="casAuthors">Mandala, Suzanne; Hajdu, Richard; Bergstrom, James; Quackenbush, Elizabeth; Xie, Jenny; Milligan, James; Thornton, Rosemary; Shei, Gan-Ju; Card, Deborah; Keohane, Carolann; Rosenbach, Mark; Hale, Jeffrey; Lynch, Christopher L.; Rupprecht, Kathleen; Parsons, William; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5566</span>),
    <span class="NLM_cas:pages">346-349</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Blood lymphocyte nos., essential for the development of efficient immune responses, are maintained by recirculation through secondary Lymphoid organs.  We show that lymphocyte trafficking is altered by the lysophospholipid sphingosine-1-phosphate (S1P) and by a phosphoryl metabolite of the immunosuppressive agent FTY720.  Both species were high-affinity agonists of at least four of the five S1P receptors.  These agonists produce lymphopenia in blood and thoracic duct lymph by sequestration of lymphocytes in lymph nodes, but not spleen.  S1P receptor agonists induced emptying of lymphoid sinuses by retention of lymphocytes on the abluminal side of sinus-lining endothelium and inhibition of egress into lymph.  Inhibition of lymphocyte recirculation by activation of S1P receptors may result in therapeutically useful immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPvwG_lLsA8LVg90H21EOLACvtfcHk0lhKdYURRPg2Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D&md5=b57cbcffe41d144e701dbd42459cf38a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.1070238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1070238%26sid%3Dliteratum%253Aachs%26aulast%3DMandala%26aufirst%3DS.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DQuackenbush%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DThornton%26aufirst%3DR.%26aulast%3DShei%26aufirst%3DG.%2BJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DKeohane%26aufirst%3DC.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DRupprecht%26aufirst%3DK.%26aulast%3DParsons%26aufirst%3DW.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DAlteration%2520of%2520lymphocyte%2520trafficking%2520by%2520sphingosine-1-phosphate%2520receptor%2520agonists%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D346%26epage%3D349%26doi%3D10.1126%2Fscience.1070238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monnier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menyhart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatfield, J.</span></span> <span> </span><span class="NLM_article-title">FTY720 Phosphate activates sphingosine-1-phosphate receptor 2 and selectively couples to Gα12/13/rho/rock to induce myofibroblast contraction</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1124/mol.114.097261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1124%2Fmol.114.097261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=25762025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Wlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=916-927&author=K.+Sobelauthor=L.+Monnierauthor=K.+Menyhartauthor=M.+Bolingerauthor=R.+Studerauthor=O.+Naylerauthor=J.+Gatfield&title=FTY720+Phosphate+activates+sphingosine-1-phosphate+receptor+2+and+selectively+couples+to+G%CE%B112%2F13%2Frho%2Frock+to+induce+myofibroblast+contraction&doi=10.1124%2Fmol.114.097261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">FTY720 phosphate activates sphingosine-1-phosphate receptor 2 and selectively couples to Gα12/13/Rho/ROCK to induce myofibroblast contraction</span></div><div class="casAuthors">Sobel, Katrin; Monnier, Lucile; Menyhart, Katalin; Bolinger, Matthias; Studer, Rolf; Nayler, Oliver; Gatfield, John</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">916-927</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">FTY720 phosphate (FTY720-P; 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol, monodihydrogen phosphate ester) is a nonselective sphingosine-1-phosphate (S1P) receptor agonist thought to be devoid of activity at the S1P2 receptor subtype.  However, we have recently shown that FTY720-P displays significant S1P2 receptor agonist activity in recombinant cells and fibroblasts expressing endogenous S1P2 receptors.  To elucidate the S1P2-dependent signaling pathways that were activated by FTY720-P, we employed second messenger assays and impedance-based assays in combination with pharmacol. and small interfering RNA-based pathway inhibition in recombinant Chinese hamster ovary (CHO)-S1P2 cells as well as human lung myofibroblasts generated in vitro.  In CHO-S1P2 cells, FTY720-P did not modulate cAMP or calcium levels.  However, reporter-gene assays, impedance-based assays with a selective Rho-assocd. kinase (ROCK) inhibitor, Gα12/13 knockdown and activated Rho-pull-down assays demonstrated that FTY720-P potently activated Gα12/13/Rho/ROCK signaling.  S1P similarly activated Gα12/13/Rho/ROCK signaling via S1P2 receptors, whereas the two selective S1P1 receptor agonists (Z,Z)-5-(3-chloro-4-[(2R)-2,3-dihydroxy-propoxy]-benzylidene)-2-propylimino-3-o-tolyl-thiazolidin-4-one (ponesimond) and 5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-3-[3-(trifluoromethyl)phenyl]1,2,4-oxadiazole (SEW2871) were inactive.  In lung myofibroblasts, which mainly expressed the S1P2 receptor subtype, we showed that FTY720-P selectively activated the Gα12/13/Rho/ROCK pathway via the S1P2 receptor.  Moreover, the activation of the Gα12/13/Rho/ROCK pathway in myofibroblasts by FTY720-P caused potent myofibroblast contraction similar to that induced by the natural ligand S1P.  Thus, complementing second messenger assays with unbiased label-free assays or phenotypic assays in native expression systems can uncover activation of addnl. pathways, such as Gα12/13/Rho/ROCK signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_-lB6CsWDu7Vg90H21EOLACvtfcHk0lhKdYURRPg2Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Wlu78%253D&md5=32484e6fbe2b9fd8c5c02c115c70085a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.097261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.097261%26sid%3Dliteratum%253Aachs%26aulast%3DSobel%26aufirst%3DK.%26aulast%3DMonnier%26aufirst%3DL.%26aulast%3DMenyhart%26aufirst%3DK.%26aulast%3DBolinger%26aufirst%3DM.%26aulast%3DStuder%26aufirst%3DR.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DGatfield%26aufirst%3DJ.%26atitle%3DFTY720%2520Phosphate%2520activates%2520sphingosine-1-phosphate%2520receptor%25202%2520and%2520selectively%2520couples%2520to%2520G%25CE%25B112%252F13%252Frho%252Frock%2520to%2520induce%2520myofibroblast%2520contraction%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D87%26spage%3D916%26epage%3D927%26doi%3D10.1124%2Fmol.114.097261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Serriere-Lanneau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira-Clerc, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schippers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wries, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Van-Nhieu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poelstra, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpentier, S.</span></span> <span> </span><span class="NLM_article-title">The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2013</span>, <span class="refDoi"> DOI: 10.1096/fj.06-6889com</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1096%2Ffj.06-6889com" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=17341687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvVagsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=2005-2013&author=V.+Serriere-Lanneauauthor=F.+Teixeira-Clercauthor=L.+Liauthor=M.+Schippersauthor=W.+de+Wriesauthor=B.+Julienauthor=J.+Tran-Van-Nhieuauthor=S.+Maninauthor=K.+Poelstraauthor=J.+Chunauthor=S.+Carpentier&title=The+sphingosine+1-phosphate+receptor+S1P2+triggers+hepatic+wound+healing&doi=10.1096%2Ffj.06-6889com"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing</span></div><div class="casAuthors">Serriere-Lanneau, Valerie; Teixeira-Clerc, Fatima; Li, Liying; Schippers, Marlies; de Wries, Willie; Julien, Boris; Tran-Van-Nhieu, Jeanne; Manin, Sylvie; Poelstra, Klaas; Chun, Jerold; Carpentier, Stephane; Levade, Thierry; Mallat, Ariane; Lotersztajn, Sophie</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2005-2013</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid produced by sphingosine kinase (SphK1 and 2).  We previously showed that S1P receptors (S1P1, S1P2, and S1P3) are expressed in hepatic myofibroblasts (hMF), a population of cells that triggers matrix remodeling during liver injury.  Here we investigated the function of these receptors in the wound healing response to acute liver injury elicited by carbon tetrachloride, a process that assocs. hepatocyte proliferation and matrix remodeling.  Acute liver injury was assocd. with the induction of S1P2, S1P3, SphK1, and SphK2 mRNAs and increased SphK activity, with no change in S1P1 expression.  Necrosis, inflammation, and hepatocyte regeneration were similar in S1P2-/- and wild-type (WT) mice.  However, compared with WT mice, S1P2-/- mice displayed reduced accumulation of hMF, as shown by lower induction of smooth muscle α-actin mRNA and lower induction of TIMP-1, TGF-β1, and PDGF-BB mRNAs, overall reflecting reduced activation of remodeling in response to liver injury.  The wound healing response was similar in S1P3-/- and WT mice.  In vitro, S1P enhanced proliferation of cultured WT hMF, and PDGF-BB further enhanced the mitogenic effect of S1P.  In keeping with these findings, PDGF-BB up-regulated S1P2 and SphK1 mRNAs, increased SphK activity, and S1P2 induced PDGF-BB mRNA.  These effects were blunted in S1P2-/- cells, and S1P2-/- hMF exhibited reduced mitogenic and comitogenic responses to S1P.  These results unravel a novel major role of S1P2 in the wound healing response to acute liver injury by a mechanism involving enhanced proliferation of hMF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYiGmx2M3IlLVg90H21EOLACvtfcHk0lhlRgVudUDvyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvVagsrs%253D&md5=564e2307315530db783d65fb43546c01</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1096%2Ffj.06-6889com&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.06-6889com%26sid%3Dliteratum%253Aachs%26aulast%3DSerriere-Lanneau%26aufirst%3DV.%26aulast%3DTeixeira-Clerc%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSchippers%26aufirst%3DM.%26aulast%3Dde%2BWries%26aufirst%3DW.%26aulast%3DJulien%26aufirst%3DB.%26aulast%3DTran-Van-Nhieu%26aufirst%3DJ.%26aulast%3DManin%26aufirst%3DS.%26aulast%3DPoelstra%26aufirst%3DK.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DCarpentier%26aufirst%3DS.%26atitle%3DThe%2520sphingosine%25201-phosphate%2520receptor%2520S1P2%2520triggers%2520hepatic%2520wound%2520healing%26jtitle%3DFASEB%2520J.%26date%3D2007%26volume%3D21%26spage%3D2005%26epage%3D2013%26doi%3D10.1096%2Ffj.06-6889com" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Takuwa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takuwa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, K.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate as a mediator involved in development of fibrotic diseases</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1831</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/j.bbalip.2012.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.bbalip.2012.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=22735357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOls7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1831&publication_year=2013&pages=185-192&author=Y.+Takuwaauthor=H.+Ikedaauthor=Y.+Okamotoauthor=N.+Takuwaauthor=K.+Yoshioka&title=Sphingosine-1-phosphate+as+a+mediator+involved+in+development+of+fibrotic+diseases&doi=10.1016%2Fj.bbalip.2012.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate as a mediator involved in development of fibrotic diseases</span></div><div class="casAuthors">Takuwa, Yoh; Ikeda, Hitoshi; Okamoto, Yasuo; Takuwa, Noriko; Yoshioka, Kazuaki</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1831</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-192</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Fibrosis is a pathol. process characterized by massive deposition of extracellular matrix (ECM) such as type I/III collagens and fibronectin that are secreted by an expanded pool of myofibroblasts, which are phenotypically altered fibroblasts with more contractile, proliferative, migratory and secretory activities.  Fibrosis occurs in various organs including the lung, heart, liver and kidney, resulting in loss of normal tissue architecture and functions.  Myofibroblasts could originate from multiple sources including tissue-resident fibroblasts, epithelial and endothelial cells through mechanisms of epithelial/endothelial-mesenchymal transition (EMT/EndMT), and bone marrow-derived circulating progenitors called fibrocytes.  Emerging evidence in recent years shows that sphingosine-1-phosphate (S1P) acts on several types of target cells and is engaged in pro-fibrotic inflammatory process and fibrogenic process through multiple mechanisms, which include vascular permeability change, leukocyte infiltration, and migration, proliferation and myofibroblast differentiation of fibroblasts.  Many of these S1P actions are receptor subtype-specific.  In these actions, S1P has multiple cross-talks with other cytokines, particularly transforming growth factor-β (TGFβ), which plays a major role in fibrosis.  The cross-talks include the regulation of S1P prodn. through altered expression and activity of sphingosine kinases in fibrotic lesions, altered expression of S1P receptors, and S1P receptor-mediated transactivation of TGFβ signaling pathway.  These cross-talks may give rise to a feed-forward, amplifying loop between S1P and TGFβ, and possibly with other cytokines in stimulating fibrogenesis.  Another lysophospholipid mediator lysophosphatidic acid has also been recently implicated in fibrosis.  The lysophospholipid signaling pathways represent novel, promising therapeutic targets for treating refractory fibrotic diseases.  This article is part of a Special Issue entitled Advances in Lysophospholipid Research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4lDJqsJR9kLVg90H21EOLACvtfcHk0lhlRgVudUDvyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOls7vP&md5=1efb314cbf84b6c76fbf93985bac7146</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2012.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2012.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DTakuwa%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DTakuwa%26aufirst%3DN.%26aulast%3DYoshioka%26aufirst%3DK.%26atitle%3DSphingosine-1-phosphate%2520as%2520a%2520mediator%2520involved%2520in%2520development%2520of%2520fibrotic%2520diseases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2013%26volume%3D1831%26spage%3D185%26epage%3D192%26doi%3D10.1016%2Fj.bbalip.2012.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Blankenbach, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeilschifter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer zu Heringdorf, D.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate receptor-2 antagonists: therapeutic potential and potential risks</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">167</span>, <span class="refDoi"> DOI: 10.3389/fphar.2016.00167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.3389%2Ffphar.2016.00167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=27445808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsV2gtb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=167&author=K.+V.+Blankenbachauthor=S.+Schwalmauthor=J.+Pfeilschifterauthor=D.+Meyer+zu+Heringdorf&title=Sphingosine-1-phosphate+receptor-2+antagonists%3A+therapeutic+potential+and+potential+risks&doi=10.3389%2Ffphar.2016.00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate receptor-2 antagonists: therapeutic potential and potential risks</span></div><div class="casAuthors">Blankenbach, Kira V.; Schwalm, Stephanie; Pfeilschifter, Josef; Meyer zu Heringdorf, Dagmar</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167/1-167/14</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The sphingosine-1-phosphate (S1P) signaling system with its specific G-protein-coupled S1P receptors, the enzymes of S1P metab. and the S1P transporters, offers a multitude of promising targets for drug development.  Until today, drug development in this area has nearly exclusively focused on (functional) antagonists at the S1P1 receptor, which cause a unique phenotype of immunomodulation.  Accordingly, the first-in class S1P1 receptor modulator, fingolimod, has been approved for the treatment of relapsing-remitting multiple sclerosis, and novel S1P1 receptor (functional) antagonists are being developed for autoimmune and inflammatory diseases such as psoriasis, inflammatory bowel disease, lupus erythematodes, or polymyositis.  Besides the S1P1 receptor, also S1P2 and S1P3 are widely expressed and regulate many diverse functions throughout the body.  The S1P2 receptor, in particular, often exerts cellular functions which are opposed to the functions of the S1P1 receptor.  As a consequence, antagonists at the S1P2 receptor have the potential to be useful in a contrasting context and different areas of indication compared to S1P1 antagonists.  The present review will focus on the therapeutic potential of S1P2 receptor antagonists and discuss their opportunities as well as their potential risks.  Open questions and areas which require further investigations will be emphasized in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL5VfhXuFlNLVg90H21EOLACvtfcHk0lhtfUX8fX6JRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsV2gtb7N&md5=27f116df6e35db621cc1bf8583f086be</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2016.00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2016.00167%26sid%3Dliteratum%253Aachs%26aulast%3DBlankenbach%26aufirst%3DK.%2BV.%26aulast%3DSchwalm%26aufirst%3DS.%26aulast%3DPfeilschifter%26aufirst%3DJ.%26aulast%3DMeyer%2Bzu%2BHeringdorf%26aufirst%3DD.%26atitle%3DSphingosine-1-phosphate%2520receptor-2%2520antagonists%253A%2520therapeutic%2520potential%2520and%2520potential%2520risks%26jtitle%3DFront.%2520Pharmacol.%26date%3D2016%26volume%3D7%26spage%3D167%26doi%3D10.3389%2Ffphar.2016.00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Takuwa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takuwa, Y.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate signalling and cardiac fibrosis</span>. <i>Inflammation Regener.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">096</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.2492/inflammregen.33.096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.2492%2Finflammregen.33.096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsFSqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=096-108&author=N.+Takuwaauthor=Y.+Okamotoauthor=K.+Yoshiokaauthor=Y.+Takuwa&title=Sphingosine-1-phosphate+signalling+and+cardiac+fibrosis&doi=10.2492%2Finflammregen.33.096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11dR"><div class="casContent"><span class="casTitleNuber">11d</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate signaling and cardiac fibrosis</span></div><div class="casAuthors">Takuwa, Noriko; Okamoto, Yasuo; Yoshioka, Kazuaki; Takuwa, Yoh</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation and Regeneration</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">96-108</span>CODEN:
                <span class="NLM_cas:coden">IRNECG</span>;
        ISSN:<span class="NLM_cas:issn">1880-9693</span>.
    
            (<span class="NLM_cas:orgname">Nippon Ensho/Saisei Igakkai</span>)
        </div><div class="casAbstract">A review.  Sphingosine-1-phosphate (S1P) is a pleiotropic lysophospholipid mediator that acts on 5 members of the G protein-coupled S1P receptor family to induce diverse biol. responses.  S1P1, S1P2 and S1P3, which are widely expressed receptor subtypes, exert distinct regulatory effects on cytoarchitecture, cell migration, proliferation and gene expression, through differential coupling to heterotrimeric G proteins and downstream signaling, including activation of Rac and Rho small GTPases.  Recent studies indicate the involvement of the S1P signaling system in inflammation and fibrosis.  Investigations into genetically engineered mice have provided evidence that S1P2 and S1P3 receptors, together with sphingosine kinase 1 (SphK1), which is a major S1P synthesizing enzyme, participate in fibrogenic processes, through mechanisms involving activation of the Rho-dependent pathway and cross-talk with TGFβ signaling.  This review will focus on the basics of the S1P signaling system, which include S1P receptor subtype-specific signaling and biol. activities, prodn. and degrdn. of S1P, and currently available in vivo data, including our own data, regarding how S1P signaling is involved in cardiac fibrosis, a pathol. feature of cardiac remodeling that leads to chronic heart failure, which is one of leading causes of death in developed countries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra7G9oVC6zAbVg90H21EOLACvtfcHk0lhtfUX8fX6JRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsFSqtb4%253D&md5=1091bcad3010c744c96452f0a68af317</span></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.2492%2Finflammregen.33.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2492%252Finflammregen.33.096%26sid%3Dliteratum%253Aachs%26aulast%3DTakuwa%26aufirst%3DN.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DYoshioka%26aufirst%3DK.%26aulast%3DTakuwa%26aufirst%3DY.%26atitle%3DSphingosine-1-phosphate%2520signalling%2520and%2520cardiac%2520fibrosis%26jtitle%3DInflammation%2520Regener.%26date%3D2013%26volume%3D33%26spage%3D096%26epage%3D108%26doi%3D10.2492%2Finflammregen.33.096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeilschifter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwiler, A.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate: A Janus-faced mediator of fibrotic diseases</span>. <i>Biochim. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1831</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/j.bbalip.2012.07.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.bbalip.2012.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=22889995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GksbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1831&publication_year=2013&pages=239-250&author=S.+Schwalmauthor=J.+Pfeilschifterauthor=A.+Huwiler&title=Sphingosine-1-phosphate%3A+A+Janus-faced+mediator+of+fibrotic+diseases&doi=10.1016%2Fj.bbalip.2012.07.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11eR"><div class="casContent"><span class="casTitleNuber">11e</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate: A Janus-faced mediator of fibrotic diseases</span></div><div class="casAuthors">Schwalm, Stephanie; Pfeilschifter, Josef; Huwiler, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1831</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">239-250</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Sphingosine-1-phosphate (S1P) is a pleiotropic lipid mediator that acts either on G protein-coupled S1P receptors on the cell surface or via intracellular target sites.  In addn. to the well established effects of S1P in angiogenesis, carcinogenesis and immunity, evidence is now continuously accumulating which demonstrates that S1P is an important regulator of fibrosis.  The contribution of S1P to fibrosis is of a Janus-faced nature as S1P exhibits both pro- and anti-fibrotic effects depending on its site of action.  Extracellular S1P promotes fibrotic processes in a S1P receptor-dependent manner, whereas intracellular S1P has an opposite effect and dampens a fibrotic reaction by yet unidentified mechanisms.  Fibrosis is a result of chronic irritation by various factors and is defined by an excess prodn. of extracellular matrix leading to tissue scarring and organ dysfunction.  In this review, we highlight the general effects of extracellular and intracellular S1P on the multistep cascade of pathol. fibrogenesis including tissue injury, inflammation and the action of pro-fibrotic cytokines that stimulate ECM prodn. and deposition.  In a second part we summarize the current knowledge about the involvement of S1P signaling in the development of organ fibrosis of the lung, kidney, liver, heart and skin.  Altogether, it is becoming clear that targeting the sphingosine kinase-1/S1P signaling pathway offers therapeutic potential in the treatment of various fibrotic processes.  This article is part of a Special Issue entitled Advances in Lysophospholipid Research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpohZuLnS4FLLVg90H21EOLACvtfcHk0lhtfUX8fX6JRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GksbjK&md5=d2a704f167af1b096e4b4d0a31af1f41</span></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2012.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2012.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DSchwalm%26aufirst%3DS.%26aulast%3DPfeilschifter%26aufirst%3DJ.%26aulast%3DHuwiler%26aufirst%3DA.%26atitle%3DSphingosine-1-phosphate%253A%2520A%2520Janus-faced%2520mediator%2520of%2520fibrotic%2520diseases%26jtitle%3DBiochim.%2520Biophys.%26date%3D2013%26volume%3D1831%26spage%3D239%26epage%3D250%26doi%3D10.1016%2Fj.bbalip.2012.07.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="note"><p class="first last">and references therein.</p></div><div class="NLM_citation" id="cit11f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, M.</span></span> <span> </span><span class="NLM_article-title">Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-β1</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2007-0065OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1165%2Frcmb.2007-0065OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=17641298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOntbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2007&pages=395-404&author=Y.+Konoauthor=T.+Nishiumaauthor=Y.+Nishimuraauthor=Y.+Kotaniauthor=T.+Okadaauthor=S.+Nakamuraauthor=M.+Yokoyama&title=Sphingosine+kinase+1+regulates+differentiation+of+human+and+mouse+lung+fibroblasts+mediated+by+TGF-%CE%B21&doi=10.1165%2Frcmb.2007-0065OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11fR"><div class="casContent"><span class="casTitleNuber">11f</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-β1</span></div><div class="casAuthors">Kono, Yuko; Nishiuma, Teruaki; Nishimura, Yoshihiro; Kotani, Yoshikazu; Okada, Taro; Nakamura, Shun-ichi; Yokoyama, Mitsuhiro</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">395-404</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Transforming growth factor β (TGF-β) contributes to the progression of pulmonary fibrosis through up-regulation of α-smooth muscle actin (α-SMA) as lung myofibroblast differentiation.  Bioactive sphingosine 1-phosphate (S1P) has been shown to mimic TGF-β signals; however, the function of S1P in lung fibrotic process has not been well documented.  We found, in a mouse model of bleomycin lung fibrosis, that SPHK1 and α-SMA were colocalized within lung fibrotic foci and that these expressions were significantly increased in primary cultured fibroblasts.  Using human lung fibroblasts WI-38, we explored the rationale of sphingosine kinase (SPHK) with TGF-β1 stimulation.  SPHK inhibitors and small interference RNA (siRNA) targeted SPHK1 decreased α-SMA and fibronectin expression up-regulated by TGF-β1.  In the meantime, SPHK1 inhibition did not affect smad2 phosphorylation in response to TGF-β1.  Then we examd. whether S1P receptors transactivation may affect TGF-β signals.  SiRNA against S1P2 and S1P3, but not S1P1, reduced α-SMA expression as well as Y-27632, Rho kinase inhibitor.  We also detected activation of Rho GTPase upon stimulation of TGF-β1 on the cell membrane where S1P2 or S1P3 was overexpressed.  These data suggested that SPHK1 activation by TGF-β1 leads to Rho-assocd. myofibroblasts differentiation mediated by transactivated S1P receptors in the lung fibrogenic process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjN3YaovatirVg90H21EOLACvtfcHk0lh1GPWJ--GKyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOntbfP&md5=4acb28e02cebf24be8a9c797160a049c</span></div><a href="/servlet/linkout?suffix=cit11f&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2007-0065OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2007-0065OC%26sid%3Dliteratum%253Aachs%26aulast%3DKono%26aufirst%3DY.%26aulast%3DNishiuma%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DY.%26aulast%3DKotani%26aufirst%3DY.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DYokoyama%26aufirst%3DM.%26atitle%3DSphingosine%2520kinase%25201%2520regulates%2520differentiation%2520of%2520human%2520and%2520mouse%2520lung%2520fibroblasts%2520mediated%2520by%2520TGF-%25CE%25B21%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2007%26volume%3D37%26spage%3D395%26epage%3D404%26doi%3D10.1165%2Frcmb.2007-0065OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimosawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomiya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtomo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanoue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iitsuka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatomi, Y.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1194/jlr.M800496-JLR200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1194%2Fjlr.M800496-JLR200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=18955732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlCqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=556-564&author=H.+Ikedaauthor=N.+Watanabeauthor=I.+Ishiiauthor=T.+Shimosawaauthor=Y.+Kumeauthor=T.+Tomiyaauthor=Y.+Inoueauthor=T.+Nishikawaauthor=N.+Ohtomoauthor=Y.+Tanoueauthor=S.+Iitsukaauthor=R.+Fujitaauthor=M.+Omataauthor=J.+Chunauthor=Y.+Yatomi&title=Sphingosine+1-phosphate+regulates+regeneration+and+fibrosis+after+liver+injury+via+sphingosine+1-phosphate+receptor+2&doi=10.1194%2Fjlr.M800496-JLR200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11gR"><div class="casContent"><span class="casTitleNuber">11g</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2</span></div><div class="casAuthors">Ikeda, Hitoshi; Watanabe, Naoko; Ishii, Isao; Shimosawa, Tatsuo; Kume, Yukio; Tomiya, Tomoaki; Inoue, Yukiko; Nishikawa, Takako; Ohtomo, Natsuko; Tanoue, Yasushi; Iitsuka, Satoko; Fujita, Ryoto; Omata, Masao; Chun, Jerold; Yatomi, Yutaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">556-564</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P), a bioactive lipid mediator, stimulates proliferation and contractility in hepatic stellate cells, the principal matrix-producing cells in the liver, and inhibits proliferation via S1P receptor 2 (S1P2) in hepatocytes in rats in vitro.  A potential role of S1P and S1P2 in liver regeneration and fibrosis was examd. in S1P2-deficient mice.  Nuclear 5-bromo-2'-deoxy-uridine labeling, proliferating cell nuclear antigen (PCNA) staining in hepatocytes, and the ratio of liver wt. to body wt. were enhanced at 48 h in S1P2-deficient mice after a single carbon tetrachloride (CCl4) injection.  After dimethylnitrosamine (DMN) administration with a LD, PCNA staining in hepatocytes was enhanced at 48 h and survival rate was higher in S1P2-deficient mice.  Serum aminotransferase level was unaltered in those mice compared with wild-type mice in both CCl4- and DMN-induced liver injury, suggesting that S1P2 inactivation accelerated regeneration not as a response to enhanced liver damage.  After chronic CCl4 administration, fibrosis was less apparent, with reduced expression of smooth-muscle α-actin-pos. cells in the livers of S1P2-deficient mice, suggesting that S1P2 inactivation ameliorated CCl4-induced fibrosis due to the decreased accumulation of hepatic stellate cells.  Thus, S1P plays a significant role in regeneration and fibrosis after liver injury via S1P2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoU7Xhm7Qlt7Vg90H21EOLACvtfcHk0lh1GPWJ--GKyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlCqtbo%253D&md5=69a265513d07fa16057c341ebcfd695f</span></div><a href="/servlet/linkout?suffix=cit11g&amp;dbid=16384&amp;doi=10.1194%2Fjlr.M800496-JLR200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.M800496-JLR200%26sid%3Dliteratum%253Aachs%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DIshii%26aufirst%3DI.%26aulast%3DShimosawa%26aufirst%3DT.%26aulast%3DKume%26aufirst%3DY.%26aulast%3DTomiya%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DNishikawa%26aufirst%3DT.%26aulast%3DOhtomo%26aufirst%3DN.%26aulast%3DTanoue%26aufirst%3DY.%26aulast%3DIitsuka%26aufirst%3DS.%26aulast%3DFujita%26aufirst%3DR.%26aulast%3DOmata%26aufirst%3DM.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DYatomi%26aufirst%3DY.%26atitle%3DSphingosine%25201-phosphate%2520regulates%2520regeneration%2520and%2520fibrosis%2520after%2520liver%2520injury%2520via%2520sphingosine%25201-phosphate%2520receptor%25202%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2009%26volume%3D50%26spage%3D556%26epage%3D564%26doi%3D10.1194%2Fjlr.M800496-JLR200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Milara, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peiró, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramón, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortijo, J.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1136/thoraxjnl-2011-200026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1136%2Fthoraxjnl-2011-200026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=22106015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A280%3ADC%252BC387msVKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2012&pages=147-156&author=J.+Milaraauthor=R.+Navarroauthor=G.+Juanauthor=T.+Peir%C3%B3author=A.+Serranoauthor=M.+Ram%C3%B3nauthor=E.+Morcilloauthor=J.+Cortijo&title=Sphingosine-1-phosphate+is+increased+in+patients+with+idiopathic+pulmonary+fibrosis+and+mediates+epithelial+to+mesenchymal+transition&doi=10.1136%2Fthoraxjnl-2011-200026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11hR"><div class="casContent"><span class="casTitleNuber">11h</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition</span></div><div class="casAuthors">Milara Javier; Navarro Rafael; Juan Gustavo; Peiro Teresa; Serrano Adela; Ramon Mercedes; Morcillo Esteban; Cortijo Julio</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Idiopathic pulmonary fibrosis (IPF) is characterised by the aberrant epithelial to mesenchymal transition (EMT) and myofibroblast accumulation.  Sphingosine-1-phosphate (S1P) and sphingosine kinase 1 (SPHK1) have been implicated in lung myofibroblast transition, but their role in EMT and their expression in patients with IPF is unknown.  METHODS AND RESULTS:  S1P levels were measured in serum (n=27) and bronchoalveolar lavage (BAL; n=15) from patients with IPF and controls (n=30 for serum and n=15 for BAL studies).  SPHK1 expression was measured in lung tissue from patients with IPF (n=12) and controls (n=15).  Alveolar type II transformation into mesenchymal cells was studied in response to S1P (10(-9)-10(-5) M).  The median (IQR) of S1P serum levels was increased in patients with IPF (1.4 (0.4) μM) versus controls (1 (0.26) μM; p<0.0001).  BAL S1P levels were increased in patients with IPF (1.12 (0.53) μM) versus controls (0.2 (0.5); p<0.0001) and correlated with diffusion capacity of the lung for carbon monoxide, forced expiratory volume in 1 s and forced vital capacity (Spearman's r=-0.87, -0.72 and -0.68, respectively) in patients with IPF.  SPHK1 was upregulated in lung tissue from patients with IPF and correlated with α-smooth muscle actin, vimentin and collagen type I (Spearman's r=0.82, 0.85 and 0.72, respectively).  S1P induced EMT in alveolar type II cells by interacting with S1P(2) and S1P(3), as well as by the activation of p-Smad3, RhoA-GTP, oxidative stress and transforming growth factor-β1 (TGF-β1) release.  Furthermore, TGF-β1-induced EMT was partially conducted by the S1P/SPHK1 activation, suggesting crosstalk between TGF-β1 and the S1P/SPHK1 axis.  CONCLUSIONS:  S1P is elevated in patients with IPF, correlates with the lung function and mediates EMT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDkweGaX9BB-2mnZh2OgS0fW6udTcc2eYCZXe1ERNCmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387msVKkug%253D%253D&md5=4531bf84fcebd74364cdedc5462daad4</span></div><a href="/servlet/linkout?suffix=cit11h&amp;dbid=16384&amp;doi=10.1136%2Fthoraxjnl-2011-200026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthoraxjnl-2011-200026%26sid%3Dliteratum%253Aachs%26aulast%3DMilara%26aufirst%3DJ.%26aulast%3DNavarro%26aufirst%3DR.%26aulast%3DJuan%26aufirst%3DG.%26aulast%3DPeir%25C3%25B3%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DA.%26aulast%3DRam%25C3%25B3n%26aufirst%3DM.%26aulast%3DMorcillo%26aufirst%3DE.%26aulast%3DCortijo%26aufirst%3DJ.%26atitle%3DSphingosine-1-phosphate%2520is%2520increased%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%2520and%2520mediates%2520epithelial%2520to%2520mesenchymal%2520transition%26jtitle%3DThorax%26date%3D2012%26volume%3D67%26spage%3D147%26epage%3D156%26doi%3D10.1136%2Fthoraxjnl-2011-200026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, D. S.</span></span> <span> </span><span class="NLM_article-title">Deficiency of Sphingosine-1-Phosphate Receptor 2 (S1P2) attenuates bleomycin-induced pulmonary fibrosis</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2018.131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.4062%2Fbiomolther.2018.131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A280%3ADC%252BB3czmsFKiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=318-326&author=S.+J.+Parkauthor=D.+S.+Im&title=Deficiency+of+Sphingosine-1-Phosphate+Receptor+2+%28S1P2%29+attenuates+bleomycin-induced+pulmonary+fibrosis&doi=10.4062%2Fbiomolther.2018.131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Deficiency of Sphingosine-1-Phosphate Receptor 2 (S1P2) Attenuates Bleomycin-Induced Pulmonary Fibrosis</span></div><div class="casAuthors">Park Soo-Jin; Im Dong-Soon</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-326</span>
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) levels are often found to be elevated in serum, bronchoalveolar lavage, and lung tissue of idiopathic pulmonary fibrosis patients and experimental mouse models.  Although the roles of sphingosine kinase 1 and S1P receptors have been implicated in fibrosis, the underlying mechanism of fibrosis via Sphingosine 1-phosphate receptor 2 (S1P2) has not been fully investigated.  Therefore, in this study, the roles of S1P2 in lung inflammation and fibrosis was investigated by means of a bleomycin-induced lung fibrosis model and lung epithelial cells.  Bleomycin was found to induce lung inflammation on day 7 and fibrosis on day 28 of treatment.  On the 7(th) day after bleomycin administration, S1P2 deficient mice exhibited significantly less pulmonary inflammation, including cell infiltration and pro-inflammatory cytokine induction, than the wild type mice.  On the 28(th) day after bleomycin treatment, severe inflammation and fibrosis were observed in lung tissues from wild type mice, while lung tissues from S1P2 deficient mice showed less inflammation and fibrosis.  Increase in TGF-β1-induced extracellular matrix accumulation and epithelial-mesenchymal transition were inhibited by JTE-013, a S1P2 antagonist, in A549 lung epithelial cells.  Taken together, pro-inflammatory and pro-fibrotic functions of S1P2 were elucidated using a bleomycin-induced fibrosis model.  Notably, S1P2 was found to mediate epithelial-mesenchymal transition in fibrotic responses.  Therefore, the results of this study indicate that S1P2 could be a promising therapeutic target for the treatment of pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSYSKhydluNM6__Jf7-eMvJfW6udTcc2eYCZXe1ERNCmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czmsFKiug%253D%253D&md5=47aa485144720d3f2e5006024c86e88c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2018.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2018.131%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DIm%26aufirst%3DD.%2BS.%26atitle%3DDeficiency%2520of%2520Sphingosine-1-Phosphate%2520Receptor%25202%2520%2528S1P2%2529%2520attenuates%2520bleomycin-induced%2520pulmonary%2520fibrosis%26jtitle%3DBiomol.%2520Ther.%26date%3D2019%26volume%3D27%26spage%3D318%26epage%3D326%26doi%3D10.4062%2Fbiomolther.2018.131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishimaru, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takuwa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takuwa, Y.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate receptor-2 facilitates pulmonary fibrosis through potentiating IL-13 pathway in macrophages</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0197604</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0197604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1371%2Fjournal.pone.0197604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=29782549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsl2iu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=J.+Zhaoauthor=Y.+Okamotoauthor=Y.+Asanoauthor=K.+Ishimaruauthor=S.+Akiauthor=K.+Yoshiokaauthor=N.+Takuwaauthor=T.+Wadaauthor=Y.+Inagakiauthor=C.+Takahashiauthor=T.+Nishiuchiauthor=Y.+Takuwa&title=Sphingosine-1-phosphate+receptor-2+facilitates+pulmonary+fibrosis+through+potentiating+IL-13+pathway+in+macrophages&doi=10.1371%2Fjournal.pone.0197604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate receptor-2 facilitates pulmonary fibrosis through potentiating IL-13 pathway in macrophages</span></div><div class="casAuthors">Zhao, Juanjuan; Okamoto, Yasuo; Asano, Yuya; Ishimaru, Kazuhiro; Aki, Sho; Yoshioka, Kazuaki; Takuwa, Noriko; Wada, Takashi; Inagaki, Yutaka; Takahashi, Chiaki; Nishiuchi, Takumi; Takuwa, Yoh</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e0197604/1-e0197604/22</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a devastating disease with poor prognosis.  The pathogenic role of the lysophospholipid mediator sphingosine-1-phosphate and its receptor S1PR2 in lung fibrosis is unknown.  We show here that genetic deletion of S1pr2 strikingly attenuated lung fibrosis induced by repeated injections of bleomycin in mice.  We obsd. by using S1pr2LacZ/+ mice that S1PR2 was expressed in alveolar macrophages, vascular endothelial cells and alveolar epithelial cells in the lung and that S1PR2-expressing cells accumulated in the fibrotic legions.  Bone marrow chimera expts. suggested that S1PR2 in bone marrow-derived cells contributes to the development of lung fibrosis.  Depletion of macrophages greatly attenuated lung fibrosis.  Bleomycin administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1, Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly diminished the stimulated expression of these genes.  BALF cells from bleomycin-administered wild-type mice showed a marked increase in phosphorylation of STAT6, a transcription factor which is activated downstream of IL-13, compared with saline-administered wild-type mice.  Interestingly, in bleomycin-administered S1pr2-/- mice, STAT6 phosphorylation in BALF cells was substantially diminished compared with wild-type mice.  Finally, pharmacol. S1PR2 blockade in S1pr2+/+ mice alleviated bleomycin-induced lung fibrosis.  Thus, S1PR2 facilitates lung fibrosis through the mechanisms involving augmentation of IL-13 expression and its signaling in BALF cells, and represents a novel target for treating lung fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4uV_lAvZAA7Vg90H21EOLACvtfcHk0ljv38VRp-JyIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsl2iu7vJ&md5=a07ad0e6ebca38c0e17bcde33e2b04e6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0197604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0197604%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DAsano%26aufirst%3DY.%26aulast%3DIshimaru%26aufirst%3DK.%26aulast%3DAki%26aufirst%3DS.%26aulast%3DYoshioka%26aufirst%3DK.%26aulast%3DTakuwa%26aufirst%3DN.%26aulast%3DWada%26aufirst%3DT.%26aulast%3DInagaki%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DC.%26aulast%3DNishiuchi%26aufirst%3DT.%26aulast%3DTakuwa%26aufirst%3DY.%26atitle%3DSphingosine-1-phosphate%2520receptor-2%2520facilitates%2520pulmonary%2520fibrosis%2520through%2520potentiating%2520IL-13%2520pathway%2520in%2520macrophages%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0197604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cattoretti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelbaum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahler, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadburn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalla-Favera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqualucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLennan, A. J.</span></span> <span> </span><span class="NLM_article-title">Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">8686</span>– <span class="NLM_lpage">8692</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-1110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1158%2F0008-5472.CAN-09-1110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=19903857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2rsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8686-8692&author=G.+Cattorettiauthor=J.+Mandelbaumauthor=N.+Leeauthor=A.+H.+Chavesauthor=A.+M.+Mahlerauthor=A.+Chadburnauthor=R.+Dalla-Faveraauthor=L.+Pasqualucciauthor=A.+J.+MacLennan&title=Targeted+disruption+of+the+S1P2+sphingosine+1-phosphate+receptor+gene+leads+to+diffuse+large+B-cell+lymphoma+formation&doi=10.1158%2F0008-5472.CAN-09-1110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Disruption of the S1P2 Sphingosine 1-Phosphate Receptor Gene Leads to Diffuse Large B-Cell Lymphoma Formation</span></div><div class="casAuthors">Cattoretti, Giorgio; Mandelbaum, Jonathan; Lee, Nancy; Chaves, Alicia H.; Mahler, Ashley M.; Chadburn, Amy; Dalla-Favera, Riccardo; Pasqualucci, Laura; MacLennan, A. John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8686-8692</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">S1P2 sphingosine 1-phosphate receptor signaling can regulate proliferation, survival, morphol., and migration in many cell types in vitro.  Here, we report that S1P2-/- mice develop clonal B-cell lymphomas with age, such that approx. half of the animals display this neoplasm by 1.5 to 2 years of age.  Histol., immunophenotypic, and mol. analyses revealed a uniform tumor phenotype with features of germinal center (GC)-derived diffuse large B-cell lymphoma (DLBCL).  Tumor formation was preceded by increases in GC B cells and CD69+ T cells, as well as an increased formation of spontaneous GCs, suggesting that S1P2 loss may promote lymphomagenesis in part by disrupting GC B-cells homeostasis.  With the sole exception of rare lung tumors, the effect of S1P2 gene disruption is remarkably restricted to DLBCL.  In humans, 28 of 106 (26%) DLBCL samples were found to harbor multiple somatic mutations in the 5' sequences of the S1P2 gene.  Mutations displayed features resembling those generated by the IgV-assocd. somatic hypermutation mechanism, but were not detected at significant levels in normal GC B cells, indicating a tumor-assocd. aberrant function.  Collectively, our data suggest that S1P2 signaling may play a crit. role in suppressing DLBCL formation in vivo.  The high incidence of DLBCL in S1P2-/- mice, its onset at old age, and the relative lack of other neoplasms identify these mice as a novel, and potentially valuable, model for this highly prevalent and aggressive human malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3620dw7SMErVg90H21EOLACvtfcHk0ljv38VRp-JyIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2rsbfK&md5=33a8486cdf776f8b0df3b18117f68262</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-1110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-1110%26sid%3Dliteratum%253Aachs%26aulast%3DCattoretti%26aufirst%3DG.%26aulast%3DMandelbaum%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DChaves%26aufirst%3DA.%2BH.%26aulast%3DMahler%26aufirst%3DA.%2BM.%26aulast%3DChadburn%26aufirst%3DA.%26aulast%3DDalla-Favera%26aufirst%3DR.%26aulast%3DPasqualucci%26aufirst%3DL.%26aulast%3DMacLennan%26aufirst%3DA.%2BJ.%26atitle%3DTargeted%2520disruption%2520of%2520the%2520S1P2%2520sphingosine%25201-phosphate%2520receptor%2520gene%2520leads%2520to%2520diffuse%2520large%2520B-cell%2520lymphoma%2520formation%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8686%26epage%3D8692%26doi%3D10.1158%2F0008-5472.CAN-09-1110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muppidi, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenwald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimsza, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeland, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braziel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubbs, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisenburger, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidehi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyster, J. G.</span></span> <span> </span><span class="NLM_article-title">Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>516</i></span>,  <span class="NLM_fpage">254</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1038/nature13765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1038%2Fnature13765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=25274307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVemtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=516&publication_year=2014&pages=254-258&author=J.+R.+Muppidiauthor=R.+Schmitzauthor=J.+A.+Greenauthor=W.+Xiaoauthor=A.+B.+Larsenauthor=S.+E.+Braunauthor=J.+Anauthor=Y.+Xuauthor=A.+Rosenwaldauthor=G.+Ottauthor=R.+D.+Gascoyneauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=N.+Vaidehiauthor=L.+M.+Staudtauthor=J.+G.+Cyster&title=Loss+of+signalling+via+G%CE%B113+in+germinal+centre+B-cell-derived+lymphoma&doi=10.1038%2Fnature13765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma</span></div><div class="casAuthors">Muppidi, Jagan R.; Schmitz, Roland; Green, Jesse A.; Xiao, Wenming; Larsen, Adrien B.; Braun, Sterling E.; An, Jinping; Xu, Ying; Rosenwald, Andreas; Ott, German; Gascoyne, Randy D.; Rimsza, Lisa M.; Campo, Elias; Jaffe, Elaine S.; Delabie, Jan; Smeland, Erlend B.; Braziel, Rita M.; Tubbs, Raymond R.; Cook, J. R.; Weisenburger, Dennis D.; Chan, Wing C.; Vaidehi, Nagarajan; Staudt, Louis M.; Cyster, Jason G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">516</span>
        (<span class="NLM_cas:issue">7530</span>),
    <span class="NLM_cas:pages">254-258</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Germinal center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL) is a common malignancy, yet the signalling pathways that are deregulated and the factors leading to its systemic dissemination are poorly defined.  Work in mice showed that sphingosine-1-phosphate receptor-2 (S1PR2), a Gα12 and Gα13 coupled receptor, promotes growth regulation and local confinement of germinal center B cells.  Recent deep sequencing studies of GCB-DLBCL have revealed mutations in many genes in this cancer, including in GNA13 (encoding Gα13) and S1PR2 (refs 5,6, 7).  Here we show, using in vitro and in vivo assays, that GCB-DLBCL-assocd. mutations occurring in S1PR2 frequently disrupt the receptor's Akt and migration inhibitory functions.  Gα13-deficient mouse germinal center B cells and human GCB-DLBCL cells were unable to suppress pAkt and migration in response to S1P, and Gα13-deficient mice developed germinal center B-cell-derived lymphoma.  Germinal center B cells, unlike most lymphocytes, are tightly confined in lymphoid organs and do not recirculate.  Remarkably, deficiency in Gα13, but not S1PR2, led to germinal center B-cell dissemination into lymph and blood.  GCB-DLBCL cell lines frequently carried mutations in the Gα13 effector ARHGEF1, and Arhgef1 deficiency also led to germinal center B-cell dissemination.  The incomplete phenocopy of Gα13- and S1PR2 deficiency led us to discover that P2RY8, an orphan receptor that is mutated in GCB-DLBCL and another germinal center B-cell-derived malignancy, Burkitt's lymphoma, also represses germinal center B-cell growth and promotes confinement via Gα13.  These findings identify a Gα13-dependent pathway that exerts dual actions in suppressing growth and blocking dissemination of germinal center B cells that is frequently disrupted in germinal center B-cell-derived lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohskT6-Npw6rVg90H21EOLACvtfcHk0liUkE55Mv-Mcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVemtrrN&md5=0fea0ad604221300c533414842d8fc5d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnature13765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13765%26sid%3Dliteratum%253Aachs%26aulast%3DMuppidi%26aufirst%3DJ.%2BR.%26aulast%3DSchmitz%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DJ.%2BA.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DLarsen%26aufirst%3DA.%2BB.%26aulast%3DBraun%26aufirst%3DS.%2BE.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DVaidehi%26aufirst%3DN.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26atitle%3DLoss%2520of%2520signalling%2520via%2520G%25CE%25B113%2520in%2520germinal%2520centre%2520B-cell-derived%2520lymphoma%26jtitle%3DNature%26date%3D2014%26volume%3D516%26spage%3D254%26epage%3D258%26doi%3D10.1038%2Fnature13765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanaji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seko, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel S1P2 antagonists. Part 1: Discovery of 1,3-bis(aryloxy)benzene derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1479</span>– <span class="NLM_lpage">1482</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.bmcl.2015.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=25746814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsFCqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1479-1482&author=K.+Kusumiauthor=K.+Shinozakiauthor=T.+Kanajiauthor=H.+Kurataauthor=A.+Naganawaauthor=K.+Otsukiauthor=T.+Matsushitaauthor=T.+Sekiguchiauthor=A.+Kakuuchiauthor=T.+Seko&title=Discovery+of+novel+S1P2+antagonists.+Part+1%3A+Discovery+of+1%2C3-bis%28aryloxy%29benzene+derivatives&doi=10.1016%2Fj.bmcl.2015.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel S1P2 antagonists. Part 1: Discovery of 1,3-bis(aryloxy)benzene derivatives</span></div><div class="casAuthors">Kusumi, Kensuke; Shinozaki, Koji; Kanaji, Toshiya; Kurata, Haruto; Naganawa, Atsushi; Otsuki, Kazuhiro; Matsushita, Takeshi; Sekiguchi, Tetsuya; Kakuuchi, Akito; Seko, Takuya</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1479-1482</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity relationships of a novel series of sphingosine-1-phosphate receptor antagonists have been examd. in detail.  The initial hit compd. 1 was modified through synthesis to improve its S1P2 activity.  The synthesis of a series of analogs revealed that 1,3-bis(aryloxy)benzene derivs., as represented by 22, are potent and selective S1P2 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNuea159OT2rVg90H21EOLACvtfcHk0liUkE55Mv-Mcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsFCqsLg%253D&md5=2b2ec854e2f5d0b5716055c874adcc1f</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DKusumi%26aufirst%3DK.%26aulast%3DShinozaki%26aufirst%3DK.%26aulast%3DKanaji%26aufirst%3DT.%26aulast%3DKurata%26aufirst%3DH.%26aulast%3DNaganawa%26aufirst%3DA.%26aulast%3DOtsuki%26aufirst%3DK.%26aulast%3DMatsushita%26aufirst%3DT.%26aulast%3DSekiguchi%26aufirst%3DT.%26aulast%3DKakuuchi%26aufirst%3DA.%26aulast%3DSeko%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520novel%2520S1P2%2520antagonists.%2520Part%25201%253A%2520Discovery%2520of%25201%252C3-bis%2528aryloxy%2529benzene%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1479%26epage%3D1482%26doi%3D10.1016%2Fj.bmcl.2015.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seko, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel S1P2 antagonists. Part 2: Improving the profile of a series of 1,3-bis(aryloxy)benzene derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4387</span>– <span class="NLM_lpage">4392</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.bmcl.2015.09.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=26384288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWku7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4387-4392&author=K.+Kusumiauthor=K.+Shinozakiauthor=Y.+Yamauraauthor=A.+Hashimotoauthor=H.+Kurataauthor=A.+Naganawaauthor=H.+Uedaauthor=K.+Otsukiauthor=T.+Matsushitaauthor=T.+Sekiguchiauthor=A.+Kakuuchiauthor=T.+Seko&title=Discovery+of+novel+S1P2+antagonists.+Part+2%3A+Improving+the+profile+of+a+series+of+1%2C3-bis%28aryloxy%29benzene+derivatives&doi=10.1016%2Fj.bmcl.2015.09.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel S1P2 antagonists. Part 2: Improving the profile of a series of 1,3-bis(aryloxy)benzene derivatives</span></div><div class="casAuthors">Kusumi, Kensuke; Shinozaki, Koji; Yamaura, Yoshiyuki; Hashimoto, Ai; Kurata, Haruto; Naganawa, Atsushi; Ueda, Hideyuki; Otsuki, Kazuhiro; Matsushita, Takeshi; Sekiguchi, Tetsuya; Kakuuchi, Akito; Seko, Takuya</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4387-4392</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The initial lead compd. was modified to improve its metabolic stability.  The resulting compd. showed excellent metabolic stability in rat and human liver microsomes.  The authors subsequently designed and synthesized compd. N-[3-[4-(aminocarbonyl)phenoxy]-5-(4-fluorophenoxy)phenyl]-4-(4-chlorophenyl)-4-hydroxy-1-piperidinecarboxamide (I), which showed improved S1P2 antagonist activity and good metabolic stability.  The subsequent introduction of a carboxylic acid moiety into I resulted in 4-[3-(4-fluorophenoxy)-5-[[[4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]carbonyl]amino]phenoxy]benzoic acid (II), which showed potent antagonist activity towards S1P2 with a much smaller species difference between human S1P2 and rat S1P2.  Compd. II also showed good metabolic stability and an improved safety profile compared with compd. I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV9GPuG8l-2bVg90H21EOLACvtfcHk0ljLRkftnS5_nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWku7vO&md5=c70cd9c405bacbca0c5efe02502c51c7</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.022%26sid%3Dliteratum%253Aachs%26aulast%3DKusumi%26aufirst%3DK.%26aulast%3DShinozaki%26aufirst%3DK.%26aulast%3DYamaura%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DKurata%26aufirst%3DH.%26aulast%3DNaganawa%26aufirst%3DA.%26aulast%3DUeda%26aufirst%3DH.%26aulast%3DOtsuki%26aufirst%3DK.%26aulast%3DMatsushita%26aufirst%3DT.%26aulast%3DSekiguchi%26aufirst%3DT.%26aulast%3DKakuuchi%26aufirst%3DA.%26aulast%3DSeko%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520novel%2520S1P2%2520antagonists.%2520Part%25202%253A%2520Improving%2520the%2520profile%2520of%2520a%2520series%2520of%25201%252C3-bis%2528aryloxy%2529benzene%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4387%26epage%3D4392%26doi%3D10.1016%2Fj.bmcl.2015.09.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seko, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel S1P2 antagonists. Part 3: Improving the oral bioavailability of a series of 1,3-bis(aryloxy)benzene derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1209</span>– <span class="NLM_lpage">1213</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.01.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.bmcl.2016.01.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=26794040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1elurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1209-1213&author=K.+Kusumiauthor=K.+Shinozakiauthor=Y.+Yamauraauthor=A.+Hashimotoauthor=H.+Kurataauthor=A.+Naganawaauthor=K.+Otsukiauthor=T.+Matsushitaauthor=T.+Sekiguchiauthor=A.+Kakuuchiauthor=H.+Yamamotoauthor=T.+Seko&title=Discovery+of+novel+S1P2+antagonists.+Part+3%3A+Improving+the+oral+bioavailability+of+a+series+of+1%2C3-bis%28aryloxy%29benzene+derivatives&doi=10.1016%2Fj.bmcl.2016.01.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel S1P2 antagonists, part 3: Improving the oral bioavailability of a series of 1,3-bis(aryloxy)benzene derivatives</span></div><div class="casAuthors">Kusumi, Kensuke; Shinozaki, Koji; Yamaura, Yoshiyuki; Hashimoto, Ai; Kurata, Haruto; Naganawa, Atsushi; Otsuki, Kazuhiro; Matsushita, Takeshi; Sekiguchi, Tetsuya; Kakuuchi, Akito; Yamamoto, Hiroshi; Seko, Takuya</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1209-1213</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure of the S1P2 antagonist 1 has been modified with the aim of improving its oral bioavailability.  The chem. modification of the alkyl chain and carboxylic acid moieties of 1 led to significant improvements in the oral exposure of compds. belonging to this series.  The optimization of the ring size of the urea portion of these mols. also led to remarkable improvements in the oral exposure.  Based on these changes, the pyrrolidine deriv. I was identified as a suitable candidate compd. and showed excellent pharmacokinetic profiles in rat and dog, while maintaining high levels of potency and selective antagonistic activity toward S1P2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW5Oh4Cs44RLVg90H21EOLACvtfcHk0ljLRkftnS5_nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1elurs%253D&md5=afaf3444a370c35cd6ec6301850bc90a</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.01.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.01.031%26sid%3Dliteratum%253Aachs%26aulast%3DKusumi%26aufirst%3DK.%26aulast%3DShinozaki%26aufirst%3DK.%26aulast%3DYamaura%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DKurata%26aufirst%3DH.%26aulast%3DNaganawa%26aufirst%3DA.%26aulast%3DOtsuki%26aufirst%3DK.%26aulast%3DMatsushita%26aufirst%3DT.%26aulast%3DSekiguchi%26aufirst%3DT.%26aulast%3DKakuuchi%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DSeko%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520novel%2520S1P2%2520antagonists.%2520Part%25203%253A%2520Improving%2520the%2520oral%2520bioavailability%2520of%2520a%2520series%2520of%25201%252C3-bis%2528aryloxy%2529benzene%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1209%26epage%3D1213%26doi%3D10.1016%2Fj.bmcl.2016.01.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiendl, H.</span></span> <span> </span><span class="NLM_article-title">Benefit–risk profile of sphingosine-1-phosphate receptor modulators in relapsing and secondary progressive multiple sclerosis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1755</span>– <span class="NLM_lpage">1768</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0814-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1007%2Fs40265-017-0814-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=28905255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyqs7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1755-1768&author=G.+Comiauthor=H.+P.+Hartungauthor=R.+Bakshiauthor=I.+M.+Williamsauthor=H.+Wiendl&title=Benefit%E2%80%93risk+profile+of+sphingosine-1-phosphate+receptor+modulators+in+relapsing+and+secondary+progressive+multiple+sclerosis&doi=10.1007%2Fs40265-017-0814-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis</span></div><div class="casAuthors">Comi, Giancarlo; Hartung, Hans-Peter; Bakshi, Rajesh; Williams, Ian M.; Wiendl, Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1755-1768</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Since the approval of fingolimod, several selective sphingosine-1-phosphate receptor modulators have entered clin. development for multiple sclerosis.  However, side effects can occur with sphingosine-1-phosphate receptor modulators.  By considering short-term data across the drug class and longer term fingolimod data, we aim to highlight the potential of sphingosine-1-phosphate receptor modulators in multiple sclerosis, while offering reassurance that their benefit-risk profiles are suitable for long-term therapy.  Short-term fingolimod studies demonstrated the efficacy of this drug class, showed that cardiac events upon first-dose administration are transient and manageable, and showed that serious adverse events are rare.  Early-phase studies of selective sphingosine-1-phosphate receptor modulators also show efficacy with a similar or improved safety profile, and treatment initiation effects were reduced with dose titrn.  Longer term fingolimod studies demonstrated sustained efficacy and raised no new safety concerns, with no increases in macular edema, infection, or malignancy rates.  Switch studies identified no safety concerns and greater patient satisfaction and persistence with fingolimod when switching from injectable therapies with no washout period.  Better outcomes were seen with short than with long washouts when switching from natalizumab.  The specific immunomodulatory effects of sphingosine-1-phosphate receptor modulators are consistent with the low obsd. rates of long-term, drug-related adverse effects with fingolimod.  Short-term data for selective sphingosine-1-phosphate receptor modulators support their potential effectiveness in multiple sclerosis, and improved side-effect profiles may widen patient access to this drug class.  The long-term safety, tolerability, and persistence profiles of fingolimod should reassure clinicians that sphingosine-1-phosphate receptor modulators are likely to be suitable for the long-term treatment of multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Qwfw8DUoKbVg90H21EOLACvtfcHk0ljM6pf2ZZ4pqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyqs7vM&md5=751d178461b15286f460a8fe8f4dedae</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0814-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0814-1%26sid%3Dliteratum%253Aachs%26aulast%3DComi%26aufirst%3DG.%26aulast%3DHartung%26aufirst%3DH.%2BP.%26aulast%3DBakshi%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DI.%2BM.%26aulast%3DWiendl%26aufirst%3DH.%26atitle%3DBenefit%25E2%2580%2593risk%2520profile%2520of%2520sphingosine-1-phosphate%2520receptor%2520modulators%2520in%2520relapsing%2520and%2520secondary%2520progressive%2520multiple%2520sclerosis%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1755%26epage%3D1768%26doi%3D10.1007%2Fs40265-017-0814-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span>; <span class="NLM_string-name">Ozawa, K.</span>; <span class="NLM_string-name">Yamamoto, K.</span></span> <span> </span><span class="NLM_article-title">Preparation of pyrazolopyridine compounds and use thereof as remedies for fibrosis</span>. <span class="NLM_patent">WO 2001098301A1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=H.+Kawasaki&author=K.+Ozawa&author=K.+Yamamoto&title=Preparation+of+pyrazolopyridine+compounds+and+use+thereof+as+remedies+for+fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKawasaki%26aufirst%3DH.%26atitle%3DPreparation%2520of%2520pyrazolopyridine%2520compounds%2520and%2520use%2520thereof%2520as%2520remedies%2520for%2520fibrosis%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. J.</span></span> <span> </span><span class="NLM_article-title">Bicyclic compounds for treatment of inflammatory or allergic conditions and their preparation</span>. <span class="NLM_patent">WO2008107436A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+J.+Taylor&title=Bicyclic+compounds+for+treatment+of+inflammatory+or+allergic+conditions+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26atitle%3DBicyclic%2520compounds%2520for%2520treatment%2520of%2520inflammatory%2520or%2520allergic%2520conditions%2520and%2520their%2520preparation%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, A.</span>; <span class="NLM_string-name">Kusumi, K.</span>; <span class="NLM_string-name">Otsuki, K.</span>; <span class="NLM_string-name">Sekiguchi, T.</span>; <span class="NLM_string-name">Kakuuchi, A.</span>; <span class="NLM_string-name">Shinozaki, K.</span>; <span class="NLM_string-name">Yamamoto, H.</span>; <span class="NLM_string-name">Nonaka, S.</span></span> <span> </span><span class="NLM_article-title">Preparation of phenyl derivatives as S1P2 receptor antagonists</span>. <span class="NLM_patent">WO 2013047701A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+Naganawa&author=K.+Kusumi&author=K.+Otsuki&author=T.+Sekiguchi&author=A.+Kakuuchi&author=K.+Shinozaki&author=H.+Yamamoto&author=S.+Nonaka&title=Preparation+of+phenyl+derivatives+as+S1P2+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNaganawa%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520phenyl%2520derivatives%2520as%2520S1P2%2520receptor%2520antagonists%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span>; <span class="NLM_string-name">Jilishitz, I.</span>; <span class="NLM_string-name">Meinke, P.</span>; <span class="NLM_string-name">Stamford, A.</span>; <span class="NLM_string-name">Foley, M.</span>; <span class="NLM_string-name">Sato, A.</span>; <span class="NLM_string-name">Wada, Y.</span>; <span class="NLM_string-name">Fukase, Y.</span>; <span class="NLM_string-name">Asato Kina, A.</span>; <span class="NLM_string-name">Takahagi, H.</span>; <span class="NLM_string-name">Igawa, H.</span>; <span class="NLM_string-name">Polvino, W. J.</span></span> <span> </span><span class="NLM_article-title">Pyridinone- and pyridazinone-based compounds and medical uses thereof</span>. <span class="NLM_patent">WO2019173790A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=T.+Hla&author=I.+Jilishitz&author=P.+Meinke&author=A.+Stamford&author=M.+Foley&author=A.+Sato&author=Y.+Wada&author=Y.+Fukase&author=A.+Asato+Kina&author=H.+Takahagi&author=H.+Igawa&author=W.+J.+Polvino&title=Pyridinone-+and+pyridazinone-based+compounds+and+medical+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHla%26aufirst%3DT.%26atitle%3DPyridinone-%2520and%2520pyridazinone-based%2520compounds%2520and%2520medical%2520uses%2520thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saldana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayanan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schürer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhhatarai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span> <span> </span><span class="NLM_article-title">A sphingosine 1-phosphate receptor 2 selective allosteric agonist</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5373</span>– <span class="NLM_lpage">5382</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.bmc.2013.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=23849205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVyju7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=5373-5382&author=H.+Satsuauthor=M.+T.+Schaefferauthor=M.+Guerreroauthor=A.+Saldanaauthor=C.+Eberhartauthor=P.+Hodderauthor=C.+Cayananauthor=S.+Sch%C3%BCrerauthor=B.+Bhhataraiauthor=E.+Robertsauthor=H.+Rosenauthor=S.+J.+Brown&title=A+sphingosine+1-phosphate+receptor+2+selective+allosteric+agonist&doi=10.1016%2Fj.bmc.2013.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A sphingosine 1-phosphate receptor 2 selective allosteric agonist</span></div><div class="casAuthors">Satsu, Hideo; Schaeffer, Marie-Therese; Guerrero, Miguel; Saldana, Adrian; Eberhart, Christina; Hodder, Peter; Cayanan, Charmagne; Schurer, Stephan; Bhhatarai, Barun; Roberts, Ed; Rosen, Hugh; Brown, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5373-5382</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mol. probe tool compds. for the sphingosine 1-phosphate receptor 2 (S1PR2) are important for investigating the multiple biol. processes in which the S1PR2 receptor has been implicated.  Amongst these are NF-κB-mediated tumor cell survival and fibroblast chemotaxis to fibronectin.  Identified are selective chem. probes for S1PR2 and their characterization.  High throughput screening is used to identify two compds. which activate the S1PR2 receptor.  SAR optimization led to compds. with high nanomolar potency.  These compds., XAX-162 and CYM-5520, are highly selective and do not activate other S1P receptors.  Binding of CYM-5520 is not competitive with the antagonist JTE-013.  Mutation of receptor residues responsible for binding to the zwitterionic headgroup of sphingosine 1-phosphate (S1P) abolishes S1P activation of the receptor, but not activation by CYM-5520.  Competitive binding expts. with radiolabeled S1P demonstrate that CYM-5520 is an allosteric agonist and does not displace the native ligand.  Computational modeling suggests that CYM-5520 binds lower in the orthosteric binding pocket, and that co-binding with S1P is energetically well tolerated.  In summary, we have prepd. and identified an allosteric S1PR2 selective agonist compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYMrwZEQm6erVg90H21EOLACvtfcHk0ljM6pf2ZZ4pqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVyju7rE&md5=7e7c0cc3d53d30b4330fca2458d7c4fa</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DSatsu%26aufirst%3DH.%26aulast%3DSchaeffer%26aufirst%3DM.%2BT.%26aulast%3DGuerrero%26aufirst%3DM.%26aulast%3DSaldana%26aufirst%3DA.%26aulast%3DEberhart%26aufirst%3DC.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DCayanan%26aufirst%3DC.%26aulast%3DSch%25C3%25BCrer%26aufirst%3DS.%26aulast%3DBhhatarai%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DE.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26atitle%3DA%2520sphingosine%25201-phosphate%2520receptor%25202%2520selective%2520allosteric%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D5373%26epage%3D5382%26doi%3D10.1016%2Fj.bmc.2013.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><a href="https://www.simulations-plus.com/" class="extLink">https://www.simulations-plus.com/</a> (accessed Nov 22, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.simulations-plus.com%2F+%28accessed+Nov+22%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+further+insights+by+examining+carbo-+and+hetero-aromatic+and+-aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0lhJvE_-8JdY4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520-aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tafazoli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashregi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, P. J.</span></span> <span> </span><span class="NLM_article-title">Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>229</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2008.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.taap.2008.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=18295292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslWrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=2008&pages=94-101&author=S.+Tafazoliauthor=M.+Mashregiauthor=P.+J.+O%E2%80%99Brien&title=Role+of+hydrazine+in+isoniazid-induced+hepatotoxicity+in+a+hepatocyte+inflammation+model&doi=10.1016%2Fj.taap.2008.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model</span></div><div class="casAuthors">Tafazoli, Shahrzad; Mashregi, Mariam; O'Brien, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-101</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Isoniazid is an anti-tuberculosis drug that can cause hepatotoxicity in 20% of patients that is usually assocd. with an inflammatory response.  Hepatocytes when exposed to non-toxic levels of H2O2, to simulate H2O2 formation by inflammatory cells, became twice as sensitive to isoniazid toxicity.  Isoniazid cytotoxicity was prevented by 1-aminobenzotriazole, a non-selective P 450 inhibitor or by bis-p-nitrophenyl phosphate (BNPP), an esterase inhibitor.  Moreover, the cytotoxicity of hydrazine, the metabolite formed by amidase-catalyzed hydrolysis of isoniazid, was increased 16-fold by a non-toxic H2O2-generating system.  The acetylhydrazine metabolite was much less cytotoxic than hydrazine in this hepatocyte inflammation model.  Hydrazine, therefore, seems to be the isoniazid reactive metabolite in this inflammation model.  The mol. mechanism of hydrazine-induced cytotoxicity was attributed to oxidative stress as reactive oxygen species (ROS) and protein carbonyl formation occurred before the onset of hepatocyte toxicity.  Hydrazine toxicity also involved significant prodn. of endogenous H2O2 which resulted in lysosomal membrane damage and leads to a collapse in mitochondrial membrane potential.  These results implicated H2O2, a cellular mediator of inflammation, as a potential risk factor for the manifestation of adverse drug reactions, particularly those caused by hydrazine contg. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbxswcqxbg_bVg90H21EOLACvtfcHk0lhJvE_-8JdY4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslWrtbo%253D&md5=36cba43b6cc79f28540a3802a7d0ab44</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2008.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2008.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DTafazoli%26aufirst%3DS.%26aulast%3DMashregi%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DP.%2BJ.%26atitle%3DRole%2520of%2520hydrazine%2520in%2520isoniazid-induced%2520hepatotoxicity%2520in%2520a%2520hepatocyte%2520inflammation%2520model%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2008%26volume%3D229%26spage%3D94%26epage%3D101%26doi%3D10.1016%2Fj.taap.2008.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Waeber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomone, S.</span></span> <span> </span><span class="NLM_article-title">Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=21779246" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=1-8&author=C.+Waeberauthor=S.+Salomone&title=Selectivity+and+specificity+of+sphingosine-1-phosphate+receptor+ligands%3A+caveats+and+critical+thinking+in+characterizing+receptor-mediated+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWaeber%26aufirst%3DC.%26aulast%3DSalomone%26aufirst%3DS.%26atitle%3DSelectivity%2520and%2520specificity%2520of%2520sphingosine-1-phosphate%2520receptor%2520ligands%253A%2520caveats%2520and%2520critical%2520thinking%2520in%2520characterizing%2520receptor-mediated%2520effects%26jtitle%3DFront.%2520Pharmacol.%26date%3D2011%26volume%3D2%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strong, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicol, G. D.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate receptor 2 antagonist JTE-013 increases the excitability of sensory neurons independently of the receptor</span>. <i>J. Neurophysiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">1473</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1152/jn.00825.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1152%2Fjn.00825.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=22673325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1SqsbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2012&pages=1473-1483&author=C.+Liauthor=X.+X.+Chiauthor=W.+Xieauthor=J.+A.+Strongauthor=J.+M.+Zhangauthor=G.+D.+Nicol&title=Sphingosine+1-phosphate+receptor+2+antagonist+JTE-013+increases+the+excitability+of+sensory+neurons+independently+of+the+receptor&doi=10.1152%2Fjn.00825.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate receptor 2 antagonist JTE-013 increases the excitability of sensory neurons independently of the receptor</span></div><div class="casAuthors">Li, Chao; Chi, Xian Xuan; Xie, Wenrui; Strong, J. A.; Zhang, J.-M.; Nicol, G. D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurophysiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1473-1483</span>CODEN:
                <span class="NLM_cas:coden">JONEA4</span>;
        ISSN:<span class="NLM_cas:issn">0022-3077</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Previously we demonstrated that sphingosine 1-phosphate receptor 1 (S1PR1) played a prominent, but not exclusive, role in enhancing the excitability of small-diam. sensory neurons, suggesting that other S1PRs can modulate neuronal excitability.  To examine the potential role of S1PR2 in regulating neuronal excitability we used the established selective antagonist of S1PR2, JTE-013.  Here we report that exposure to JTE-013 alone produced a significant increase in excitability in a time- and concn.-dependent manner in 70-80% of recorded neurons.  Internal perfusion of sensory neurons with guanosine 5'-O-(2-thiodiphosphate) (GDP-β-S) via the recording pipet inhibited the sensitization produced by JTE-013 as well as prostaglandin E2.  Pretreatment with pertussis toxin or the selective S1PR1 antagonist W146 blocked the sensitization produced by JTE-013.  These results indicate that JTE-013 might act as an agonist at other G protein-coupled receptors.  In neurons that were sensitized by JTE-013, single-cell RT-PCR studies demonstrated that these neurons did not express the mRNA for S1PR2.  In behavioral studies, injection of JTE-013 into the rat's hindpaw produced a significant increase in the mech. sensitivity in the ipsilateral, but not contralateral, paw.  Injection of JTE-013 did not affect the withdrawal latency to thermal stimulation.  Thus JTE-013 augments neuronal excitability independently of S1PR2 by unknown mechanisms that may involve activation of other G protein-coupled receptors such as S1PR1.  Clearly, further studies are warranted to establish the causal nature of this increased sensitivity, and future studies of neuronal function using JTE-013 should be interpreted with caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGripYsWX5bbprVg90H21EOLACvtfcHk0lhxcA2G-YBDHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1SqsbnM&md5=416a3775302d00f061b6baff94db2bce</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1152%2Fjn.00825.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fjn.00825.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DChi%26aufirst%3DX.%2BX.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DStrong%26aufirst%3DJ.%2BA.%26aulast%3DZhang%26aufirst%3DJ.%2BM.%26aulast%3DNicol%26aufirst%3DG.%2BD.%26atitle%3DSphingosine%25201-phosphate%2520receptor%25202%2520antagonist%2520JTE-013%2520increases%2520the%2520excitability%2520of%2520sensory%2520neurons%2520independently%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Neurophysiol.%26date%3D2012%26volume%3D108%26spage%3D1473%26epage%3D1483%26doi%3D10.1152%2Fjn.00825.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W. K.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Corpuz, E.G.</span>; <span class="NLM_string-name">Chow, K.</span>; <span class="NLM_string-name">Im, Wha B.</span></span> <span> </span><span class="NLM_article-title">Preparation of condensed pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors</span>. <span class="NLM_patent">WO2011041287A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=W.+K.+Fang&author=L.+Wang&author=E.G.+Corpuz&author=K.+Chow&author=Wha+B.+Im&title=Preparation+of+condensed+pyridine+compounds+as+subtype-selective+modulators+of+sphingosine-1-phosphate-2+%28S1P2%29+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DW.%2BK.%26atitle%3DPreparation%2520of%2520condensed%2520pyridine%2520compounds%2520as%2520subtype-selective%2520modulators%2520of%2520sphingosine-1-phosphate-2%2520%2528S1P2%2529%2520receptors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, R. E.</span></span> <span> </span><span class="NLM_article-title">Preparation of novel N-(pyrazolopyridinylamino) ureas as sphingosine 1-phosphate receptor antagonists</span>. <span class="NLM_patent">WO2013148460A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+E.+Swenson&title=Preparation+of+novel+N-%28pyrazolopyridinylamino%29+ureas+as+sphingosine+1-phosphate+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSwenson%26aufirst%3DR.%2BE.%26atitle%3DPreparation%2520of%2520novel%2520N-%2528pyrazolopyridinylamino%2529%2520ureas%2520as%2520sphingosine%25201-phosphate%2520receptor%2520antagonists%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, R. E.</span>; <span class="NLM_string-name">Raju, N.</span>; <span class="NLM_string-name">Estrella-Jimenez, M. E.</span>; <span class="NLM_string-name">Ramalingam, K.</span></span> <span> </span><span class="NLM_article-title">Preparation of pyrazolopyridine derivatives for use as S1P2 and SIP5 receptor modulators</span>. <span class="NLM_patent">WO2011159864A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=R.+E.+Swenson&author=N.+Raju&author=M.+E.+Estrella-Jimenez&author=K.+Ramalingam&title=Preparation+of+pyrazolopyridine+derivatives+for+use+as+S1P2+and+SIP5+receptor+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSwenson%26aufirst%3DR.%2BE.%26atitle%3DPreparation%2520of%2520pyrazolopyridine%2520derivatives%2520for%2520use%2520as%2520S1P2%2520and%2520SIP5%2520receptor%2520modulators%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx-Lafrance, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helal, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleiman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menniti, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, S.</span></span> <span> </span><span class="NLM_article-title">Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7946</span>– <span class="NLM_lpage">7949</span>, <span class="refDoi"> DOI: 10.1021/jm9015334</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9015334" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsValtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7946-7949&author=P.+R.+Verhoestauthor=C.+Proulx-Lafranceauthor=M.+Cormanauthor=L.+Chenardauthor=C.+J.+Helalauthor=X.+Houauthor=R.+Kleimanauthor=S.+Liuauthor=E.+Marrauthor=F.+S.+Mennitiauthor=C.+J.+Schmidtauthor=M.+Vanase-Frawleyauthor=A.+W.+Schmidtauthor=R.+D.+Williamsauthor=F.+R.+Nelsonauthor=K.+R.+Fonsecaauthor=S.+Liras&title=Identification+of+a+brain+penetrant+PDE9A+inhibitor+utilizing+prospective+design+and+chemical+enablement+as+a+rapid+lead+optimization+strategy&doi=10.1021%2Fjm9015334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Brain Penetrant PDE9A Inhibitor Utilizing Prospective Design and Chemical Enablement as a Rapid Lead Optimization Strategy</span></div><div class="casAuthors">Verhoest, Patrick R.; Proulx-Lafrance, Caroline; Corman, Michael; Chenard, Lois; Helal, Christopher J.; Hou, Xinjun; Kleiman, Robin; Liu, Shenping; Marr, Eric; Menniti, Frank S.; Schmidt, Christopher J.; Vanase-Frawley, Michelle; Schmidt, Anne W.; Williams, Robert D.; Nelson, Frederick R.; Fonseca, Kari R.; Liras, Spiros</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7946-7949</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of selective, brain penetrant PDE9A inhibitors I (R1 = i-Pr, i-Bu, cyclopentyl, R2 = Ph; R1 = cyclopentyl, R2 = 3-MeC6H4, 2-pyridyl, 6-quinoxalinyl, etc.) has been identified that are capable of producing in vivo elevations of brain cGMP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou_Q49qDJV3bVg90H21EOLACvtfcHk0lgN2h3KHhWHVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsValtbzI&md5=4e1a67684031737596a83d1feb4bee08</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm9015334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9015334%26sid%3Dliteratum%253Aachs%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DProulx-Lafrance%26aufirst%3DC.%26aulast%3DCorman%26aufirst%3DM.%26aulast%3DChenard%26aufirst%3DL.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DKleiman%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMarr%26aufirst%3DE.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26aulast%3DVanase-Frawley%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DWilliams%26aufirst%3DR.%2BD.%26aulast%3DNelson%26aufirst%3DF.%2BR.%26aulast%3DFonseca%26aufirst%3DK.%2BR.%26aulast%3DLiras%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520a%2520brain%2520penetrant%2520PDE9A%2520inhibitor%2520utilizing%2520prospective%2520design%2520and%2520chemical%2520enablement%2520as%2520a%2520rapid%2520lead%2520optimization%2520strategy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7946%26epage%3D7949%26doi%3D10.1021%2Fjm9015334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. J.</span></span> <span> </span><span class="NLM_article-title">Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2007.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.tips.2007.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=17629959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlWltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=374-381&author=J.+G.+Bakerauthor=S.+J.+Hill&title=Multiple+GPCR+conformations+and+signalling+pathways%3A+implications+for+antagonist+affinity+estimates&doi=10.1016%2Fj.tips.2007.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple GPCR conformations and signaling pathways: implications for antagonist affinity estimates</span></div><div class="casAuthors">Baker, Jillian G.; Hill, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">374-381</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Antagonist affinity measurements have traditionally been considered important in characterizing the cell-surface receptors present in a particular cell or tissue.  A central assumption has been that antagonist affinity is const. for a given receptor-antagonist interaction, regardless of the agonist used to stimulate that receptor or the downstream response that is measured.  As a consequence, changes in antagonist affinity values have been taken as initial evidence for the presence of novel receptor subtypes.  Emerging evidence suggests, however, that receptors can possess multiple binding sites and the same receptor can show different antagonist affinity measurements under distinct exptl. conditions.  Here, we discuss several mechanisms by which antagonists have different affinities for the same receptor as a consequence of allosterism, coupling to different G proteins, multiple (but non-interacting) receptor sites, and signal-pathway-dependent pharmacol. (where the pharmacol. obsd. varies depending on the signaling pathway measured).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcWqdG7J1LyLVg90H21EOLACvtfcHk0lgN2h3KHhWHVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlWltLo%253D&md5=ac0bbf5922dd08316f502a3e981b2444</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26aulast%3DHill%26aufirst%3DS.%2BJ.%26atitle%3DMultiple%2520GPCR%2520conformations%2520and%2520signalling%2520pathways%253A%2520implications%2520for%2520antagonist%2520affinity%2520estimates%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D374%26epage%3D381%26doi%3D10.1016%2Fj.tips.2007.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipophilic efficiency as an important metric in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6401</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6401-6420&author=T.+W.+Johnsonauthor=R.+A.+Gallegoauthor=M.+P.+Edwards&title=Lipophilic+efficiency+as+an+important+metric+in+drug+design&doi=10.1021%2Facs.jmedchem.8b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Efficiency as an Important Metric in Drug Design</span></div><div class="casAuthors">Johnson, Ted W.; Gallego, Rebecca A.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6401-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chem. lead optimization programs.  In this perspective, using literature drug discovery examples, we discuss the concept of rigorously applying LipE to guide medicinal chem. lead optimization toward drug candidates with potential for superior in vivo efficacy and safety, esp. when guided by physiochem. property-based optimization (PPBO).  Also highlighted are examples of small structural modifications such as addn. of single atoms, small functional groups, and cyclizations that produce large increases in LipE.  Understanding the factors that may contribute to LipE changes through anal. of ligand-protein crystal structures and using structure-based drug design (SBDD) to increase LipE by design is also discussed.  Herein we advocate for use of LipE anal. coupled with PPBO and SBDD as an efficient mechanism for drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ8DOcOj6GrVg90H21EOLACvtfcHk0lgztTDcfD4uNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D&md5=29f38880914fa75c33be3a640ace4309</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DGallego%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DLipophilic%2520efficiency%2520as%2520an%2520important%2520metric%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6401%26epage%3D6420%26doi%3D10.1021%2Facs.jmedchem.8b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">and references therein.</p></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keane, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arenberg, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. P.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whyte, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannettoni, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilke, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiGiovine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strieter, R. M.</span></span> <span> </span><span class="NLM_article-title">The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">1437</span>– <span class="NLM_lpage">1443</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=9233641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADyaK2sXkslKku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=1997&pages=1437-1443&author=M.+P.+Keaneauthor=D.+A.+Arenbergauthor=J.+P.+Lynchauthor=R.+I.+Whyteauthor=M.+D.+Iannettoniauthor=M.+D.+Burdickauthor=C.+A.+Wilkeauthor=S.+B.+Morrisauthor=M.+C.+Glassauthor=B.+DiGiovineauthor=S.+L.+Kunkelauthor=R.+M.+Strieter&title=The+CXC+chemokines%2C+IL-8+and+IP-10%2C+regulate+angiogenic+activity+in+idiopathic+pulmonary+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Keane, Michael P.; Arenberg, Douglas A.; Lynch, Joseph P., III; Whyte, Richard I.; Iannettoni, Mark D.; Burdick, Marie D.; Wilke, Carol A.; Morris, Susan B.; Glass, Mary C.; DiGiovine, Bruno; Kunkel, Steven L.; Strieter, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1437-1443</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic and often fatal disorder.  Fibroplasia and deposition of extracellular matrix are dependent, in part, on angiogenesis.  The authors postulated that an imbalance exists in the expression of angiogenic (IL-8) vs. angiostatic (IFN-γ-inducible protein (IP-10)) CXC chemokines, which favors net angiogenesis in IPF.  To test this hypothesis, the authors obtained open lung biopsies either from normal patients undergoing thoracic surgery for reasons other than interstitial lung disease (control) or from patients with IPF.  The authors found that levels of IL-8 were greater from tissue specimens of IPF patients than from those of controls.  In contrast, IP-10 levels were higher from tissue specimens obtained from controls subjects than from those from IPF patients.  When IL-8 or IP-10 was depleted from IPF tissue specimens, tissue-derived angiogenic activity was markedly reduced or enhanced, resp.  Immunolocalization of IL-8 demonstrated that the pulmonary fibroblast (PF) of IPF lung was the predominant cellular source of IL-8.  Isolated PF from IPF patients constitutively produced more IL-8 and less IP-10 than control PF.  Conditioned media from IPF-PFs demonstrated constitutive angiogenic activity that was attributable, in part, to IL-8.  Depletion of IP-10 from IPF-PF CM resulted in an increase in corneal neovascularization.  These findings support the notion that IL-8 and IP-10 are important factors that regulate angiogenic activity in IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU_H7j5ISw0rVg90H21EOLACvtfcHk0lgztTDcfD4uNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkslKku7k%253D&md5=47af62036e3dd1fe772af51362c462fb</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeane%26aufirst%3DM.%2BP.%26aulast%3DArenberg%26aufirst%3DD.%2BA.%26aulast%3DLynch%26aufirst%3DJ.%2BP.%26aulast%3DWhyte%26aufirst%3DR.%2BI.%26aulast%3DIannettoni%26aufirst%3DM.%2BD.%26aulast%3DBurdick%26aufirst%3DM.%2BD.%26aulast%3DWilke%26aufirst%3DC.%2BA.%26aulast%3DMorris%26aufirst%3DS.%2BB.%26aulast%3DGlass%26aufirst%3DM.%2BC.%26aulast%3DDiGiovine%26aufirst%3DB.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26atitle%3DThe%2520CXC%2520chemokines%252C%2520IL-8%2520and%2520IP-10%252C%2520regulate%2520angiogenic%2520activity%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Immunol.%26date%3D1997%26volume%3D159%26spage%3D1437%26epage%3D1443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. G.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate (S1P) induced interleukin-8 (IL-8) release is mediated by S1P receptor 2 and nuclear factor κB in BEAS-2B cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e95566</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0095566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1371%2Fjournal.pone.0095566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=24743449" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=M.+J.+O%E2%80%99Sullivanauthor=N.+Hirotaauthor=J.+G.+Martin&title=Sphingosine+1-phosphate+%28S1P%29+induced+interleukin-8+%28IL-8%29+release+is+mediated+by+S1P+receptor+2+and+nuclear+factor+%CE%BAB+in+BEAS-2B+cells&doi=10.1371%2Fjournal.pone.0095566"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0095566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0095566%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DM.%2BJ.%26aulast%3DHirota%26aufirst%3DN.%26aulast%3DMartin%26aufirst%3DJ.%2BG.%26atitle%3DSphingosine%25201-phosphate%2520%2528S1P%2529%2520induced%2520interleukin-8%2520%2528IL-8%2529%2520release%2520is%2520mediated%2520by%2520S1P%2520receptor%25202%2520and%2520nuclear%2520factor%2520%25CE%25BAB%2520in%2520BEAS-2B%2520cells%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0095566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E. C. A.</span></span> <span> </span><span class="NLM_article-title">Rational use of plasma protein and tissue binding data in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8238</span>– <span class="NLM_lpage">8248</span>, <span class="refDoi"> DOI: 10.1021/jm5007935</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5007935" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8238-8248&author=X.+Liuauthor=M.+Wrightauthor=C.+E.+C.+A.+Hop&title=Rational+use+of+plasma+protein+and+tissue+binding+data+in+drug+design&doi=10.1021%2Fjm5007935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Use of Plasma Protein and Tissue Binding Data in Drug Design</span></div><div class="casAuthors">Liu, Xingrong; Wright, Matthew; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8238-8248</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is a commonly accepted assumption that only unbound drug mols. are available to interact with their targets.  Therefore, one of the objectives in drug design is to optimize the compd. structure to increase in vivo unbound drug concn.  In this review, theor. analyses and exptl. observations are presented to illustrate that low plasma protein binding does not necessarily lead to high in vivo unbound plasma concn.  Similarly, low brain tissue binding does not lead to high in vivo unbound brain tissue concn.  Instead, low intrinsic clearance leads to high in vivo unbound plasma concn., and low efflux transport activity at the blood-brain barrier leads to high unbound brain concn.  Plasma protein and brain tissue binding are very important parameters in understanding pharmacokinetics, pharmacodynamics, and toxicities of drugs, but these parameters should not be targeted for optimization in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKiYUz9ljIDrVg90H21EOLACvtfcHk0liN4agJ2PH-EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M&md5=53ffbdb88ddf500a90a0eee14b0e641f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm5007935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5007935%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26atitle%3DRational%2520use%2520of%2520plasma%2520protein%2520and%2520tissue%2520binding%2520data%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8238%26epage%3D8248%26doi%3D10.1021%2Fjm5007935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustakas, D. T.</span></span> <span> </span><span class="NLM_article-title">The necessary nitrogen atom: a versatile high-impact design element for multiparameter optimization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3552</span>– <span class="NLM_lpage">3579</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01807</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01807" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1yit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3552-3579&author=L.+D.+Penningtonauthor=D.+T.+Moustakas&title=The+necessary+nitrogen+atom%3A+a+versatile+high-impact+design+element+for+multiparameter+optimization&doi=10.1021%2Facs.jmedchem.6b01807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization</span></div><div class="casAuthors">Pennington, Lewis D.; Moustakas, Demetri T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3552-3579</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  There is a continued desire in biomedical research to reduce the no. and duration of design cycles required to optimize lead compds. into high-quality chem. probes or safe and efficacious drug candidates.  The insightful application of impactful mol. design elements is one approach toward achieving this goal.  The replacement of a CH group with a N atom in arom. and heteroarom. ring systems can have many important effects on mol. and physicochem. properties and intra- and intermol. interactions that can translate to improved pharmacol. profiles.  In this Perspective, the "necessary nitrogen atom" is shown to be a versatile high-impact design element for multiparameter optimization, wherein ≥10-, 100-, or 1000-fold improvement in a variety of key pharmacol. parameters can be realized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ZLKZMgt6IbVg90H21EOLACvtfcHk0liN4agJ2PH-EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1yit74%253D&md5=002aaee48995e7954647a1f75183db4d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01807%26sid%3Dliteratum%253Aachs%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMoustakas%26aufirst%3DD.%2BT.%26atitle%3DThe%2520necessary%2520nitrogen%2520atom%253A%2520a%2520versatile%2520high-impact%2520design%2520element%2520for%2520multiparameter%2520optimization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3552%26epage%3D3579%26doi%3D10.1021%2Facs.jmedchem.6b01807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Methyl effects on protein–ligand binding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4489</span>– <span class="NLM_lpage">4500</span>, <span class="refDoi"> DOI: 10.1021/jm3003697</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003697" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4489-4500&author=C.+S.+Leungauthor=S.+S.+F.+Leungauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Methyl+effects+on+protein%E2%80%93ligand+binding&doi=10.1021%2Fjm3003697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Methyl Effects on Protein-Ligand Binding</span></div><div class="casAuthors">Leung, Cheryl S.; Leung, Siegfried S. F.; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4489-4500</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The effects of addn. of a Me group to a lead compd. on biol. activity are examd.  A literature anal. of >2000 cases reveals that an activity boost of a factor of 10 or more is found with an 8% frequency, and a 100-fold boost is a 1 in 200 event.  Four cases in the latter category are analyzed in depth to elucidate any unusual aspects of the protein-ligand binding, distribution of water mols., and changes in conformational energetics.  The analyses include Monte Carlo/free-energy perturbation (MC/FEP) calcns. for Me replacements in inhibitor series for p38α MAP kinase, ACK1, PTP1B, and thrombin.  Me substitutions ortho to an aryl ring can be particularly effective at improving activity by inducing a propitious conformational change.  The greatest improvements in activity arise from coupling the conformational gain with the burial of the Me group in a hydrophobic region of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0Czyhgy6KbVg90H21EOLACvtfcHk0li1PBGxmyWeGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D&md5=0ea58d9c1bf845d383931b6a017f9b37</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm3003697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003697%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.%2BS.%26aulast%3DLeung%26aufirst%3DS.%2BS.%2BF.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DMethyl%2520effects%2520on%2520protein%25E2%2580%2593ligand%2520binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4489%26epage%3D4500%26doi%3D10.1021%2Fjm3003697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mammoliti, O.</span>; <span class="NLM_string-name">Jansen, K.K.</span>; <span class="NLM_string-name">Palisse, A. E.</span>; <span class="NLM_string-name">Joannesse, C. M. A.-M.</span>; <span class="NLM_string-name">Menet, C. J. M.</span>; <span class="NLM_string-name">Allart, B.</span>; <span class="NLM_string-name">El Bkassiny, S.</span></span> <span> </span><span class="NLM_article-title">Preparation of pyridazine derivatives for the prophylaxis and treatment of diseases including fibrosis</span>. <span class="NLM_patent">WO2017148787A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=O.+Mammoliti&author=K.K.+Jansen&author=A.+E.+Palisse&author=C.+M.+A.-M.+Joannesse&author=C.+J.+M.+Menet&author=B.+Allart&author=S.+El+Bkassiny&title=Preparation+of+pyridazine+derivatives+for+the+prophylaxis+and+treatment+of+diseases+including+fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMammoliti%26aufirst%3DO.%26atitle%3DPreparation%2520of%2520pyridazine%2520derivatives%2520for%2520the%2520prophylaxis%2520and%2520treatment%2520of%2520diseases%2520including%2520fibrosis%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ask, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warburton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauldie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, M.</span></span> <span> </span><span class="NLM_article-title">The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2007.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.biocel.2007.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=17936056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitVentrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=362-382&author=A.+Moellerauthor=K.+Askauthor=D.+Warburtonauthor=J.+Gauldieauthor=M.+Kolb&title=The+bleomycin+animal+model%3A+a+useful+tool+to+investigate+treatment+options+for+idiopathic+pulmonary+fibrosis%3F&doi=10.1016%2Fj.biocel.2007.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?</span></div><div class="casAuthors">Moeller, Antje; Ask, Kjetil; Warburton, David; Gauldie, Jack; Kolb, Martin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">362-382</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Different animal models of pulmonary fibrosis were developed to investigate potential therapies for idiopathic pulmonary fibrosis (IPF).  The most common is the bleomycin model in rodents (mouse, rat and hamster).  Over the years, numerous agents were shown to inhibit fibrosis in this model.  However, to date none of these compds. are used in the clin. management of IPF and none has shown a comparable antifibrotic effect in humans.  We performed a systematic review of publications on drug efficacy studies in the bleomycin model to evaluate the value of this model regarding transferability to clin. use.  Between 1980 and 2006 we identified 240 exptl. studies describing beneficial antifibrotic compds. in the bleomycin model. 222 of those used a preventive regimen (drug given ≤7 days after last bleomycin application), only 13 were therapeutic trials (>7 days after last bleomycin application).  In 5 studies we did not find enough details about the timing of drug application to allow inter-study comparison.  It is crit. to distinguish between drugs interfering with the inflammatory and early fibrogenic response from those preventing progression of fibrosis, the latter likely much more meaningful for clin. application.  All potential antifibrotic compds. should be evaluated in the phase of established fibrosis rather than in the early period of bleomycin-induced inflammation for assessment of its antifibrotic properties.  Further care should be taken in extrapolation of drugs successfully tested in the bleomycin model due to partial reversibility of bleomycin-induced fibrosis over time.  The use of alternative and more robust animal models, which better reflect human IPF, is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO707NgQcoCLVg90H21EOLACvtfcHk0li1PBGxmyWeGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitVentrg%253D&md5=2d9caf63cbe8d6092cdf4b011e46dfce</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2007.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2007.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DMoeller%26aufirst%3DA.%26aulast%3DAsk%26aufirst%3DK.%26aulast%3DWarburton%26aufirst%3DD.%26aulast%3DGauldie%26aufirst%3DJ.%26aulast%3DKolb%26aufirst%3DM.%26atitle%3DThe%2520bleomycin%2520animal%2520model%253A%2520a%2520useful%2520tool%2520to%2520investigate%2520treatment%2520options%2520for%2520idiopathic%2520pulmonary%2520fibrosis%253F%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2008%26volume%3D40%26spage%3D362%26epage%3D382%26doi%3D10.1016%2Fj.biocel.2007.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costabel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glassberg, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kardatzke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancaster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szwarcberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeyre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">du Bois, R. M.</span></span>; <span class="NLM_contrib-group">CAPACITY Study Group</span> <span> </span><span class="NLM_article-title">Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1760</span>– <span class="NLM_lpage">1769</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)60405-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2FS0140-6736%2811%2960405-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=21571362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtl2ktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2011&pages=1760-1769&author=P.+W.+Nobleauthor=C.+Alberaauthor=W.+Z.+Bradfordauthor=U.+Costabelauthor=M.+K.+Glassbergauthor=D.+Kardatzkeauthor=T.+E.+Kingauthor=L.+Lancasterauthor=S.+A.+Sahnauthor=J.+Szwarcbergauthor=D.+Valeyreauthor=R.+M.+du+Boisauthor=CAPACITY+Study+Group&title=Pirfenidone+in+patients+with+idiopathic+pulmonary+fibrosis+%28CAPACITY%29%3A+two+randomised+trials&doi=10.1016%2FS0140-6736%2811%2960405-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials</span></div><div class="casAuthors">Noble, Paul W.; Albera, Carlo; Bradford, Williamson Z.; Costabel, Ulrich; Glassberg, Marilyn K.; Kardatzke, David; King, Talmadge E., Jr.; Lancaster, Lisa; Sahn, Steven A.; Szwarcberg, Javier; Valeyre, Dominique; du Bois, Roland M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9779</span>),
    <span class="NLM_cas:pages">1760-1769</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function.  The CAPACITY program (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis.  In two concurrent trials (004 and 006), patients (aged 40-80 years) with idiopathic pulmonary fibrosis were randomly assigned to oral pirfenidone or placebo for a min. of 72 wk in 110 centers in Australia, Europe, and North America.  In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo.  The randomization code (permuted block design) was computer generated and stratified by region.  All study personnel were masked to treatment group assignment until after final database lock.  Treatments were administered orally, 801 mg or 399 mg three times a day.  The primary endpoint was change in percentage predicted forced vital capacity (FVC) at week 72.  Anal. was by intention to treat.  The studies are registered with ClinicalTrials.gov, nos. NCT00287729 and NCT00287716.  In study 004, 174 of 435 patients were assigned to pirfenidone 2403 mg/day, 87 to pirfenidone 1197 mg/day, and 174 to placebo.  In study 006, 171 of 344 patients were assigned to pirfenidone 2403 mg/day, and 173 to placebo.  All patients in both studies were analyzed.  In study 004, pirfenidone reduced decline in FVC (p = 0.001).  Mean FVC change at week 72 was -8.0% (SD 16.5) in the pirfenidone 2403 mg/day group and -12.4% (18.5) in the placebo group (difference 4.4%, 95% CI 0.7 to 9.1); 35 (20%) of 174 vs. 60 (35%) of 174 patients, resp., had a decline of at least 10%.  A significant treatment effect was noted at all timepoints from week 24 and in an anal. over all study timepoints (p = 0.0007).  Mean change in percentage FVC in the pirfenidone 1197 mg/day group was intermediate to that in the pirfenidone 2403 mg/day and placebo groups.  In study 006, the difference between groups in FVC change at week 72 was not significant (p = 0.501).  Mean change in FVC at week 72 was -9.0% (SD 19.6) in the pirfenidone group and -9.6% (19.1) in the placebo group, and the difference between groups in predicted FVC change at week 72 was not significant (0.6%, -3.5 to 4.7); however, a consistent pirfenidone effect was apparent until week 48 (p = 0.005) and in an anal. of all study timepoints (p = 0.007).  Patients in the pirfenidone 2403 mg/day group had higher incidences of nausea (125 [36%] of 345 vs 60 [17%] of 347), dyspepsia (66 [19%] vs 26 [7%]), vomiting (47 [14%] vs 15 [4%]), anorexia (37 [11%] vs 13 [4%]), photosensitivity (42 [12%] vs 6 [2%]), rash (111 [32%] vs 40 [12%]), and dizziness (63 [18%] vs 35 [10%]) than did those in the placebo group.  Fewer overall deaths (19 [6%] vs 29 [8%]) and fewer deaths related to idiopathic pulmonary fibrosis (12 [3%] vs 25 [7%]) occurred in the pirfenidone 2403 mg/day groups than in the placebo groups.  The data show pirfenidone has a favorable benefit risk profile and represents an appropriate treatment option for patients with idiopathic pulmonary fibrosis.  Funding: InterMune.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKu0rjQ2oNaLVg90H21EOLACvtfcHk0ljI2-xx4onlKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtl2ktrg%253D&md5=b32d8b1f0b3b1f8401d3744fc18c662a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960405-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960405-4%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DAlbera%26aufirst%3DC.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DKardatzke%26aufirst%3DD.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DSahn%26aufirst%3DS.%2BA.%26aulast%3DSzwarcberg%26aufirst%3DJ.%26aulast%3DValeyre%26aufirst%3DD.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26aulast%3D%26atitle%3DPirfenidone%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%2520%2528CAPACITY%2529%253A%2520two%2520randomised%2520trials%26jtitle%3DLancet%26date%3D2011%26volume%3D377%26spage%3D1760%26epage%3D1769%26doi%3D10.1016%2FS0140-6736%2811%2960405-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timbrell, V.</span></span> <span> </span><span class="NLM_article-title">Simple method of estimating severity of pulmonary fibrosis on a numerical scale</span>. <i>J. Clin. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1136/jcp.41.4.467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1136%2Fjcp.41.4.467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=3366935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A280%3ADyaL1c3htlOltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1988&pages=467-470&author=T.+Ashcroftauthor=J.+M.+Simpsonauthor=V.+Timbrell&title=Simple+method+of+estimating+severity+of+pulmonary+fibrosis+on+a+numerical+scale&doi=10.1136%2Fjcp.41.4.467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Simple method of estimating severity of pulmonary fibrosis on a numerical scale</span></div><div class="casAuthors">Ashcroft T; Simpson J M; Timbrell V</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical pathology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">467-70</span>
        ISSN:<span class="NLM_cas:issn">0021-9746</span>.
    </div><div class="casAbstract">A continuous numerical scale for determining the degree of fibrosis in lung specimens was devised for correlation with other pulmonary variables such as lung function tests or mineral burden.  Grading was scored on a scale from 0 to 8, using the average of microscope field scores.  The system allows fibrosis to be measured in small samples of tissue (1 cm) which can provide a detailed description of the changes in a lung, currently not possible with most existing methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5mGFCkDKSIzUE-swuRqsHfW6udTcc2ebKqYxI6nwNQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c3htlOltg%253D%253D&md5=d1da07e3ba735d309aa78d3955474bfd</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1136%2Fjcp.41.4.467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjcp.41.4.467%26sid%3Dliteratum%253Aachs%26aulast%3DAshcroft%26aufirst%3DT.%26aulast%3DSimpson%26aufirst%3DJ.%2BM.%26aulast%3DTimbrell%26aufirst%3DV.%26atitle%3DSimple%2520method%2520of%2520estimating%2520severity%2520of%2520pulmonary%2520fibrosis%2520on%2520a%2520numerical%2520scale%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D1988%26volume%3D41%26spage%3D467%26epage%3D470%26doi%3D10.1136%2Fjcp.41.4.467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuse, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teramoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuhashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uejima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouchi, Y.</span></span> <span> </span><span class="NLM_article-title">ICAM-1 mediates lung leukocyte recruitment but not pulmonary fibrosis in a murine model of bleomycin-induced lung injury</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1183/09031936.99.13107199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1183%2F09031936.99.13107199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10836326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADyaK1MXhtlymsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1999&pages=71-77&author=T.+Matsuseauthor=S.+Teramotoauthor=H.+Katayamaauthor=E.+Sudoauthor=H.+Ekimotoauthor=H.+Mitsuhashiauthor=Y.+Uejimaauthor=Y.+Fukuchiauthor=Y.+Ouchi&title=ICAM-1+mediates+lung+leukocyte+recruitment+but+not+pulmonary+fibrosis+in+a+murine+model+of+bleomycin-induced+lung+injury&doi=10.1183%2F09031936.99.13107199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">ICAM-1 mediates lung leukocyte recruitment but not pulmonary fibrosis in a murine model of bleomycin-induced lung injury</span></div><div class="casAuthors">Matsuse, T.; Teramoto, S.; Katayama, H.; Sudo, E.; Ekimoto, H.; Mitsuhashi, H.; Uejima, Y.; Fukuchi, Y.; Ouchi, Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-77</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">Bleomycin-induced lung injury has been extensively used as a model of interstitial pneumonia and pulmonary fibrosis.  Intercellular adhesion mol. (ICAM)-1 is a ligand for lymphocyte function-assocd. antigen (LFA)-1α and has been shown to be required for leukocyte migration into inflamed areas.  The purpose here was to investigate the role of the ICAM-1/LFA-1α pathway in a murine model of bleomycin-induced lung injury.  Animals received 75 mg/kg-1 bleomycin (BLM) i.v. followed by treatment with phosphate-buffered saline (BLM group), anti-ICAM-1 and LFA-1α monoclonal antibodies (mAb) (BLM+mAb group).  Inflammatory cell counts of bronchoalveolar lavage (BAL) fluid, hydroxyproline content, and histol. findings were compared between these groups.  In the BLM group, increases in total cell count, macrophage count, and neutrophil count of BAL fluid were obsd. on days 7 and 14.  In the BLM+mAb group, bleomycin-induced accumulation of neutrophils was reduced on days 7 and 14.  However, the administration of mAb to ICAM-1 and LFA-1α did not decrease the lung hydroxyproline content or the histopathol. fibrosis grading score, indicating that the antagonism of ICAM-1 and LFA-1α did not attenuate bleomycin-induced pulmonary fibrosis.  Apparently, the ICAM-1/LFA-1α pathway mediates the accumulation of inflammatory cells in the injured lung caused by bleomycin; however, other mechanisms are important for the subsequent development of pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp1vLl5CSzmLVg90H21EOLACvtfcHk0ljI2-xx4onlKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtlymsL4%253D&md5=eaae85d8e5354d6eb20c74c643481c91</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1183%2F09031936.99.13107199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.99.13107199%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuse%26aufirst%3DT.%26aulast%3DTeramoto%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DH.%26aulast%3DSudo%26aufirst%3DE.%26aulast%3DEkimoto%26aufirst%3DH.%26aulast%3DMitsuhashi%26aufirst%3DH.%26aulast%3DUejima%26aufirst%3DY.%26aulast%3DFukuchi%26aufirst%3DY.%26aulast%3DOuchi%26aufirst%3DY.%26atitle%3DICAM-1%2520mediates%2520lung%2520leukocyte%2520recruitment%2520but%2520not%2520pulmonary%2520fibrosis%2520in%2520a%2520murine%2520model%2520of%2520bleomycin-induced%2520lung%2520injury%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D1999%26volume%3D13%26spage%3D71%26epage%3D77%26doi%3D10.1183%2F09031936.99.13107199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratner, M. A.</span></span> <span> </span><span class="NLM_article-title">The mechanism of aluminum-catalyzed Meerwein–Schmidt–Ponndorf–Verley reduction of carbonyls to alcohols</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">14796</span>– <span class="NLM_lpage">14803</span>, <span class="refDoi"> DOI: 10.1021/ja047613m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja047613m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVKgt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=14796-14803&author=R.+Cohenauthor=C.+R.+Gravesauthor=S.+T.+Nguyenauthor=J.+M.+L.+Martinauthor=M.+A.+Ratner&title=The+mechanism+of+aluminum-catalyzed+Meerwein%E2%80%93Schmidt%E2%80%93Ponndorf%E2%80%93Verley+reduction+of+carbonyls+to+alcohols&doi=10.1021%2Fja047613m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The Mechanism of Aluminum-Catalyzed Meerwein-Schmidt-Ponndorf-Verley Reduction of Carbonyls to Alcohols</span></div><div class="casAuthors">Cohen, Revital; Graves, Christopher R.; Nguyen, SonBinh T.; Martin, Jan M. L.; Ratner, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">14796-14803</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mechanistic details of the Meerwein-Schmidt-Ponndorf-Verley (MSPV) redn. of ketones to the corresponding alcs. were investigated both exptl. and computationally.  D. functional theory (DFT) was used to assess the energetics of several proposed pathways (direct hydrogen transfer, hydridic, and radical).  Our results demonstrate that a direct hydrogen transfer mechanism involving a concerted six-membered ring transition state is the most favorable pathway for all calcd. systems starting from a small model system and concluding with the exptl. investigated BINOLate/Al/iPrOH/MePhC:O system.  Exptl. values for the activation parameters of acetophenone redn. using the BINOLate/Al/iPrOH system (ΔG# = 21.8 kcal/mol, ΔH# = 18.5 kcal/mol, ΔS# = -11.7 au) were detd. on the basis of kinetic investigation of the reaction and are in good agreement with the computational findings for this system.  Calcd. and exptl. kinetic isotope effects support the concerted mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFjaUOH-GVG7Vg90H21EOLACvtfcHk0lhhkJGkiyikLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVKgt7k%253D&md5=84725c08d4b73836d2039dd4d3d5b1e8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fja047613m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja047613m%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DR.%26aulast%3DGraves%26aufirst%3DC.%2BR.%26aulast%3DNguyen%26aufirst%3DS.%2BT.%26aulast%3DMartin%26aufirst%3DJ.%2BM.%2BL.%26aulast%3DRatner%26aufirst%3DM.%2BA.%26atitle%3DThe%2520mechanism%2520of%2520aluminum-catalyzed%2520Meerwein%25E2%2580%2593Schmidt%25E2%2580%2593Ponndorf%25E2%2580%2593Verley%2520reduction%2520of%2520carbonyls%2520to%2520alcohols%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2004%26volume%3D126%26spage%3D14796%26epage%3D14803%26doi%3D10.1021%2Fja047613m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayama, T.</span>; <span class="NLM_string-name">Hayashi, K.</span>; <span class="NLM_string-name">Honma, M.</span>; <span class="NLM_string-name">Takahashi, I.</span></span> <span> </span><span class="NLM_article-title">Preparation of <i>N,N’-</i>biarylurea derivatives as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6)</span>. <span class="NLM_patent">WO2001007411A1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=T.+Hayama&author=K.+Hayashi&author=M.+Honma&author=I.+Takahashi&title=Preparation+of+N%2CN%E2%80%99-biarylurea+derivatives+as+inhibitors+of+cyclin-dependent+kinases+%28Cdk4+and+Cdk6%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHayama%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520N%252CN%25E2%2580%2599-biarylurea%2520derivatives%2520as%2520inhibitors%2520of%2520cyclin-dependent%2520kinases%2520%2528Cdk4%2520and%2520Cdk6%2529%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1049</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=8894503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADyaK28XmsVeitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1996&pages=1047-1049&author=R.+S.+Obach&title=The+importance+of+nonspecific+binding+in+in+vitro+matrices%2C+its+impact+on+enzyme+kinetic+studies+of+drug+metabolism+reactions%2C+and+implications+for+in+vitro-in+vivo+correlations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The importance of nonspecific binding in vitro matrixes, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1047-1049</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Problems in enzyme kinetic studies of drug metab. enzymes are encountered when the nonspecific binding of the substrate in in vitro systems is not taken into account.  It is recommended that the nonspecific binding in in vitro incubation matrixes be detd. and corrections be included when reporting the KM and Ki values.  The nonspecific binding of drugs to liver microsomes represents and important parameter to measure when attempting the prediction of in vivo pharmacokinetics from enzyme kinetic data.  If not cor., values should be reported as "apparent" values [KM(app) and Ki(app)], which would be considered to be unique to a given set of incubation conditions.  Without correction, the apparent KM and Ki values are of little use in predicting in vivo metab. unless the unbound fraction approaches 100%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol_XF-L8KEMbVg90H21EOLACvtfcHk0lhhkJGkiyikLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVeitro%253D&md5=d9f64b5cda472e1be2821005a929d21f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DThe%2520importance%2520of%2520nonspecific%2520binding%2520in%2520in%2520vitro%2520matrices%252C%2520its%2520impact%2520on%2520enzyme%2520kinetic%2520studies%2520of%2520drug%2520metabolism%2520reactions%252C%2520and%2520implications%2520for%2520in%2520vitro-in%2520vivo%2520correlations%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1996%26volume%3D24%26spage%3D1047%26epage%3D1049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Svetnik, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culberson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuston, B. P.</span></span> <span> </span><span class="NLM_article-title">Random forest: a classification and regression tool for compound classification and QSAR modeling</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1947</span>– <span class="NLM_lpage">1958</span>, <span class="refDoi"> DOI: 10.1021/ci034160g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci034160g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Wiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2003&pages=1947-1958&author=V.+Svetnikauthor=A.+Liawauthor=C.+Tongauthor=J.+C.+Culbersonauthor=R.+P.+Sheridanauthor=B.+P.+Feuston&title=Random+forest%3A+a+classification+and+regression+tool+for+compound+classification+and+QSAR+modeling&doi=10.1021%2Fci034160g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Random Forest: A Classification and Regression Tool for Compound Classification and QSAR Modeling</span></div><div class="casAuthors">Svetnik, Vladimir; Liaw, Andy; Tong, Christopher; Culberson, J. Christopher; Sheridan, Robert P.; Feuston, Bradley P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1947-1958</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new classification and regression tool, Random Forest, is introduced and investigated for predicting a compd.'s quant. or categorical biol. activity based on a quant. description of the compd.'s mol. structure.  Random Forest is an ensemble of unpruned classification or regression trees created by using bootstrap samples of the training data and random feature selection in tree induction.  Prediction is made by aggregating (majority vote or averaging) the predictions of the ensemble.  The authors built predictive models for six cheminformatics data sets.  The authors anal. demonstrates that Random Forest is a powerful tool capable of delivering performance that is among the most accurate methods to date.  The authors also present three addnl. features of Random Forest: built-in performance assessment, a measure of relative importance of descriptors, and a measure of compd. similarity that is weighted by the relative importance of descriptors.  It is the combination of relatively high prediction accuracy and its collection of desired features that makes Random Forest uniquely suited for modeling in cheminformatics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjoRt5v7rYwLVg90H21EOLACvtfcHk0lg5tUwXCZUy_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Wiu7s%253D&md5=dea7867551ec30260b0091b90593a660</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fci034160g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci034160g%26sid%3Dliteratum%253Aachs%26aulast%3DSvetnik%26aufirst%3DV.%26aulast%3DLiaw%26aufirst%3DA.%26aulast%3DTong%26aufirst%3DC.%26aulast%3DCulberson%26aufirst%3DJ.%2BC.%26aulast%3DSheridan%26aufirst%3DR.%2BP.%26aulast%3DFeuston%26aufirst%3DB.%2BP.%26atitle%3DRandom%2520forest%253A%2520a%2520classification%2520and%2520regression%2520tool%2520for%2520compound%2520classification%2520and%2520QSAR%2520modeling%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2003%26volume%3D43%26spage%3D1947%26epage%3D1958%26doi%3D10.1021%2Fci034160g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c','cit1d','cit1e','cit1f'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b','cit11c','cit11d','cit11e','cit11f','cit11g','cit11h'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b','cit16c'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26a','cit26b'],'ref27':['cit27a','cit27b'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of sphingosine-1-phosphate (S1P, <b>1</b>), FTY720 (<b>2</b>), and its active form, FTY720-P (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of published S1P2 antagonists (<b>4</b>–<b>8</b>) and allosteric antagonist CYM-5520 (<b>9</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical enablement to obtain S1P2 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Broad exploration of pyridine’s C5 position by a chemical enablement strategy. (a) Representation of chemotypes. (b) Potency in calcium flux assay vs potency in GTPγS assay. (c) Clearance unbound in mouse liver microsomes vs potency in IL8 assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Lipophilicity vs pIC<sub>50</sub> (calcium flux) for matched pairs between pyridine and pyridazine series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Activity of compound <b>40</b> in a cell contraction assay in HPF cells. S1P was used as trigger at 1 μM. Bar height: mean values. Error bars: 95% CI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Ashcroft score at D14 following intranasal bleomycin challenge. Data are given as group median. *<i>p</i> < 0.05 vs BLM/vehicle control (Mann–Whitney test). #<i>p</i> < 0.05 vs BLM/Vehicle (Wilcoxon signed-rank test); cpd <b>40</b>: <i>n</i> = 15 per group; cpd <b>48</b>: <i>n</i> = 14 per group. Animals: male C57BL/6 mice (<b>40</b>: 8 weeks old on arrival; <b>48</b>: 7 weeks old on arrival. One week acclimation).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>12</b>–<b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl hydrazinecarboxylate, Cs<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, toluene, 100 °C; (b) 2,6-dichloro-4-isocyanatopyridine, THF, rt; (c) 4 M HCl in 1,4-dioxane, DCM, 40 °C; (d) Ar-B(OR)<sub>2</sub>, 2 M K<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane, 130 °C, μw; (e) Ar-B(OR)<sub>2</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane, 150 °C, μw.</p></p></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>22</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>10a</b>, LiOH, H<sub>2</sub>O/THF; (b) 2,6-dichloro-4-isocyanatopyridine, THF, rt; (c) 4 M HCl in 1,4-dioxane, DCM, 40 °C; (d) R<sup>1</sup>R<sup>2</sup>NH, HATU, DIPEA, DMF, DCM, rt.</p></p></figure><figure data-id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>25</b> and <b>27</b>–<b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 150 °C; (b) Ar-B(OR)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane, H<sub>2</sub>O, 100 °C; (c) BH<sub>3</sub>·SMe<sub>2</sub>, THF, 45 °C; (d) 2,5,6-trichloro-1<i>H</i>-benzo[<i>d</i>]imidazole, MeCN, 170 °C, μw; (e) RCOOH, HATU, DIPEA, DMF, DCM, rt or 45 °C; (f) RNCO, THF, rt; (g) 2-chloro-6-ethoxypyridin-4-amine, CDT, pyridine, DCM, rt.</p></p></figure><figure data-id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Cs<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 1,4-dioxane, H<sub>2</sub>O, 100 °C; (b) EtOH, NaH, rt; (c) Zn, NH<sub>4</sub>Cl, MeOH, rt; (d) CNBr, EtOH, 45 °C; (e) Ti(O<i>i</i>Pr)<sub>4</sub>, EtOH, 60 °C.</p></p></figure><figure data-id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH<sub>4</sub>, NiCl<sub>2</sub>·6H<sub>2</sub>O, Boc<sub>2</sub>O, MeOH, rt; (b) TFA, DCM, 45 °C; (c) 2-ethoxy-6-(trifluoromethyl)pyridin-4-amine, CDT, pyridine, DCM, 45 °C; then <b>2e</b>, DIPEA, THF, rt; (d) HCHO (37% H<sub>2</sub>O), 4-methylmorpholine, <i>t</i>BuNH<sub>2,</sub> EtOH/H<sub>2</sub>O, 100 °C; (e) 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine, Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, NaO<i>t</i>Bu, toluene, 70 °C; (f) 1,4-dioxane/6 M NaOH, 100 °C.</p></p></figure><figure data-id="sch6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/medium/jm1c00138_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>37</b>–<b>43</b>, <b>46</b>–<b>48</b>, <b>50</b>, and <b>51</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00138/20210506/images/large/jm1c00138_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00138&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions (a) 3.3 M NaOH, reflux; (b) Zn(CN)<sub>2</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, DMF, 120 °C; (c) POCl<sub>3</sub>, MeCN, reflux; (d) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, rt; then 2.5 M Na<sub>2</sub>CO<sub>3</sub>, 85 °C; (e) Pd/C, H<sub>2</sub> gas (1 atm), 6 M HCl, MeOH, rt; (f) NaBH<sub>4</sub>, TFA, NiCl<sub>2</sub>.6H<sub>2</sub>O, MeOH, rt; (g) RNH<sub>2</sub>, CDT, pyridine, DCM, 45 °C; then <b>6f</b>, DIPEA, THF, rt; (h) RNH<sub>2</sub>, CDT, pyridine, DCM, 45 °C; then <b>7f</b>, rt.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i127">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24186" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24186" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 45 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fyrst, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saba, J. D.</span></span> <span> </span><span class="NLM_article-title">An update on sphingosine-1-phosphate and other sphingolipid mediators</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1038/nchembio.392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1038%2Fnchembio.392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=20559316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFKitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=489-497&author=H.+Fyrstauthor=J.+D.+Saba&title=An+update+on+sphingosine-1-phosphate+and+other+sphingolipid+mediators&doi=10.1038%2Fnchembio.392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">An update on sphingosine-1-phosphate and other sphingolipid mediators</span></div><div class="casAuthors">Fyrst, Henrik; Saba, Julie D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-497</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sphingolipids comprise a complex family of naturally occurring mols. that are enriched in lipid rafts and contribute to their unique biochem. properties.  Membrane sphingolipids also serve as a reservoir for bioactive metabolites including sphingosine, ceramide, sphingosine 1-phosphate (S1P) and ceramide 1-phosphate.  Among these, S1P has emerged as a central regulator of mammalian biol.  S1P is essential for mammalian brain and cardiac development and for maturation of the systemic circulatory system and lymphatics.  In addn., S1P contributes to trafficking and effector functions of lymphocytes and other hematopoietic cells and protects against various forms of tissue injury.  However, S1P is also an oncogenic lipid that promotes tumor growth and progression.  Recent preclin. and clin. investigations using pharmacol. agents that target S1P, its receptors, and the enzymes required for its biosynthesis and degrdn. demonstrate the promise and potential risks of modulating S1P signaling in treatment strategies for autoimmunity, cancer, cardiovascular disease, and other pathol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp1G3TLMu507Vg90H21EOLACvtfcHk0lh-TGs-pCt2xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFKitLk%253D&md5=6128ea6a4f1a910deed32f7db8827840</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.392%26sid%3Dliteratum%253Aachs%26aulast%3DFyrst%26aufirst%3DH.%26aulast%3DSaba%26aufirst%3DJ.%2BD.%26atitle%3DAn%2520update%2520on%2520sphingosine-1-phosphate%2520and%2520other%2520sphingolipid%2520mediators%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D489%26epage%3D497%26doi%3D10.1038%2Fnchembio.392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Strub, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maceyka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hait, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Extracellular and intracellular actions of sphingosine-1-phosphate</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>688</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1007/978-1-4419-6741-1_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1007%2F978-1-4419-6741-1_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=20919652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=688&publication_year=2010&pages=141-155&author=G.+M.+Strubauthor=M.+Maceykaauthor=N.+C.+Haitauthor=S.+Milstienauthor=S.+Spiegel&title=Extracellular+and+intracellular+actions+of+sphingosine-1-phosphate&doi=10.1007%2F978-1-4419-6741-1_10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular and intracellular actions of sphingosine-1-phosphate</span></div><div class="casAuthors">Strub, Graham M.; Maceyka, Michael; Hait, Nitai C.; Milstien, Sheldon; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">688</span>
        (<span class="NLM_cas:issue">Sphingolipids as Signaling and Regulatory Molecules</span>),
    <span class="NLM_cas:pages">141-155</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator with crucial roles in a wide variety of cellular functions across a broad range of organisms.  Though a simple mol. in structure, S1P functions are complex.  The formation of S1P is catalyzed by one of two sphingosine kinases that have differential cellular distributions as well as both overlapping and opposing functions and which are activated by many different stimuli.  S1P can act on a family of G protein-coupled receptors (S1PRs) that are also differentially expressed in different cell types, which influences the cellular responses to S1P.  In addn. to acting on receptors located on the plasma membrane, S1P can also function inside the cell, independently of S1PRs.  It also appears that both the intracellular location and the isotype of sphingosine kinase involved are major determinants of inside-out signaling of S1P in response to many extracellular stimuli.  This chapter is focused on the current literature on extracellular and intracellular actions of S1P.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra126VCu0n9bVg90H21EOLACvtfcHk0lgXag1wW5Acgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFGgsQ%253D%253D&md5=0544bfe25e635257810a6bf5ffad93d6</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1007%2F978-1-4419-6741-1_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4419-6741-1_10%26sid%3Dliteratum%253Aachs%26aulast%3DStrub%26aufirst%3DG.%2BM.%26aulast%3DMaceyka%26aufirst%3DM.%26aulast%3DHait%26aufirst%3DN.%2BC.%26aulast%3DMilstien%26aufirst%3DS.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DExtracellular%2520and%2520intracellular%2520actions%2520of%2520sphingosine-1-phosphate%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2010%26volume%3D688%26spage%3D141%26epage%3D155%26doi%3D10.1007%2F978-1-4419-6741-1_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Blaho, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span> <span> </span><span class="NLM_article-title">An update on the biology of sphingosine 1-phosphate receptors</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1596</span>– <span class="NLM_lpage">1608</span>, <span class="refDoi"> DOI: 10.1194/jlr.R046300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1194%2Fjlr.R046300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=24459205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1596-1608&author=V.+A.+Blahoauthor=T.+Hla&title=An+update+on+the+biology+of+sphingosine+1-phosphate+receptors&doi=10.1194%2Fjlr.R046300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">An update on the biology of sphingosine 1-phosphate receptors</span></div><div class="casAuthors">Blaho, Victoria A.; Hla, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1596-1608</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) is a membrane-derived lysophospholipid that acts primarily as an extracellular signaling mol.  Signals initiated by S1P are transduced by five G protein-coupled receptors, named S1P1-5.  Cellular and temporal expression of the S1P receptors (S1PRs) det. their specific roles in various organ systems, but they are particularly crit. for regulation of the cardiovascular, immune, and nervous systems, with the most well-known contributions of S1PR signaling being modulation of vascular barrier function, vascular tone, and regulation of lymphocyte trafficking.  However, our knowledge of S1PR biol. is rapidly increasing as they become attractive therapeutic targets in several diseases, such as chronic inflammatory pathologies, autoimmunity, and cancer.  Understanding how the S1PRs regulate interactions between biol. systems will allow for greater efficacy in this novel therapeutic strategy as well as characterization of complex physiol. networks.  Because of the rapidly expanding body of research, this review will focus on the most recent advances in S1PRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIZfnE0tv0rbVg90H21EOLACvtfcHk0lgXag1wW5Acgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agsrnP&md5=3939398b28359c3be8d38b3b49be3d4c</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R046300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R046300%26sid%3Dliteratum%253Aachs%26aulast%3DBlaho%26aufirst%3DV.%2BA.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DAn%2520update%2520on%2520the%2520biology%2520of%2520sphingosine%25201-phosphate%2520receptors%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2014%26volume%3D55%26spage%3D1596%26epage%3D1608%26doi%3D10.1194%2Fjlr.R046300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstien, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate: an enigmatic signalling lipid</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1038/nrm1103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1038%2Fnrm1103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=12728273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlalt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=397-407&author=S.+Spiegelauthor=S.+Milstien&title=Sphingosine-1-phosphate%3A+an+enigmatic+signalling+lipid&doi=10.1038%2Fnrm1103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate: an enigmatic signalling lipid</span></div><div class="casAuthors">Spiegel, Sarah; Milstien, Sheldon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">397-407</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The evolutionarily conserved actions of the sphingolipid metabolite, sphingosine-1-phosphate (S1P), in yeast, plants, and mammals have shown that it has important functions.  In higher eukaryotes, S1P is the ligand for a family of 5 G protein-coupled receptors.  These S1P receptors are differentially expressed, coupled to various G proteins, and regulate angiogenesis, vascular maturation, cardiac development, and immunity, and are important for directed cell movement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos0XUAxYZwqLVg90H21EOLACvtfcHk0lgXag1wW5Acgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlalt7o%253D&md5=689a33cfeb4bae72637b64cd90e6c910</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1038%2Fnrm1103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1103%26sid%3Dliteratum%253Aachs%26aulast%3DSpiegel%26aufirst%3DS.%26aulast%3DMilstien%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%253A%2520an%2520enigmatic%2520signalling%2520lipid%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2003%26volume%3D4%26spage%3D397%26epage%3D407%26doi%3D10.1038%2Fnrm1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2007.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.pharmthera.2007.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=17561264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntFyiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2007&pages=84-105&author=V.+Brinkmann&title=Sphingosine+1-phosphate+receptors+in+health+and+disease%3A+mechanistic+insights+from+gene+deletion+studies+and+reverse+pharmacology&doi=10.1016%2Fj.pharmthera.2007.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1eR"><div class="casContent"><span class="casTitleNuber">1e</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology</span></div><div class="casAuthors">Brinkmann, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-105</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid that is critically involved in the embryonic development of the cardiovascular and central nervous systems.  In the adult, S1P can produce cytoskeletal re-arrangements in many cell types to regulate immune cell trafficking, vascular homeostasis and cell communication in the central nervous system.  S1P is contained in body fluids and tissues at different concns., and excessive prodn. of the pleiotropic mediator at inflammatory sites may participate in various pathol. conditions.  Gene deletion studies and reverse pharmacol. (techniques aiming to identify both ligands and function of receptors) provided evidence that many effects of S1P are mediated via five G-protein-coupled S1P receptor subtypes, and novel therapeutic strategies based on interaction with these receptors are being initiated.  The prototype S1P receptor modulator, FTY720 (fingolimod), targets four of the five S1P receptor subtypes and may act at several levels to modulate lymphocyte trafficking via lymphocytic and endothelial S1P1 and, perhaps, other inflammatory processes through addnl. S1P receptor subtypes.  A recently completed Phase II clin. trial suggested that the drug may provide an effective treatment of relapsing-remitting multiple sclerosis.  FTY720 is currently being evaluated in larger-scale, longer-term, Phase III studies.  This review provides an overview on S1P activities and S1P receptor function in health and disease, and summarizes the clin. experience with FTY720 in transplantation and multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGbwKhZo2vLrVg90H21EOLACvtfcHk0li2hRrcDz9D_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntFyiur0%253D&md5=cacdb374439270734f34a0ca4771ca3d</span></div><a href="/servlet/linkout?suffix=cit1e&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2007.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2007.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26atitle%3DSphingosine%25201-phosphate%2520receptors%2520in%2520health%2520and%2520disease%253A%2520mechanistic%2520insights%2520from%2520gene%2520deletion%2520studies%2520and%2520reverse%2520pharmacology%26jtitle%3DPharmacol.%2520Ther.%26date%3D2007%26volume%3D115%26spage%3D84%26epage%3D105%26doi%3D10.1016%2Fj.pharmthera.2007.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mutoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span> <span> </span><span class="NLM_article-title">Insights into the pharmacological relevance of lysophospholipid receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01622.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1111%2Fj.1476-5381.2011.01622.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=21838759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFGqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=829-844&author=T.+Mutohauthor=R.+Riveraauthor=J.+Chun&title=Insights+into+the+pharmacological+relevance+of+lysophospholipid+receptors&doi=10.1111%2Fj.1476-5381.2011.01622.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1fR"><div class="casContent"><span class="casTitleNuber">1f</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the pharmacological relevance of lysophospholipid receptors</span></div><div class="casAuthors">Mutoh, Tetsuji; Rivera, Richard; Chun, Jerold</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">829-844</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The discovery of lysophospholipid (LP) 7-transmembrane, G protein-coupled receptors (GPCRs) that began in the 1990s, together with research into the functional roles of the major LPs known as lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), have opened new research avenues into their biol. processes and mechanisms.  Major examples of LP signaling effects include embryogenesis, nervous system development, vascular development, uterine implantation, immune cell trafficking, and inflammatory reactions.  LP signaling also influences the pathophysiol. of many diseases including cancer, autoimmune and inflammatory diseases, which indicate that LP receptors may be attractive targets for pharmacol. therapies.  A key example of such a therapeutic agent is the S1P receptor modulator FTY720, which upon phosphorylation and continued drug exposure, acts as an S1P receptor functional antagonist.  This compd. (also known as fingolimod or Gilenya) has recently been approved by the FDA for the treatment of relapsing forms of multiple sclerosis.  Continued basic and translational research on LP signaling should provide novel insights into both basic biol. mechanisms, as well as novel therapeutic approaches to combat a range of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1qOGwbmBPirVg90H21EOLACvtfcHk0li2hRrcDz9D_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFGqsLs%253D&md5=cf240e202ccfa00c40366f7309e36b78</span></div><a href="/servlet/linkout?suffix=cit1f&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01622.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01622.x%26sid%3Dliteratum%253Aachs%26aulast%3DMutoh%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DR.%26aulast%3DChun%26aufirst%3DJ.%26atitle%3DInsights%2520into%2520the%2520pharmacological%2520relevance%2520of%2520lysophospholipid%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26spage%3D829%26epage%3D844%26doi%3D10.1111%2Fj.1476-5381.2011.01622.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepanovska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwiler, A.</span></span> <span> </span><span class="NLM_article-title">Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">104170</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2019.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.phrs.2019.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=30776422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1Ggu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2020&pages=104170&author=B.+Stepanovskaauthor=A.+Huwiler&title=Targeting+the+S1P+receptor+signaling+pathways+as+a+promising+approach+for+treatment+of+autoimmune+and+inflammatory+diseases&doi=10.1016%2Fj.phrs.2019.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases</span></div><div class="casAuthors">Stepanovska, Bisera; Huwiler, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104170</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The past two decades of intense research have revealed a key role of the sphingolipid mol. sphingosine 1-phosphate (S1P) in regulating multiple physiol. and pathophysiol. processes including cell proliferation and survival, cell migration, inflammatory mediator synthesis and tissue remodeling.  S1P mainly acts through five high-affinity G protein-coupled S1P receptors, which are ubiquitously expressed and mediate a complex network of signaling in a cell type dependent manner.  S1P receptors have become an attractive pharmacol. target to interfere with S1P-mediated cellular responses, which contribute to various autoimmune and inflammatory diseases.  Pioneering in this field was the synthesis of FTY720 (fingolimod, Gilenya) from myriocin, one of the metabolites of the fungus Isaria sinclairii known from traditional Chinese medicine for its antibacterial and energy boosting effect.  Fingolimod turned out as a very potent immunomodulatory agent that subsequently passed all clin. trials successfully and is now approved for the treatment of relapsing-remitting multiple sclerosis.  Novel S1PR modulators are now being developed with a more selective receptor activation profile and improved pharmacokinetic characteristics.  In this review, we will summarize the state-of-the-art approaches that target directly or indirectly S1P signaling and may be useful as novel strategies to treat autoimmune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdQEm8IluDvrVg90H21EOLACvtfcHk0li2hRrcDz9D_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1Ggu74%253D&md5=3c40bb1f714671216d3aafeb9d420805</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2019.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2019.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DStepanovska%26aufirst%3DB.%26aulast%3DHuwiler%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520S1P%2520receptor%2520signaling%2520pathways%2520as%2520a%2520promising%2520approach%2520for%2520treatment%2520of%2520autoimmune%2520and%2520inflammatory%2520diseases%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D154%26spage%3D104170%26doi%3D10.1016%2Fj.phrs.2019.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demont, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bit, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowell, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldred, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaskin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renaux, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, G. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smethurst, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witherington, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of tetrahydropyrazolopyridine as sphingosine 1-phosphate receptor 3 (S1P3)-sparing S1P1 agonists active at low oral doses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1003</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01512</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01512" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslertQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1003-1020&author=E.+H.+Demontauthor=J.+M.+Baileyauthor=R.+A.+Bitauthor=J.+A.+Brownauthor=C.+A.+Campbellauthor=N.+Deeksauthor=S.+J.+Dowellauthor=C.+Eldredauthor=P.+Gaskinauthor=J.+R.+J.+Grayauthor=A.+Haynesauthor=D.+J.+Hirstauthor=D.+S.+Holmesauthor=U.+Kumarauthor=M.+A.+Morseauthor=G.+J.+Osborneauthor=J.+F.+Renauxauthor=G.+A.+L.+Sealauthor=C.+A.+Smethurstauthor=S.+Taylorauthor=R.+Watsonauthor=R.+Willisauthor=J.+Witherington&title=Discovery+of+tetrahydropyrazolopyridine+as+sphingosine+1-phosphate+receptor+3+%28S1P3%29-sparing+S1P1+agonists+active+at+low+oral+doses&doi=10.1021%2Facs.jmedchem.5b01512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses</span></div><div class="casAuthors">Demont, Emmanuel H.; Bailey, James M.; Bit, Rino A.; Brown, Jack A.; Campbell, Colin A.; Deeks, Nigel; Dowell, Simon J.; Eldred, Colin; Gaskin, Pam; Gray, James R. J.; Haynes, Andrea; Hirst, David J.; Holmes, Duncan S.; Kumar, Umesh; Morse, Mary A.; Osborne, Greg J.; Renaux, Jessica F.; Seal, Gail A. L.; Smethurst, Chris A.; Taylor, Simon; Watson, Robert; Willis, Robert; Witherington, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1003-1020</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FTY720 is the first oral small mol. approved for the treatment of people suffering from relapsing-remitting multiple sclerosis.  It is a potent agonist of the S1P1 receptor, but its lack of selectivity against the S1P3 receptor has been linked to most of the cardiovascular side effects obsd. in the clinic.  These findings have triggered intensive efforts toward the identification of a second generation of S1P3-sparing S1P1 agonists.  The authors have recently disclosed a series of orally active tetrahydroisoquinoline (THIQ) compds. matching these criteria.  The authors defined and implemented a strategy aiming at the discovery of selective structurally distinct follow-up agonists.  This effort culminated with the identification of a series of orally active tetrahydropyrazolopyridines, e.g. I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrDxdhn4Vr3bVg90H21EOLACvtfcHk0lj2n68m0px2TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslertQ%253D%253D&md5=578a3b903bac10da197a83fa2b766722</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01512%26sid%3Dliteratum%253Aachs%26aulast%3DDemont%26aufirst%3DE.%2BH.%26aulast%3DBailey%26aufirst%3DJ.%2BM.%26aulast%3DBit%26aufirst%3DR.%2BA.%26aulast%3DBrown%26aufirst%3DJ.%2BA.%26aulast%3DCampbell%26aufirst%3DC.%2BA.%26aulast%3DDeeks%26aufirst%3DN.%26aulast%3DDowell%26aufirst%3DS.%2BJ.%26aulast%3DEldred%26aufirst%3DC.%26aulast%3DGaskin%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DHaynes%26aufirst%3DA.%26aulast%3DHirst%26aufirst%3DD.%2BJ.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DKumar%26aufirst%3DU.%26aulast%3DMorse%26aufirst%3DM.%2BA.%26aulast%3DOsborne%26aufirst%3DG.%2BJ.%26aulast%3DRenaux%26aufirst%3DJ.%2BF.%26aulast%3DSeal%26aufirst%3DG.%2BA.%2BL.%26aulast%3DSmethurst%26aufirst%3DC.%2BA.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DWillis%26aufirst%3DR.%26aulast%3DWitherington%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520tetrahydropyrazolopyridine%2520as%2520sphingosine%25201-phosphate%2520receptor%25203%2520%2528S1P3%2529-sparing%2520S1P1%2520agonists%2520active%2520at%2520low%2520oral%2520doses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1003%26epage%3D1020%26doi%3D10.1021%2Facs.jmedchem.5b01512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">and references therein.</p></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumruker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heining, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmouder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aradhye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtin, P.</span></span> <span> </span><span class="NLM_article-title">Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">897</span>, <span class="refDoi"> DOI: 10.1038/nrd3248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1038%2Fnrd3248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=21031003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCqsr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=883-897&author=V.+Brinkmannauthor=A.+Billichauthor=T.+Baumrukerauthor=P.+Heiningauthor=R.+Schmouderauthor=G.+Francisauthor=S.+Aradhyeauthor=P.+Burtin&title=Fingolimod+%28FTY720%29%3A+Discovery+and+development+of+an+oral+drug+to+treat+multiple+sclerosis&doi=10.1038%2Fnrd3248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis</span></div><div class="casAuthors">Brinkmann, Volker; Billich, Andreas; Baumruker, Thomas; Heining, Peter; Schmouder, Robert; Francis, Gordon; Aradhye, Shreeram; Burtin, Pascale</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">883-897</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory drug, has opened up new approaches to the treatment of multiple sclerosis, the most common inflammatory disorder of the central nervous system.  Elucidation of the effects of fingolimod - mediated by the modulation of sphingosine 1-phosphate (S1P) receptors - has indicated that its therapeutic activity could be due to regulation of the migration of selected lymphocyte subsets into the central nervous system and direct effects on neural cells, particularly astrocytes.  An improved understanding of the biol. of S1P receptors has also been gained.  This article describes the discovery and development of fingolimod, which was approved by the US Food and Drug Administration in Sept. 2010 as a first-line treatment for relapsing forms of multiple sclerosis, thereby becoming the first oral disease-modifying therapy to be approved for multiple sclerosis in the United States.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr80U6QfXSJMbVg90H21EOLACvtfcHk0lik19MJ_ezOHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCqsr%252FL&md5=0f6dd60ef115079f3652e9d12d82e215</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd3248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3248%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DBaumruker%26aufirst%3DT.%26aulast%3DHeining%26aufirst%3DP.%26aulast%3DSchmouder%26aufirst%3DR.%26aulast%3DFrancis%26aufirst%3DG.%26aulast%3DAradhye%26aufirst%3DS.%26aulast%3DBurtin%26aufirst%3DP.%26atitle%3DFingolimod%2520%2528FTY720%2529%253A%2520Discovery%2520and%2520development%2520of%2520an%2520oral%2520drug%2520to%2520treat%2520multiple%2520sclerosis%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D883%26epage%3D897%26doi%3D10.1038%2Fnrd3248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span> <i>NDA
02257-FDA Approved Labeling Text for Gilenya (Fingolimod) Capsules</i>. Sep 21, <span class="NLM_year">2010</span>, <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022527s000lbl.pdf" class="extLink">www.accessdata.fda.gov/drugsatfda_docs/label/2010/022527s000lbl.pdf</a> (accessed Dec 15, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+NDA%0A02257-FDA+Approved+Labeling+Text+for+Gilenya+%28Fingolimod%29+Capsules.+Sep+21%2C+2010%2C+www.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2010%2F022527s000lbl.pdf+%28accessed+Dec+15%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNDA%250A02257-FDA%2520Approved%2520Labeling%2520Text%2520for%2520Gilenya%2520%2528Fingolimod%2529%2520Capsules%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shea, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontaine, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luster, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tager, A. M.</span></span> <span> </span><span class="NLM_article-title">Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2009-0345OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1165%2Frcmb.2009-0345OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=20081052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2010&pages=662-673&author=B.+S.+Sheaauthor=S.+F.+Brooksauthor=B.+A.+Fontaineauthor=J.+Chunauthor=A.+D.+Lusterauthor=A.+M.+Tager&title=Prolonged+exposure+to+sphingosine+1-phosphate+receptor-1+agonists+exacerbates+vascular+leak%2C+fibrosis%2C+and+mortality+after+lung+injury&doi=10.1165%2Frcmb.2009-0345OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury</span></div><div class="casAuthors">Shea, Barry S.; Brooks, Sarah F.; Fontaine, Benjamin A.; Chun, Jerold; Luster, Andrew D.; Tager, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) is a key endogenous regulator of the response to lung injury, maintaining endothelial barrier integrity through interaction with one of its receptors, S1P1.  The short-term administration of S1P or S1P1 receptor agonists enhances endothelial monolayer barrier function in vitro, and attenuates injury-induced vascular leak in the lung and other organ systems in vivo.  Although S1P1 agonists bind to and activate S1P1, several of these agents also induce receptor internalization and degrdn., and may therefore act as functional antagonists of S1P1 after extended exposure.  Here we report on the effects of prolonged exposure to these agents in bleomycin-induced lung injury.  We demonstrate that repeated administration of S1P1 agonists dramatically worsened lung injury after bleomycin challenge, as manifested by increased vascular leak and mortality.  Consistent with these results, prolonged exposure to S1P1 agonists in vitro eliminated the ability of endothelial cell monolayers to respond appropriately to the barrier-protective effects of S1P, indicating a loss of normal S1P-S1P1 signaling.  As bleomycin-induced lung injury progressed, continued exposure to S1P1 agonists also resulted in increased pulmonary fibrosis.  These data indicate that S1P1 agonists can act as functional antagonists of S1P1 on endothelial cells in vivo, which should be considered in developing these agents as therapies for vascular leak syndromes.  Our findings also support the hypothesis that vascular leak is an important component of the fibrogenic response to lung injury, and suggest that targeting the S1P-S1P1 pathway may also be an effective therapeutic strategy for fibrotic lung diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG8d_yM8ZpErVg90H21EOLACvtfcHk0lik19MJ_ezOHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtr%252FM&md5=1b0c0384272545d0ca4dfb3c4df0c8c9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2009-0345OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2009-0345OC%26sid%3Dliteratum%253Aachs%26aulast%3DShea%26aufirst%3DB.%2BS.%26aulast%3DBrooks%26aufirst%3DS.%2BF.%26aulast%3DFontaine%26aufirst%3DB.%2BA.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26aulast%3DTager%26aufirst%3DA.%2BM.%26atitle%3DProlonged%2520exposure%2520to%2520sphingosine%25201-phosphate%2520receptor-1%2520agonists%2520exacerbates%2520vascular%2520leak%252C%2520fibrosis%252C%2520and%2520mortality%2520after%2520lung%2520injury%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2010%26volume%3D43%26spage%3D662%26epage%3D673%26doi%3D10.1165%2Frcmb.2009-0345OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gellings Lowe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbadini, R. A.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-β-stimulated collagen production by cardiac fibroblasts</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvp056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1093%2Fcvr%2Fcvp056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=19228708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVaktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2009&pages=303-312&author=N.+Gellings+Loweauthor=J.+S.+Swaneyauthor=K.+M.+Morenoauthor=R.+A.+Sabbadini&title=Sphingosine-1-phosphate+and+sphingosine+kinase+are+critical+for+transforming+growth+factor-%CE%B2-stimulated+collagen+production+by+cardiac+fibroblasts&doi=10.1093%2Fcvr%2Fcvp056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-β-stimulated collagen production by cardiac fibroblasts</span></div><div class="casAuthors">Gellings Lowe, Nicole; Swaney, James S.; Moreno, Kelli M.; Sabbadini, Roger A.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">303-312</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims Following injury, fibroblasts transform into myofibroblasts and produce extracellular matrix (ECM).  Excess prodn. of ECM assocd. with cardiac fibrosis severely inhibits cardiac function.  Sphingosine-1-phosphate (S1P), a bioactive lysophospholipid, regulates the function of numerous cell types.  In this study, we detd. the role of S1P in promoting pro-fibrotic actions of cardiac fibroblasts (CFs).  Methods and results S1P-mediated effects on myofibroblast transformation, collagen prodn., and cross-talk with transforming growth factor-β (TGF-β) using mouse CF were examd.  S1P increased α-smooth muscle actin (a myofibroblast marker) and collagen expression in a S1P2 receptor- and Rho kinase-dependent manner.  TGF-β increased sphingosine kinase 1 (SphK1; the enzyme responsible for S1P prodn.) expression and activity.  TGF-β-stimulated collagen prodn. was inhibited by SphK1 or S1P2 siRNA, a SphK inhibitor, and an anti-S1P monoclonal antibody.  Conclusion These findings suggest that TGF-β-stimulated collagen prodn. in CF involves inside-out' S1P signalling whereby S1P produced intracellularly by SphK1 can be released and act in an autocrine/paracrine fashion to activate S1P2 and increase collagen prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorZb1d6ne23bVg90H21EOLACvtfcHk0lik19MJ_ezOHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVaktrs%253D&md5=1dddcb911770c5bf80022c18ffbe0299</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvp056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvp056%26sid%3Dliteratum%253Aachs%26aulast%3DGellings%2BLowe%26aufirst%3DN.%26aulast%3DSwaney%26aufirst%3DJ.%2BS.%26aulast%3DMoreno%26aufirst%3DK.%2BM.%26aulast%3DSabbadini%26aufirst%3DR.%2BA.%26atitle%3DSphingosine-1-phosphate%2520and%2520sphingosine%2520kinase%2520are%2520critical%2520for%2520transforming%2520growth%2520factor-%25CE%25B2-stimulated%2520collagen%2520production%2520by%2520cardiac%2520fibroblasts%26jtitle%3DCardiovasc.%2520Res.%26date%3D2009%26volume%3D82%26spage%3D303%26epage%3D312%26doi%3D10.1093%2Fcvr%2Fcvp056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tölle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Giet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radeke, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer
Korting, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleuser, B.</span></span> <span> </span><span class="NLM_article-title">Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 <i>signaling</i></span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2007.060485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.2353%2Fajpath.2007.060485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=17200201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FgtlOgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2007&pages=281-292&author=C.+D.+Kellerauthor=P.+R.+Gilauthor=M.+T%C3%B6lleauthor=M.+van+der+Gietauthor=J.+Chunauthor=H.+H.+Radekeauthor=M.+Sch%C3%A4fer%0AKortingauthor=B.+Kleuser&title=Immunomodulator+FTY720+induces+myofibroblast+differentiation+via+the+lysophospholipid+receptor+S1P3+and+Smad3+signaling&doi=10.2353%2Fajpath.2007.060485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling</span></div><div class="casAuthors">Keller Christina D; Rivera Gil Pilar; Tolle Markus; van der Giet Markus; Chun Jerold; Radeke Heinfried H; Schafer-Korting Monika; Kleuser Burkhard</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of pathology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-92</span>
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    </div><div class="casAbstract">The novel immunomodulator FTY720 is an effective immunosuppressive agent in experimental models of transplantation and autoimmunity and is currently undergoing phase III clinical trials for multiple sclerosis.  Phosphorylated FTY720 is a structural analogue of sphingosine 1-phosphate (S1P) and therefore acts as a high-affinity agonist at four of the five G protein-coupled S1P receptors.  It has been well established that there exists a crosstalk between S1P and transforming growth factor (TGF)-beta signaling.  Because TGF-beta is the most prominent inductor of fibrosis and myofibroblasts are primarily responsible for excessive matrix protein formation, we examined whether FTY720, in analogy to TGF-beta, induces differentiation of fibroblasts into myofibroblasts.  Indeed, FTY720 provoked myofibroblast differentiation comparable with that of TGF-beta.  For biological efficacy, FTY720 required endogenous phosphorylation because inhibition of sphingosine kinase completely prevented FTY720 from inducing the differentiation process.  Moreover, we identified the lysophospholipid receptor S1P3 as the crucial receptor subtype for FTY720-induced myofibroblast differentiation because the effect was abolished in fibroblasts isolated from S1P3 knockout mice.  Finally, we determined that downstream of S1P3 signaling Smad3 activation is essential for myofibroblast differentiation in response to FTY720.  Thus, FTY720 may have adverse fibrotic effects related to its activity on S1P3 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZ2f3qQMjhEwwxfk_AGB-EfW6udTcc2eb22PcN7ecNhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FgtlOgtA%253D%253D&md5=fe9a2ae10e35623be18fcbbf26f1daeb</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2007.060485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2007.060485%26sid%3Dliteratum%253Aachs%26aulast%3DKeller%26aufirst%3DC.%2BD.%26aulast%3DGil%26aufirst%3DP.%2BR.%26aulast%3DT%25C3%25B6lle%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BGiet%26aufirst%3DM.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DRadeke%26aufirst%3DH.%2BH.%26aulast%3DSch%25C3%25A4fer%2BKorting%26aufirst%3DM.%26aulast%3DKleuser%26aufirst%3DB.%26atitle%3DImmunomodulator%2520FTY720%2520induces%2520myofibroblast%2520differentiation%2520via%2520the%2520lysophospholipid%2520receptor%2520S1P3%2520and%2520Smad3%2520signaling%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2007%26volume%3D170%26spage%3D281%26epage%3D292%26doi%3D10.2353%2Fajpath.2007.060485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Urata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, M.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate induces α-smooth muscle actin expression in lung fibroblasts via Rho-kinase</span>. <i>Kobe J. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">27</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=16199931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2005&pages=17-27&author=Y.+Urataauthor=Y.+Nishimuraauthor=T.+Hiraseauthor=M.+Yokoyama&title=Sphingosine+1-phosphate+induces+%CE%B1-smooth+muscle+actin+expression+in+lung+fibroblasts+via+Rho-kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate induces alpha-smooth muscle actin expression in lung fibroblasts via Rho-kinase</span></div><div class="casAuthors">Urata, Yoshiko; Nishimura, Yoshihiro; Hirase, Tetsuaki; Yokoyama, Mitsuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Kobe Journal of Medical Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">17-27</span>CODEN:
                <span class="NLM_cas:coden">KJMDA6</span>;
        ISSN:<span class="NLM_cas:issn">0023-2513</span>.
    
            (<span class="NLM_cas:orgname">Kobe University, Graduate School of Medicine</span>)
        </div><div class="casAbstract">Transformation of fibroblasts into myofibroblasts is an important phenomenon that contributes to airway remodeling in bronchial asthma.  Although several articles have recently indicated that a bioactive lysosphingolipid sphingosine 1-phosphate (S1P) plays roles in the pathogenesis of bronchial asthma, the role of S1P in the remodeling process is poorly understood.  In the present study, we examd. the effects of S1P on alpha-smooth muscle actin (SMA) expression and the morphol. in lung fibroblasts.  S1P stimulated the expression of alpha-SMA in a human lung fibroblast cell line WI38 that expresses EDG/S1P receptors.  These processes were inhibited by Y-27632, but not by pertussis toxin.  These results suggest that S1P induces a phenotypic change of lung fibroblasts via Rho-kinase that may lead to airway remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvfNMaUlVJh7Vg90H21EOLACvtfcHk0lgv3RIUsDVCwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWltrc%253D&md5=fdd31d3d13f635ef88c9e816fa6f30da</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUrata%26aufirst%3DY.%26aulast%3DNishimura%26aufirst%3DY.%26aulast%3DHirase%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DM.%26atitle%3DSphingosine%25201-phosphate%2520induces%2520%25CE%25B1-smooth%2520muscle%2520actin%2520expression%2520in%2520lung%2520fibroblasts%2520via%2520Rho-kinase%26jtitle%3DKobe%2520J.%2520Med.%2520Sci.%26date%3D2005%26volume%3D51%26spage%3D17%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menyhart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Killer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renault, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolli, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatfield, J.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate (s1p) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and smad-independent signalling</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">14839</span>– <span class="NLM_lpage">14851</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.426726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1074%2Fjbc.M112.426726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=23589284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1Whsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=14839-14851&author=K.+Sobelauthor=K.+Menyhartauthor=N.+Killerauthor=B.+Renaultauthor=Y.+Bauerauthor=R.+Studerauthor=B.+Steinerauthor=M.+H.+Bolliauthor=O.+Naylerauthor=J.+Gatfield&title=Sphingosine+1-phosphate+%28s1p%29+receptor+agonists+mediate+pro-fibrotic+responses+in+normal+human+lung+fibroblasts+via+S1P2+and+S1P3+receptors+and+smad-independent+signalling&doi=10.1074%2Fjbc.M112.426726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-Phosphate (S1P) Receptor Agonists Mediate Pro-fibrotic Responses in Normal Human Lung Fibroblasts via S1P2 and S1P3 Receptors and Smad-independent Signaling</span></div><div class="casAuthors">Sobel, Katrin; Menyhart, Katalin; Killer, Nina; Renault, Berengere; Bauer, Yasmina; Studer, Rolf; Steiner, Beat; Bolli, Martin H.; Nayler, Oliver; Gatfield, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">14839-14851</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Synthetic sphingosine 1-phosphate receptor 1 modulators constitute a new class of drugs for the treatment of autoimmune diseases.  Sphingosine 1-phosphate (S1P) signaling, however, is also involved in the development of fibrosis.  Using normal human lung fibroblasts, we investigated the induction of fibrotic responses by the S1P receptor (S1PR) agonists S1P, FTY720-P, ponesimod, and SEW2871 and compared them with the responses induced by the known fibrotic mediator TGF-β1.  In contrast to TGF-β1, S1PR agonists did not induce expression of the myofibroblast marker α-smooth muscle actin.  However, TGF-β1, S1P, and FTY720-P caused robust stimulation of extracellular matrix (ECM) synthesis and increased pro-fibrotic marker gene expression including connective tissue growth factor.  Ponesimod showed limited and SEW2871 showed no pro-fibrotic potential in these readouts.  Anal. of pro-fibrotic signaling pathways showed that in contrast to TGF-β1, S1PR agonists did not activate Smad2/3 signaling but rather activated PI3K/Akt and ERK1/2 signaling to induce ECM synthesis.  The strong induction of ECM synthesis by the nonselective agonists S1P and FTY720-P was due to the stimulation of S1P2 and S1P3 receptors, whereas the weaker induction of ECM synthesis at high concns. of ponesimod was due to a low potency activation of S1P3 receptors.  Finally, in normal human lung fibroblast-derived myofibroblasts that were generated by TGF-β1 pretreatment, S1P and FTY720-P were effective stimulators of ECM synthesis, whereas ponesimod was inactive, because of the down-regulation of S1P3R expression in myofibroblasts.  These data demonstrate that S1PR agonists are pro-fibrotic via S1P2R and S1P3R stimulation using Smad-independent pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRUfNcFmSowLVg90H21EOLACvtfcHk0lhkY_VT0BUEiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1Whsrk%253D&md5=d0af5fcbed012ce1554b2239a701d000</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.426726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.426726%26sid%3Dliteratum%253Aachs%26aulast%3DSobel%26aufirst%3DK.%26aulast%3DMenyhart%26aufirst%3DK.%26aulast%3DKiller%26aufirst%3DN.%26aulast%3DRenault%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DY.%26aulast%3DStuder%26aufirst%3DR.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DGatfield%26aufirst%3DJ.%26atitle%3DSphingosine%25201-phosphate%2520%2528s1p%2529%2520receptor%2520agonists%2520mediate%2520pro-fibrotic%2520responses%2520in%2520normal%2520human%2520lung%2520fibroblasts%2520via%2520S1P2%2520and%2520S1P3%2520receptors%2520and%2520smad-independent%2520signalling%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D14839%26epage%3D14851%26doi%3D10.1074%2Fjbc.M112.426726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajdu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quackenbush, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shei, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Card, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keohane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupprecht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span> <span> </span><span class="NLM_article-title">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1126/science.1070238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1126%2Fscience.1070238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=11923495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=346-349&author=S.+Mandalaauthor=R.+Hajduauthor=J.+Bergstromauthor=E.+Quackenbushauthor=J.+Xieauthor=J.+Milliganauthor=R.+Thorntonauthor=G.+J.+Sheiauthor=D.+Cardauthor=C.+Keohaneauthor=M.+Rosenbachauthor=J.+Haleauthor=C.+L.+Lynchauthor=K.+Rupprechtauthor=W.+Parsonsauthor=H.+Rosen&title=Alteration+of+lymphocyte+trafficking+by+sphingosine-1-phosphate+receptor+agonists&doi=10.1126%2Fscience.1070238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span></div><div class="casAuthors">Mandala, Suzanne; Hajdu, Richard; Bergstrom, James; Quackenbush, Elizabeth; Xie, Jenny; Milligan, James; Thornton, Rosemary; Shei, Gan-Ju; Card, Deborah; Keohane, Carolann; Rosenbach, Mark; Hale, Jeffrey; Lynch, Christopher L.; Rupprecht, Kathleen; Parsons, William; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5566</span>),
    <span class="NLM_cas:pages">346-349</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Blood lymphocyte nos., essential for the development of efficient immune responses, are maintained by recirculation through secondary Lymphoid organs.  We show that lymphocyte trafficking is altered by the lysophospholipid sphingosine-1-phosphate (S1P) and by a phosphoryl metabolite of the immunosuppressive agent FTY720.  Both species were high-affinity agonists of at least four of the five S1P receptors.  These agonists produce lymphopenia in blood and thoracic duct lymph by sequestration of lymphocytes in lymph nodes, but not spleen.  S1P receptor agonists induced emptying of lymphoid sinuses by retention of lymphocytes on the abluminal side of sinus-lining endothelium and inhibition of egress into lymph.  Inhibition of lymphocyte recirculation by activation of S1P receptors may result in therapeutically useful immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPvwG_lLsA8LVg90H21EOLACvtfcHk0lhkY_VT0BUEiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D&md5=b57cbcffe41d144e701dbd42459cf38a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.1070238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1070238%26sid%3Dliteratum%253Aachs%26aulast%3DMandala%26aufirst%3DS.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DQuackenbush%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DThornton%26aufirst%3DR.%26aulast%3DShei%26aufirst%3DG.%2BJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DKeohane%26aufirst%3DC.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DRupprecht%26aufirst%3DK.%26aulast%3DParsons%26aufirst%3DW.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DAlteration%2520of%2520lymphocyte%2520trafficking%2520by%2520sphingosine-1-phosphate%2520receptor%2520agonists%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D346%26epage%3D349%26doi%3D10.1126%2Fscience.1070238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monnier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menyhart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatfield, J.</span></span> <span> </span><span class="NLM_article-title">FTY720 Phosphate activates sphingosine-1-phosphate receptor 2 and selectively couples to Gα12/13/rho/rock to induce myofibroblast contraction</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1124/mol.114.097261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1124%2Fmol.114.097261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=25762025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Wlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=916-927&author=K.+Sobelauthor=L.+Monnierauthor=K.+Menyhartauthor=M.+Bolingerauthor=R.+Studerauthor=O.+Naylerauthor=J.+Gatfield&title=FTY720+Phosphate+activates+sphingosine-1-phosphate+receptor+2+and+selectively+couples+to+G%CE%B112%2F13%2Frho%2Frock+to+induce+myofibroblast+contraction&doi=10.1124%2Fmol.114.097261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">FTY720 phosphate activates sphingosine-1-phosphate receptor 2 and selectively couples to Gα12/13/Rho/ROCK to induce myofibroblast contraction</span></div><div class="casAuthors">Sobel, Katrin; Monnier, Lucile; Menyhart, Katalin; Bolinger, Matthias; Studer, Rolf; Nayler, Oliver; Gatfield, John</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">916-927</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">FTY720 phosphate (FTY720-P; 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol, monodihydrogen phosphate ester) is a nonselective sphingosine-1-phosphate (S1P) receptor agonist thought to be devoid of activity at the S1P2 receptor subtype.  However, we have recently shown that FTY720-P displays significant S1P2 receptor agonist activity in recombinant cells and fibroblasts expressing endogenous S1P2 receptors.  To elucidate the S1P2-dependent signaling pathways that were activated by FTY720-P, we employed second messenger assays and impedance-based assays in combination with pharmacol. and small interfering RNA-based pathway inhibition in recombinant Chinese hamster ovary (CHO)-S1P2 cells as well as human lung myofibroblasts generated in vitro.  In CHO-S1P2 cells, FTY720-P did not modulate cAMP or calcium levels.  However, reporter-gene assays, impedance-based assays with a selective Rho-assocd. kinase (ROCK) inhibitor, Gα12/13 knockdown and activated Rho-pull-down assays demonstrated that FTY720-P potently activated Gα12/13/Rho/ROCK signaling.  S1P similarly activated Gα12/13/Rho/ROCK signaling via S1P2 receptors, whereas the two selective S1P1 receptor agonists (Z,Z)-5-(3-chloro-4-[(2R)-2,3-dihydroxy-propoxy]-benzylidene)-2-propylimino-3-o-tolyl-thiazolidin-4-one (ponesimond) and 5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-3-[3-(trifluoromethyl)phenyl]1,2,4-oxadiazole (SEW2871) were inactive.  In lung myofibroblasts, which mainly expressed the S1P2 receptor subtype, we showed that FTY720-P selectively activated the Gα12/13/Rho/ROCK pathway via the S1P2 receptor.  Moreover, the activation of the Gα12/13/Rho/ROCK pathway in myofibroblasts by FTY720-P caused potent myofibroblast contraction similar to that induced by the natural ligand S1P.  Thus, complementing second messenger assays with unbiased label-free assays or phenotypic assays in native expression systems can uncover activation of addnl. pathways, such as Gα12/13/Rho/ROCK signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_-lB6CsWDu7Vg90H21EOLACvtfcHk0liLBfkSSEk1Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Wlu78%253D&md5=32484e6fbe2b9fd8c5c02c115c70085a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.097261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.097261%26sid%3Dliteratum%253Aachs%26aulast%3DSobel%26aufirst%3DK.%26aulast%3DMonnier%26aufirst%3DL.%26aulast%3DMenyhart%26aufirst%3DK.%26aulast%3DBolinger%26aufirst%3DM.%26aulast%3DStuder%26aufirst%3DR.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DGatfield%26aufirst%3DJ.%26atitle%3DFTY720%2520Phosphate%2520activates%2520sphingosine-1-phosphate%2520receptor%25202%2520and%2520selectively%2520couples%2520to%2520G%25CE%25B112%252F13%252Frho%252Frock%2520to%2520induce%2520myofibroblast%2520contraction%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D87%26spage%3D916%26epage%3D927%26doi%3D10.1124%2Fmol.114.097261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Serriere-Lanneau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira-Clerc, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schippers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wries, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Van-Nhieu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poelstra, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpentier, S.</span></span> <span> </span><span class="NLM_article-title">The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2013</span>, <span class="refDoi"> DOI: 10.1096/fj.06-6889com</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1096%2Ffj.06-6889com" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=17341687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvVagsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=2005-2013&author=V.+Serriere-Lanneauauthor=F.+Teixeira-Clercauthor=L.+Liauthor=M.+Schippersauthor=W.+de+Wriesauthor=B.+Julienauthor=J.+Tran-Van-Nhieuauthor=S.+Maninauthor=K.+Poelstraauthor=J.+Chunauthor=S.+Carpentier&title=The+sphingosine+1-phosphate+receptor+S1P2+triggers+hepatic+wound+healing&doi=10.1096%2Ffj.06-6889com"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing</span></div><div class="casAuthors">Serriere-Lanneau, Valerie; Teixeira-Clerc, Fatima; Li, Liying; Schippers, Marlies; de Wries, Willie; Julien, Boris; Tran-Van-Nhieu, Jeanne; Manin, Sylvie; Poelstra, Klaas; Chun, Jerold; Carpentier, Stephane; Levade, Thierry; Mallat, Ariane; Lotersztajn, Sophie</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2005-2013</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid produced by sphingosine kinase (SphK1 and 2).  We previously showed that S1P receptors (S1P1, S1P2, and S1P3) are expressed in hepatic myofibroblasts (hMF), a population of cells that triggers matrix remodeling during liver injury.  Here we investigated the function of these receptors in the wound healing response to acute liver injury elicited by carbon tetrachloride, a process that assocs. hepatocyte proliferation and matrix remodeling.  Acute liver injury was assocd. with the induction of S1P2, S1P3, SphK1, and SphK2 mRNAs and increased SphK activity, with no change in S1P1 expression.  Necrosis, inflammation, and hepatocyte regeneration were similar in S1P2-/- and wild-type (WT) mice.  However, compared with WT mice, S1P2-/- mice displayed reduced accumulation of hMF, as shown by lower induction of smooth muscle α-actin mRNA and lower induction of TIMP-1, TGF-β1, and PDGF-BB mRNAs, overall reflecting reduced activation of remodeling in response to liver injury.  The wound healing response was similar in S1P3-/- and WT mice.  In vitro, S1P enhanced proliferation of cultured WT hMF, and PDGF-BB further enhanced the mitogenic effect of S1P.  In keeping with these findings, PDGF-BB up-regulated S1P2 and SphK1 mRNAs, increased SphK activity, and S1P2 induced PDGF-BB mRNA.  These effects were blunted in S1P2-/- cells, and S1P2-/- hMF exhibited reduced mitogenic and comitogenic responses to S1P.  These results unravel a novel major role of S1P2 in the wound healing response to acute liver injury by a mechanism involving enhanced proliferation of hMF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYiGmx2M3IlLVg90H21EOLACvtfcHk0liLBfkSSEk1Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvVagsrs%253D&md5=564e2307315530db783d65fb43546c01</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1096%2Ffj.06-6889com&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.06-6889com%26sid%3Dliteratum%253Aachs%26aulast%3DSerriere-Lanneau%26aufirst%3DV.%26aulast%3DTeixeira-Clerc%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSchippers%26aufirst%3DM.%26aulast%3Dde%2BWries%26aufirst%3DW.%26aulast%3DJulien%26aufirst%3DB.%26aulast%3DTran-Van-Nhieu%26aufirst%3DJ.%26aulast%3DManin%26aufirst%3DS.%26aulast%3DPoelstra%26aufirst%3DK.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DCarpentier%26aufirst%3DS.%26atitle%3DThe%2520sphingosine%25201-phosphate%2520receptor%2520S1P2%2520triggers%2520hepatic%2520wound%2520healing%26jtitle%3DFASEB%2520J.%26date%3D2007%26volume%3D21%26spage%3D2005%26epage%3D2013%26doi%3D10.1096%2Ffj.06-6889com" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Takuwa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takuwa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, K.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate as a mediator involved in development of fibrotic diseases</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1831</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/j.bbalip.2012.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.bbalip.2012.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=22735357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOls7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1831&publication_year=2013&pages=185-192&author=Y.+Takuwaauthor=H.+Ikedaauthor=Y.+Okamotoauthor=N.+Takuwaauthor=K.+Yoshioka&title=Sphingosine-1-phosphate+as+a+mediator+involved+in+development+of+fibrotic+diseases&doi=10.1016%2Fj.bbalip.2012.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate as a mediator involved in development of fibrotic diseases</span></div><div class="casAuthors">Takuwa, Yoh; Ikeda, Hitoshi; Okamoto, Yasuo; Takuwa, Noriko; Yoshioka, Kazuaki</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1831</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-192</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Fibrosis is a pathol. process characterized by massive deposition of extracellular matrix (ECM) such as type I/III collagens and fibronectin that are secreted by an expanded pool of myofibroblasts, which are phenotypically altered fibroblasts with more contractile, proliferative, migratory and secretory activities.  Fibrosis occurs in various organs including the lung, heart, liver and kidney, resulting in loss of normal tissue architecture and functions.  Myofibroblasts could originate from multiple sources including tissue-resident fibroblasts, epithelial and endothelial cells through mechanisms of epithelial/endothelial-mesenchymal transition (EMT/EndMT), and bone marrow-derived circulating progenitors called fibrocytes.  Emerging evidence in recent years shows that sphingosine-1-phosphate (S1P) acts on several types of target cells and is engaged in pro-fibrotic inflammatory process and fibrogenic process through multiple mechanisms, which include vascular permeability change, leukocyte infiltration, and migration, proliferation and myofibroblast differentiation of fibroblasts.  Many of these S1P actions are receptor subtype-specific.  In these actions, S1P has multiple cross-talks with other cytokines, particularly transforming growth factor-β (TGFβ), which plays a major role in fibrosis.  The cross-talks include the regulation of S1P prodn. through altered expression and activity of sphingosine kinases in fibrotic lesions, altered expression of S1P receptors, and S1P receptor-mediated transactivation of TGFβ signaling pathway.  These cross-talks may give rise to a feed-forward, amplifying loop between S1P and TGFβ, and possibly with other cytokines in stimulating fibrogenesis.  Another lysophospholipid mediator lysophosphatidic acid has also been recently implicated in fibrosis.  The lysophospholipid signaling pathways represent novel, promising therapeutic targets for treating refractory fibrotic diseases.  This article is part of a Special Issue entitled Advances in Lysophospholipid Research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4lDJqsJR9kLVg90H21EOLACvtfcHk0ljMYRVjVTlqQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOls7vP&md5=1efb314cbf84b6c76fbf93985bac7146</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2012.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2012.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DTakuwa%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DTakuwa%26aufirst%3DN.%26aulast%3DYoshioka%26aufirst%3DK.%26atitle%3DSphingosine-1-phosphate%2520as%2520a%2520mediator%2520involved%2520in%2520development%2520of%2520fibrotic%2520diseases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2013%26volume%3D1831%26spage%3D185%26epage%3D192%26doi%3D10.1016%2Fj.bbalip.2012.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Blankenbach, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeilschifter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer zu Heringdorf, D.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate receptor-2 antagonists: therapeutic potential and potential risks</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">167</span>, <span class="refDoi"> DOI: 10.3389/fphar.2016.00167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.3389%2Ffphar.2016.00167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=27445808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsV2gtb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=167&author=K.+V.+Blankenbachauthor=S.+Schwalmauthor=J.+Pfeilschifterauthor=D.+Meyer+zu+Heringdorf&title=Sphingosine-1-phosphate+receptor-2+antagonists%3A+therapeutic+potential+and+potential+risks&doi=10.3389%2Ffphar.2016.00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate receptor-2 antagonists: therapeutic potential and potential risks</span></div><div class="casAuthors">Blankenbach, Kira V.; Schwalm, Stephanie; Pfeilschifter, Josef; Meyer zu Heringdorf, Dagmar</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167/1-167/14</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The sphingosine-1-phosphate (S1P) signaling system with its specific G-protein-coupled S1P receptors, the enzymes of S1P metab. and the S1P transporters, offers a multitude of promising targets for drug development.  Until today, drug development in this area has nearly exclusively focused on (functional) antagonists at the S1P1 receptor, which cause a unique phenotype of immunomodulation.  Accordingly, the first-in class S1P1 receptor modulator, fingolimod, has been approved for the treatment of relapsing-remitting multiple sclerosis, and novel S1P1 receptor (functional) antagonists are being developed for autoimmune and inflammatory diseases such as psoriasis, inflammatory bowel disease, lupus erythematodes, or polymyositis.  Besides the S1P1 receptor, also S1P2 and S1P3 are widely expressed and regulate many diverse functions throughout the body.  The S1P2 receptor, in particular, often exerts cellular functions which are opposed to the functions of the S1P1 receptor.  As a consequence, antagonists at the S1P2 receptor have the potential to be useful in a contrasting context and different areas of indication compared to S1P1 antagonists.  The present review will focus on the therapeutic potential of S1P2 receptor antagonists and discuss their opportunities as well as their potential risks.  Open questions and areas which require further investigations will be emphasized in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL5VfhXuFlNLVg90H21EOLACvtfcHk0ljMYRVjVTlqQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsV2gtb7N&md5=27f116df6e35db621cc1bf8583f086be</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2016.00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2016.00167%26sid%3Dliteratum%253Aachs%26aulast%3DBlankenbach%26aufirst%3DK.%2BV.%26aulast%3DSchwalm%26aufirst%3DS.%26aulast%3DPfeilschifter%26aufirst%3DJ.%26aulast%3DMeyer%2Bzu%2BHeringdorf%26aufirst%3DD.%26atitle%3DSphingosine-1-phosphate%2520receptor-2%2520antagonists%253A%2520therapeutic%2520potential%2520and%2520potential%2520risks%26jtitle%3DFront.%2520Pharmacol.%26date%3D2016%26volume%3D7%26spage%3D167%26doi%3D10.3389%2Ffphar.2016.00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Takuwa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takuwa, Y.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate signalling and cardiac fibrosis</span>. <i>Inflammation Regener.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">096</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.2492/inflammregen.33.096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.2492%2Finflammregen.33.096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsFSqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=096-108&author=N.+Takuwaauthor=Y.+Okamotoauthor=K.+Yoshiokaauthor=Y.+Takuwa&title=Sphingosine-1-phosphate+signalling+and+cardiac+fibrosis&doi=10.2492%2Finflammregen.33.096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11dR"><div class="casContent"><span class="casTitleNuber">11d</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate signaling and cardiac fibrosis</span></div><div class="casAuthors">Takuwa, Noriko; Okamoto, Yasuo; Yoshioka, Kazuaki; Takuwa, Yoh</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation and Regeneration</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">96-108</span>CODEN:
                <span class="NLM_cas:coden">IRNECG</span>;
        ISSN:<span class="NLM_cas:issn">1880-9693</span>.
    
            (<span class="NLM_cas:orgname">Nippon Ensho/Saisei Igakkai</span>)
        </div><div class="casAbstract">A review.  Sphingosine-1-phosphate (S1P) is a pleiotropic lysophospholipid mediator that acts on 5 members of the G protein-coupled S1P receptor family to induce diverse biol. responses.  S1P1, S1P2 and S1P3, which are widely expressed receptor subtypes, exert distinct regulatory effects on cytoarchitecture, cell migration, proliferation and gene expression, through differential coupling to heterotrimeric G proteins and downstream signaling, including activation of Rac and Rho small GTPases.  Recent studies indicate the involvement of the S1P signaling system in inflammation and fibrosis.  Investigations into genetically engineered mice have provided evidence that S1P2 and S1P3 receptors, together with sphingosine kinase 1 (SphK1), which is a major S1P synthesizing enzyme, participate in fibrogenic processes, through mechanisms involving activation of the Rho-dependent pathway and cross-talk with TGFβ signaling.  This review will focus on the basics of the S1P signaling system, which include S1P receptor subtype-specific signaling and biol. activities, prodn. and degrdn. of S1P, and currently available in vivo data, including our own data, regarding how S1P signaling is involved in cardiac fibrosis, a pathol. feature of cardiac remodeling that leads to chronic heart failure, which is one of leading causes of death in developed countries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra7G9oVC6zAbVg90H21EOLACvtfcHk0lgf_VFF1Em3zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsFSqtb4%253D&md5=1091bcad3010c744c96452f0a68af317</span></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.2492%2Finflammregen.33.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2492%252Finflammregen.33.096%26sid%3Dliteratum%253Aachs%26aulast%3DTakuwa%26aufirst%3DN.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DYoshioka%26aufirst%3DK.%26aulast%3DTakuwa%26aufirst%3DY.%26atitle%3DSphingosine-1-phosphate%2520signalling%2520and%2520cardiac%2520fibrosis%26jtitle%3DInflammation%2520Regener.%26date%3D2013%26volume%3D33%26spage%3D096%26epage%3D108%26doi%3D10.2492%2Finflammregen.33.096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeilschifter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwiler, A.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate: A Janus-faced mediator of fibrotic diseases</span>. <i>Biochim. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1831</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/j.bbalip.2012.07.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.bbalip.2012.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=22889995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GksbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1831&publication_year=2013&pages=239-250&author=S.+Schwalmauthor=J.+Pfeilschifterauthor=A.+Huwiler&title=Sphingosine-1-phosphate%3A+A+Janus-faced+mediator+of+fibrotic+diseases&doi=10.1016%2Fj.bbalip.2012.07.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11eR"><div class="casContent"><span class="casTitleNuber">11e</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate: A Janus-faced mediator of fibrotic diseases</span></div><div class="casAuthors">Schwalm, Stephanie; Pfeilschifter, Josef; Huwiler, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1831</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">239-250</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Sphingosine-1-phosphate (S1P) is a pleiotropic lipid mediator that acts either on G protein-coupled S1P receptors on the cell surface or via intracellular target sites.  In addn. to the well established effects of S1P in angiogenesis, carcinogenesis and immunity, evidence is now continuously accumulating which demonstrates that S1P is an important regulator of fibrosis.  The contribution of S1P to fibrosis is of a Janus-faced nature as S1P exhibits both pro- and anti-fibrotic effects depending on its site of action.  Extracellular S1P promotes fibrotic processes in a S1P receptor-dependent manner, whereas intracellular S1P has an opposite effect and dampens a fibrotic reaction by yet unidentified mechanisms.  Fibrosis is a result of chronic irritation by various factors and is defined by an excess prodn. of extracellular matrix leading to tissue scarring and organ dysfunction.  In this review, we highlight the general effects of extracellular and intracellular S1P on the multistep cascade of pathol. fibrogenesis including tissue injury, inflammation and the action of pro-fibrotic cytokines that stimulate ECM prodn. and deposition.  In a second part we summarize the current knowledge about the involvement of S1P signaling in the development of organ fibrosis of the lung, kidney, liver, heart and skin.  Altogether, it is becoming clear that targeting the sphingosine kinase-1/S1P signaling pathway offers therapeutic potential in the treatment of various fibrotic processes.  This article is part of a Special Issue entitled Advances in Lysophospholipid Research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpohZuLnS4FLLVg90H21EOLACvtfcHk0lgf_VFF1Em3zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GksbjK&md5=d2a704f167af1b096e4b4d0a31af1f41</span></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2012.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2012.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DSchwalm%26aufirst%3DS.%26aulast%3DPfeilschifter%26aufirst%3DJ.%26aulast%3DHuwiler%26aufirst%3DA.%26atitle%3DSphingosine-1-phosphate%253A%2520A%2520Janus-faced%2520mediator%2520of%2520fibrotic%2520diseases%26jtitle%3DBiochim.%2520Biophys.%26date%3D2013%26volume%3D1831%26spage%3D239%26epage%3D250%26doi%3D10.1016%2Fj.bbalip.2012.07.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="note"><p class="first last">and references therein.</p></div><div class="NLM_citation" id="rightTab-cit11f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, M.</span></span> <span> </span><span class="NLM_article-title">Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-β1</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2007-0065OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1165%2Frcmb.2007-0065OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=17641298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOntbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2007&pages=395-404&author=Y.+Konoauthor=T.+Nishiumaauthor=Y.+Nishimuraauthor=Y.+Kotaniauthor=T.+Okadaauthor=S.+Nakamuraauthor=M.+Yokoyama&title=Sphingosine+kinase+1+regulates+differentiation+of+human+and+mouse+lung+fibroblasts+mediated+by+TGF-%CE%B21&doi=10.1165%2Frcmb.2007-0065OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11fR"><div class="casContent"><span class="casTitleNuber">11f</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-β1</span></div><div class="casAuthors">Kono, Yuko; Nishiuma, Teruaki; Nishimura, Yoshihiro; Kotani, Yoshikazu; Okada, Taro; Nakamura, Shun-ichi; Yokoyama, Mitsuhiro</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">395-404</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Transforming growth factor β (TGF-β) contributes to the progression of pulmonary fibrosis through up-regulation of α-smooth muscle actin (α-SMA) as lung myofibroblast differentiation.  Bioactive sphingosine 1-phosphate (S1P) has been shown to mimic TGF-β signals; however, the function of S1P in lung fibrotic process has not been well documented.  We found, in a mouse model of bleomycin lung fibrosis, that SPHK1 and α-SMA were colocalized within lung fibrotic foci and that these expressions were significantly increased in primary cultured fibroblasts.  Using human lung fibroblasts WI-38, we explored the rationale of sphingosine kinase (SPHK) with TGF-β1 stimulation.  SPHK inhibitors and small interference RNA (siRNA) targeted SPHK1 decreased α-SMA and fibronectin expression up-regulated by TGF-β1.  In the meantime, SPHK1 inhibition did not affect smad2 phosphorylation in response to TGF-β1.  Then we examd. whether S1P receptors transactivation may affect TGF-β signals.  SiRNA against S1P2 and S1P3, but not S1P1, reduced α-SMA expression as well as Y-27632, Rho kinase inhibitor.  We also detected activation of Rho GTPase upon stimulation of TGF-β1 on the cell membrane where S1P2 or S1P3 was overexpressed.  These data suggested that SPHK1 activation by TGF-β1 leads to Rho-assocd. myofibroblasts differentiation mediated by transactivated S1P receptors in the lung fibrogenic process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjN3YaovatirVg90H21EOLACvtfcHk0lgf_VFF1Em3zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOntbfP&md5=4acb28e02cebf24be8a9c797160a049c</span></div><a href="/servlet/linkout?suffix=cit11f&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2007-0065OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2007-0065OC%26sid%3Dliteratum%253Aachs%26aulast%3DKono%26aufirst%3DY.%26aulast%3DNishiuma%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DY.%26aulast%3DKotani%26aufirst%3DY.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DYokoyama%26aufirst%3DM.%26atitle%3DSphingosine%2520kinase%25201%2520regulates%2520differentiation%2520of%2520human%2520and%2520mouse%2520lung%2520fibroblasts%2520mediated%2520by%2520TGF-%25CE%25B21%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2007%26volume%3D37%26spage%3D395%26epage%3D404%26doi%3D10.1165%2Frcmb.2007-0065OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimosawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomiya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtomo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanoue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iitsuka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatomi, Y.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1194/jlr.M800496-JLR200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1194%2Fjlr.M800496-JLR200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=18955732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlCqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=556-564&author=H.+Ikedaauthor=N.+Watanabeauthor=I.+Ishiiauthor=T.+Shimosawaauthor=Y.+Kumeauthor=T.+Tomiyaauthor=Y.+Inoueauthor=T.+Nishikawaauthor=N.+Ohtomoauthor=Y.+Tanoueauthor=S.+Iitsukaauthor=R.+Fujitaauthor=M.+Omataauthor=J.+Chunauthor=Y.+Yatomi&title=Sphingosine+1-phosphate+regulates+regeneration+and+fibrosis+after+liver+injury+via+sphingosine+1-phosphate+receptor+2&doi=10.1194%2Fjlr.M800496-JLR200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11gR"><div class="casContent"><span class="casTitleNuber">11g</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2</span></div><div class="casAuthors">Ikeda, Hitoshi; Watanabe, Naoko; Ishii, Isao; Shimosawa, Tatsuo; Kume, Yukio; Tomiya, Tomoaki; Inoue, Yukiko; Nishikawa, Takako; Ohtomo, Natsuko; Tanoue, Yasushi; Iitsuka, Satoko; Fujita, Ryoto; Omata, Masao; Chun, Jerold; Yatomi, Yutaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">556-564</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P), a bioactive lipid mediator, stimulates proliferation and contractility in hepatic stellate cells, the principal matrix-producing cells in the liver, and inhibits proliferation via S1P receptor 2 (S1P2) in hepatocytes in rats in vitro.  A potential role of S1P and S1P2 in liver regeneration and fibrosis was examd. in S1P2-deficient mice.  Nuclear 5-bromo-2'-deoxy-uridine labeling, proliferating cell nuclear antigen (PCNA) staining in hepatocytes, and the ratio of liver wt. to body wt. were enhanced at 48 h in S1P2-deficient mice after a single carbon tetrachloride (CCl4) injection.  After dimethylnitrosamine (DMN) administration with a LD, PCNA staining in hepatocytes was enhanced at 48 h and survival rate was higher in S1P2-deficient mice.  Serum aminotransferase level was unaltered in those mice compared with wild-type mice in both CCl4- and DMN-induced liver injury, suggesting that S1P2 inactivation accelerated regeneration not as a response to enhanced liver damage.  After chronic CCl4 administration, fibrosis was less apparent, with reduced expression of smooth-muscle α-actin-pos. cells in the livers of S1P2-deficient mice, suggesting that S1P2 inactivation ameliorated CCl4-induced fibrosis due to the decreased accumulation of hepatic stellate cells.  Thus, S1P plays a significant role in regeneration and fibrosis after liver injury via S1P2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoU7Xhm7Qlt7Vg90H21EOLACvtfcHk0liYAj5Ex1kH4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlCqtbo%253D&md5=69a265513d07fa16057c341ebcfd695f</span></div><a href="/servlet/linkout?suffix=cit11g&amp;dbid=16384&amp;doi=10.1194%2Fjlr.M800496-JLR200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.M800496-JLR200%26sid%3Dliteratum%253Aachs%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DIshii%26aufirst%3DI.%26aulast%3DShimosawa%26aufirst%3DT.%26aulast%3DKume%26aufirst%3DY.%26aulast%3DTomiya%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DNishikawa%26aufirst%3DT.%26aulast%3DOhtomo%26aufirst%3DN.%26aulast%3DTanoue%26aufirst%3DY.%26aulast%3DIitsuka%26aufirst%3DS.%26aulast%3DFujita%26aufirst%3DR.%26aulast%3DOmata%26aufirst%3DM.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DYatomi%26aufirst%3DY.%26atitle%3DSphingosine%25201-phosphate%2520regulates%2520regeneration%2520and%2520fibrosis%2520after%2520liver%2520injury%2520via%2520sphingosine%25201-phosphate%2520receptor%25202%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2009%26volume%3D50%26spage%3D556%26epage%3D564%26doi%3D10.1194%2Fjlr.M800496-JLR200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Milara, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peiró, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramón, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortijo, J.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1136/thoraxjnl-2011-200026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1136%2Fthoraxjnl-2011-200026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=22106015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A280%3ADC%252BC387msVKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2012&pages=147-156&author=J.+Milaraauthor=R.+Navarroauthor=G.+Juanauthor=T.+Peir%C3%B3author=A.+Serranoauthor=M.+Ram%C3%B3nauthor=E.+Morcilloauthor=J.+Cortijo&title=Sphingosine-1-phosphate+is+increased+in+patients+with+idiopathic+pulmonary+fibrosis+and+mediates+epithelial+to+mesenchymal+transition&doi=10.1136%2Fthoraxjnl-2011-200026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11hR"><div class="casContent"><span class="casTitleNuber">11h</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition</span></div><div class="casAuthors">Milara Javier; Navarro Rafael; Juan Gustavo; Peiro Teresa; Serrano Adela; Ramon Mercedes; Morcillo Esteban; Cortijo Julio</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Idiopathic pulmonary fibrosis (IPF) is characterised by the aberrant epithelial to mesenchymal transition (EMT) and myofibroblast accumulation.  Sphingosine-1-phosphate (S1P) and sphingosine kinase 1 (SPHK1) have been implicated in lung myofibroblast transition, but their role in EMT and their expression in patients with IPF is unknown.  METHODS AND RESULTS:  S1P levels were measured in serum (n=27) and bronchoalveolar lavage (BAL; n=15) from patients with IPF and controls (n=30 for serum and n=15 for BAL studies).  SPHK1 expression was measured in lung tissue from patients with IPF (n=12) and controls (n=15).  Alveolar type II transformation into mesenchymal cells was studied in response to S1P (10(-9)-10(-5) M).  The median (IQR) of S1P serum levels was increased in patients with IPF (1.4 (0.4) μM) versus controls (1 (0.26) μM; p<0.0001).  BAL S1P levels were increased in patients with IPF (1.12 (0.53) μM) versus controls (0.2 (0.5); p<0.0001) and correlated with diffusion capacity of the lung for carbon monoxide, forced expiratory volume in 1 s and forced vital capacity (Spearman's r=-0.87, -0.72 and -0.68, respectively) in patients with IPF.  SPHK1 was upregulated in lung tissue from patients with IPF and correlated with α-smooth muscle actin, vimentin and collagen type I (Spearman's r=0.82, 0.85 and 0.72, respectively).  S1P induced EMT in alveolar type II cells by interacting with S1P(2) and S1P(3), as well as by the activation of p-Smad3, RhoA-GTP, oxidative stress and transforming growth factor-β1 (TGF-β1) release.  Furthermore, TGF-β1-induced EMT was partially conducted by the S1P/SPHK1 activation, suggesting crosstalk between TGF-β1 and the S1P/SPHK1 axis.  CONCLUSIONS:  S1P is elevated in patients with IPF, correlates with the lung function and mediates EMT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDkweGaX9BB-2mnZh2OgS0fW6udTcc2eal6zs30ZdmQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387msVKkug%253D%253D&md5=4531bf84fcebd74364cdedc5462daad4</span></div><a href="/servlet/linkout?suffix=cit11h&amp;dbid=16384&amp;doi=10.1136%2Fthoraxjnl-2011-200026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthoraxjnl-2011-200026%26sid%3Dliteratum%253Aachs%26aulast%3DMilara%26aufirst%3DJ.%26aulast%3DNavarro%26aufirst%3DR.%26aulast%3DJuan%26aufirst%3DG.%26aulast%3DPeir%25C3%25B3%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DA.%26aulast%3DRam%25C3%25B3n%26aufirst%3DM.%26aulast%3DMorcillo%26aufirst%3DE.%26aulast%3DCortijo%26aufirst%3DJ.%26atitle%3DSphingosine-1-phosphate%2520is%2520increased%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%2520and%2520mediates%2520epithelial%2520to%2520mesenchymal%2520transition%26jtitle%3DThorax%26date%3D2012%26volume%3D67%26spage%3D147%26epage%3D156%26doi%3D10.1136%2Fthoraxjnl-2011-200026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, D. S.</span></span> <span> </span><span class="NLM_article-title">Deficiency of Sphingosine-1-Phosphate Receptor 2 (S1P2) attenuates bleomycin-induced pulmonary fibrosis</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2018.131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.4062%2Fbiomolther.2018.131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A280%3ADC%252BB3czmsFKiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=318-326&author=S.+J.+Parkauthor=D.+S.+Im&title=Deficiency+of+Sphingosine-1-Phosphate+Receptor+2+%28S1P2%29+attenuates+bleomycin-induced+pulmonary+fibrosis&doi=10.4062%2Fbiomolther.2018.131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Deficiency of Sphingosine-1-Phosphate Receptor 2 (S1P2) Attenuates Bleomycin-Induced Pulmonary Fibrosis</span></div><div class="casAuthors">Park Soo-Jin; Im Dong-Soon</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-326</span>
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) levels are often found to be elevated in serum, bronchoalveolar lavage, and lung tissue of idiopathic pulmonary fibrosis patients and experimental mouse models.  Although the roles of sphingosine kinase 1 and S1P receptors have been implicated in fibrosis, the underlying mechanism of fibrosis via Sphingosine 1-phosphate receptor 2 (S1P2) has not been fully investigated.  Therefore, in this study, the roles of S1P2 in lung inflammation and fibrosis was investigated by means of a bleomycin-induced lung fibrosis model and lung epithelial cells.  Bleomycin was found to induce lung inflammation on day 7 and fibrosis on day 28 of treatment.  On the 7(th) day after bleomycin administration, S1P2 deficient mice exhibited significantly less pulmonary inflammation, including cell infiltration and pro-inflammatory cytokine induction, than the wild type mice.  On the 28(th) day after bleomycin treatment, severe inflammation and fibrosis were observed in lung tissues from wild type mice, while lung tissues from S1P2 deficient mice showed less inflammation and fibrosis.  Increase in TGF-β1-induced extracellular matrix accumulation and epithelial-mesenchymal transition were inhibited by JTE-013, a S1P2 antagonist, in A549 lung epithelial cells.  Taken together, pro-inflammatory and pro-fibrotic functions of S1P2 were elucidated using a bleomycin-induced fibrosis model.  Notably, S1P2 was found to mediate epithelial-mesenchymal transition in fibrotic responses.  Therefore, the results of this study indicate that S1P2 could be a promising therapeutic target for the treatment of pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSYSKhydluNM6__Jf7-eMvJfW6udTcc2ea-lJnpq15N_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czmsFKiug%253D%253D&md5=47aa485144720d3f2e5006024c86e88c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2018.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2018.131%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DIm%26aufirst%3DD.%2BS.%26atitle%3DDeficiency%2520of%2520Sphingosine-1-Phosphate%2520Receptor%25202%2520%2528S1P2%2529%2520attenuates%2520bleomycin-induced%2520pulmonary%2520fibrosis%26jtitle%3DBiomol.%2520Ther.%26date%3D2019%26volume%3D27%26spage%3D318%26epage%3D326%26doi%3D10.4062%2Fbiomolther.2018.131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishimaru, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takuwa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takuwa, Y.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate receptor-2 facilitates pulmonary fibrosis through potentiating IL-13 pathway in macrophages</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0197604</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0197604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1371%2Fjournal.pone.0197604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=29782549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsl2iu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=J.+Zhaoauthor=Y.+Okamotoauthor=Y.+Asanoauthor=K.+Ishimaruauthor=S.+Akiauthor=K.+Yoshiokaauthor=N.+Takuwaauthor=T.+Wadaauthor=Y.+Inagakiauthor=C.+Takahashiauthor=T.+Nishiuchiauthor=Y.+Takuwa&title=Sphingosine-1-phosphate+receptor-2+facilitates+pulmonary+fibrosis+through+potentiating+IL-13+pathway+in+macrophages&doi=10.1371%2Fjournal.pone.0197604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate receptor-2 facilitates pulmonary fibrosis through potentiating IL-13 pathway in macrophages</span></div><div class="casAuthors">Zhao, Juanjuan; Okamoto, Yasuo; Asano, Yuya; Ishimaru, Kazuhiro; Aki, Sho; Yoshioka, Kazuaki; Takuwa, Noriko; Wada, Takashi; Inagaki, Yutaka; Takahashi, Chiaki; Nishiuchi, Takumi; Takuwa, Yoh</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e0197604/1-e0197604/22</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a devastating disease with poor prognosis.  The pathogenic role of the lysophospholipid mediator sphingosine-1-phosphate and its receptor S1PR2 in lung fibrosis is unknown.  We show here that genetic deletion of S1pr2 strikingly attenuated lung fibrosis induced by repeated injections of bleomycin in mice.  We obsd. by using S1pr2LacZ/+ mice that S1PR2 was expressed in alveolar macrophages, vascular endothelial cells and alveolar epithelial cells in the lung and that S1PR2-expressing cells accumulated in the fibrotic legions.  Bone marrow chimera expts. suggested that S1PR2 in bone marrow-derived cells contributes to the development of lung fibrosis.  Depletion of macrophages greatly attenuated lung fibrosis.  Bleomycin administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1, Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly diminished the stimulated expression of these genes.  BALF cells from bleomycin-administered wild-type mice showed a marked increase in phosphorylation of STAT6, a transcription factor which is activated downstream of IL-13, compared with saline-administered wild-type mice.  Interestingly, in bleomycin-administered S1pr2-/- mice, STAT6 phosphorylation in BALF cells was substantially diminished compared with wild-type mice.  Finally, pharmacol. S1PR2 blockade in S1pr2+/+ mice alleviated bleomycin-induced lung fibrosis.  Thus, S1PR2 facilitates lung fibrosis through the mechanisms involving augmentation of IL-13 expression and its signaling in BALF cells, and represents a novel target for treating lung fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4uV_lAvZAA7Vg90H21EOLACvtfcHk0lh7E05gT8mSyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsl2iu7vJ&md5=a07ad0e6ebca38c0e17bcde33e2b04e6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0197604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0197604%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DAsano%26aufirst%3DY.%26aulast%3DIshimaru%26aufirst%3DK.%26aulast%3DAki%26aufirst%3DS.%26aulast%3DYoshioka%26aufirst%3DK.%26aulast%3DTakuwa%26aufirst%3DN.%26aulast%3DWada%26aufirst%3DT.%26aulast%3DInagaki%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DC.%26aulast%3DNishiuchi%26aufirst%3DT.%26aulast%3DTakuwa%26aufirst%3DY.%26atitle%3DSphingosine-1-phosphate%2520receptor-2%2520facilitates%2520pulmonary%2520fibrosis%2520through%2520potentiating%2520IL-13%2520pathway%2520in%2520macrophages%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0197604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cattoretti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelbaum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahler, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadburn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalla-Favera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqualucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLennan, A. J.</span></span> <span> </span><span class="NLM_article-title">Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">8686</span>– <span class="NLM_lpage">8692</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-1110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1158%2F0008-5472.CAN-09-1110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=19903857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2rsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8686-8692&author=G.+Cattorettiauthor=J.+Mandelbaumauthor=N.+Leeauthor=A.+H.+Chavesauthor=A.+M.+Mahlerauthor=A.+Chadburnauthor=R.+Dalla-Faveraauthor=L.+Pasqualucciauthor=A.+J.+MacLennan&title=Targeted+disruption+of+the+S1P2+sphingosine+1-phosphate+receptor+gene+leads+to+diffuse+large+B-cell+lymphoma+formation&doi=10.1158%2F0008-5472.CAN-09-1110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Disruption of the S1P2 Sphingosine 1-Phosphate Receptor Gene Leads to Diffuse Large B-Cell Lymphoma Formation</span></div><div class="casAuthors">Cattoretti, Giorgio; Mandelbaum, Jonathan; Lee, Nancy; Chaves, Alicia H.; Mahler, Ashley M.; Chadburn, Amy; Dalla-Favera, Riccardo; Pasqualucci, Laura; MacLennan, A. John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8686-8692</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">S1P2 sphingosine 1-phosphate receptor signaling can regulate proliferation, survival, morphol., and migration in many cell types in vitro.  Here, we report that S1P2-/- mice develop clonal B-cell lymphomas with age, such that approx. half of the animals display this neoplasm by 1.5 to 2 years of age.  Histol., immunophenotypic, and mol. analyses revealed a uniform tumor phenotype with features of germinal center (GC)-derived diffuse large B-cell lymphoma (DLBCL).  Tumor formation was preceded by increases in GC B cells and CD69+ T cells, as well as an increased formation of spontaneous GCs, suggesting that S1P2 loss may promote lymphomagenesis in part by disrupting GC B-cells homeostasis.  With the sole exception of rare lung tumors, the effect of S1P2 gene disruption is remarkably restricted to DLBCL.  In humans, 28 of 106 (26%) DLBCL samples were found to harbor multiple somatic mutations in the 5' sequences of the S1P2 gene.  Mutations displayed features resembling those generated by the IgV-assocd. somatic hypermutation mechanism, but were not detected at significant levels in normal GC B cells, indicating a tumor-assocd. aberrant function.  Collectively, our data suggest that S1P2 signaling may play a crit. role in suppressing DLBCL formation in vivo.  The high incidence of DLBCL in S1P2-/- mice, its onset at old age, and the relative lack of other neoplasms identify these mice as a novel, and potentially valuable, model for this highly prevalent and aggressive human malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3620dw7SMErVg90H21EOLACvtfcHk0lhmKCvSXQCF4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2rsbfK&md5=33a8486cdf776f8b0df3b18117f68262</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-1110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-1110%26sid%3Dliteratum%253Aachs%26aulast%3DCattoretti%26aufirst%3DG.%26aulast%3DMandelbaum%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DChaves%26aufirst%3DA.%2BH.%26aulast%3DMahler%26aufirst%3DA.%2BM.%26aulast%3DChadburn%26aufirst%3DA.%26aulast%3DDalla-Favera%26aufirst%3DR.%26aulast%3DPasqualucci%26aufirst%3DL.%26aulast%3DMacLennan%26aufirst%3DA.%2BJ.%26atitle%3DTargeted%2520disruption%2520of%2520the%2520S1P2%2520sphingosine%25201-phosphate%2520receptor%2520gene%2520leads%2520to%2520diffuse%2520large%2520B-cell%2520lymphoma%2520formation%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8686%26epage%3D8692%26doi%3D10.1158%2F0008-5472.CAN-09-1110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muppidi, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenwald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimsza, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeland, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braziel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubbs, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisenburger, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidehi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyster, J. G.</span></span> <span> </span><span class="NLM_article-title">Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>516</i></span>,  <span class="NLM_fpage">254</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1038/nature13765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1038%2Fnature13765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=25274307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVemtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=516&publication_year=2014&pages=254-258&author=J.+R.+Muppidiauthor=R.+Schmitzauthor=J.+A.+Greenauthor=W.+Xiaoauthor=A.+B.+Larsenauthor=S.+E.+Braunauthor=J.+Anauthor=Y.+Xuauthor=A.+Rosenwaldauthor=G.+Ottauthor=R.+D.+Gascoyneauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=N.+Vaidehiauthor=L.+M.+Staudtauthor=J.+G.+Cyster&title=Loss+of+signalling+via+G%CE%B113+in+germinal+centre+B-cell-derived+lymphoma&doi=10.1038%2Fnature13765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma</span></div><div class="casAuthors">Muppidi, Jagan R.; Schmitz, Roland; Green, Jesse A.; Xiao, Wenming; Larsen, Adrien B.; Braun, Sterling E.; An, Jinping; Xu, Ying; Rosenwald, Andreas; Ott, German; Gascoyne, Randy D.; Rimsza, Lisa M.; Campo, Elias; Jaffe, Elaine S.; Delabie, Jan; Smeland, Erlend B.; Braziel, Rita M.; Tubbs, Raymond R.; Cook, J. R.; Weisenburger, Dennis D.; Chan, Wing C.; Vaidehi, Nagarajan; Staudt, Louis M.; Cyster, Jason G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">516</span>
        (<span class="NLM_cas:issue">7530</span>),
    <span class="NLM_cas:pages">254-258</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Germinal center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL) is a common malignancy, yet the signalling pathways that are deregulated and the factors leading to its systemic dissemination are poorly defined.  Work in mice showed that sphingosine-1-phosphate receptor-2 (S1PR2), a Gα12 and Gα13 coupled receptor, promotes growth regulation and local confinement of germinal center B cells.  Recent deep sequencing studies of GCB-DLBCL have revealed mutations in many genes in this cancer, including in GNA13 (encoding Gα13) and S1PR2 (refs 5,6, 7).  Here we show, using in vitro and in vivo assays, that GCB-DLBCL-assocd. mutations occurring in S1PR2 frequently disrupt the receptor's Akt and migration inhibitory functions.  Gα13-deficient mouse germinal center B cells and human GCB-DLBCL cells were unable to suppress pAkt and migration in response to S1P, and Gα13-deficient mice developed germinal center B-cell-derived lymphoma.  Germinal center B cells, unlike most lymphocytes, are tightly confined in lymphoid organs and do not recirculate.  Remarkably, deficiency in Gα13, but not S1PR2, led to germinal center B-cell dissemination into lymph and blood.  GCB-DLBCL cell lines frequently carried mutations in the Gα13 effector ARHGEF1, and Arhgef1 deficiency also led to germinal center B-cell dissemination.  The incomplete phenocopy of Gα13- and S1PR2 deficiency led us to discover that P2RY8, an orphan receptor that is mutated in GCB-DLBCL and another germinal center B-cell-derived malignancy, Burkitt's lymphoma, also represses germinal center B-cell growth and promotes confinement via Gα13.  These findings identify a Gα13-dependent pathway that exerts dual actions in suppressing growth and blocking dissemination of germinal center B cells that is frequently disrupted in germinal center B-cell-derived lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohskT6-Npw6rVg90H21EOLACvtfcHk0lhmKCvSXQCF4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVemtrrN&md5=0fea0ad604221300c533414842d8fc5d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnature13765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13765%26sid%3Dliteratum%253Aachs%26aulast%3DMuppidi%26aufirst%3DJ.%2BR.%26aulast%3DSchmitz%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DJ.%2BA.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DLarsen%26aufirst%3DA.%2BB.%26aulast%3DBraun%26aufirst%3DS.%2BE.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DVaidehi%26aufirst%3DN.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26atitle%3DLoss%2520of%2520signalling%2520via%2520G%25CE%25B113%2520in%2520germinal%2520centre%2520B-cell-derived%2520lymphoma%26jtitle%3DNature%26date%3D2014%26volume%3D516%26spage%3D254%26epage%3D258%26doi%3D10.1038%2Fnature13765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanaji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seko, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel S1P2 antagonists. Part 1: Discovery of 1,3-bis(aryloxy)benzene derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1479</span>– <span class="NLM_lpage">1482</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.bmcl.2015.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=25746814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsFCqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1479-1482&author=K.+Kusumiauthor=K.+Shinozakiauthor=T.+Kanajiauthor=H.+Kurataauthor=A.+Naganawaauthor=K.+Otsukiauthor=T.+Matsushitaauthor=T.+Sekiguchiauthor=A.+Kakuuchiauthor=T.+Seko&title=Discovery+of+novel+S1P2+antagonists.+Part+1%3A+Discovery+of+1%2C3-bis%28aryloxy%29benzene+derivatives&doi=10.1016%2Fj.bmcl.2015.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel S1P2 antagonists. Part 1: Discovery of 1,3-bis(aryloxy)benzene derivatives</span></div><div class="casAuthors">Kusumi, Kensuke; Shinozaki, Koji; Kanaji, Toshiya; Kurata, Haruto; Naganawa, Atsushi; Otsuki, Kazuhiro; Matsushita, Takeshi; Sekiguchi, Tetsuya; Kakuuchi, Akito; Seko, Takuya</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1479-1482</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity relationships of a novel series of sphingosine-1-phosphate receptor antagonists have been examd. in detail.  The initial hit compd. 1 was modified through synthesis to improve its S1P2 activity.  The synthesis of a series of analogs revealed that 1,3-bis(aryloxy)benzene derivs., as represented by 22, are potent and selective S1P2 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNuea159OT2rVg90H21EOLACvtfcHk0liOw5jpL_7IQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsFCqsLg%253D&md5=2b2ec854e2f5d0b5716055c874adcc1f</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DKusumi%26aufirst%3DK.%26aulast%3DShinozaki%26aufirst%3DK.%26aulast%3DKanaji%26aufirst%3DT.%26aulast%3DKurata%26aufirst%3DH.%26aulast%3DNaganawa%26aufirst%3DA.%26aulast%3DOtsuki%26aufirst%3DK.%26aulast%3DMatsushita%26aufirst%3DT.%26aulast%3DSekiguchi%26aufirst%3DT.%26aulast%3DKakuuchi%26aufirst%3DA.%26aulast%3DSeko%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520novel%2520S1P2%2520antagonists.%2520Part%25201%253A%2520Discovery%2520of%25201%252C3-bis%2528aryloxy%2529benzene%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1479%26epage%3D1482%26doi%3D10.1016%2Fj.bmcl.2015.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seko, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel S1P2 antagonists. Part 2: Improving the profile of a series of 1,3-bis(aryloxy)benzene derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4387</span>– <span class="NLM_lpage">4392</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.bmcl.2015.09.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=26384288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWku7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4387-4392&author=K.+Kusumiauthor=K.+Shinozakiauthor=Y.+Yamauraauthor=A.+Hashimotoauthor=H.+Kurataauthor=A.+Naganawaauthor=H.+Uedaauthor=K.+Otsukiauthor=T.+Matsushitaauthor=T.+Sekiguchiauthor=A.+Kakuuchiauthor=T.+Seko&title=Discovery+of+novel+S1P2+antagonists.+Part+2%3A+Improving+the+profile+of+a+series+of+1%2C3-bis%28aryloxy%29benzene+derivatives&doi=10.1016%2Fj.bmcl.2015.09.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel S1P2 antagonists. Part 2: Improving the profile of a series of 1,3-bis(aryloxy)benzene derivatives</span></div><div class="casAuthors">Kusumi, Kensuke; Shinozaki, Koji; Yamaura, Yoshiyuki; Hashimoto, Ai; Kurata, Haruto; Naganawa, Atsushi; Ueda, Hideyuki; Otsuki, Kazuhiro; Matsushita, Takeshi; Sekiguchi, Tetsuya; Kakuuchi, Akito; Seko, Takuya</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4387-4392</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The initial lead compd. was modified to improve its metabolic stability.  The resulting compd. showed excellent metabolic stability in rat and human liver microsomes.  The authors subsequently designed and synthesized compd. N-[3-[4-(aminocarbonyl)phenoxy]-5-(4-fluorophenoxy)phenyl]-4-(4-chlorophenyl)-4-hydroxy-1-piperidinecarboxamide (I), which showed improved S1P2 antagonist activity and good metabolic stability.  The subsequent introduction of a carboxylic acid moiety into I resulted in 4-[3-(4-fluorophenoxy)-5-[[[4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]carbonyl]amino]phenoxy]benzoic acid (II), which showed potent antagonist activity towards S1P2 with a much smaller species difference between human S1P2 and rat S1P2.  Compd. II also showed good metabolic stability and an improved safety profile compared with compd. I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV9GPuG8l-2bVg90H21EOLACvtfcHk0liOw5jpL_7IQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWku7vO&md5=c70cd9c405bacbca0c5efe02502c51c7</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.022%26sid%3Dliteratum%253Aachs%26aulast%3DKusumi%26aufirst%3DK.%26aulast%3DShinozaki%26aufirst%3DK.%26aulast%3DYamaura%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DKurata%26aufirst%3DH.%26aulast%3DNaganawa%26aufirst%3DA.%26aulast%3DUeda%26aufirst%3DH.%26aulast%3DOtsuki%26aufirst%3DK.%26aulast%3DMatsushita%26aufirst%3DT.%26aulast%3DSekiguchi%26aufirst%3DT.%26aulast%3DKakuuchi%26aufirst%3DA.%26aulast%3DSeko%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520novel%2520S1P2%2520antagonists.%2520Part%25202%253A%2520Improving%2520the%2520profile%2520of%2520a%2520series%2520of%25201%252C3-bis%2528aryloxy%2529benzene%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4387%26epage%3D4392%26doi%3D10.1016%2Fj.bmcl.2015.09.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seko, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel S1P2 antagonists. Part 3: Improving the oral bioavailability of a series of 1,3-bis(aryloxy)benzene derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1209</span>– <span class="NLM_lpage">1213</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.01.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.bmcl.2016.01.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=26794040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1elurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1209-1213&author=K.+Kusumiauthor=K.+Shinozakiauthor=Y.+Yamauraauthor=A.+Hashimotoauthor=H.+Kurataauthor=A.+Naganawaauthor=K.+Otsukiauthor=T.+Matsushitaauthor=T.+Sekiguchiauthor=A.+Kakuuchiauthor=H.+Yamamotoauthor=T.+Seko&title=Discovery+of+novel+S1P2+antagonists.+Part+3%3A+Improving+the+oral+bioavailability+of+a+series+of+1%2C3-bis%28aryloxy%29benzene+derivatives&doi=10.1016%2Fj.bmcl.2016.01.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel S1P2 antagonists, part 3: Improving the oral bioavailability of a series of 1,3-bis(aryloxy)benzene derivatives</span></div><div class="casAuthors">Kusumi, Kensuke; Shinozaki, Koji; Yamaura, Yoshiyuki; Hashimoto, Ai; Kurata, Haruto; Naganawa, Atsushi; Otsuki, Kazuhiro; Matsushita, Takeshi; Sekiguchi, Tetsuya; Kakuuchi, Akito; Yamamoto, Hiroshi; Seko, Takuya</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1209-1213</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure of the S1P2 antagonist 1 has been modified with the aim of improving its oral bioavailability.  The chem. modification of the alkyl chain and carboxylic acid moieties of 1 led to significant improvements in the oral exposure of compds. belonging to this series.  The optimization of the ring size of the urea portion of these mols. also led to remarkable improvements in the oral exposure.  Based on these changes, the pyrrolidine deriv. I was identified as a suitable candidate compd. and showed excellent pharmacokinetic profiles in rat and dog, while maintaining high levels of potency and selective antagonistic activity toward S1P2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW5Oh4Cs44RLVg90H21EOLACvtfcHk0lgLMX-STZDOmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1elurs%253D&md5=afaf3444a370c35cd6ec6301850bc90a</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.01.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.01.031%26sid%3Dliteratum%253Aachs%26aulast%3DKusumi%26aufirst%3DK.%26aulast%3DShinozaki%26aufirst%3DK.%26aulast%3DYamaura%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DKurata%26aufirst%3DH.%26aulast%3DNaganawa%26aufirst%3DA.%26aulast%3DOtsuki%26aufirst%3DK.%26aulast%3DMatsushita%26aufirst%3DT.%26aulast%3DSekiguchi%26aufirst%3DT.%26aulast%3DKakuuchi%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DSeko%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520novel%2520S1P2%2520antagonists.%2520Part%25203%253A%2520Improving%2520the%2520oral%2520bioavailability%2520of%2520a%2520series%2520of%25201%252C3-bis%2528aryloxy%2529benzene%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1209%26epage%3D1213%26doi%3D10.1016%2Fj.bmcl.2016.01.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiendl, H.</span></span> <span> </span><span class="NLM_article-title">Benefit–risk profile of sphingosine-1-phosphate receptor modulators in relapsing and secondary progressive multiple sclerosis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1755</span>– <span class="NLM_lpage">1768</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0814-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1007%2Fs40265-017-0814-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=28905255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyqs7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1755-1768&author=G.+Comiauthor=H.+P.+Hartungauthor=R.+Bakshiauthor=I.+M.+Williamsauthor=H.+Wiendl&title=Benefit%E2%80%93risk+profile+of+sphingosine-1-phosphate+receptor+modulators+in+relapsing+and+secondary+progressive+multiple+sclerosis&doi=10.1007%2Fs40265-017-0814-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis</span></div><div class="casAuthors">Comi, Giancarlo; Hartung, Hans-Peter; Bakshi, Rajesh; Williams, Ian M.; Wiendl, Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1755-1768</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Since the approval of fingolimod, several selective sphingosine-1-phosphate receptor modulators have entered clin. development for multiple sclerosis.  However, side effects can occur with sphingosine-1-phosphate receptor modulators.  By considering short-term data across the drug class and longer term fingolimod data, we aim to highlight the potential of sphingosine-1-phosphate receptor modulators in multiple sclerosis, while offering reassurance that their benefit-risk profiles are suitable for long-term therapy.  Short-term fingolimod studies demonstrated the efficacy of this drug class, showed that cardiac events upon first-dose administration are transient and manageable, and showed that serious adverse events are rare.  Early-phase studies of selective sphingosine-1-phosphate receptor modulators also show efficacy with a similar or improved safety profile, and treatment initiation effects were reduced with dose titrn.  Longer term fingolimod studies demonstrated sustained efficacy and raised no new safety concerns, with no increases in macular edema, infection, or malignancy rates.  Switch studies identified no safety concerns and greater patient satisfaction and persistence with fingolimod when switching from injectable therapies with no washout period.  Better outcomes were seen with short than with long washouts when switching from natalizumab.  The specific immunomodulatory effects of sphingosine-1-phosphate receptor modulators are consistent with the low obsd. rates of long-term, drug-related adverse effects with fingolimod.  Short-term data for selective sphingosine-1-phosphate receptor modulators support their potential effectiveness in multiple sclerosis, and improved side-effect profiles may widen patient access to this drug class.  The long-term safety, tolerability, and persistence profiles of fingolimod should reassure clinicians that sphingosine-1-phosphate receptor modulators are likely to be suitable for the long-term treatment of multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Qwfw8DUoKbVg90H21EOLACvtfcHk0lgLMX-STZDOmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyqs7vM&md5=751d178461b15286f460a8fe8f4dedae</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0814-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0814-1%26sid%3Dliteratum%253Aachs%26aulast%3DComi%26aufirst%3DG.%26aulast%3DHartung%26aufirst%3DH.%2BP.%26aulast%3DBakshi%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DI.%2BM.%26aulast%3DWiendl%26aufirst%3DH.%26atitle%3DBenefit%25E2%2580%2593risk%2520profile%2520of%2520sphingosine-1-phosphate%2520receptor%2520modulators%2520in%2520relapsing%2520and%2520secondary%2520progressive%2520multiple%2520sclerosis%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1755%26epage%3D1768%26doi%3D10.1007%2Fs40265-017-0814-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span>; <span class="NLM_string-name">Ozawa, K.</span>; <span class="NLM_string-name">Yamamoto, K.</span></span> <span> </span><span class="NLM_article-title">Preparation of pyrazolopyridine compounds and use thereof as remedies for fibrosis</span>. <span class="NLM_patent">WO 2001098301A1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=H.+Kawasaki&author=K.+Ozawa&author=K.+Yamamoto&title=Preparation+of+pyrazolopyridine+compounds+and+use+thereof+as+remedies+for+fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKawasaki%26aufirst%3DH.%26atitle%3DPreparation%2520of%2520pyrazolopyridine%2520compounds%2520and%2520use%2520thereof%2520as%2520remedies%2520for%2520fibrosis%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. J.</span></span> <span> </span><span class="NLM_article-title">Bicyclic compounds for treatment of inflammatory or allergic conditions and their preparation</span>. <span class="NLM_patent">WO2008107436A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+J.+Taylor&title=Bicyclic+compounds+for+treatment+of+inflammatory+or+allergic+conditions+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26atitle%3DBicyclic%2520compounds%2520for%2520treatment%2520of%2520inflammatory%2520or%2520allergic%2520conditions%2520and%2520their%2520preparation%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, A.</span>; <span class="NLM_string-name">Kusumi, K.</span>; <span class="NLM_string-name">Otsuki, K.</span>; <span class="NLM_string-name">Sekiguchi, T.</span>; <span class="NLM_string-name">Kakuuchi, A.</span>; <span class="NLM_string-name">Shinozaki, K.</span>; <span class="NLM_string-name">Yamamoto, H.</span>; <span class="NLM_string-name">Nonaka, S.</span></span> <span> </span><span class="NLM_article-title">Preparation of phenyl derivatives as S1P2 receptor antagonists</span>. <span class="NLM_patent">WO 2013047701A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+Naganawa&author=K.+Kusumi&author=K.+Otsuki&author=T.+Sekiguchi&author=A.+Kakuuchi&author=K.+Shinozaki&author=H.+Yamamoto&author=S.+Nonaka&title=Preparation+of+phenyl+derivatives+as+S1P2+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNaganawa%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520phenyl%2520derivatives%2520as%2520S1P2%2520receptor%2520antagonists%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span>; <span class="NLM_string-name">Jilishitz, I.</span>; <span class="NLM_string-name">Meinke, P.</span>; <span class="NLM_string-name">Stamford, A.</span>; <span class="NLM_string-name">Foley, M.</span>; <span class="NLM_string-name">Sato, A.</span>; <span class="NLM_string-name">Wada, Y.</span>; <span class="NLM_string-name">Fukase, Y.</span>; <span class="NLM_string-name">Asato Kina, A.</span>; <span class="NLM_string-name">Takahagi, H.</span>; <span class="NLM_string-name">Igawa, H.</span>; <span class="NLM_string-name">Polvino, W. J.</span></span> <span> </span><span class="NLM_article-title">Pyridinone- and pyridazinone-based compounds and medical uses thereof</span>. <span class="NLM_patent">WO2019173790A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=T.+Hla&author=I.+Jilishitz&author=P.+Meinke&author=A.+Stamford&author=M.+Foley&author=A.+Sato&author=Y.+Wada&author=Y.+Fukase&author=A.+Asato+Kina&author=H.+Takahagi&author=H.+Igawa&author=W.+J.+Polvino&title=Pyridinone-+and+pyridazinone-based+compounds+and+medical+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHla%26aufirst%3DT.%26atitle%3DPyridinone-%2520and%2520pyridazinone-based%2520compounds%2520and%2520medical%2520uses%2520thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saldana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayanan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schürer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhhatarai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span> <span> </span><span class="NLM_article-title">A sphingosine 1-phosphate receptor 2 selective allosteric agonist</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5373</span>– <span class="NLM_lpage">5382</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.bmc.2013.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=23849205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVyju7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=5373-5382&author=H.+Satsuauthor=M.+T.+Schaefferauthor=M.+Guerreroauthor=A.+Saldanaauthor=C.+Eberhartauthor=P.+Hodderauthor=C.+Cayananauthor=S.+Sch%C3%BCrerauthor=B.+Bhhataraiauthor=E.+Robertsauthor=H.+Rosenauthor=S.+J.+Brown&title=A+sphingosine+1-phosphate+receptor+2+selective+allosteric+agonist&doi=10.1016%2Fj.bmc.2013.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A sphingosine 1-phosphate receptor 2 selective allosteric agonist</span></div><div class="casAuthors">Satsu, Hideo; Schaeffer, Marie-Therese; Guerrero, Miguel; Saldana, Adrian; Eberhart, Christina; Hodder, Peter; Cayanan, Charmagne; Schurer, Stephan; Bhhatarai, Barun; Roberts, Ed; Rosen, Hugh; Brown, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5373-5382</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mol. probe tool compds. for the sphingosine 1-phosphate receptor 2 (S1PR2) are important for investigating the multiple biol. processes in which the S1PR2 receptor has been implicated.  Amongst these are NF-κB-mediated tumor cell survival and fibroblast chemotaxis to fibronectin.  Identified are selective chem. probes for S1PR2 and their characterization.  High throughput screening is used to identify two compds. which activate the S1PR2 receptor.  SAR optimization led to compds. with high nanomolar potency.  These compds., XAX-162 and CYM-5520, are highly selective and do not activate other S1P receptors.  Binding of CYM-5520 is not competitive with the antagonist JTE-013.  Mutation of receptor residues responsible for binding to the zwitterionic headgroup of sphingosine 1-phosphate (S1P) abolishes S1P activation of the receptor, but not activation by CYM-5520.  Competitive binding expts. with radiolabeled S1P demonstrate that CYM-5520 is an allosteric agonist and does not displace the native ligand.  Computational modeling suggests that CYM-5520 binds lower in the orthosteric binding pocket, and that co-binding with S1P is energetically well tolerated.  In summary, we have prepd. and identified an allosteric S1PR2 selective agonist compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYMrwZEQm6erVg90H21EOLACvtfcHk0ljbRGj9d4JACw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVyju7rE&md5=7e7c0cc3d53d30b4330fca2458d7c4fa</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DSatsu%26aufirst%3DH.%26aulast%3DSchaeffer%26aufirst%3DM.%2BT.%26aulast%3DGuerrero%26aufirst%3DM.%26aulast%3DSaldana%26aufirst%3DA.%26aulast%3DEberhart%26aufirst%3DC.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DCayanan%26aufirst%3DC.%26aulast%3DSch%25C3%25BCrer%26aufirst%3DS.%26aulast%3DBhhatarai%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DE.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26atitle%3DA%2520sphingosine%25201-phosphate%2520receptor%25202%2520selective%2520allosteric%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D5373%26epage%3D5382%26doi%3D10.1016%2Fj.bmc.2013.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><a href="https://www.simulations-plus.com/" class="extLink">https://www.simulations-plus.com/</a> (accessed Nov 22, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.simulations-plus.com%2F+%28accessed+Nov+22%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+further+insights+by+examining+carbo-+and+hetero-aromatic+and+-aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0lh66-0RwkwSCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520-aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tafazoli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashregi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, P. J.</span></span> <span> </span><span class="NLM_article-title">Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>229</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2008.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.taap.2008.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=18295292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslWrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=2008&pages=94-101&author=S.+Tafazoliauthor=M.+Mashregiauthor=P.+J.+O%E2%80%99Brien&title=Role+of+hydrazine+in+isoniazid-induced+hepatotoxicity+in+a+hepatocyte+inflammation+model&doi=10.1016%2Fj.taap.2008.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model</span></div><div class="casAuthors">Tafazoli, Shahrzad; Mashregi, Mariam; O'Brien, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-101</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Isoniazid is an anti-tuberculosis drug that can cause hepatotoxicity in 20% of patients that is usually assocd. with an inflammatory response.  Hepatocytes when exposed to non-toxic levels of H2O2, to simulate H2O2 formation by inflammatory cells, became twice as sensitive to isoniazid toxicity.  Isoniazid cytotoxicity was prevented by 1-aminobenzotriazole, a non-selective P 450 inhibitor or by bis-p-nitrophenyl phosphate (BNPP), an esterase inhibitor.  Moreover, the cytotoxicity of hydrazine, the metabolite formed by amidase-catalyzed hydrolysis of isoniazid, was increased 16-fold by a non-toxic H2O2-generating system.  The acetylhydrazine metabolite was much less cytotoxic than hydrazine in this hepatocyte inflammation model.  Hydrazine, therefore, seems to be the isoniazid reactive metabolite in this inflammation model.  The mol. mechanism of hydrazine-induced cytotoxicity was attributed to oxidative stress as reactive oxygen species (ROS) and protein carbonyl formation occurred before the onset of hepatocyte toxicity.  Hydrazine toxicity also involved significant prodn. of endogenous H2O2 which resulted in lysosomal membrane damage and leads to a collapse in mitochondrial membrane potential.  These results implicated H2O2, a cellular mediator of inflammation, as a potential risk factor for the manifestation of adverse drug reactions, particularly those caused by hydrazine contg. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbxswcqxbg_bVg90H21EOLACvtfcHk0lh66-0RwkwSCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslWrtbo%253D&md5=36cba43b6cc79f28540a3802a7d0ab44</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2008.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2008.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DTafazoli%26aufirst%3DS.%26aulast%3DMashregi%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DP.%2BJ.%26atitle%3DRole%2520of%2520hydrazine%2520in%2520isoniazid-induced%2520hepatotoxicity%2520in%2520a%2520hepatocyte%2520inflammation%2520model%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2008%26volume%3D229%26spage%3D94%26epage%3D101%26doi%3D10.1016%2Fj.taap.2008.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Waeber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomone, S.</span></span> <span> </span><span class="NLM_article-title">Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=21779246" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=1-8&author=C.+Waeberauthor=S.+Salomone&title=Selectivity+and+specificity+of+sphingosine-1-phosphate+receptor+ligands%3A+caveats+and+critical+thinking+in+characterizing+receptor-mediated+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWaeber%26aufirst%3DC.%26aulast%3DSalomone%26aufirst%3DS.%26atitle%3DSelectivity%2520and%2520specificity%2520of%2520sphingosine-1-phosphate%2520receptor%2520ligands%253A%2520caveats%2520and%2520critical%2520thinking%2520in%2520characterizing%2520receptor-mediated%2520effects%26jtitle%3DFront.%2520Pharmacol.%26date%3D2011%26volume%3D2%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strong, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicol, G. D.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate receptor 2 antagonist JTE-013 increases the excitability of sensory neurons independently of the receptor</span>. <i>J. Neurophysiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">1473</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1152/jn.00825.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1152%2Fjn.00825.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=22673325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1SqsbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2012&pages=1473-1483&author=C.+Liauthor=X.+X.+Chiauthor=W.+Xieauthor=J.+A.+Strongauthor=J.+M.+Zhangauthor=G.+D.+Nicol&title=Sphingosine+1-phosphate+receptor+2+antagonist+JTE-013+increases+the+excitability+of+sensory+neurons+independently+of+the+receptor&doi=10.1152%2Fjn.00825.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate receptor 2 antagonist JTE-013 increases the excitability of sensory neurons independently of the receptor</span></div><div class="casAuthors">Li, Chao; Chi, Xian Xuan; Xie, Wenrui; Strong, J. A.; Zhang, J.-M.; Nicol, G. D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurophysiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1473-1483</span>CODEN:
                <span class="NLM_cas:coden">JONEA4</span>;
        ISSN:<span class="NLM_cas:issn">0022-3077</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Previously we demonstrated that sphingosine 1-phosphate receptor 1 (S1PR1) played a prominent, but not exclusive, role in enhancing the excitability of small-diam. sensory neurons, suggesting that other S1PRs can modulate neuronal excitability.  To examine the potential role of S1PR2 in regulating neuronal excitability we used the established selective antagonist of S1PR2, JTE-013.  Here we report that exposure to JTE-013 alone produced a significant increase in excitability in a time- and concn.-dependent manner in 70-80% of recorded neurons.  Internal perfusion of sensory neurons with guanosine 5'-O-(2-thiodiphosphate) (GDP-β-S) via the recording pipet inhibited the sensitization produced by JTE-013 as well as prostaglandin E2.  Pretreatment with pertussis toxin or the selective S1PR1 antagonist W146 blocked the sensitization produced by JTE-013.  These results indicate that JTE-013 might act as an agonist at other G protein-coupled receptors.  In neurons that were sensitized by JTE-013, single-cell RT-PCR studies demonstrated that these neurons did not express the mRNA for S1PR2.  In behavioral studies, injection of JTE-013 into the rat's hindpaw produced a significant increase in the mech. sensitivity in the ipsilateral, but not contralateral, paw.  Injection of JTE-013 did not affect the withdrawal latency to thermal stimulation.  Thus JTE-013 augments neuronal excitability independently of S1PR2 by unknown mechanisms that may involve activation of other G protein-coupled receptors such as S1PR1.  Clearly, further studies are warranted to establish the causal nature of this increased sensitivity, and future studies of neuronal function using JTE-013 should be interpreted with caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGripYsWX5bbprVg90H21EOLACvtfcHk0lid3o8OKsVJLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1SqsbnM&md5=416a3775302d00f061b6baff94db2bce</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1152%2Fjn.00825.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fjn.00825.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DChi%26aufirst%3DX.%2BX.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DStrong%26aufirst%3DJ.%2BA.%26aulast%3DZhang%26aufirst%3DJ.%2BM.%26aulast%3DNicol%26aufirst%3DG.%2BD.%26atitle%3DSphingosine%25201-phosphate%2520receptor%25202%2520antagonist%2520JTE-013%2520increases%2520the%2520excitability%2520of%2520sensory%2520neurons%2520independently%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Neurophysiol.%26date%3D2012%26volume%3D108%26spage%3D1473%26epage%3D1483%26doi%3D10.1152%2Fjn.00825.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W. K.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Corpuz, E.G.</span>; <span class="NLM_string-name">Chow, K.</span>; <span class="NLM_string-name">Im, Wha B.</span></span> <span> </span><span class="NLM_article-title">Preparation of condensed pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors</span>. <span class="NLM_patent">WO2011041287A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=W.+K.+Fang&author=L.+Wang&author=E.G.+Corpuz&author=K.+Chow&author=Wha+B.+Im&title=Preparation+of+condensed+pyridine+compounds+as+subtype-selective+modulators+of+sphingosine-1-phosphate-2+%28S1P2%29+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DW.%2BK.%26atitle%3DPreparation%2520of%2520condensed%2520pyridine%2520compounds%2520as%2520subtype-selective%2520modulators%2520of%2520sphingosine-1-phosphate-2%2520%2528S1P2%2529%2520receptors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, R. E.</span></span> <span> </span><span class="NLM_article-title">Preparation of novel N-(pyrazolopyridinylamino) ureas as sphingosine 1-phosphate receptor antagonists</span>. <span class="NLM_patent">WO2013148460A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+E.+Swenson&title=Preparation+of+novel+N-%28pyrazolopyridinylamino%29+ureas+as+sphingosine+1-phosphate+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSwenson%26aufirst%3DR.%2BE.%26atitle%3DPreparation%2520of%2520novel%2520N-%2528pyrazolopyridinylamino%2529%2520ureas%2520as%2520sphingosine%25201-phosphate%2520receptor%2520antagonists%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, R. E.</span>; <span class="NLM_string-name">Raju, N.</span>; <span class="NLM_string-name">Estrella-Jimenez, M. E.</span>; <span class="NLM_string-name">Ramalingam, K.</span></span> <span> </span><span class="NLM_article-title">Preparation of pyrazolopyridine derivatives for use as S1P2 and SIP5 receptor modulators</span>. <span class="NLM_patent">WO2011159864A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=R.+E.+Swenson&author=N.+Raju&author=M.+E.+Estrella-Jimenez&author=K.+Ramalingam&title=Preparation+of+pyrazolopyridine+derivatives+for+use+as+S1P2+and+SIP5+receptor+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSwenson%26aufirst%3DR.%2BE.%26atitle%3DPreparation%2520of%2520pyrazolopyridine%2520derivatives%2520for%2520use%2520as%2520S1P2%2520and%2520SIP5%2520receptor%2520modulators%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx-Lafrance, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helal, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleiman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menniti, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, S.</span></span> <span> </span><span class="NLM_article-title">Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7946</span>– <span class="NLM_lpage">7949</span>, <span class="refDoi"> DOI: 10.1021/jm9015334</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9015334" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsValtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7946-7949&author=P.+R.+Verhoestauthor=C.+Proulx-Lafranceauthor=M.+Cormanauthor=L.+Chenardauthor=C.+J.+Helalauthor=X.+Houauthor=R.+Kleimanauthor=S.+Liuauthor=E.+Marrauthor=F.+S.+Mennitiauthor=C.+J.+Schmidtauthor=M.+Vanase-Frawleyauthor=A.+W.+Schmidtauthor=R.+D.+Williamsauthor=F.+R.+Nelsonauthor=K.+R.+Fonsecaauthor=S.+Liras&title=Identification+of+a+brain+penetrant+PDE9A+inhibitor+utilizing+prospective+design+and+chemical+enablement+as+a+rapid+lead+optimization+strategy&doi=10.1021%2Fjm9015334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Brain Penetrant PDE9A Inhibitor Utilizing Prospective Design and Chemical Enablement as a Rapid Lead Optimization Strategy</span></div><div class="casAuthors">Verhoest, Patrick R.; Proulx-Lafrance, Caroline; Corman, Michael; Chenard, Lois; Helal, Christopher J.; Hou, Xinjun; Kleiman, Robin; Liu, Shenping; Marr, Eric; Menniti, Frank S.; Schmidt, Christopher J.; Vanase-Frawley, Michelle; Schmidt, Anne W.; Williams, Robert D.; Nelson, Frederick R.; Fonseca, Kari R.; Liras, Spiros</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7946-7949</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of selective, brain penetrant PDE9A inhibitors I (R1 = i-Pr, i-Bu, cyclopentyl, R2 = Ph; R1 = cyclopentyl, R2 = 3-MeC6H4, 2-pyridyl, 6-quinoxalinyl, etc.) has been identified that are capable of producing in vivo elevations of brain cGMP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou_Q49qDJV3bVg90H21EOLACvtfcHk0lid3o8OKsVJLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsValtbzI&md5=4e1a67684031737596a83d1feb4bee08</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm9015334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9015334%26sid%3Dliteratum%253Aachs%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DProulx-Lafrance%26aufirst%3DC.%26aulast%3DCorman%26aufirst%3DM.%26aulast%3DChenard%26aufirst%3DL.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DKleiman%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMarr%26aufirst%3DE.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26aulast%3DVanase-Frawley%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DWilliams%26aufirst%3DR.%2BD.%26aulast%3DNelson%26aufirst%3DF.%2BR.%26aulast%3DFonseca%26aufirst%3DK.%2BR.%26aulast%3DLiras%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520a%2520brain%2520penetrant%2520PDE9A%2520inhibitor%2520utilizing%2520prospective%2520design%2520and%2520chemical%2520enablement%2520as%2520a%2520rapid%2520lead%2520optimization%2520strategy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7946%26epage%3D7949%26doi%3D10.1021%2Fjm9015334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. J.</span></span> <span> </span><span class="NLM_article-title">Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2007.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.tips.2007.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=17629959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlWltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=374-381&author=J.+G.+Bakerauthor=S.+J.+Hill&title=Multiple+GPCR+conformations+and+signalling+pathways%3A+implications+for+antagonist+affinity+estimates&doi=10.1016%2Fj.tips.2007.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple GPCR conformations and signaling pathways: implications for antagonist affinity estimates</span></div><div class="casAuthors">Baker, Jillian G.; Hill, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">374-381</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Antagonist affinity measurements have traditionally been considered important in characterizing the cell-surface receptors present in a particular cell or tissue.  A central assumption has been that antagonist affinity is const. for a given receptor-antagonist interaction, regardless of the agonist used to stimulate that receptor or the downstream response that is measured.  As a consequence, changes in antagonist affinity values have been taken as initial evidence for the presence of novel receptor subtypes.  Emerging evidence suggests, however, that receptors can possess multiple binding sites and the same receptor can show different antagonist affinity measurements under distinct exptl. conditions.  Here, we discuss several mechanisms by which antagonists have different affinities for the same receptor as a consequence of allosterism, coupling to different G proteins, multiple (but non-interacting) receptor sites, and signal-pathway-dependent pharmacol. (where the pharmacol. obsd. varies depending on the signaling pathway measured).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcWqdG7J1LyLVg90H21EOLACvtfcHk0ljiNhmYG0aBJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlWltLo%253D&md5=ac0bbf5922dd08316f502a3e981b2444</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26aulast%3DHill%26aufirst%3DS.%2BJ.%26atitle%3DMultiple%2520GPCR%2520conformations%2520and%2520signalling%2520pathways%253A%2520implications%2520for%2520antagonist%2520affinity%2520estimates%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D374%26epage%3D381%26doi%3D10.1016%2Fj.tips.2007.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipophilic efficiency as an important metric in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6401</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6401-6420&author=T.+W.+Johnsonauthor=R.+A.+Gallegoauthor=M.+P.+Edwards&title=Lipophilic+efficiency+as+an+important+metric+in+drug+design&doi=10.1021%2Facs.jmedchem.8b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Efficiency as an Important Metric in Drug Design</span></div><div class="casAuthors">Johnson, Ted W.; Gallego, Rebecca A.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6401-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chem. lead optimization programs.  In this perspective, using literature drug discovery examples, we discuss the concept of rigorously applying LipE to guide medicinal chem. lead optimization toward drug candidates with potential for superior in vivo efficacy and safety, esp. when guided by physiochem. property-based optimization (PPBO).  Also highlighted are examples of small structural modifications such as addn. of single atoms, small functional groups, and cyclizations that produce large increases in LipE.  Understanding the factors that may contribute to LipE changes through anal. of ligand-protein crystal structures and using structure-based drug design (SBDD) to increase LipE by design is also discussed.  Herein we advocate for use of LipE anal. coupled with PPBO and SBDD as an efficient mechanism for drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ8DOcOj6GrVg90H21EOLACvtfcHk0ljiNhmYG0aBJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D&md5=29f38880914fa75c33be3a640ace4309</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DGallego%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DLipophilic%2520efficiency%2520as%2520an%2520important%2520metric%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6401%26epage%3D6420%26doi%3D10.1021%2Facs.jmedchem.8b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">and references therein.</p></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keane, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arenberg, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. P.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whyte, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannettoni, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilke, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiGiovine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strieter, R. M.</span></span> <span> </span><span class="NLM_article-title">The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">1437</span>– <span class="NLM_lpage">1443</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=9233641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADyaK2sXkslKku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=1997&pages=1437-1443&author=M.+P.+Keaneauthor=D.+A.+Arenbergauthor=J.+P.+Lynchauthor=R.+I.+Whyteauthor=M.+D.+Iannettoniauthor=M.+D.+Burdickauthor=C.+A.+Wilkeauthor=S.+B.+Morrisauthor=M.+C.+Glassauthor=B.+DiGiovineauthor=S.+L.+Kunkelauthor=R.+M.+Strieter&title=The+CXC+chemokines%2C+IL-8+and+IP-10%2C+regulate+angiogenic+activity+in+idiopathic+pulmonary+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Keane, Michael P.; Arenberg, Douglas A.; Lynch, Joseph P., III; Whyte, Richard I.; Iannettoni, Mark D.; Burdick, Marie D.; Wilke, Carol A.; Morris, Susan B.; Glass, Mary C.; DiGiovine, Bruno; Kunkel, Steven L.; Strieter, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1437-1443</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic and often fatal disorder.  Fibroplasia and deposition of extracellular matrix are dependent, in part, on angiogenesis.  The authors postulated that an imbalance exists in the expression of angiogenic (IL-8) vs. angiostatic (IFN-γ-inducible protein (IP-10)) CXC chemokines, which favors net angiogenesis in IPF.  To test this hypothesis, the authors obtained open lung biopsies either from normal patients undergoing thoracic surgery for reasons other than interstitial lung disease (control) or from patients with IPF.  The authors found that levels of IL-8 were greater from tissue specimens of IPF patients than from those of controls.  In contrast, IP-10 levels were higher from tissue specimens obtained from controls subjects than from those from IPF patients.  When IL-8 or IP-10 was depleted from IPF tissue specimens, tissue-derived angiogenic activity was markedly reduced or enhanced, resp.  Immunolocalization of IL-8 demonstrated that the pulmonary fibroblast (PF) of IPF lung was the predominant cellular source of IL-8.  Isolated PF from IPF patients constitutively produced more IL-8 and less IP-10 than control PF.  Conditioned media from IPF-PFs demonstrated constitutive angiogenic activity that was attributable, in part, to IL-8.  Depletion of IP-10 from IPF-PF CM resulted in an increase in corneal neovascularization.  These findings support the notion that IL-8 and IP-10 are important factors that regulate angiogenic activity in IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU_H7j5ISw0rVg90H21EOLACvtfcHk0ljlgbl3k1TxRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkslKku7k%253D&md5=47af62036e3dd1fe772af51362c462fb</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeane%26aufirst%3DM.%2BP.%26aulast%3DArenberg%26aufirst%3DD.%2BA.%26aulast%3DLynch%26aufirst%3DJ.%2BP.%26aulast%3DWhyte%26aufirst%3DR.%2BI.%26aulast%3DIannettoni%26aufirst%3DM.%2BD.%26aulast%3DBurdick%26aufirst%3DM.%2BD.%26aulast%3DWilke%26aufirst%3DC.%2BA.%26aulast%3DMorris%26aufirst%3DS.%2BB.%26aulast%3DGlass%26aufirst%3DM.%2BC.%26aulast%3DDiGiovine%26aufirst%3DB.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26atitle%3DThe%2520CXC%2520chemokines%252C%2520IL-8%2520and%2520IP-10%252C%2520regulate%2520angiogenic%2520activity%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Immunol.%26date%3D1997%26volume%3D159%26spage%3D1437%26epage%3D1443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. G.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate (S1P) induced interleukin-8 (IL-8) release is mediated by S1P receptor 2 and nuclear factor κB in BEAS-2B cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e95566</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0095566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1371%2Fjournal.pone.0095566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=24743449" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=M.+J.+O%E2%80%99Sullivanauthor=N.+Hirotaauthor=J.+G.+Martin&title=Sphingosine+1-phosphate+%28S1P%29+induced+interleukin-8+%28IL-8%29+release+is+mediated+by+S1P+receptor+2+and+nuclear+factor+%CE%BAB+in+BEAS-2B+cells&doi=10.1371%2Fjournal.pone.0095566"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0095566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0095566%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DM.%2BJ.%26aulast%3DHirota%26aufirst%3DN.%26aulast%3DMartin%26aufirst%3DJ.%2BG.%26atitle%3DSphingosine%25201-phosphate%2520%2528S1P%2529%2520induced%2520interleukin-8%2520%2528IL-8%2529%2520release%2520is%2520mediated%2520by%2520S1P%2520receptor%25202%2520and%2520nuclear%2520factor%2520%25CE%25BAB%2520in%2520BEAS-2B%2520cells%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0095566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E. C. A.</span></span> <span> </span><span class="NLM_article-title">Rational use of plasma protein and tissue binding data in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8238</span>– <span class="NLM_lpage">8248</span>, <span class="refDoi"> DOI: 10.1021/jm5007935</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5007935" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8238-8248&author=X.+Liuauthor=M.+Wrightauthor=C.+E.+C.+A.+Hop&title=Rational+use+of+plasma+protein+and+tissue+binding+data+in+drug+design&doi=10.1021%2Fjm5007935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Use of Plasma Protein and Tissue Binding Data in Drug Design</span></div><div class="casAuthors">Liu, Xingrong; Wright, Matthew; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8238-8248</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is a commonly accepted assumption that only unbound drug mols. are available to interact with their targets.  Therefore, one of the objectives in drug design is to optimize the compd. structure to increase in vivo unbound drug concn.  In this review, theor. analyses and exptl. observations are presented to illustrate that low plasma protein binding does not necessarily lead to high in vivo unbound plasma concn.  Similarly, low brain tissue binding does not lead to high in vivo unbound brain tissue concn.  Instead, low intrinsic clearance leads to high in vivo unbound plasma concn., and low efflux transport activity at the blood-brain barrier leads to high unbound brain concn.  Plasma protein and brain tissue binding are very important parameters in understanding pharmacokinetics, pharmacodynamics, and toxicities of drugs, but these parameters should not be targeted for optimization in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKiYUz9ljIDrVg90H21EOLACvtfcHk0ljlgbl3k1TxRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M&md5=53ffbdb88ddf500a90a0eee14b0e641f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm5007935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5007935%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26atitle%3DRational%2520use%2520of%2520plasma%2520protein%2520and%2520tissue%2520binding%2520data%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8238%26epage%3D8248%26doi%3D10.1021%2Fjm5007935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustakas, D. T.</span></span> <span> </span><span class="NLM_article-title">The necessary nitrogen atom: a versatile high-impact design element for multiparameter optimization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3552</span>– <span class="NLM_lpage">3579</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01807</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01807" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1yit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3552-3579&author=L.+D.+Penningtonauthor=D.+T.+Moustakas&title=The+necessary+nitrogen+atom%3A+a+versatile+high-impact+design+element+for+multiparameter+optimization&doi=10.1021%2Facs.jmedchem.6b01807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization</span></div><div class="casAuthors">Pennington, Lewis D.; Moustakas, Demetri T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3552-3579</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  There is a continued desire in biomedical research to reduce the no. and duration of design cycles required to optimize lead compds. into high-quality chem. probes or safe and efficacious drug candidates.  The insightful application of impactful mol. design elements is one approach toward achieving this goal.  The replacement of a CH group with a N atom in arom. and heteroarom. ring systems can have many important effects on mol. and physicochem. properties and intra- and intermol. interactions that can translate to improved pharmacol. profiles.  In this Perspective, the "necessary nitrogen atom" is shown to be a versatile high-impact design element for multiparameter optimization, wherein ≥10-, 100-, or 1000-fold improvement in a variety of key pharmacol. parameters can be realized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ZLKZMgt6IbVg90H21EOLACvtfcHk0ljAQmX29wqE3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1yit74%253D&md5=002aaee48995e7954647a1f75183db4d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01807%26sid%3Dliteratum%253Aachs%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMoustakas%26aufirst%3DD.%2BT.%26atitle%3DThe%2520necessary%2520nitrogen%2520atom%253A%2520a%2520versatile%2520high-impact%2520design%2520element%2520for%2520multiparameter%2520optimization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3552%26epage%3D3579%26doi%3D10.1021%2Facs.jmedchem.6b01807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Methyl effects on protein–ligand binding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4489</span>– <span class="NLM_lpage">4500</span>, <span class="refDoi"> DOI: 10.1021/jm3003697</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003697" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4489-4500&author=C.+S.+Leungauthor=S.+S.+F.+Leungauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Methyl+effects+on+protein%E2%80%93ligand+binding&doi=10.1021%2Fjm3003697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Methyl Effects on Protein-Ligand Binding</span></div><div class="casAuthors">Leung, Cheryl S.; Leung, Siegfried S. F.; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4489-4500</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The effects of addn. of a Me group to a lead compd. on biol. activity are examd.  A literature anal. of >2000 cases reveals that an activity boost of a factor of 10 or more is found with an 8% frequency, and a 100-fold boost is a 1 in 200 event.  Four cases in the latter category are analyzed in depth to elucidate any unusual aspects of the protein-ligand binding, distribution of water mols., and changes in conformational energetics.  The analyses include Monte Carlo/free-energy perturbation (MC/FEP) calcns. for Me replacements in inhibitor series for p38α MAP kinase, ACK1, PTP1B, and thrombin.  Me substitutions ortho to an aryl ring can be particularly effective at improving activity by inducing a propitious conformational change.  The greatest improvements in activity arise from coupling the conformational gain with the burial of the Me group in a hydrophobic region of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0Czyhgy6KbVg90H21EOLACvtfcHk0ljAQmX29wqE3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D&md5=0ea58d9c1bf845d383931b6a017f9b37</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm3003697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003697%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.%2BS.%26aulast%3DLeung%26aufirst%3DS.%2BS.%2BF.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DMethyl%2520effects%2520on%2520protein%25E2%2580%2593ligand%2520binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4489%26epage%3D4500%26doi%3D10.1021%2Fjm3003697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mammoliti, O.</span>; <span class="NLM_string-name">Jansen, K.K.</span>; <span class="NLM_string-name">Palisse, A. E.</span>; <span class="NLM_string-name">Joannesse, C. M. A.-M.</span>; <span class="NLM_string-name">Menet, C. J. M.</span>; <span class="NLM_string-name">Allart, B.</span>; <span class="NLM_string-name">El Bkassiny, S.</span></span> <span> </span><span class="NLM_article-title">Preparation of pyridazine derivatives for the prophylaxis and treatment of diseases including fibrosis</span>. <span class="NLM_patent">WO2017148787A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=O.+Mammoliti&author=K.K.+Jansen&author=A.+E.+Palisse&author=C.+M.+A.-M.+Joannesse&author=C.+J.+M.+Menet&author=B.+Allart&author=S.+El+Bkassiny&title=Preparation+of+pyridazine+derivatives+for+the+prophylaxis+and+treatment+of+diseases+including+fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMammoliti%26aufirst%3DO.%26atitle%3DPreparation%2520of%2520pyridazine%2520derivatives%2520for%2520the%2520prophylaxis%2520and%2520treatment%2520of%2520diseases%2520including%2520fibrosis%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ask, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warburton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauldie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, M.</span></span> <span> </span><span class="NLM_article-title">The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2007.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2Fj.biocel.2007.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=17936056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitVentrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=362-382&author=A.+Moellerauthor=K.+Askauthor=D.+Warburtonauthor=J.+Gauldieauthor=M.+Kolb&title=The+bleomycin+animal+model%3A+a+useful+tool+to+investigate+treatment+options+for+idiopathic+pulmonary+fibrosis%3F&doi=10.1016%2Fj.biocel.2007.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?</span></div><div class="casAuthors">Moeller, Antje; Ask, Kjetil; Warburton, David; Gauldie, Jack; Kolb, Martin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">362-382</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Different animal models of pulmonary fibrosis were developed to investigate potential therapies for idiopathic pulmonary fibrosis (IPF).  The most common is the bleomycin model in rodents (mouse, rat and hamster).  Over the years, numerous agents were shown to inhibit fibrosis in this model.  However, to date none of these compds. are used in the clin. management of IPF and none has shown a comparable antifibrotic effect in humans.  We performed a systematic review of publications on drug efficacy studies in the bleomycin model to evaluate the value of this model regarding transferability to clin. use.  Between 1980 and 2006 we identified 240 exptl. studies describing beneficial antifibrotic compds. in the bleomycin model. 222 of those used a preventive regimen (drug given ≤7 days after last bleomycin application), only 13 were therapeutic trials (>7 days after last bleomycin application).  In 5 studies we did not find enough details about the timing of drug application to allow inter-study comparison.  It is crit. to distinguish between drugs interfering with the inflammatory and early fibrogenic response from those preventing progression of fibrosis, the latter likely much more meaningful for clin. application.  All potential antifibrotic compds. should be evaluated in the phase of established fibrosis rather than in the early period of bleomycin-induced inflammation for assessment of its antifibrotic properties.  Further care should be taken in extrapolation of drugs successfully tested in the bleomycin model due to partial reversibility of bleomycin-induced fibrosis over time.  The use of alternative and more robust animal models, which better reflect human IPF, is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO707NgQcoCLVg90H21EOLACvtfcHk0ljMUXEgErLD3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitVentrg%253D&md5=2d9caf63cbe8d6092cdf4b011e46dfce</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2007.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2007.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DMoeller%26aufirst%3DA.%26aulast%3DAsk%26aufirst%3DK.%26aulast%3DWarburton%26aufirst%3DD.%26aulast%3DGauldie%26aufirst%3DJ.%26aulast%3DKolb%26aufirst%3DM.%26atitle%3DThe%2520bleomycin%2520animal%2520model%253A%2520a%2520useful%2520tool%2520to%2520investigate%2520treatment%2520options%2520for%2520idiopathic%2520pulmonary%2520fibrosis%253F%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2008%26volume%3D40%26spage%3D362%26epage%3D382%26doi%3D10.1016%2Fj.biocel.2007.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costabel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glassberg, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kardatzke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancaster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szwarcberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeyre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">du Bois, R. M.</span></span>; <span class="NLM_contrib-group">CAPACITY Study Group</span> <span> </span><span class="NLM_article-title">Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1760</span>– <span class="NLM_lpage">1769</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)60405-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1016%2FS0140-6736%2811%2960405-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=21571362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtl2ktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2011&pages=1760-1769&author=P.+W.+Nobleauthor=C.+Alberaauthor=W.+Z.+Bradfordauthor=U.+Costabelauthor=M.+K.+Glassbergauthor=D.+Kardatzkeauthor=T.+E.+Kingauthor=L.+Lancasterauthor=S.+A.+Sahnauthor=J.+Szwarcbergauthor=D.+Valeyreauthor=R.+M.+du+Boisauthor=CAPACITY+Study+Group&title=Pirfenidone+in+patients+with+idiopathic+pulmonary+fibrosis+%28CAPACITY%29%3A+two+randomised+trials&doi=10.1016%2FS0140-6736%2811%2960405-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials</span></div><div class="casAuthors">Noble, Paul W.; Albera, Carlo; Bradford, Williamson Z.; Costabel, Ulrich; Glassberg, Marilyn K.; Kardatzke, David; King, Talmadge E., Jr.; Lancaster, Lisa; Sahn, Steven A.; Szwarcberg, Javier; Valeyre, Dominique; du Bois, Roland M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9779</span>),
    <span class="NLM_cas:pages">1760-1769</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function.  The CAPACITY program (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis.  In two concurrent trials (004 and 006), patients (aged 40-80 years) with idiopathic pulmonary fibrosis were randomly assigned to oral pirfenidone or placebo for a min. of 72 wk in 110 centers in Australia, Europe, and North America.  In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo.  The randomization code (permuted block design) was computer generated and stratified by region.  All study personnel were masked to treatment group assignment until after final database lock.  Treatments were administered orally, 801 mg or 399 mg three times a day.  The primary endpoint was change in percentage predicted forced vital capacity (FVC) at week 72.  Anal. was by intention to treat.  The studies are registered with ClinicalTrials.gov, nos. NCT00287729 and NCT00287716.  In study 004, 174 of 435 patients were assigned to pirfenidone 2403 mg/day, 87 to pirfenidone 1197 mg/day, and 174 to placebo.  In study 006, 171 of 344 patients were assigned to pirfenidone 2403 mg/day, and 173 to placebo.  All patients in both studies were analyzed.  In study 004, pirfenidone reduced decline in FVC (p = 0.001).  Mean FVC change at week 72 was -8.0% (SD 16.5) in the pirfenidone 2403 mg/day group and -12.4% (18.5) in the placebo group (difference 4.4%, 95% CI 0.7 to 9.1); 35 (20%) of 174 vs. 60 (35%) of 174 patients, resp., had a decline of at least 10%.  A significant treatment effect was noted at all timepoints from week 24 and in an anal. over all study timepoints (p = 0.0007).  Mean change in percentage FVC in the pirfenidone 1197 mg/day group was intermediate to that in the pirfenidone 2403 mg/day and placebo groups.  In study 006, the difference between groups in FVC change at week 72 was not significant (p = 0.501).  Mean change in FVC at week 72 was -9.0% (SD 19.6) in the pirfenidone group and -9.6% (19.1) in the placebo group, and the difference between groups in predicted FVC change at week 72 was not significant (0.6%, -3.5 to 4.7); however, a consistent pirfenidone effect was apparent until week 48 (p = 0.005) and in an anal. of all study timepoints (p = 0.007).  Patients in the pirfenidone 2403 mg/day group had higher incidences of nausea (125 [36%] of 345 vs 60 [17%] of 347), dyspepsia (66 [19%] vs 26 [7%]), vomiting (47 [14%] vs 15 [4%]), anorexia (37 [11%] vs 13 [4%]), photosensitivity (42 [12%] vs 6 [2%]), rash (111 [32%] vs 40 [12%]), and dizziness (63 [18%] vs 35 [10%]) than did those in the placebo group.  Fewer overall deaths (19 [6%] vs 29 [8%]) and fewer deaths related to idiopathic pulmonary fibrosis (12 [3%] vs 25 [7%]) occurred in the pirfenidone 2403 mg/day groups than in the placebo groups.  The data show pirfenidone has a favorable benefit risk profile and represents an appropriate treatment option for patients with idiopathic pulmonary fibrosis.  Funding: InterMune.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKu0rjQ2oNaLVg90H21EOLACvtfcHk0ljMUXEgErLD3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtl2ktrg%253D&md5=b32d8b1f0b3b1f8401d3744fc18c662a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960405-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960405-4%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DAlbera%26aufirst%3DC.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DKardatzke%26aufirst%3DD.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DSahn%26aufirst%3DS.%2BA.%26aulast%3DSzwarcberg%26aufirst%3DJ.%26aulast%3DValeyre%26aufirst%3DD.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26aulast%3D%26atitle%3DPirfenidone%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%2520%2528CAPACITY%2529%253A%2520two%2520randomised%2520trials%26jtitle%3DLancet%26date%3D2011%26volume%3D377%26spage%3D1760%26epage%3D1769%26doi%3D10.1016%2FS0140-6736%2811%2960405-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timbrell, V.</span></span> <span> </span><span class="NLM_article-title">Simple method of estimating severity of pulmonary fibrosis on a numerical scale</span>. <i>J. Clin. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1136/jcp.41.4.467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1136%2Fjcp.41.4.467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=3366935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A280%3ADyaL1c3htlOltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1988&pages=467-470&author=T.+Ashcroftauthor=J.+M.+Simpsonauthor=V.+Timbrell&title=Simple+method+of+estimating+severity+of+pulmonary+fibrosis+on+a+numerical+scale&doi=10.1136%2Fjcp.41.4.467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Simple method of estimating severity of pulmonary fibrosis on a numerical scale</span></div><div class="casAuthors">Ashcroft T; Simpson J M; Timbrell V</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical pathology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">467-70</span>
        ISSN:<span class="NLM_cas:issn">0021-9746</span>.
    </div><div class="casAbstract">A continuous numerical scale for determining the degree of fibrosis in lung specimens was devised for correlation with other pulmonary variables such as lung function tests or mineral burden.  Grading was scored on a scale from 0 to 8, using the average of microscope field scores.  The system allows fibrosis to be measured in small samples of tissue (1 cm) which can provide a detailed description of the changes in a lung, currently not possible with most existing methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5mGFCkDKSIzUE-swuRqsHfW6udTcc2ebZCJyV3Bd8zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c3htlOltg%253D%253D&md5=d1da07e3ba735d309aa78d3955474bfd</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1136%2Fjcp.41.4.467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjcp.41.4.467%26sid%3Dliteratum%253Aachs%26aulast%3DAshcroft%26aufirst%3DT.%26aulast%3DSimpson%26aufirst%3DJ.%2BM.%26aulast%3DTimbrell%26aufirst%3DV.%26atitle%3DSimple%2520method%2520of%2520estimating%2520severity%2520of%2520pulmonary%2520fibrosis%2520on%2520a%2520numerical%2520scale%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D1988%26volume%3D41%26spage%3D467%26epage%3D470%26doi%3D10.1136%2Fjcp.41.4.467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuse, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teramoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuhashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uejima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouchi, Y.</span></span> <span> </span><span class="NLM_article-title">ICAM-1 mediates lung leukocyte recruitment but not pulmonary fibrosis in a murine model of bleomycin-induced lung injury</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1183/09031936.99.13107199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10.1183%2F09031936.99.13107199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=10836326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADyaK1MXhtlymsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1999&pages=71-77&author=T.+Matsuseauthor=S.+Teramotoauthor=H.+Katayamaauthor=E.+Sudoauthor=H.+Ekimotoauthor=H.+Mitsuhashiauthor=Y.+Uejimaauthor=Y.+Fukuchiauthor=Y.+Ouchi&title=ICAM-1+mediates+lung+leukocyte+recruitment+but+not+pulmonary+fibrosis+in+a+murine+model+of+bleomycin-induced+lung+injury&doi=10.1183%2F09031936.99.13107199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">ICAM-1 mediates lung leukocyte recruitment but not pulmonary fibrosis in a murine model of bleomycin-induced lung injury</span></div><div class="casAuthors">Matsuse, T.; Teramoto, S.; Katayama, H.; Sudo, E.; Ekimoto, H.; Mitsuhashi, H.; Uejima, Y.; Fukuchi, Y.; Ouchi, Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-77</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">Bleomycin-induced lung injury has been extensively used as a model of interstitial pneumonia and pulmonary fibrosis.  Intercellular adhesion mol. (ICAM)-1 is a ligand for lymphocyte function-assocd. antigen (LFA)-1α and has been shown to be required for leukocyte migration into inflamed areas.  The purpose here was to investigate the role of the ICAM-1/LFA-1α pathway in a murine model of bleomycin-induced lung injury.  Animals received 75 mg/kg-1 bleomycin (BLM) i.v. followed by treatment with phosphate-buffered saline (BLM group), anti-ICAM-1 and LFA-1α monoclonal antibodies (mAb) (BLM+mAb group).  Inflammatory cell counts of bronchoalveolar lavage (BAL) fluid, hydroxyproline content, and histol. findings were compared between these groups.  In the BLM group, increases in total cell count, macrophage count, and neutrophil count of BAL fluid were obsd. on days 7 and 14.  In the BLM+mAb group, bleomycin-induced accumulation of neutrophils was reduced on days 7 and 14.  However, the administration of mAb to ICAM-1 and LFA-1α did not decrease the lung hydroxyproline content or the histopathol. fibrosis grading score, indicating that the antagonism of ICAM-1 and LFA-1α did not attenuate bleomycin-induced pulmonary fibrosis.  Apparently, the ICAM-1/LFA-1α pathway mediates the accumulation of inflammatory cells in the injured lung caused by bleomycin; however, other mechanisms are important for the subsequent development of pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp1vLl5CSzmLVg90H21EOLACvtfcHk0ljO0hCvk4FevQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtlymsL4%253D&md5=eaae85d8e5354d6eb20c74c643481c91</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1183%2F09031936.99.13107199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.99.13107199%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuse%26aufirst%3DT.%26aulast%3DTeramoto%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DH.%26aulast%3DSudo%26aufirst%3DE.%26aulast%3DEkimoto%26aufirst%3DH.%26aulast%3DMitsuhashi%26aufirst%3DH.%26aulast%3DUejima%26aufirst%3DY.%26aulast%3DFukuchi%26aufirst%3DY.%26aulast%3DOuchi%26aufirst%3DY.%26atitle%3DICAM-1%2520mediates%2520lung%2520leukocyte%2520recruitment%2520but%2520not%2520pulmonary%2520fibrosis%2520in%2520a%2520murine%2520model%2520of%2520bleomycin-induced%2520lung%2520injury%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D1999%26volume%3D13%26spage%3D71%26epage%3D77%26doi%3D10.1183%2F09031936.99.13107199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratner, M. A.</span></span> <span> </span><span class="NLM_article-title">The mechanism of aluminum-catalyzed Meerwein–Schmidt–Ponndorf–Verley reduction of carbonyls to alcohols</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">14796</span>– <span class="NLM_lpage">14803</span>, <span class="refDoi"> DOI: 10.1021/ja047613m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja047613m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVKgt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=14796-14803&author=R.+Cohenauthor=C.+R.+Gravesauthor=S.+T.+Nguyenauthor=J.+M.+L.+Martinauthor=M.+A.+Ratner&title=The+mechanism+of+aluminum-catalyzed+Meerwein%E2%80%93Schmidt%E2%80%93Ponndorf%E2%80%93Verley+reduction+of+carbonyls+to+alcohols&doi=10.1021%2Fja047613m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The Mechanism of Aluminum-Catalyzed Meerwein-Schmidt-Ponndorf-Verley Reduction of Carbonyls to Alcohols</span></div><div class="casAuthors">Cohen, Revital; Graves, Christopher R.; Nguyen, SonBinh T.; Martin, Jan M. L.; Ratner, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">14796-14803</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mechanistic details of the Meerwein-Schmidt-Ponndorf-Verley (MSPV) redn. of ketones to the corresponding alcs. were investigated both exptl. and computationally.  D. functional theory (DFT) was used to assess the energetics of several proposed pathways (direct hydrogen transfer, hydridic, and radical).  Our results demonstrate that a direct hydrogen transfer mechanism involving a concerted six-membered ring transition state is the most favorable pathway for all calcd. systems starting from a small model system and concluding with the exptl. investigated BINOLate/Al/iPrOH/MePhC:O system.  Exptl. values for the activation parameters of acetophenone redn. using the BINOLate/Al/iPrOH system (ΔG# = 21.8 kcal/mol, ΔH# = 18.5 kcal/mol, ΔS# = -11.7 au) were detd. on the basis of kinetic investigation of the reaction and are in good agreement with the computational findings for this system.  Calcd. and exptl. kinetic isotope effects support the concerted mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFjaUOH-GVG7Vg90H21EOLACvtfcHk0ljO0hCvk4FevQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVKgt7k%253D&md5=84725c08d4b73836d2039dd4d3d5b1e8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fja047613m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja047613m%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DR.%26aulast%3DGraves%26aufirst%3DC.%2BR.%26aulast%3DNguyen%26aufirst%3DS.%2BT.%26aulast%3DMartin%26aufirst%3DJ.%2BM.%2BL.%26aulast%3DRatner%26aufirst%3DM.%2BA.%26atitle%3DThe%2520mechanism%2520of%2520aluminum-catalyzed%2520Meerwein%25E2%2580%2593Schmidt%25E2%2580%2593Ponndorf%25E2%2580%2593Verley%2520reduction%2520of%2520carbonyls%2520to%2520alcohols%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2004%26volume%3D126%26spage%3D14796%26epage%3D14803%26doi%3D10.1021%2Fja047613m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayama, T.</span>; <span class="NLM_string-name">Hayashi, K.</span>; <span class="NLM_string-name">Honma, M.</span>; <span class="NLM_string-name">Takahashi, I.</span></span> <span> </span><span class="NLM_article-title">Preparation of <i>N,N’-</i>biarylurea derivatives as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6)</span>. <span class="NLM_patent">WO2001007411A1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=T.+Hayama&author=K.+Hayashi&author=M.+Honma&author=I.+Takahashi&title=Preparation+of+N%2CN%E2%80%99-biarylurea+derivatives+as+inhibitors+of+cyclin-dependent+kinases+%28Cdk4+and+Cdk6%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHayama%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520N%252CN%25E2%2580%2599-biarylurea%2520derivatives%2520as%2520inhibitors%2520of%2520cyclin-dependent%2520kinases%2520%2528Cdk4%2520and%2520Cdk6%2529%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1049</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=8894503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADyaK28XmsVeitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1996&pages=1047-1049&author=R.+S.+Obach&title=The+importance+of+nonspecific+binding+in+in+vitro+matrices%2C+its+impact+on+enzyme+kinetic+studies+of+drug+metabolism+reactions%2C+and+implications+for+in+vitro-in+vivo+correlations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The importance of nonspecific binding in vitro matrixes, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1047-1049</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Problems in enzyme kinetic studies of drug metab. enzymes are encountered when the nonspecific binding of the substrate in in vitro systems is not taken into account.  It is recommended that the nonspecific binding in in vitro incubation matrixes be detd. and corrections be included when reporting the KM and Ki values.  The nonspecific binding of drugs to liver microsomes represents and important parameter to measure when attempting the prediction of in vivo pharmacokinetics from enzyme kinetic data.  If not cor., values should be reported as "apparent" values [KM(app) and Ki(app)], which would be considered to be unique to a given set of incubation conditions.  Without correction, the apparent KM and Ki values are of little use in predicting in vivo metab. unless the unbound fraction approaches 100%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol_XF-L8KEMbVg90H21EOLACvtfcHk0lg_zSQljL_dJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVeitro%253D&md5=d9f64b5cda472e1be2821005a929d21f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DThe%2520importance%2520of%2520nonspecific%2520binding%2520in%2520in%2520vitro%2520matrices%252C%2520its%2520impact%2520on%2520enzyme%2520kinetic%2520studies%2520of%2520drug%2520metabolism%2520reactions%252C%2520and%2520implications%2520for%2520in%2520vitro-in%2520vivo%2520correlations%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1996%26volume%3D24%26spage%3D1047%26epage%3D1049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Svetnik, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culberson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuston, B. P.</span></span> <span> </span><span class="NLM_article-title">Random forest: a classification and regression tool for compound classification and QSAR modeling</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1947</span>– <span class="NLM_lpage">1958</span>, <span class="refDoi"> DOI: 10.1021/ci034160g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci034160g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Wiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2003&pages=1947-1958&author=V.+Svetnikauthor=A.+Liawauthor=C.+Tongauthor=J.+C.+Culbersonauthor=R.+P.+Sheridanauthor=B.+P.+Feuston&title=Random+forest%3A+a+classification+and+regression+tool+for+compound+classification+and+QSAR+modeling&doi=10.1021%2Fci034160g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Random Forest: A Classification and Regression Tool for Compound Classification and QSAR Modeling</span></div><div class="casAuthors">Svetnik, Vladimir; Liaw, Andy; Tong, Christopher; Culberson, J. Christopher; Sheridan, Robert P.; Feuston, Bradley P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1947-1958</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new classification and regression tool, Random Forest, is introduced and investigated for predicting a compd.'s quant. or categorical biol. activity based on a quant. description of the compd.'s mol. structure.  Random Forest is an ensemble of unpruned classification or regression trees created by using bootstrap samples of the training data and random feature selection in tree induction.  Prediction is made by aggregating (majority vote or averaging) the predictions of the ensemble.  The authors built predictive models for six cheminformatics data sets.  The authors anal. demonstrates that Random Forest is a powerful tool capable of delivering performance that is among the most accurate methods to date.  The authors also present three addnl. features of Random Forest: built-in performance assessment, a measure of relative importance of descriptors, and a measure of compd. similarity that is weighted by the relative importance of descriptors.  It is the combination of relatively high prediction accuracy and its collection of desired features that makes Random Forest uniquely suited for modeling in cheminformatics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjoRt5v7rYwLVg90H21EOLACvtfcHk0lg_zSQljL_dJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Wiu7s%253D&md5=dea7867551ec30260b0091b90593a660</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fci034160g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci034160g%26sid%3Dliteratum%253Aachs%26aulast%3DSvetnik%26aufirst%3DV.%26aulast%3DLiaw%26aufirst%3DA.%26aulast%3DTong%26aufirst%3DC.%26aulast%3DCulberson%26aufirst%3DJ.%2BC.%26aulast%3DSheridan%26aufirst%3DR.%2BP.%26aulast%3DFeuston%26aufirst%3DB.%2BP.%26atitle%3DRandom%2520forest%253A%2520a%2520classification%2520and%2520regression%2520tool%2520for%2520compound%2520classification%2520and%2520QSAR%2520modeling%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2003%26volume%3D43%26spage%3D1947%26epage%3D1958%26doi%3D10.1021%2Fci034160g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i123"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00138">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_77763"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00138?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00138</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Activity of <b>40</b> against S1P receptors; activity of <b>48</b> against S1P receptors; DR of <b>40</b> against receptors and enzymes from a Cerep broad selectivity panel; steady state PK and IC<sub>50</sub> coverage of compound <b>40</b> (IL8 assay) in BLM-induced pulmonary fibrosis model; synthesis of 4-aminopyridines intermediates for the synthesis of final compounds <b>38</b>–<b>51</b>; synthesis of final compounds <b>44</b>, <b>45</b>, and <b>49</b>; synthesis of final compounds <b>36</b>, <b>52</b>–<b>57</b>, <b>97</b>, <b>98</b>, and <b>101</b>; detailed SAR of investigation of the C5 position of pyridine series; synthesis of final compounds <b>65</b>, <b>72</b>, and <b>120</b>–<b>124</b>; recombinant CYP inhibition of compounds <b>34</b>, <b>37</b>, and <b>40</b>; CYP HLM inhibition of compound <b>40</b>; chemical stability at different pH values and plasma stability of compound <b>40</b>; hERG inhibition of compound <b>40</b>; LCMS analyses of compounds <b>34</b>, <b>40</b>, and <b>48</b> and HRMS spectra of <b>40</b> and <b>48</b>; SAR of compounds <b>52</b>–<b>57</b> (from <a id="rightTab-" class=" internalNav" href="#fig5">Figure <a id="rightTab-" class=" internalNav" href="#fig5">5</a></a> of the main text); and IC<sub>50</sub> values in S1P2 calcium flux assay (all runs) for compounds <b>19</b> and <b>20</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_001.pdf">jm1c00138_si_001.pdf (742.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00138/suppl_file/jm1c00138_si_002.csv">jm1c00138_si_002.csv (3.16 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00138&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-9%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00138%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00138" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c4331f7024d3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
